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“I am careful not to confuse excellence with perfection. 
Excellence, I can reach for;  
perfection is God’s business.” 
               (Michael J. Fox) 
 
 
& 
 
 
“I do the very best I know how - the very best I can; 
and I mean to keep on doing so until the end.” 
 (Abraham Lincoln) 
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Abstract 
Evaluation of Novel Tools to Ensure Asthma and COPD Patients Use the 
Approved Inhalation Technique when They Use an Inhaler 
Wesam Ghazi Ammari, B.Sc. Pharm., M.Sc. Pharm. Sci. 
KEYWORDS: Inhalers, Inhalation Technique, Inhalation Tools, Asthma, COPD, 
Specific Disease Outcomes 
Many respiratory patients misuse their inhaler. Although training improves their 
inhaler technique, patients do forget the correct inhaler use with time. In the current 
work, three clinical studies investigated novel tools designed with feedback 
mechanisms to ensure patients use the correct inhalation method when using their 
inhaler. Research Ethics Committee approval was obtained and all the participants 
signed an informed consent form.  
In the first study, the recruited asthmatic children (n=17) and adults (n=39) had their 
metered dose inhaler (MDI) technique assessed. Those who attained the recommended 
inhalation flow rate (IFR) of < 90 l/min through their MDI formed the control group. 
Whilst those who had a poor MDI technique with an IFR ≥ 90 l/min were randomized 
into either the verbal counselling (VC) group; or the 2ToneTrainer (2TT) group that, in 
addition to the verbal training, received the 2ToneTrainer MDI technique training 
device equipped with an audible feedback mechanism of correct inhalation flow. All 
the participants were assessed on two occasions (6 weeks apart) for their inhalation 
flow rate, asthma control and quality of life. The study showed that the 2ToneTrainer 
tool was as efficient as verbal training in improving and maintaining the asthmatic 
patients‟ MDI technique, particularly using the recommended slow inhalation flow 
through the MDI. Although statistically insignificant, potential improvement in quality 
of life was demonstrated. The 2ToneTrainer tool has the advantage of being available 
to the patients all the time to use when they are in doubt of their MDI technique. 
In the second research study, the inhalation profiles of asthmatic children (n=58) and 
adults (n=63), and of COPD patients (n=63) were obtained when they inhaled through 
the novel Spiromax dry powder inhaler (DPI) which was connected to an electronic 
pressure change recorder. From these inspiratory profiles; the peak inhalation flow, 
inhalation volume and inhalation acceleration rate were determined. The variability 
(23% - 58%) found in these inhalation profile parameters among various patient 
groups would be expected in all DPIs. The effect of the inhalation acceleration rates 
and volumes on dose emission characteristics from DPIs should be investigated. 
Attention, though, should be paid to the patients‟ realistic inhalation profile 
parameters, rather than the recommended Pharmacopoeial optimal inhalation standard 
condition, when evaluating the in-vitro performance of DPIs. 
Finally, in preschool asthmatic children, the routine use of the current AeroChamber 
Plus spacer (n=9) was compared with that of a novel version; the AeroChamber Plus 
with Flow-Vu spacer (n=10) over a 12-week period. The Flow-Vu spacer has a visual 
feedback indicator confirming inhalation and tight mask-face seal. The study showed 
that the new AeroChamber Plus with Flow-Vu spacer provided the same asthma 
control as the AeroChamber Plus in preschool children and maintained the same 
asthma-related quality of life of their parents. However, the parents preferred the new 
Flow-Vu spacer because its visual feedback indicator of inhalation reassured them that 
their asthmatic children did take their inhaled medication sufficiently. 
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Obstructive pulmonary conditions, namely asthma and chronic obstructive pulmonary 
disease (COPD), are considered among the worldwide healthcare burdens affecting 
not only the patients themselves but also their families, healthcare providers and their 
societies. The global prevalence of asthma, according to the Global Initiative for 
Asthma Management Report (GINA, 2008), is between 1% and 18% of the population 
in different countries. On the other hand, the prevalence of the clinically significant 
COPD cases is about 4-6% of the European adult population (Tschopp, 2007). COPD 
is currently ranked as the forth leading cause of death worldwide (Szafranski et al., 
2003; Stockley et al., 2006), and is predicted to be the third leading cause of death by 
the year 2020 (Stockley et al., 2006). 
Inhaled respiratory therapy is the cornerstone for drug delivery in the management of 
asthma and COPD. The inhalation route allows delivering small medicine dosages 
directly to their therapeutic sites of action in the lung which would result in a faster 
onset of action and less drug related side effects compared with other drug delivery 
routes (Newman et al., 1981a; Pedersen et al., 1986; Minai et al., 2004). Therefore, 
almost all key therapeutic drugs used in the treatment of asthma and COPD, including 
bronchodilators and anti-inflammatory agents, have been formulated so that they can 
be administered via inhalation. Consequently, different types of inhaler devices have 
been introduced to the market and have become the principal methods for drug 
administration for the treatment of these respiratory conditions (van Beerendonk et al., 
1998; Acerbi et al., 2007). 
Pressurized metered dose inhalers (MDIs) are widely prescribed, and a correct inhaler 
technique by the patient is critical for the success of the therapy (Horsley and Bailie, 
1988; Larsen et al., 1994; Virchow et al., 2008). The most commonly encountered 
MDI technique problems include; poor coordination of inhalation with inhaler 
actuation, ceasing to inhale shortly after activating the MDI and inspiration through 
   
25 
the nose (Pedersen et al., 1986). Moreover, many patients fail to inhale slowly and 
deeply through their MDI to achieve the desirable inhalation flow rate of < 90 l/min 
for a sufficient lung deposition (Al-Showair et al., 2007b). Many studies into poor 
MDI technique have been previously reported and have highlighted the magnitude of 
the problem; 14% to 89% of the patients using the MDI have either made at least one 
technique error or completely misused their inhaler (Paterson and Crompton, 1976; 
Epstein et al., 1979; Larsen et al., 1994). Indeed, because of the incorrect inhaler 
technique, less than 50% of the children receiving inhaler therapy benefit from it 
(Minai et al., 2004). In this regard and to overcome the inadequate MDI use in the 
patients who continue to have a poor inhalation method even after repeated training; a 
spacer device can be considered for use with the MDI (Walia et al., 2006) or 
alternatively breath-activated inhalers, such as dry powder inhalers (DPIs), can be 
prescribed (Virchow et al., 2008). 
Unlike the MDI technique, patients using DPIs are generally  required to inhale as 
“hard (fast) and deep” as they can through their inhalers to achieve effective drug 
delivery to the peripheral regions of the lung (Chege and Chrystyn, 2000; Borgstrom, 
2001; Van Der Palen, 2003). Dose emission from all the currently available DPIs is 
flow dependent; and it is generally accepted that a minimum peak inhalation flow 
(PIF) of 30 l/min through the inhaler is sufficient to create a total emitted dose with 
fine drug particles able to deposit in the lung (Chrystyn, 2009). However, not all DPI 
users are able to achieve a sufficient inhalation flow through their device (Al-Showair 
et al., 2007a). 
Instructing and training the patients on the correct inhaler (MDI or DPI) technique 
improve their device use (Newman et al., 1980; Horsley and Bailie, 1988; Broeders et 
al., 2003a). However, this improvement is temporary and wears off with time after the 
training session (Larsen et al., 1994; Kamps et al., 2000; Chrystyn, 2003; Minai et al., 
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2004; Crompton et al., 2006). Therefore, a regular check up on the inhaler technique is 
critically important even if the patient has been using their inhaler for a long period 
(Nimmo et al., 1993; van der Palen et al., 1997; van Beerendonk et al., 1998). 
Furthermore, an inhaler device with a multiple feedback mechanism reassuring the 
patient of adequate inhaler use should be beneficial, and would improve the patient‟s 
compliance and thus disease control (Crompton et al., 2006; Chrystyn, 2009).  
In the current PhD thesis, the use of novel inhaler technique training devices and 
spacers, which have different feedback indicators of a good inhaler technique, has 
been investigated in asthmatic children and adults. The impact of using these devices 
on the patients‟ inhalation characteristics, disease control and health-related quality of 
life has been studied. Moreover, realistic inhalation profiles and acceleration rates of 
asthmatic children and of adults with asthma and COPD through a novel DPI device 
have been investigated. Conclusions drawn from these research studies may have 
implications on the clinical and pharmaceutical practice of the efficient MDI and DPI 
use. 
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Inhalation Route for Drug Delivery 
2.1 The Human Respiratory System 
Respiration (Latin, Spiro; “I breathe”), also known as ventilation, is the process through 
which an organism exchanges gases between its internal and external environments. 
This gas-exchange process primarily involves inhaling oxygen (O2) in and exhaling 
carbon dioxide (CO2) out. Oxygen is a major component in the energy-producing 
metabolic processes of living cells, which end up with the production of the acidic CO2 
as a by-product. Respiration, thus, plays an important role in homeostasis (i.e. 
maintaining a constant composition of the internal fluid environment surrounding the 
cells despite changes in the external environment) (Davies and Moores, 2002; Marieb 
and Hoehn, 2010). 
The respiratory system (Figure 2-1) is responsible for the breathing process. The upper 
respiratory system consists of the nose, nasal cavity, pharynx and larynx. On the other 
hand, the lower respiratory system is made up of the airways and the lungs, which are 
located within and protected by the thoracic cage (cavity). Other functions of the 
respiratory system (other than gas-exchange) include: body defence and immunity, 
smell, speech (through the vocal cords) (Ward, 2006; Marieb and Hoehn, 2010) and 
some metabolic processes (Ward, 2006). 
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Figure 2-1: The Human Respiratory System (Source: www.colorado.edu/intphys/Class/IPHY3430-
200/image/17-1.jpg). 
 
2.1.1 The Airways 
The lower respiratory tract starts with the trachea (windpipe) which descends from the 
larynx and subdivides repeatedly into smaller airway branches distributed in the right 
and left lungs ( the bronchial or respiratory tree) (Figure 2-2), also known as the 
conducting zone structures. The trachea is about 10-12 cm long and 2 cm in diameter. 
Anatomically, the trachea and its two main right and left subdivisions; the bronchi, are 
composed of U-shaped cartilage linked posteriorly by smooth muscles and connective 
tissues. The inner walls of the trachea and the bronchi are primarily lined with a 
pseudostratified ciliated columnar epithelium and the mucus-producing goblet cells; the 
continuous cilia movement expels any mucus-entrapped foreign particles towards the 
upper respiratory system (as a body defence mechanism). The bronchial tree has 23 
branching generations (Figure 2-2) which end up with the alveolar sacs (generation 23) 
in the respiratory zone. The further the bronchial tree goes down, the smaller the 
diameter the air passages have. Moreover, the cartilage support decreases till it is no 
longer found at the bronchioles level; the epithelium lining becomes thinner and 
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changes to an un-ciliated cubical type at the terminal bronchioles generation and the 
amount of the smooth muscles in the airways‟ walls increases (Ward, 2006; Marieb and 
Hoehn, 2010). 
 
 
Figure 2-2: The pulmonary tree generations (Source: 
www.mmi.mcgill.ca/mmimediasampler2002/images/eidelman-12no3.gif). 
 
2.1.2 The Lungs  
The lungs are the soft, spongy, elastic, cone-shaped organs embed within the thoracic 
cavity and both weigh just over 1 kg. Each lung is surrounded with the pleura, with its 
surface in close contact with the ribs forming the curvature costal surface. The inferior 
base of the lungs rests on the diaphragm. The right lung, which is divided into three 
lobes, is larger than the left one which consists of two lobes; this is due to that part of 
the heart that is accommodated in the medial aspect of the left lung. The lungs 
accommodate the respiratory zone structures that extend from the respiratory 
bronchioles further down to the alveolar ducts which in turn lead to clusters of gas-filled 
   
31 
alveoli; known as the alveolar sacs. These provide a huge surface area for gas exchange. 
The blood and lymphatic vessels, the nerves and the bronchus go into each lung through 
the indentation on the mediastinal surface; the hilum (Ward, 2006; Marieb and Hoehn, 
2010).  
2.1.3 Respiration Control and Lung Function Test 
Breathing is controlled by different mechanical, chemical and neural mechanisms. 
Briefly, the negative intrapulmonary pressure (within the alveoli) relative to the 
intrapleural pressure (within the pleural cavity surrounding the lungs) facilitated by the 
contraction of the diaphragm and the intercostal muscles (Figure 2-1) (which increases 
the volume of the thoracic cavity) promote the flow of air into the lungs (inspiration) 
until the intrapulmonary and the atmospheric pressures are equal. Subsequently, when 
the respiratory muscles start to relax; the intrapulmonary pressure exceeds the 
atmospheric one, thus, exhalation occurs. The chemical control of ventilation is 
mediated by central (surface of medulla) chemoreceptors and peripheral (within the 
carotid and aorta bodies) chemoreceptors, which detect arterial PCO2 and pH (centrally 
and peripherally) and PO2 (peripherally only), and modulate ventilation via a distributed 
network of neurons in the brainstem. PCO2 is the most important factor. Stimulation of 
the central chemoreceptors by a fall in the CSF pH (due to high blood PCO2) causes an 
increase in ventilation. Whereas, the carotid bodies respond peripherally to high PCO2 or 
[H
+
] and low PO2 by increasing the firing rate in the carotid sinus nerve and thus 
increasing ventilation. The neural control of breathing involves a central pattern 
generator in the brainstem that sets the basic rhythm and pattern of breathing and 
controls the respiratory muscles. The involved neural networks are complex, reflecting 
the need to coordinate ventilation with other functions such as coughing, swallowing 
and vocalization (Ward, 2006; Marieb and Hoehn, 2010). 
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Lung function evaluation is important to confirm or exclude the diagnosis of many 
respiratory diseases as well as to assess/follow up on any related medical intervention in 
both clinical practice and research. A lung function test is commonly performed using a 
spirometer which gives many outcome measures that are normally compared to 
predicted values based on the subject‟s age, sex and height (Quanjer et al., 1993). The 
most commonly used spirometric parameters are (Ward, 2006): 
 Peak expiratory flow (PEF) (litre/minute): the subject is asked to inhale to their 
total lung capacity (TLC) and then to breathe out as hard and fast as possible to 
the residual volume (RV). The PEF is normally used to monitor respiratory 
diseases (especially asthma) once the diagnosis has been made. 
 Forced Vital Capacity (FVC) (litres): the volume of air exhaled during a forced 
expiratory manoeuvre starting from a maximal inspiration. 
 Forced Expiratory Volume in one second (FEV1) (litres): this is the volume of 
air expelled during the first second of a FVC manoeuvre. It is very important as 
it is reproducible and correlates well with lung function and disease prognosis.  
Both the FEV1 and FVC can be read off the spirometric plots; however, modern 
spirometry instruments automatically provide these parameters along with the normal 
predicted values for the subject‟s age, sex and height (Quanjer et al., 1993). The use of 
the FEV1 and FVC in respiratory disease diagnosis and severity classification is 
described later (under the relevant sections). 
Respiratory system illnesses that impede breathing are classified under two main 
categories; restrictive and obstructive lung diseases (Quanjer et al., 1993). Restrictive 
lung diseases are chronic conditions in which normal lung expansion is restricted, thus, 
adversely affecting the volume of inhaled air (e.g. pulmonary fibrosis and sarcoidosis). 
Whereas, obstructive lung diseases are characterized by a narrowing in the airways‟ 
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calibre which in turn imposes a resistance to airflow (e.g. asthma and COPD). The 
domain of the current work is the obstructive lung disorders only. 
2.2 Obstructive Lung Diseases         
2.2.1 Asthma 
The recent report of the Global Initiative for Asthma Management (GINA, 2008) has 
defined asthma as “a chronic inflammatory disorder of the airways in susceptible 
individuals, inflammatory symptoms are usually associated with a widespread but 
variable airflow obstruction and an increase in airway response to a variety of stimuli. 
Obstruction is often reversible, either spontaneously or with treatment”. The classical 
symptoms of asthma are wheezing, cough, shortness of breath and chest tightness. 
These symptoms tend to be worse at night (or in early morning) and are provoked by 
several triggers including exercise, pollens, dust, animals, viral infections and 
environmental smoke (GINA, 2008; BTS/SIGN, 2009). Asthma affects adult subjects 
(Chung et al., 2002) as well as children of all age groups (Chung et al., 2002; 
Sennhauser et al., 2005), and is associated with quality of life impairments (Akinbami 
and Schoendorf, 2002; Sennhauser et al., 2005). Despite the advances in the medical 
treatment of asthma, the worldwide prevalence of the disease has significantly increased 
in the last few decades, with nearly 300 million asthmatic patients (Braman, 2006; 
Peters et al., 2006). Moreover, this figure is expected to rise globally by 50% each 
decade (Braman, 2006) which would continue to impose a huge economic burden on the 
healthcare systems (Barnes et al., 1996; Bahadori et al., 2009). 
2.2.1.1 Pathophysiology of Asthma 
Asthma is a chronic respiratory condition that is described by two distinctive criteria; 
these are inflammation and hyperresponsiveness of the conducting zone of the 
respiratory system; however, in severe asthma these may extend to the distal respiratory 
regions. The disease is primarily classified into two types; atopic (allergic) and non-
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atopic asthma (Kay, 2005; Holgate, 2008). In atopic asthma, the immune response at the 
surface of the involved airways is regulated in a way that it recognizes certain 
environmental stimuli (allergens); thus initiating multicellular inflammatory processes 
(Schieken, 2002). These environmental irritants may include cigarette smoke, dust, air 
pollution, pollens and fungal spores (Gilmour et al., 2006). Figure 2-3 presents the 
pathways of the inflammation associated with allergic asthma. In summary, dendritic 
cells distributed in the epithelial lining of the airways uptake (internalize) the inhaled 
allergens; consequently acting as antigen-presenting cells to the T-lymphocytes (Th2-
Type cells). This allergen internalization is promoted and enhanced by the 
immunoglobulin E (IgE) bound to the surface of the dendritic cells (Holgate, 2008). 
 
Figure 2-3: The inflammatory pathways of atopic asthma (Holgate, 2008). 
Once the antigen peptide is presented to the T-cells; sensitization of the immune 
response is initiated. As a result and under the influence of the chemokines, T-cells 
(Th2-Type) proliferate at the site of antigen presentation on the airways‟ surface and 
start producing a wide range of cytokines which, in turn, attract secondary effector cells 
(eosinophils, basophiles and macrophages) to the inflammation site and activate them to 
secrete their inflammatory mediators (Figure 2-3). In more severe asthma conditions, 
the Th1-Type T lymphocytes are also involved in the inflammation process causing 
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tissue damaging through the secretion of the tumor necrosis factor (TNF)-α and 
interferon (INF)-γ (Smit and Lukacs, 2006; Holgate, 2008).  
Mast cells have also a major role in both the early asthmatic reaction (EAR) (immediate 
and lasts 30-60 min) and in the late asthmatic reaction (LAR) starting 4-6 hours later 
(Smit and Lukacs, 2006); this is due to their localization in the bronchial smooth 
muscles of asthmatic patients, but not in normal subjects (Bradding et al., 2006). 
Provocation of the mast cells (mainly by IgE binding to their receptors FcεRI) initiates 
the EAR through their main mediators; leukotriene (LT)D4, prostaglandin (PG)D2, 
histamine, tryptase, heparin and cytokines, leading to the asthmatic distinctive 
inflammatory features of bronchoconstriction, increase in microvascular permeability 
and thus cellular infiltration, fibrogenesis and smooth muscle remodelling (airway 
thickening) (Bradding et al., 2006; Holgate, 2008). Moreover, eosinophil leukocytes 
contribute to the inflammatory responses through their various mediators and cause 
tissue remodelling by the production of the transforming growth factor (TGF)-ß1 (Kay, 
2005). Other leukocytes; basophiles, monocytes and macrophages, have been shown to 
contribute in the pathogenesis of asthma (Holgate, 2008). 
Although the majority of asthma cases are of an allergic pathogenesis, the non-atopic 
asthma represents the remaining percentage of the diagnosed disorder. The exact 
underlying pathophysiology of the non-atopic asthma is not very clear yet; however, 
some non-IgE dependent provocation caused by occupational chemicals (Holgate, 
2008), exposure to certain viral and bacterial infections (Herz et al., 1999) and exercise-
induced bronchoconstriction (Carlsen et al., 2008) may have a role. The late onset of the 
non-atopic asthma coupled with its overlapping with COPD symptoms mandate a 
thorough medical investigation before a confirmed diagnosis can be made (Holgate, 
2008).        
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2.2.1.2 Diagnosis and Severity Classification of Asthma 
A properly diagnosed asthma is crucially important to draw up an effective management 
plan; however, the heterogeneous nature of the disease makes it difficult sometimes to 
reach a straightforward conclusion. The recently updated GINA (2008) guidelines and 
the asthma management guideline of the British Thoracic Society (BTS)/Scottish 
Intercollegiate Guidelines Network (SIGN) (2009) state that the diagnosis of asthma 
should be primarily based on a careful assessment of the subject‟s clinical history; 
taking into consideration both the classical symptoms of asthma (wheezing, cough, 
chest tightness and shortness of breath) and the associated key features that increase the 
probability of asthma diagnosis (GINA, 2008; BTS/SIGN, 2009). Moreover, the 
objective lung function measures, including PEF, FEV1 and FVC, are recommended to 
confirm the diagnosis before initiating a long-term therapy; as these spirometric 
measures can be compared to the normal predicted values for age, gender and height. 
The GINA guidelines (2008) suggest that an increase in the FEV1 by ≥12% (or 200 ml) 
or an increase in the PEF by ≥20% (or 60 l/min) from baseline following the 
administration of a short-acting bronchodilator is usually indicative of asthma; however, 
not all patients show reversibility in the FEV1 or the PEF all the times particularly those 
with normal or near-normal lung function spirometry; therefore, assessment of airflow 
limitation expressed by the FEV1/FVC ratio is more practically useful, mainly in 
differential diagnosis. This ratio is normally >0.75 - 0.80 in adults and probably >0.90 
in children. In the very difficult to diagnose situations, airway responsiveness 
(methacholine challenge), airway inflammation markers and allergic examinations 
might be done to reach a decisive confirmation. 
Diagnosis of asthma in children is more difficult than in adults, especially in those at the 
preschool age (<5 - 6 years). Consequently, a careful evaluation of the clinical 
presentation and risk factors should be made because confirmatory spirometry and other 
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examinations are usually challenging to perform in young children (GINA, 2008; 
BTS/SIGN, 2009). Moreover, it is very important to differentiate between various 
wheezing phenotypes and their inducers which are common in children <5 years old, as 
this has significant treatment consequences (Brand et al., 2008). 
Once the diagnosis has been confirmed, asthma should be classified based on the 
severity level of the airways limitation as this categorization has key implications on 
both pharmacotherapy initiation and disease monitoring. The GINA (2008) guidelines, 
hence, classify asthma into 4 severity categories; intermittent, mild, moderate and 
severe asthma (Table 2-1). 
 
Table 2-1: Severity classification of asthma (GINA, 2008). 
2.2.1.3 Pharmacotherapy and Management Guidelines of 
Asthma  
Based on the pathophysiology and subsequently the clinical symptoms of asthma; the 
inhalation route is considered the cornerstone for the delivery of the main anti-asthmatic 
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therapeutic agents which are primarily classified into the following pharmacological 
categories (Katzung, 2007; GINA, 2008): 
 Bronchodilators: these are medicines that induce bronchial smooth muscle 
relaxation; thus, alleviating bronchoconstriction through various mechanisms of 
action. Bronchodilators are sub-classified into: 
1. ß2-agonists: depending on their onset and duration of action; the short-
acting ß2-agonists (SABA), e.g. salbutamol (albuterol), terbutaline and 
fenoterol, are used as rescue (reliever) bronchodilators on “as- and when-
needed” administration basis. On the other hand, the long-acting ß2-
agonists (LABA), e.g. salmeterol and formoterol, are used as controller 
agents in combination with corticosteroids. Formoterol has been shown 
to have both short and long acting effects. 
2. Anticholinergics (ipratropium bromide and oxitropium bromide): are 
used as reliever (short-acting) bronchodilators in asthma, however, they 
are less effective than the ß2-agonists in the management of asthma.  
3. Theophylline: is an oral bronchodilator that might be prescribed as an 
add-on therapy to the inhaled asthma medications as a second-line 
controller (because it is less effective than the LABA and has significant 
side effects at higher doses). 
 Glucocorticosteroids: inhaled corticosteroids (ICSs) are considered the most 
effective anti-inflammatory agents (preventer therapy) in the treatment of 
asthma as they reduce asthma symptoms, improve lung function, improve 
quality of life and reduce the frequency and severity of acute exacerbations. A 
number of ICSs are available, and these differ in their potency and 
bioavailability; e.g. beclomethasone, budesonide, fluticasone and ciclesonide. 
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 Leukotriene modifiers (montelukast and zafirlukast): these agents have been 
shown to exert some bronchodilation, improve lung function and reduce asthma 
symptoms and exacerbations. They are usually prescribed as an oral add-on 
therapy. 
 Cromones (sodium cromoglycate and nedocromil sodium): these have a weak 
anti-inflammatory effect; therefore, they only have limited use in long-term 
asthma treatment. 
 Anti-IgE monoclonal antibody (omalizumab): is a relatively recent add-on 
therapy with a limited use only in patients with severe high-serum IgE allergic 
asthma whose symptoms are uncontrolled by a high-dose inhaled combination 
therapy. 
The non-pharmacological treatment of asthma has been discussed in the management 
guidelines, though more research is needed to confirm its effectiveness (BTS/SIGN, 
2009). This non-pharmacological treatment includes dietary modifications and 
supplements, avoidance of allergens of various origins (e.g. cigarette smoke, house mite 
and air pollution and dust), immunotherapy and weight loss in overweight and obese 
asthmatics. Furthermore, complementary and alternative medicine might have a positive 
role in certain asthma conditions. 
The effective management of asthma is achieved through a collaborative team effort. 
Proper disease diagnosis and pharmacotherapy decisions by the healthcare providers, 
along with patient/caregivers disease education would lead to the ultimate goal of 
asthma control. The BTS/SIGN (2009) guidelines recommend a stepwise approach for 
asthma pharmacotherapy in an attempt to achieve early and optimal asthma control. 
Figures 2-4 and 2-5 illustrate these stepwise approaches for both asthmatic adults and 
children. 
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Figure 2-4: The asthma stepwise approach in adults. 
 
 
Figure 2-5: The asthma stepwise approach in children (5-12 years old). 
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2.2.1.4 Asthma Control 
Asthma management guidelines define asthma control as having no or minimal daytime 
and nocturnal symptoms, no or minimal use of rescue bronchodilators, no acute 
exacerbations and normal or near-normal lung function. Moreover, these guidelines 
state that the ultimate goal of any asthma treatment plan is to achieve an optimal asthma 
control and to maintain this control thereafter (GINA, 2008; BTS/SIGN, 2009). In 
clinical practice and despite the availability of effective medications, many reasons may 
lead to poor asthma control; the most important of these include the delay in diagnosis, 
underestimation of disease severity and, hence, under-treatment, wrong inhaler device 
choice and insufficient patient education on the correct inhaler technique (Laforest et 
al., 2006; Horne et al., 2007; Haughney et al., 2008; Virchow et al., 2008). Insufficient 
asthma control is consequently translated into impairments in the patients‟ health-
related quality of life (Chen et al., 2007; Schatz et al., 2007a; Garris et al., 2008). 
Reliance on a single endpoint parameter for asthma control assessment in clinical 
practice and research; namely asthma symptoms, frequency of rescue ß2-agonist use and 
lung function measurement, may result in either overestimation of genuine asthma 
control or misclassification of poorly controlled patients as sufficiently controlled 
(Bateman et al., 2001). Therefore, instruments (questionnaires), developed specifically 
to evaluate asthma control and broadened to include all the guidelines stated asthma 
control dimensions, have been increasingly utilized whether to follow-up patients in 
clinical practice or to investigate the outcome of an intervention in clinical research 
(Bateman et al., 2001; Nathan et al., 2004; Horne et al., 2007).  
2.2.1.4.(a) The Asthma Control Questionnaire (ACQ) 
The Asthma Control Questionnaire (ACQ) is the first to be specifically designed and 
validated to quantify asthma control in adult asthmatics (Juniper et al., 1999d). The 
ACQ consists of 7 questions in total; the first five are related to the asthma symptoms 
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ranked as the most important in evaluating asthma control, the sixth question is about 
the short-acting ß2-agonist use and the last one is about FEV1 % predicted measurement 
(taken by research/clinic staff). Patients are asked to recall their asthma related 
experiences during the past week before responding to each question on a 7-point scale 
(0: no impairment and 6: maximum impairment). To work out the ACQ score, all the 
questions are equally weighted and the final result is the mean of the 7 items which 
ranges between 0 (well controlled asthma) and 6 (extremely poorly controlled asthma). 
The ACQ is presented in APPENDIX A-1 (refer to the enclosed DVD). 
Development and validation studies have shown that the ACQ is a short, an easy to 
complete and a valid instrument. Moreover, the questionnaire has been shown to be 
both an evaluative (i.e. responsive and sensitive to small, yet important, changes in 
asthma over time) and a discriminative tool (i.e. reliable to distinguish between different 
levels of asthma control among different patients at a single point in time). Therefore, 
the ACQ can be utilized confidently in both longitudinal (clinical) studies and cross-
sectional surveys, respectively, as well as in clinical practice (Juniper et al., 1999d). 
Recent studies have shown that the measurement properties (validity, responsiveness 
and reliability) of three shortened versions of the ACQ (symptom items alone, 
symptoms plus short-acting ß2-agonist use and symptoms plus FEV1 % predicted) are 
similar to those of the original 7-item ACQ, and that any of these shortened ACQ 
versions can be used (when research situations mandate) without compromising asthma 
control assessment (Juniper et al., 2001; Juniper et al., 2005). The minimal important 
difference for all ACQ versions is close to 0.5 (Juniper et al., 2005). Identifying “well-
controlled” asthmatics from those with “inadequately-controlled” ones is very important 
in both clinical research and practice, the crossover point between well- and 
inadequately-controlled is close to 1.00 on the ACQ score. An optimal cut-point of ≤ 
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0.75 indicates a “well-controlled” asthma, whilst a cut-point of ≥ 1.50 pinpoints an 
“inadequately-controlled” condition (Juniper et al., 2006). 
2.2.1.4.(b) The Asthma Control Test™ (ACT)  
The Asthma Control Test (ACT) is a 5-item patient-completed questionnaire that has 
been developed to assess asthma control in patients ≥ 12 years of age (Nathan et al., 
2004). Similar to other asthma control instruments, the ACT covers all the aspects of 
asthma control evaluation as indicated in the management guidelines including the 
disease symptoms, use of the short-acting rescue bronchodilators and the day-to-day 
activity limitations. However, the ACT is simpler in that the FEV1 measurement is not 
required as part of the questionnaire completion, although the ACT developers 
encourage to include lung function testing (whenever available) in the overall asthma 
control evaluation. Patients are asked to recall their asthma related experiences during 
the previous 4 weeks before responding to each item by choosing one of 5 response 
options corresponding to a 5-point Likert-type scale. The ACT score is the sum of the 5-
item responses which yields a total score that ranges between 5 (poorly controlled 
asthma) and 25 (completely controlled asthma). As a cut-off point, an ACT score of 19 
or less is indicative of insufficiently controlled asthma, whereas a score ranging 
between 20 and 24 represents a relatively well controlled condition, and a 25 score 
refers to a completely controlled asthma (Schatz et al., 2006). A recent large 
multinational study has confirmed the usefulness of the ACT cut-off point (≤ 19) in 
predicting the GINA-defined poorly controlled asthmatics (Thomas et al., 2009b). The 
ACT can also be completed online at: http://www.asthmacontrol.com/index.html. 
Although the ACT is freely available online for use, it has been recently copyrighted for 
commercial and research purposes (QualityMetrics owns the copyright- 
www.qualitymetric.com). The ACT is presented in APPENDIX A-2 (refer to the 
enclosed DVD).  
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Studies have shown that the ACT is a simple, rapid, reliable and valid asthma control 
instrument in patients already followed-up by an asthma specialist (Nathan et al., 2004), 
in those new to an asthma specialist management (Schatz et al., 2006), when the 
questionnaire was completed at a home setting (Schatz et al., 2007b) and when it was 
completed over the phone (Schatz et al., 2007c). Moreover, the ACT has been shown to 
be responsive to changes in asthma control over time, therefore it can be utilized in 
asthma clinical research to assess the effect of an intervention (Schatz et al., 2006). 
2.2.1.4.(c) The Childhood Asthma Control Test (C-ACT)  
To assess asthma control in young asthmatic children aged 4–11 years old, the 
Childhood Asthma Control Test (C-ACT) was developed (Liu et al., 2007). The C-ACT 
is a 7-item self-administered questionnaire in which both the asthmatic child and their 
parent/caregiver have their input toward its completion. Upon administration, the 
asthmatic child completes the first 4 items using a 4-response scale without the need to 
recall their previous asthma experiences; these child-completed items include: asthma-
induced activity limitations, cough, nocturnal awakening and how the child feels about 
their asthma on the day of the questionnaire completion. On the other hand, the 
parent/caregiver completes the next 3 items of the questionnaire using a 6-response 
scale after being asked to recall their child‟s asthma-related experiences in the past 4 
weeks; these include daytime symptoms and night-time asthma-caused awakening. The 
final C-ACT score is the sum of all items‟ individual scores, yielding a total score 
ranging between 0 and 27. A cut-off point of 19 or less represents an inadequately 
controlled asthma.  
Studies have shown that the C-ACT is a simple, valid, reliable, responsive to changes in 
asthma control over time (Jan et al., 2007; Liu et al., 2007) and predictive of health-
related quality of life (Garris et al., 2008). Thus, the C-ACT is a useful tool in 
evaluating asthma control in 4-11 year-old asthmatic children in both clinical practice 
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and research. The C-ACT can be completed online at: 
http://www.asthmacontrol.com/child.html. The C-ACT is presented in APPENDIX A-3 
(refer to the enclosed DVD).  
2.2.1.4.(d) The RCP‟s “Three Key Questions”  
The Royal College of Physicians (RCP), London, has designed a 3-item questionnaire 
as an outcome measure to assess asthma care in clinical practice, and thus the degree to 
which asthma is controlled. The asthma control dimensions included in the RCP 
questions are asthma-related daytime symptoms, nocturnal awakening and activity 
impairment (Pearson and Bucknall, 1999). The items are of the “yes/no” response-type 
with the option to include the frequency in the answer. In this regard, a negative 
response is assigned 0 score, while a positive one is given 1, and the final RCP 
questionnaire score is the sum of the 3 item points giving a potential total score ranging 
between 0 and 3. For the RCP outcome interpretation; it has been recently shown that a 
total score of 0 indicates a well controlled asthma, whereas a score of ≥1 may represent 
an inadequately controlled condition (Thomas et al., 2009a). The RCP “Three key 
Questions” are shown below.  
Although the RCP‟s “Three Key Questions” are simple and quick to complete, many 
related issues have been raised; among these, the instrument has yet to be formally 
validated and the optimal time frame for patients to recall their asthma-related incidents 
before completing the questionnaire has not been confirmed  yet, as it is either over the 
previous week or month which might lead to recall bias (Steven et al., 2002). However, 
a recent study has shown that strong cross-sectional and longitudinal correlations were 
noticed between the RCP questions and both the ACQ and quality of life instruments in 
adult asthmatics (Thomas et al., 2009a). Moreover, a strong longitudinal correlation was 
observed between the RCP questions and the ACQ in asthmatic children; yet caution 
should be practiced in the result interpretation as the validation of the ACQ use in 
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children is still underway and that additional well-structured RCP questionnaire 
validation studies are crucially required (Thomas et al., 2009a). These findings coupled 
with the British Asthma Management Guideline recommendations (BTS/SIGN, 2009), 
therefore, support the use of the RCP “three questions” as an asthma control instrument 
in both routine clinical practice and in clinical research.  
    
The RCP’s “Three Key Questions”  
In the last week/month: 
1. How many nights have you had difficulty sleeping because of your asthma symptoms 
    (including cough)? 
     ______ nights 
2. How many days have you had your usual asthma symptoms during the day (cough, 
    wheeze, chest tightness or breathlessness)?  
     ______days 
3. How many days has your asthma interfered with your usual activities (e.g. 
housework, 
    work/school, etc,)? 
     ______days 
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2.2.2 Chronic Obstructive Pulmonary Disease (COPD) 
“Chronic Obstructive Pulmonary Disease (COPD) is a respiratory disorder that is 
characterized by an airflow limitation that is not fully reversible. This airflow limitation 
is usually progressive and associated with abnormal inflammatory responses of the lung 
to irritant particles or gases” (GOLD-Guidelines, 2006). Cigarette smoking is the major 
risk factor leading to the development of COPD (Szafranski et al., 2003; Celli et al., 
2004; NICE-Guidelines, 2004; GOLD-Guidelines, 2006; Fujita and Nakanishi, 2007). 
However, only 10-20% of the smokers might develop a clinically significant COPD. 
Other COPD risk factors may include matrix metalloproteinases, apoptosis, protease–
anti-protease imbalance, exposure to occupational dust and chemicals (Fujita and 
Nakanishi, 2007) and severe hereditary alpha-1 antitrypsin deficiency (Calverley and 
Walker, 2003). Ranked as the sixth leading cause of death worldwide in 1990 
(Calverley and Walker, 2003); COPD is currently ranked as the fourth leading cause of 
death in the US, Europe (Tschopp, 2007) and worldwide (Szafranski et al., 2003; 
Stockley et al., 2006), and is predicted to rise to the third leading cause by 2020 
(GOLD-Guidelines, 2006; Stockley et al., 2006). The prevalence of clinically 
significant COPD cases is about 4-6% in the European adult population, with nearly 3 
million patients diagnosed in the UK (Tschopp, 2007). The increase in the COPD 
morbidity and mortality imposes economic as well as social burdens on the patients 
themselves, their families and the healthcare systems (GOLD-Guidelines, 2006). 
2.2.2.1 Pathophysiology of COPD 
Inhaled cigarette smoke and other noxious particles induce inflammatory responses 
which appear to be amplified and persistent in the subjects who develop COPD. 
Pathological changes in COPD involve the proximal and peripheral airways, the lung 
parenchyma (respiratory bronchioles and alveoli) and the pulmonary vasculature. These 
changes are associated with increased specific inflammatory cell types in different parts 
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of the respiratory system; the neutrophils in the airways lumen, the macrophages in the 
airways wall, lumen and parenchyma, and the CD8+lymphocytes in the airways wall 
and parenchyma. The structural changes associated with the chronic inflammation of 
COPD include mainly increased Goblet cells and enlarged submucosal glands in the 
proximal airways (both leading to mucus hypersecretion). Furthermore, airways wall 
thickening, peribronchial fibrosis, luminal inflammatory exudates and airways 
narrowing are noticed in the peripheral air passages. Alveolar wall destruction and 
apoptosis of the epithelial and the endothelial cells occur in the lung parenchymal 
region leading to Centrilobular emphysema (commonly seen in smokers) or Panacinar 
emphysema (commonly seen in alpha-1 antitrypsin deficiency). In addition, pulmonary 
hypertension in COPD patients occurs due to the thickening of the intima, endothelial 
cell dysfunction and later smooth muscle hypertrophy/hyperplasia. Progressive 
pulmonary hypertension may lead to right ventricular hypertrophy and eventually to 
right-side cardiac failure (cor pulmonale) (GOLD-Guidelines, 2006). 
The mechanisms for the amplified inflammatory responses in COPD patients are not 
well understood yet, but may be genetically determined. Oxidative stress and excess of 
proteinases in the lung amplify the inflammation in COPD. In this regard, oxidative 
stress has several adverse consequences in the lungs including activation of 
inflammatory genes, inactivation of anti-proteinases, stimulation of mucus secretion and 
stimulation of increased plasma exudation (Calverley and Walker, 2003; GOLD-
Guidelines, 2006). Oxidative stress may also cause reduction in the activity of histone 
deacetylase in the lung tissue which may lead to a reduction in the anti-inflammatory 
action of glucocorticoids. On the other hand, the protease-mediated destruction of 
elastin in the lung parenchyma of COPD patients is an important feature of emphysema 
and is likely to be irreversible (GOLD-Guidelines, 2006). Exacerbations of COPD 
represent a further amplification of the inflammatory status in the airways of the 
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patients and may be triggered by bacterial or viral infections or by environmental 
pollutants. 
The clinical presentation of patients with COPD is far from uniform, most of the COPD 
patients present in the fifth or sixth decade of life with the exception of patients with 
alpha-1 antitrypsin deficiency who may present at a younger age (Cazzola et al., 2007). 
In the recent years, there is increasing evidence that COPD involves systemic features, 
particularly in severe stages. Cachexia (loss of fat free mass), weakness and loss of 
skeletal muscle mass (due to apoptosis and disuse atrophy), osteoporosis, depression 
and chronic anaemia may develop in COPD patients (GOLD-Guidelines, 2006; Cazzola 
et al., 2007). Malnutrition leading to reduced body weight is common in COPD 
affecting 10-15% of the mild–to-moderate patients and 50% of the more advanced 
cases; a high metabolic rate that is not compensated for by caloric intake is thought to 
play an important role. Increased oxygen consumption by respiratory and non-
respiratory skeletal muscles as well as some of the medications used in COPD treatment 
are among the explanatory hypotheses that have been proposed to explain the increased 
metabolic expenditure in COPD patients (Decramer et al., 2005). Eventually, these 
systemic effects of COPD will adversely impact the patients‟ exercise tolerance and 
health status.   
2.2.2.2 Diagnosis and Severity Classification of COPD 
The national and the international COPD management guidelines (Celli et al., 2004; 
NICE-Guidelines, 2004; GOLD-Guidelines, 2006) state that COPD diagnosis should be 
considered in individuals over the age of 35 years [over the age of 40 according to 
(GOLD-Guidelines, 2006)] who are exposed to one or more of the COPD risk factors 
(mainly tobacco smoking) and present with one or more of the following symptoms: 
exertional breathlessness, chronic cough and/or regular sputum production, frequent 
winter bronchitis and wheeze. Thus, COPD diagnosis is primarily based on these 
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clinical symptoms and followed by a spirometry confirmation, where the COPD 
landmark of irreversible airflow limitation is characterized by a post-bronchodilator 
FEV1 <80 % predicted and an FEV1/FVC ratio < 0.70. 
Assessment of the COPD severity level is crucially important to initiate the proper 
pharmacotherapy treatment and subsequently evaluate the disorder prognosis. The 
severity stage determination, thus, should include the degree of airflow obstruction, 
exacerbations frequency and other prognostic factors. The NICE guidelines (2004) 
classify COPD severity into three categories based on the FEV1 as a percentage of the 
predicted value for the age, height, gender and race group (Table 2-2). Recent studies 
suggest that the use of multidimensional grading system to assess the severity and 
impact of COPD is more useful than the % predicted FEV1 measurement recommended 
by the current guidelines (Cazzola et al., 2007). 
COPD Severity  FEV1 % Predicted 
Mild 50-80% predicted 
Moderate 30-49% predicted 
Severe < 30% predicted 
Table 2-2: Classification of COPD severity according to the NICE guidelines (2004). 
 
On the other hand, the GOLD guidelines (2006) classify the severity of COPD into 4 
stages based on post-bronchodilator FEV1 measurements (Table 2-3). The 2006 
guidelines did not include a fifth severity stage of COPD; “Stage 0: At Risk”, that has 
been considered in the previous guidelines since 2001. This is due to incomplete 
evidence that individuals who meet this stage criterion (chronic cough and sputum 
production, along with normal spirometry) will necessarily develop stage I (Mild 
COPD) at some point later. 
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COPD Severity  Spirometric Measurements 
Stage I: Mild 
FEV1/FVC < 0.70 
FEV1 ≥ 80 % predicted 
Stage II: Moderate 
FEV1/FVC < 0.70 
50 ≤ FEV1 < 80 % predicted 
Stage III: Severe 
FEV1/FVC < 0.70 
30 ≤ FEV1 < 50 % predicted 
Stage IV: Very Severe 
FEV1/FVC < 0.70 
FEV1 <30 % predicted, or FEV1 <50 % predicted plus 
chronic respiratory failure. 
Table 2-3: Classification of COPD severity according to the GOLD guidelines (2006). 
 
In addition to the spirometric classification of the COPD severity; evaluation of the 
body mass index and dyspnoea (breathlessness) status in all patients have been 
recommended since those have been proved useful in predicting certain outcomes such 
as survival (Celli et al., 2004). In this regard, the Medical Research Counsel (MRC)-
Dyspnoea Scale has been recommended by the NICE guidelines (Table 2-4). 
Grade Degree of breathlessness related to activities 
1 Not troubled by breathlessness except on strenuous exercise 
2 Short of breath when hurrying or walking up a slight hill 
3 
Walks slower than contemporaries on level ground because of 
breathlessness, or has to stop for breath when walking at own pace 
4 
Stops for breath after walking about 100 m or after a few minutes on level 
ground 
5 
Too breathless to leave the house, or breathless when dressing or 
undressing 
Table 2-4: The MRC-Dyspnoea Scale for COPD patients (NICE guidelines, 2004). 
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2.2.2.3 Management of Stable COPD 
Once diagnosed, COPD and its co-morbidities cannot be cured and require continuous 
treatment; therefore, an effective management plan should aim at achieving the 
following; relieve the symptoms, prevent disease progression, improve exercise 
tolerance, improve health-related quality of life, prevent and treat exacerbations and 
associated complications and possibly reduce mortality (GOLD-Guidelines, 2006). 
The common statement that only 10-20% of the tobacco smokers develop a clinically 
significant COPD is misleading. A much higher proportion may develop abnormal lung 
function at some point if they continue to smoke (GOLD-Guidelines, 2006). Smoking 
cessation in COPD patients has the greatest capacity to influence the natural history of 
the disease (Calverley and Walker, 2003; Celli et al., 2004; GOLD-Guidelines, 2006), it 
not only returns the subsequent rate of declining lung function towards normal in early 
disease stages but also reduces future mortality (Calverley and Walker, 2003). Patient 
educational programs are vital to be included in the disease management plan and 
should be tailored to suit the patients‟ needs and environment taking into consideration 
the available healthcare resources and cost effectiveness (NICE-Guidelines, 2004; 
GOLD-Guidelines, 2006). Parallel to cigarette smoking cessation; pharmacologic and 
non-pharmacologic treatments should be initiated, as required, with as minimal adverse 
affects and complications as possible.    
2.2.2.3.(a) Pharmacotherapy of COPD 
Different categories of medications with various strengths and dosage forms are used in 
the pharmacologic treatment of COPD, and prescribed either as a monotherapy or in 
combination. However, none of the currently available COPD medications has the 
ability to modify the rate of decline in the lung function (Celli et al., 2004). Inhaled 
bronchodilators (including ß2-adrenoceptor agonists and anticholinergics) are 
considered the cornerstone in the symptomatic management of COPD. Depending on 
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their onset and duration of action, they are prescribed on “as needed” or on a “regular” 
basis. The choice between different bronchodilator classes in clinical practice depends 
on the drug availability and the patient‟s response in terms of efficacy and side effects. 
All classes of bronchodilators have been shown to improve exercise tolerance in COPD 
without necessarily producing significant changes in FEV1 (GOLD-Guidelines, 2006). 
The NICE guidelines (2004) recommend that the initial empirical therapy for the relief 
of COPD breathlessness and exercise intolerance should be the short-acting 
bronchodilators (such as the ß2-agonist salbutamol; and the anticholinergics ipratropium 
or oxitropium bromides), however, their effectiveness should not only be assessed by 
the lung function measures but should also include other improvement measures of 
symptoms, daily activities and exercise capacity. Some studies have shown that the 
combination of two short-acting bronchodilators significantly improved the FEV1 more 
than that achieved by the administration of either one alone (Wesseling et al., 1992; 
Friedman, 1995; Auerbach et al., 1997), however, no additional changes in the quality 
of life, symptom scores and morning PEF were noticed (Auerbach et al., 1997). 
In the management of COPD, the use of long-acting inhaled bronchodilators on a 
“regular” basis have been shown to be more effective and convenient than the use of 
short-acting bronchodilators (Calverley and Walker, 2003; GOLD-Guidelines, 2006). 
The inhaled long-acting ß2-agonists (LABA) class currently includes two drugs; 
salmeterol and formoterol. Their relative lipophilicity explains their prolonged duration 
of action up to 12 hours, allowing twice a day administration. Formoterol has the 
advantage of a faster onset of action, as compared with salmeterol, which provides a 
relatively immediate relief of the symptoms, similar to that seen after salbutamol 
administration (Tennant et al., 2003; Currie et al., 2006). Salmeterol and formoterol are 
formulated in either metered dose inhalers (MDIs) or dry powder inhalers (DPIs). 
Recently, arformoterol, a single [R,R-formoterol] isomer, has been approved to be the 
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first LABA nebulized inhalation solution for maintenance bronchodilator treatment in 
COPD, which provides an option for the patients who have difficulty using other inhaler 
devices correctly (Abdelghany and Merl, 2007). It has been shown that the LABA 
improve the lung function and health-related quality of life (HRQL) in COPD patients 
irrespective of disease severity (Calverley et al., 2003a).  
Tiotropium bromide is a potent long-acting inhaled muscarinic receptor antagonist 
(anticholinergic drug) that has a dose-related bronchodilator response for up to 24 hours 
(Barnes et al., 1995; Maesen et al., 1995). Its unique kinetic selectivity for M1 and M3 
muscarinic receptors, slow dissociation rate from M3 receptors and rapid dissociation 
rate from M2 receptors gave tiotropium bromide its prolonged bronchodilation effect 
(Tennant et al., 2003; Currie et al., 2006). Formulated as Spiriva
®
 Handihaler
®
 DPI (18 
μg once daily); tiotropium has resulted in consistent physiological and health outcome 
benefits including improved health status, reduced dyspnoea, exacerbation frequencies 
and hospitalizations (Casaburi et al., 2002) and reduced the use of rescue medications in 
COPD patients (Tashkin and Kesten, 2003). Long-acting anticholinergic therapy has 
been recommended as the first-line maintenance bronchodilator therapy in the treatment 
of stable COPD patients (Tashkin and Kesten, 2003; Gross, 2006). However, both ß2-
adrenoceptor agonists and anticholinergics are effective with no clear distinction 
between them at least in terms of the change in post-bronchodilator FEV1 with evidence 
of a dose-response relationship in both classes (Calverley, 2001). In a multicentre 
controlled trial in COPD patients, tiotropium bromide (18 μg once daily) was superior 
to salmeterol (50 μg twice a day) in terms of consistent and sustained improvements in 
dyspnoea and health status (Donohue et al., 2002), similar results were found by another 
multicentre RCT (Briggs et al., 2005). Van Noord et al. (2006) have shown that there is 
an added benefit of the combination therapy of tiotropium bromide and formoterol, 
where the average FEV1 improved by 0.08L, 0.16L and 0.20L with tiotropium alone, 
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added formoterol once daily and twice daily, respectively. The combination has also 
resulted in improved dynamic hyperinflation and reduced the rescue medication use, 
however, long-term studies are needed to demonstrate any improvements in clinical 
outcomes (van Noord et al., 2006). 
Methylxanthines (theophyllines), the third class of bronchodilators, should only be used 
after trials of short-acting and/or long-acting inhaled bronchodilators (NICE-Guidelines, 
2004; GOLD-Guidelines, 2006). The theophyllines‟ little added value (Thomas et al., 
1992; Nishimura et al., 1993) coupled with their greater side-effect profile have ranked 
them as a third add-on line therapy in stable COPD treatment (Calverley and Walker, 
2003; Cazzola and Matera, 2007).                    
The role of inhaled corticosteroids (ICSs) in COPD is more controversial (Friedman, 
1995; Calverley and Walker, 2003). They do not appear to affect the rate of decline of 
FEV1, however, their use has reduced acute exacerbations, the decline in health status 
(Calverley and Walker, 2003) and the mortality within a year after hospital discharge 
(Macie et al., 2006). A combination therapy of a long-acting ß2-agonist and an ICS 
(formoterol/budesonide combined in a single DPI) has resulted in improved lung 
function, prolonged time to the first exacerbation and improved quality of life compared 
with either monotherapy or placebo treatments (Calverley et al., 2003a). Similar 
conclusions have been reached in the 3-year TORCH and the 1-year TRISTAN 
randomized controlled studies with a combination DPI of salmeterol plus fluticasone 
propionate when compared with the administration of individual components and 
placebo (Calverley et al., 2003b; Calverley et al., 2007), this combination therapy has 
also been shown to decrease lung hyperinflation and to increase exercise endurance time 
(O'Donnell et al., 2006).  However, salmeterol and fluticasone propionate combination 
did not reduce the all-cause mortality when compared with placebo (Calverley et al., 
2007). A retrospective observational study has shown that regular use of fluticasone 
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propionate either alone or in combination with salmeterol is associated with improved 
survival of COPD patients managed within the UK primary care system (Soriano et al., 
2002). On the other hand, the COPD management guidelines do not recommend the use 
of oral corticosteroids as a long-term maintenance therapy in stable COPD (NICE-
Guidelines, 2004; GOLD-Guidelines, 2006).  
The use of other pharmacological therapies in COPD treatment is controversial. Other 
than treating infectious COPD exacerbations; continuous prophylactic use of antibiotics 
has no added benefits (NICE-Guidelines, 2004; GOLD-Guidelines, 2006). Regular use 
of mucolytics, antioxidants (N-acetyl cysteine), immunoregulators and anti-tussive 
agents is not recommended by the GOLD guidelines (2006). Moreover, alpha-1 
antitrypsin therapy is not recommended for COPD patients whose disease is unrelated to 
alpha-1antitrypsin deficiency (GOLD-Guidelines, 2006), whilst, the NICE guidelines 
(2004) do not recommended this therapy at all for COPD patients irrespective of the 
underlying cause. Influenza vaccines can reduce the disease seriousness and death by 
50%; therefore, yearly influenza vaccination is recommended by both guidelines.  
2.2.2.3.(b) Non-Pharmacological Management of COPD 
As required, non-pharmacological management of COPD is initiated in parallel to the 
pharmacotherapy treatment to achieve the overall goals of the disease management plan. 
Pulmonary rehabilitation programs cover a wide range of non-pulmonary problems that 
may not be adequately addressed by pharmacological therapy; these programs include 
exercise training, nutrition counselling and disease education. It has been shown that 
pulmonary rehabilitation programs have additional values in COPD management 
including improvements in exercise capacity and health status, and reductions in the 
perceived intensity of breathlessness, anxiety, depression, the number of 
hospitalizations and hospital stay periods. In stage IV (very severe) COPD patients, 
oxygen therapy might be helpful and can be administered by a number of ways 
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depending on the required therapy duration, the PaO2 level and the mobility status of the 
patient. Finally, surgical treatments (including bullectomy, lung volume reduction 
surgery (LVRS) and lung transplantation) may have positive outcomes when performed 
in carefully selected patients. However, high cost and possible post-operative 
complications should be taken into consideration (GOLD-Guidelines, 2006).     
2.3 Inhalation Route for Drug Delivery and Targeting 
Various routes of drug administration are available (including oral, transdermal, 
parenteral, rectal and inhaled). However, successful and efficient treatments should 
involve delivering sufficient drug amounts to their site of action to achieve the desired 
therapeutic response with minimal potential side effects (Everard, 2003). Drug delivery 
via the inhalation route has a number of advantages; inhaled medicines are directly 
targeted to their receptor sites in the respiratory system resulting in a faster onset of 
action compared with other drug delivery routes. Therefore, smaller inhaled dosages are 
needed to achieve the desired therapeutic outcomes, resulting consequently in a better 
efficacy to safety ratio when compared to systemic delivery (Pavia et al., 1977; 
Newman et al., 1981b; Dolovich, 1999; Virchow et al., 2008). 
The performance of any inhaler device depends normally on two parameters; the 
amount of medication to be delivered to the patient and on the particle size of that 
medication. Therefore, the term “fine particle dose”; a combination of the total emitted 
dose and the aerodynamic particle size, is being used and refers to the mass of inhaled 
particles with an aerodynamic diameter of less than 5 µm (Ross and Schultz, 1996). It is 
generally accepted that drug particles with a mass median aerodynamic diameter 
(MMAD) between 1 and 5 µm have the greatest potential for lung deposition (Rees et 
al., 1982; Newman, 1985; Ross and Schultz, 1996).      
A number of mechanisms have been suggested to be responsible for the deposition of 
the inhaled aerosol particles into the lung. However, two main mechanisms are 
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generally accountable for the deposition of aerosols with particle sizes ranging between 
0.5 μm and 10 μm (MMAD 2-5 μm); larger particles deposit mainly by an inertial 
impaction mechanism particularly when the airflow changes its direction in the mouth, 
pharynx and at the bifurcations of the large central airways. The gravitational 
sedimentation mechanism is responsible for the deposition of the smaller particle sizes 
which are able to penetrate to the very small airways and alveolar regions (Figure 2-6) 
(Goldberg and Lourenco, 1973; Newman et al., 1981b; Everard, 2003); in these 
peripheral regions of the respiratory tree the airflow slows down due to the increase in 
the cross-sectional area, thus the airborne particles have negligible momentum and 
consequently deposit under the influence of the gravity (Everard, 2003). For very small 
particles (< 0.5 µm in diameter), bombardment with gas molecules in the lungs causes 
them to deposit via a third mechanism known as the Brownian diffusion (Goldberg and 
Lourenco, 1973; Newman et al., 1981b). 
 
Figure 2-6: Deposition mechanisms of inhaled drug particles (Everard, 2003). 
Many methods can be used to investigate the degree of lung deposition and/or 
distribution following drug inhalation; these include the clinical endpoints such as 
spirometry and broncho-provocation, gamma scintigraphy (Pauwels et al., 1997; 
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Tomlinson et al., 2005) and the pharmacokinetic methods (Hindle et al., 1993; 
Lipworth, 1996).   
2.3.1 Inhalation Drug Delivery Devices 
Many inhaler devices have been developed and introduced to the pharmaceutical 
market; these include the pressurized metered dose inhaler (pMDI or MDI), the dry 
powder inhalers (DPIs) and the nebulizers (Keller, 1999). However, efficient inhalation 
systems should be able to deliver an aerosol drug dose within the respirable particle size 
range (MMAD 2-5 μm). These inhalers are relatively simple to use, portable, durable 
and cost effective ([Anon] et al., 1999). The domain of the current work is the inhalation 
techniques through the MDI and the DPIs only. 
2.3.1.1 The Pressurized Metered Dose Inhaler (pMDI or MDI) 
The pMDI has been developed and introduced since the 1960s as a delivery device for 
inhaled medications (including the ß2-adrenergic agonists, anticholinergic 
bronchodilators and the anti-inflammatory corticosteroids) for the treatment of 
respiratory diseases. The active drug is either dissolved or suspended in a carrier 
material known as the propellant and then filled in a canister under pressure (Newman 
et al., 1981b). The propellant has a very low boiling point and within the MDI canister 
is a liquid. The propellant expansion upon MDI actuation serves as an internal energy 
that results in a reproducible dose emission and dispersion with a fine particle dose that 
is independent on the patients‟ inhalation flow rate (IFR) (Ross and Schultz, 1996). The 
main components of the conventional MDI device are outlined in figure 2-7. The valve 
of the canister is designed to deliver a 25-100 μl volume from a metering chamber. 
When the canister is actuated, the vapour pressure within the canister (3-5 times the 
atmospheric pressure) is reduced to equal that of the surrounding atmosphere; as a result 
the propellant/drug mixture is released through the nozzle of the canister forming a 
plume of gas flowing at an initial speed of about 30 miles per hour. The released aerosol 
   
60 
expands rapidly and the propellant evaporates causing the cooling effect that the patient 
feels at the back of the mouth. To improve the suspension or dissolution properties of 
the drug in the propellant; a surfactant (e.g. sorbitan trioleate, oleic acid or lecithin) is 
sometimes added and is responsible for the characteristic taste of the inhaled aerosol 
(Ariyananda et al., 1996). MDIs have many advantages; they are compact, easy to carry 
and thus less noticeable (Newman et al., 1981b; Keller, 1999), durable, reliable, 
microbial robust and cost-effective (Keller, 1999). 
Chlorofluoroalkanes (CFCs) have been used for decades as propellants in MDIs. 
However, due to the atmospheric ozone layer depleting effect of the CFCs, the 1987 
Montreal congress imposed a ban on using these substances. Although MDIs were 
exempted from this ban, the pharmaceutical companies developed two environment 
friendly CFC substitutes; the hydrofluoroalkanes (HFA 134a and HFA 227). 
Differences in the physical and chemical properties between the CFC and the HFA 
propellants have dictated drug reformulation of the current CFC-driven MDIs. In 
general, the HFA-propelled MDIs deliver a softer spray with finer aerosol particles at a 
slower initial release velocity that result in a reduced oropharyngeal deposition and a 
greater peripheral lung deposition. Consequently, the new HFA-driven beclomethasone 
(BDP) MDI (QVAR, 3M Pharmaceuticals) has been shown to have a pharmacokinetic 
bioequivalence at half the dose of that of the CFC-driven counterpart, whereas, both the 
CFC- and the HFA- propelled salbutamol MDIs were bioequivalent at the same dose 
(Anderson, 2001). A shortcoming of the recent HFA-propellants is the environmentally 
harmful degradation product of the HFA-134a; trifluoroacetic acid. Moreover, these 
new propellants have 2000 times more “greenhouse” gas effect than carbon dioxide, 
which imposes an extra challenge on the pharmaceutical industry to find out better 
alternatives (Zeng et al., 2002a).        
 
   
61 
 
Figure 2-7: A schematic of the MDI (source: 
www.solvaychemicals.com/docroot/fluor/static_files/images/solkane_227_134a_pharma_application
s.jpg). 
The MDI is the most commonly prescribed inhaler device (Everard et al., 1995; [Anon] 
et al., 1999; Virchow et al., 2008). Many factors affect the extent and distribution of 
lung deposition after inhaling through an MDI (Goldberg and Lourenco, 1973; Newman 
et al., 1981b; Newman, 1985; Everard et al., 1995; Ganderton, 1997). Firstly, the mode 
of inhalation (i.e. the MDI inhalation technique) has a profound effect on the amount of 
aerosol reaching the lungs and its subsequent distribution. Secondly, the physical 
characteristics of the aerosol particles influence their degree of deposition; these include 
the size, shape, density, hygroscopic properties and any surface electrical charges of the 
inhaled particles. Thirdly, the physical characteristics of the subject using the MDI 
affect the aerosol deposition; these particularly are related to differences in the airways 
anatomy and in the functional residual capacity (Pavia et al., 1977; Newman et al., 
1981b). The MDI inhalation technique is of an interest in the current work. 
2.3.1.1.(a) The MDI Inhalation Technique and Lung Deposition 
The MDI is apparently simple to use, however, this is a deceptive simplicity. Although 
many researchers have published various inhalation manoeuvres through the pressurized 
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inhalers; uncertainties are still debated particularly those related to the correct inhalation 
flow rate, the timing of canister actuation with respect to breathing (i.e. early, in the 
middle or late into breathing) and the breath-holding period after inhalation. These 
uncertainties are confusing to the patients and the healthcare professionals alike. 
Incorrect or unsatisfactory use of the MDI may lead to less than the optimal therapeutic 
response (Newman et al., 1981b; Everard et al., 1995; Everard, 2003; Virchow et al., 
2008), and because of poor MDI technique >50% of the adult patients do not get the 
maximum clinical benefit from their inhalers (Crompton, 1990) . It has been shown that 
the greatest percentage of the released aerosol dose (>80%) is retained in the mouth and 
subsequently swallowed, this is largely due the inherited inhaler device features of high 
initial velocity and large size of the propellant droplets, on which the MDI‟s end users 
have no control. On the other hand, variation in the MDI inhalation technique among 
the patients is possible and may affect the fraction of the dose reaching to the peripheral 
regions of the lungs, subsequently affecting the clinical efficacy of the inhaled therapy 
(Newman et al., 1981b; Newman, 1985; [Anon] et al., 1999). In this regard, correct 
MDI technique is more crucial with the ICS than with the inhaled bronchodilator; as the 
later is usually administered at supra-maximal doses which in part compensate for the 
poor inhaler use. Moreover, insufficient bronchodilation response is immediately 
addressed by the patients who will take further doses, whereas, the ICSs lack this 
immediate clinical feedback (Everard, 2003).    
Several research studies investigating the inhalation modes through the MDI have been 
published, and various inhalation technique recommendations have been proposed in an 
attempt to improve the peripheral lung deposition (Epstein et al., 1979; Newman et al., 
1981b; Everard et al., 1995; Pauwels et al., 1997). Firstly, shaking the MDI canister 
before use is very important to have consistent and reproducible, total and respirable 
emitted doses; and these were greatly reduced when the MDI was left overnight and was 
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not shaken before use (Everard et al., 1995). Secondly, starting early aerosol inhalation 
results in a better peripheral deposition than late inhalation relative to the lung volume. 
Patients are instructed to take deep inhalations (from the residual volume (RV) to the 
total lung capacity). It is possible that exhalation to the RV prior to inhalation may 
hinder the attainment of improved peripheral deposition by causing some airways to 
collapse and thus resulting in poorer aerosol distribution. However, this problem can be 
overcome by inhaling from the functional residual capacity (FRC) to the total lung 
capacity when using the MDI (Newman et al., 1981b). On the other hand, high 
inhalation flow rates (IFR) adversely affect peripheral deposition of the inhaled aerosol 
particles and increase the percentage of the dose deposited on the oropharyngeal and the 
central airway regions by inertial impaction (Goldberg and Lourenco, 1973; Newman et 
al., 1981b; Clarke et al., 1982). A definite IFR value that results in an optimal aerosol 
lung deposition is still debated in the literature. Dolovich et al. (1981) have 
recommended an IFR <60 l/min for an optimal lung deposition (Dolovich et al., 1981). 
It has also been shown that a slower inhalation (10 l/min) results in a greater relative 
bioavailability of salbutamol to the lungs, compared to a faster inhalation (50 l/min) 
(Hindle et al., 1993).  Another study showed that when the inhalation flow rate was 
increased from 37 to 151 l/min, the total lung deposition decreased from 11.2 to 7.2% 
(Newman et al., 1995). Moreover, using gamma scintigraphy and a microprocessor 
controlled metered dose inhaler it was shown that an inhalation rate of 90 l/min 
produced the best lung deposition (Farr et al., 1995).  These studies indicate that the 
lung deposition when using an MDI is dependent on the flow and that inhalation rates 
below 90 l/min are the most desirable and that a flow rate of approximately 100 l/min 
and above is too fast. 
To keep up with the MDI technique recommendations; it has been confirmed that 
holding the breath for a certain time period following the aerosol inhalation allows time 
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for the inhaled drug particles to settle on the airways by gravitational sedimentation. 
Different breath-holding periods have been proposed in the literature ranging from a 
few seconds till as long as possible (Newman et al., 1981b). When more than one dose 
(puff) is needed, a one minute delay between actuations seems unnecessary and, indeed, 
it is likely that this recommendation is rarely performed by the patients. No evidence, 
however, supports the argument that a one-minute gap following the first actuation can 
enhance the bronchodilator response by the second one by opening up the airways and 
thus improving lung deposition (Everard et al., 1995).   
The most critical MDI technique manoeuvre for effective lung deposition is to inhale 
slowly and deeply through the device (Goldberg and Lourenco, 1973). A slow deep 
inhalation that is followed by a 10-second breath-holding period has been shown to give 
a maximal bronchodilator response through the MDI (Clarke et al., 1982). This 
manoeuvre has been backed-up by the results of a pharmacokinetic study measuring the 
inhaled salbutamol by a urinary excretion method after 30 minutes of different 
inhalation flows through an MDI (Hindle et al., 1993; Tomlinson et al., 2005). In 
contrast to most of the published work, one study has shown no advantage or superiority 
of the slow inhalation flow (30 l/min) compared with a fast inhalation (120 l/min) when 
using fenoterol MDI in terms of lung function measures in both asthmatic and COPD 
patients. The authors justified the failure to detect small differences in the lung function 
by the simple timing technique of inhalation, the use of an open-mouth inhalation 
technique, the short breath-holding periods and the dose of the bronchodilator used 
(Williams, 1982).  
Improper coordination between the inhalation and the actuation of the MDI canister is 
the most common problem that many patients face when using their inhalers (Newman 
et al., 1981b; Crompton, 1982; Ganderton, 1997). Most patients activate the canister 
either before the inhalation has started or after it had ended. Failure to synchronize the 
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inhalation with the aerosol release may jeopardize the therapeutic benefit of the inhaled 
medicines; therefore, the patients who continue to have this problem in spite of repeated 
inhaler technique training should have their inhaler device changed to a breath-activated 
one (Coady et al., 1976; Newman et al., 1981b; Farr et al., 1995), or alternatively the 
use of a spacer (a holding chamber) with the MDI should be considered (Allen and 
Prior, 1986; Farr et al., 1995; Cochrane et al., 2000; Walia et al., 2006).      
2.3.1.1.(b) The Most Desirable MDI Technique 
Various MDI techniques have been suggested in the literature with an ultimate goal of 
improving lung deposition of the inhaled medicine. One of the most recommended MDI 
techniques was suggested by Epstein et al (1979) (Table 2-5). This 11-step MDI 
technique was clinically studied; of the 130 enrolled asthmatic and COPD patients, only 
10.8% correctly performed the 11 manoeuvres, while 24.7% failed to perform more 
than half the manoeuvres properly. This study has also shown that regular MDI users 
performed better, and that the asthmatics had better MDI technique than the COPD 
patients particularly in inhaling slowly and deeply and in holding their breath for 10 sec 
following inspiration. However, no significant correlation was found between the 
overall MDI technique performance and the lung function measures (Epstein et al., 
1979). Studies into poor MDI technique show wide variations in results due to 
differences in study design. However, two studies highlight the magnitude of the 
problem.  It has been shown that 77.5% to 89.2% of the patients made at least one error 
while using the MDI (Larsen et al., 1994), whilst another study showed that 14% of the 
patients misused their MDI (Paterson and Crompton, 1976). 
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The most desirable MDI technique 
1) Remove the cap from the mouthpiece. 
2) Shake the inhaler. 
3) Breathe out slowly, as far as comfortable to empty your lungs. 
4) Place the mouthpiece of the inhaler between your lips. 
5) Close your lips around the mouthpiece creating a seal. 
6) Start to breathe in slowly, through your mouth and immediately press the 
            aerosol canister to release a dose (puff). 
7) Breathe in slowly until your lungs are full of air (as far as you can), the breath 
in step should take you about 5 seconds. 
8) Remove the inhaler from your mouth and seal your lips. 
9) Hold your breath for 10 seconds. 
10) Breathe out slowly. 
11) Repeat steps 1 to 10 after 30 seconds if another dose is necessary. 
Table 2-5: The most desirable MDI technique. 
In asthmatic children, limited research has been done to identify the MDI technique 
problems and how these problems affect the airways response to the inhaled medicines 
(Pedersen et al., 1986; Dolovich, 1999). These two studies have shown that  < 2% of the 
MDI bronchodilator dose was deposited on the lungs of infants and young children, and 
that the breathing patterns in this age group are the key determinant of how much of the 
aerosol dose is deposited into the lungs. Small tidal volumes, variable breathing rhythm, 
nasal breathing and high IFR (specially if the child is crying) lead to a reduced lung 
deposition along with a greater overall deposition in the central airways (Dolovich, 
1999). Although both adults and children experience the same difficulties in using their 
MDIs; these difficulties are more pronounced in children mainly because of the lack of 
thorough MDI instruction at the time of prescription. The most commonly observed 
MDI technique errors in children were the hand-lung coordination problems, ceasing to 
inhale when the aerosol was actuated and inhalation through the nose after releasing the 
aerosol cloud into the mouth. Indeed, poor technique can lead to less than 50% of the 
children benefiting from the MDI treatment (Pedersen et al., 1986) and may result in 
only slightly better efficacy than placebo (Lahdensuo and Muittari, 1986). 
   
67 
2.3.1.1.(c) Improving and Maintaining the MDI Technique  
Taking into consideration the consequences of insufficient MDI use; it has been shown 
that counselling the patients can significantly improve the MDI technique, increasing 
adequate MDI technique from 31% before counselling, to 72% immediately after 
(Horsley and Bailie, 1988), and that training the asthmatic children and their parents on 
the correct MDI use improved the percentage of the good inhaler users from 8% before 
training up to 81% after (Burkhart et al., 2005). Improved inhaler technique can result in 
a positive pharmacodynamic changes as detected by the decrease in the specific airway 
resistance (Orehek et al., 1976). Such studies justify the time and resources spent on 
counselling patients on the proper MDI technique.   
Relatively, little research has been done to evaluate the effectiveness of various methods 
used for improving and maintaining the desirable MDI technique. Savage and 
Colleagues (2003) have shown that about one-third of the MDI users had a poor initial 
MDI technique and that a brief multimedia training method was at least as good as 
reading the MDI package leaflet in increasing the patients‟ awareness on proper inhaler 
use (Savage and Goodyer, 2003). It is crucial that the healthcare providers demonstrate 
the correct inhaler technique before the patients and to give them the same opportunity 
to do so; because  verbal and/or written MDI instructions alone are not sufficient 
(Sestinti et al., 2006). Another study has shown that the asthmatic children who received 
verbal MDI technique instructions and were allowed to demonstrate that technique until 
satisfactory performance has been achieved had better MDI manoeuvre than those who 
received verbal instructions alone (Kamps et al., 2000). However, even after the MDI 
technique counselling and the subsequent demonstration by the patient of a perfect 
technique, only 50% will use their MDI correctly 1 to 30 days later (Shim and Williams, 
1980) and about 20% of the children revert to the insufficient MDI habits after a short 
period of the training session (Burkhart et al., 2005). Therefore, it is crucial that the 
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patients receive repeated counselling and monitoring sessions of their MDI technique 
(Lindgren et al., 1987; Farr et al., 1995; Kamps et al., 2000; Walia et al., 2006; Virchow 
et al., 2008), and that the healthcare professionals should be aware of- and be competent 
in the correct inhalation technique of different inhaler devices (Guidry et al., 1992; 
Kamps et al., 2000; Virchow et al., 2008).      
2.3.1.1.c.1 An MDI Technique Training Tool: The 2Tone Trainer® 
Poor MDI technique is one of the main reasons why respiratory patients do not get the 
maximum benefit of their inhaled medications, resulting, thus, in poor disease control 
(Haughney et al., 2008). An MDI inhalation technique training device; the 2Tone 
Trainer
®
 (Canday Medical Ltd., Newmarket, UK) has been, therefore, developed in an 
attempt to improve the way patients use their inhalers, namely the inhalation flow and 
the hand-lung coordination (http://www.2tonetrainer.net). The 2Tone Trainer is an 
MDI-like tool (Figure 2-8) that is made of a medical grade plastic without having a 
canister. It has been designed to give an audible feedback depending on the inhalation 
speed achieved when the user inhales through the tool. In order to do so, the 2Tone 
Trainer has a patented two sets of sensitive reeds fitted inside (see schematic below); the 
first one vibrates only when the inhalation flow is between 30-60 l/min (the ideal 
inhalation flow through the MDI) producing a mono-tone sound (low pitch). If the 
inhalation flow exceeds 60 l/min (too fast), the second set of reeds is triggered 
producing a two-tone noise (high pitch), alarming the user to slow down their 
inspiration speed. 
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When practicing the 2Tone Trainer, patients should follow the correct MDI technique 
steps (taught by their healthcare provider, and also included in the 2Tone Trainer 
leaflet) and aim to change their inspiratory efforts to maintain the feedback of the mono-
tone (low pitch) sound throughout the whole inhalation manoeuvre (i.e. inhale slowly 
and deeply). The patients should, then, try to remember to inhale in the same way when 
they use their real inhalers. The 2Tone Trainer developers recommend patients 
practicing the device regularly at home to maintain an adequate pMDI technique 
particularly when they do not see their doctors or healthcare providers for several 
months (http://www.2tonetrainer.net). 
In the literature, only one clinical study investigated the usefulness of the 2Tone Trainer 
in asthmatic adults as part of their routine management at an outpatient clinic setting 
(Al-Showair et al., 2007b). This study has shown that the 2Tone Trainer helped the 
patients to maintain a sufficient MDI technique with improvements, particularly, in the 
inhalation flow. Moreover, an improvement in the patients‟ asthma-related quality of 
life was also observed. However, further research is needed to evaluate the 2Tone 
Trainer use in both asthmatic adults and children, and when they are managed at 
Figure 2-8: The 2Tone Trainer with a schematic diagram (Registered trademark Canday Medical 
Ltd, UK). 
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community pharmacy settings with the inclusion of validated asthma control 
instruments (questionnaires).      
2.3.1.1.c.2 Spacer Devices 
Spacers, also known as valved holding chambers, are plastic or metal tube-like 
chambers that are normally recommended in patients who have issues correctly 
coordinating inhalation with MDI actuation even after repeated MDI technique training. 
Moreover, MDIs plus spacers are more preferred during non-life threatening acute 
asthma exacerbations than nebulizers (GINA, 2008; BTS/SIGN, 2009). When compared 
to the use of an MDI alone, spacers have shown many advantages; firstly, the addition 
of a spacer to an MDI improves lung deposition (Newman et al., 1981a; Newman et al., 
1989a; Silkstone et al., 2002; Roller et al., 2007; Nair et al., 2008) which would enhance 
the therapeutic efficacy (Toogood et al., 1984; Demirkan et al., 2000) with even reduced 
delivered doses (Richards et al., 2001). Secondly, spacers‟ use decreases the 
oropharyngeal deposition of the inhaled aerosol, this is achieved by reducing the initial 
aerosol velocity (inhalation from a static cloud) and by decreasing the aerosol droplet 
size, as more time is given for the propellant to evaporate (Hodges et al., 1981; Newman 
et al., 1998; Dolovich, 1999; Richards et al., 2001). As a result, oral and gastrointestinal 
absorption is reduced, thus decreasing the local and systemic side effects (this is 
particularly important with ICSs) (Toogood et al., 1984; Brown et al., 1990). Lastly, 
spacers can also reduce the unwanted “cold freon” effect of propellant evaporation 
which makes many patients prematurely stop inhalation through their inhalers (Keller, 
1999). Nevertheless, it has been shown that the use of a spacer device was as effective 
as the use of an MDI alone in delivering inhaled doses to the lower respiratory system in 
both children (Hodges et al., 1981) and adults (Dolovich et al., 1983) who have been 
trained to use their MDI alone correctly. In addition, the use of a spacer (with an MDI) 
was the least preferred by the patients (Lenney et al., 2000); probably because these 
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devices are generally bulky in size and inconvenient to carry around (Nair et al., 2008) 
which may give a rise to patient compliance issue. 
Doctors and other healthcare providers started prescribing spacers very long time ago; 
figure 2-9 shows the original (primitive) large-volume spacer used by paediatricians 
before modern spacer devices became available (Everard, 2003). Various branded 
spacers with different design and size are available on the market; among the most 
commonly known are: the Volumatic™ spacer (GlaxoSmithKline, UK) (Figure 2-10), a 
large (750 ml) spacer fitted with a valved mouthpiece and suitable for adults and 
children older than 5 years; the Nebuhaler
®
 spacer (AstraZeneca, UK) (Figure 2-11); the 
Babyhaler
®
 Infant spacer (GlaxoSmithKline, UK) (Figure 2-12); and the AeroChamber 
Plus
®
 spacers (Trudell Medical International (TMI), Canada) (Figure 2-13). One 
advantage the AeroChamber Plus
®
 spacers have over the other commercially available 
spacers is the wide range of design available to suit a wide range of patients‟ age and 
preference. 
(www.trudellmed.com/Healthcare_Professionals/hp_aerochamber_plus_vhc.asp). 
 
Figure 2-9: The original (primitive) large-volume spacer (Everard, 2003). 
 
   
72 
 
Figure 2-10: The Volumatic
(TM)
 spacer (GlaxoSmithKline, UK). 
 
 
 
Figure 2-11: The Nebuhaler
®
 spacer (a) plastic (left) (b) metal version with a facemask (right). 
 
 
 
Figure 2-12: The Babyhaler
®
 Infant spacer (GlaxoSmithKline, UK). 
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Figure 2-13: The AeroChamber Plus
®
 spacers (TMI, Canada) – mouthpiece and facemask models. 
Many factors influence the percentage of the aerosol dose depositing on the lung when a 
spacer is used. These factors include; the spacer size, shape, resistance of the spacer‟s 
valve, dead volume, the use of multiple actuations, inhalation delay and the material 
from which the chamber is constructed (Chuffart et al., 2001). All plastic spacers have 
the inherited characteristic of the electrostatic charge which is responsible for the 
adsorption of part of the aerosol particles on the inner surface of the spacer, thus 
reducing the dose available for inhalation. This static can be reduced by soaking the 
spacer in a household detergent solution followed by drip (air) drying. Metal spacers are 
superior to plastic ones even when the static is reduced, however, plastic spacers remain 
the most widely used worldwide; as cost-effectiveness and availability are of concern 
(Chuffart et al., 2001). Therefore and due to the contradiction in the published reports, 
evaluating each MDI output characteristics when attached to different spacers is 
recommended before interchangeability among spacers can be claimed (Mazhar and 
Chrystyn, 2008).  
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International and national asthma management guidelines recommend that in asthmatic 
children a metered dose inhaler connected to a spacer device is the preferred method for 
drug delivery, and those under the age of 5 years should be kept on a facemask-
equipped spacer till they can properly use a spacer with a mouthpiece (GINA, 2008; 
BTS/SIGN, 2009). However, up to 40% of children still make inhalation technique 
errors even with spacers (Kamps et al., 2000). Also, when facemask-equipped spacers 
are used in infants and young children, special attention should be drawn to have a good 
tight seal with the child‟s face, otherwise significant amount of the drug will deposit on 
the child‟s face and eyes which should be washed immediately (Everard, 2003). 
Therefore, it has been suggested that a multiple feedback mechanism for correctly 
performed inhalation technique would be useful for both the asthmatic patients and their 
caregivers, and should enhance patient compliance and asthma control (Crompton et al., 
2006).  
In this regard, the AeroChamber Plus
®
 spacer helps patients use the recommended slow 
inhalation by making a whistle sound when the inhalation flow exceeds 60 l/min. 
Recently, the feedback mechanism when using the AeroChamber Plus
®
 spacer has been 
enhanced by the inclusion of a visual feedback value to indicate inhalation; the 
AeroChamber Plus
®
 with Flow-Vu
®
 (Trudell Medical International, London, Ontario, 
Canada) (Figure 2-15). This also confirms a seal between either the lips and the 
mouthpiece or the face (when using the facemask version), and allows caregivers to 
count the patient breaths (see website: 
http://www.trudellmed.com/Consumers/cn_aerochamber_wfv.asp). The novel 
AeroChamber Plus
®
 with Flow-Vu
®
 spacer is not available on the UK market yet, and 
no clinical research has been, so far, done to evaluate its use in comparison with the 
current version of the spacer. Figures 2-14 and 2-15 show the design difference between 
the two facemask (yellow) versions of the AeroChamber Plus
®
 spacer (the Flow-Vu
®
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enhancement is also available in the other mouthpiece and facemask AeroChamber 
Plus
®
 models).  
 
Figure 2-14: The AeroChamber Plus
®
 Spacer (TMI, Canada). 
 
               The Flow-Vu®  
                                                                             
 
Figure 2-15: The AeroChamber Plus
®
 with Flow-Vu
®
 (TMI, Canada). 
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2.3.1.2 Dry Powder Inhalers (DPIs) 
The dry powder inhalers (DPIs) are breath-activated devices that have been developed 
to overcome the problem of coordination of inhalation with MDI actuation that many 
patients have (Vidgren et al., 1988; Prime et al., 1999; Tarsin et al., 2006; Virchow et 
al., 2008). Furthermore, the DPIs contain no CFC-propellants which are 
environmentally harmful to the atmospheric ozone layer and have also been related to 
some adverse effects including bronchoconstriction and heart palpitation (Pitcairn et al., 
1994). Depending on the device design; DPIs can be classified into three main types 
(Srichana et al., 1998a; Zeng et al., 2002a): (1) Single-dose unit inhalers (utilizing a 
gelatine capsule that contains the dry powder formulation) e.g. Spinhaler
®
, Rotahaler
®
, 
Handihaler
®
, Inhalator
®
 and Cyclohaler
®
; (2) Multiple-dose unit devices e.g. Diskhaler
®
 
and Accuhaler
®
 (known as Diskus
®
 outside the UK) and (3) Multiple (reservoir) doses 
DPIs e.g. Turbuhaler
®
, Easyhaler
®
, Clickhaler
®
, Pulvinal
®
 and Novolizer
®
. The ideal 
DPI device does not exist yet, however, the most important features in any inhaler 
device include; patient/environment friendly inhaler that is easy to use, compact, has a 
multi-dose reservoir with a dose counter, moisture proof and be available at a 
reasonable cost (Gustafsson et al., 2005). 
Many patients find it much easier to use the breath-activated DPIs than the MDI, where 
no hand-lung coordination is needed (Cegla, 2004; Virchow et al., 2008). However, 
Svedmyr and Colleagues (1982) have shown that administration of salbutamol (100 or 
400 µg) through an MDI and (200 or 400 µg) through a DPI (Rotahaler
®
) had 
equipotent effects in terms of dose-response relationship with no added benefit with the 
DPI over that noticed with a good coordinated MDI. However, the DPI could be a good 
alternative for patients with continued poor MDI technique (Svedmyr et al., 1982). 
Similar results have been demonstrated in asthmatic children when beclomethasone 
dipropionate was administered via these two inhaler devices (Bisgaard et al., 1984). 
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Three main factors affect lung deposition of the inhaled powder particles through the 
DPIs; these are the inhalation technique of the patient, the powder formulation and the 
design of the DPI device (Vidgren et al., 1988; Steckel and Muller, 1997b). DPIs are 
generally formulated by blending micronized drug particles with a coarse carrier 
substance (normally lactose powder); the resultant agglomerates have better flow 
characteristics allowing a reproducible powder dose to be metered. The patient‟s 
inspiration through the DPI is the only energy responsible for de-agglomeration of the 
drug-carrier complexes resulting in dispersion of the drug particles in the inspired 
airstream (Steckel and Muller, 1997b). The efficiency of separation (de-agglomeration) 
has been shown to be dependant on the IFR achieved by the patient; a higher IFR results 
in a greater “respirable” dose fraction (also known as the fine particle dose – FPD) of 
the blend (Pitcairn et al., 1994; Srichana et al., 1998b; Broeders et al., 2003c; Virchow 
et al., 2008). However, administration of drugs via DPIs is not a problem free as 
attention should be paid to powder fluidization, flow and dispersion. This is, in part, 
dependent on the characteristics of the released aerosol cloud and on the patient‟s 
respiratory cycle. To achieve reproducible lung deposition, the physiological events of 
the rate and volume of inhalation must be controlled since these variables determine 
both the fine fraction of the aerosol dose and the site of lung deposition (Bell et al., 
1971). Since both the inhalation flow and the volume of the inhaled air are limited, the 
design of the spiral channels within the DPI device should be able to assist creating a 
strong turbulent movement in the flowing air sufficient to disperse the powder 
agglomerates (Vidgren et al., 1988). 
Due to differences in the design of the DPI devices, different inspiratory efforts should 
be generated by the patients to create a minimal acceptable IFR with sufficient energy 
that is capable of disaggregating the dry powder agglomerates and thus releasing a 
“respirable” metered powder dose from each DPI. Because the IFR may vary from one 
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dose to another in a given patient as well as among patients, this may affect the 
performance of the DPI device and may consequently influence the desired clinical 
outcome (Bell et al., 1971; Ross and Schultz, 1996; Tarsin et al., 2006; Virchow et al., 
2008). An ex-vivo study on 20 adult severe asthmatics has shown that the respirable 
powder dose emitted from Seretide
®
 Diskus
®
 DPI (GlaxoSmithKline, UK) was 
relatively more consistent, reliable and independent of the patients‟ IFR when compared 
with the Symbicort
®
 Turbuhaler
®
 DPI (AstraZeneca, UK) that showed more flow-
dependent dose emission characteristics (Tarsin et al., 2006). Another in-vitro study by 
the same investigators has also confirmed the flow-dependency of dose emission from 
the Symbicort
®
 Turbuhaler (Tarsin et al., 2004). Therefore, healthcare professionals 
should not base their prescription of the DPIs on the assumption that all patients can use 
all DPIs equally well and that all devices deliver the same dose to the patients‟ airways 
and thus can be exchanged (Gustafsson et al., 2005). In addition, the patient‟s 
preferences to particular DPI devices should be taken into consideration in the disease 
management plan as this may have a positive impact on their overall therapy adherence 
and compliance (Chrystyn, 2005).   
In clinical practice, it is very important to identify the patients who can achieve the 
optimal PIF of each DPI device when a particular DPI is initially contemplated (Nsour 
et al., 2001) as well as to check if the patient is still able to achieve that PIF during acute 
exacerbations (Van Der Palen, 2003). The In-Check Dial
®
 (Clement Clarke Ltd., UK) 
(Figure 2-16) is a simple hand-held PIF meter that has been designed, by setting the 
meter‟s dial, to mimic the internal resistance of a number of marketed DPI devices (Van 
Der Palen, 2003). Using this PIF meter, Nsour et al. (2001) have shown that the 
majority of the elderly COPD patients could not generate the optimal PIF through the 
Turbuhaler (> 60 l/min), and consequently may not get the nominal dose. Similarly, 
asthma and COPD patients were able to generate the acceptable minimal IF > 30 l/min 
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through both the Diskus and Turbuhaler, however, 12% of the patients could not inhale 
optimally through the Turbuhaler (> 60 l/min). These were mainly female and/or 
exacerbated patients (Van Der Palen, 2003). Another recent study has shown a similar 
trend in stable asthma and COPD patients when the In-Check Dial was used to compare 
the achieved PIF through the Diskus and Turbuhaler devices (Broeders et al., 2003c). 
During routine clinic visits, Amirav et al. (2005) have measured the PIF achieved by 
asthmatic children through the Diskus and Turbuhaler DPIs using the In-Check Dial; 
32% of the children could not inhale optimally through the Turbuhaler (> 60 l/min), 
whereas, all the asthmatic children attained the optimal PIF through the Diskus (≥ 30 
l/min) (Amirav et al., 2005). These research studies thus support the use of such a 
simple inexpensive PIF meter in clinics as an assessment tool for initiating and 
monitoring the DPIs‟ use. 
 
 
Figure 2-16: The In-Check Dial
®
 (Clement Clarke Ltd., UK) (Van Der Palen, 2003). 
Clinical and radiolabeled studies have also confirmed that the higher the peak inhalation 
flow through the DPI, the greater the emitted “respirable” dose is and thus the lung 
deposition (Everard et al., 1997). Generally, the patients should be instructed to inhale 
through their DPIs using the “as hard and deep as you can” technique (Nsour et al., 
2001; Van Der Palen, 2003).  When instructed to use this manoeuvre through a 
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Turbuhaler (n=10 asthmatic patients), a mean of 14.2% of the inhaled radiolabeled - 
terbutaline dose deposited in the central and peripheral zones of the lung, whilst 71.6% 
deposited in the oropharynx region. The FEV1 increased from 1.40 to 1.77 litre 20 
minutes after terbutaline inhalation (Newman et al., 1989b). Pitcairn and Colleagues 
(1994) have compared lung deposition of radiolabeled salbutamol through Pulvinal
®
 
DPI (Chiesi) at two IFRs; they found that the total lung deposition was significantly 
higher (14.1%) at the fast IFR (46.0 l/min) compared to that (11.7%) achieved at the 
slow IFR (27.8 l/min). However, the deposition patterns within the lungs were similar 
with the two IFRs (Pitcairn et al., 1994). Similar trend has been shown when the lung 
deposition of inhaled budesonide through a Turbuhaler DPI was studied in healthy 
subjects using gamma scintigraphy (Borgstrom et al., 1994). 
Incorrect use of the inhaler devices may result in various negative health impacts 
including poor disease control, increased side effects, more clinic/hospital visits and 
thus increased treatment costs. Insufficient DPI technique has been reported as 23-54% 
for the Turbuhaler users, whilst it was 24-50% for the Diskus (Accuhaler) ones (Basheti 
et al., 2008). Therefore, patient education on the correct DPI technique at the time of 
first prescription along with regular reinforcement/check thereafter should be instituted 
as part of the treatment strategy to achieve long-term patient therapy adherence and 
compliance, and consequently disease control (Basheti et al., 2005; Basheti et al., 2008). 
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2.3.1.2.(a) Specific Airflow Resistance of DPIs and Inhalation 
Flow Profiles  
Regulatory health authorities require that the average drug content in the emitted dose 
and its uniformity should be determined and reported for any inhaler device (Hindle and 
Byron, 1995). In this regard, a critical issue is to determine the suitable inhalation flow 
conditions to investigate the powder dose output from the DPIs (Srichana et al., 1998b). 
Pharmacopoeial guidance recommends in-vitro testing of DPIs at an inhalation flow 
equivalent to 4kPa pressure drop with an inhalation volume of 4 litres. However, the 
tests used for such purposes should be performed at flow rates typical to those to be 
used by the patients inhaling through the inhaler device being tested (Clark and 
Hollingworth, 1993; Tarsin et al., 2006). The internal design of the air passages within 
the DPI device along with its mouthpiece design create a specific airflow resistance. 
The energy generated inside a DPI is a function of the resistance and inhalation flow 
according to this equation: √P = R.Q (where, P is the pressure drop across the DPI, R is 
the resistance and Q is the IFR) (Clark and Hollingworth, 1993). When a new DPI is 
being developed, the pressure drop across the device should be critically taken into 
consideration where moderate values in the pressure drop over a wide range of IFRs are 
desirable for the inhaler to deliver a high and reproducible fine particle fraction (FPF) of 
the inhaled aerosol. A high specific airflow resistance of a DPI is expected to generate 
higher airflow turbulence and thus a greater FPF at a given IFR. It is also conceivable 
that the higher the IFR achieved through a DPI device, the higher the released 
“respirable” powder dose would be. However, DPI devices through which a high 
turbulence is achieved at a low IFR are considered a preferred option. Despite 
differences in the specific resistance among various DPIs, the same FPF can be obtained 
when the DPIs are used at the optimal IFR specific to each device provided that the 
same powder formulation is used (Srichana et al., 1998a). Figure 2-17 compares the 
specific resistance of a number of available DPIs (Chrystyn, 2009). 
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Figure 2-17: The resistance of various DPIs (Adapted from (Chrystyn, 2009)). 
Generally, an IFR of 60 l/min was found to give similar FPF of the same drug 
formulation from various DPIs. On the other hand, the resultant FPF at a low IFR of 30 
l/min was highly device-dependent (Srichana et al., 1998a); however, it is necessary to 
evaluate different DPIs at different flow rates depending on their internal resistance 
values (Steckel and Muller, 1997a; Steckel and Muller, 1997b). Hindle and Byron 
(1995) have investigated the effect of two flow rates (60 and 100 l/min) on dose 
emission from various DPI devices and correlated their results to the specific resistance 
of each inhaler; it has been shown that the dose emission of the relatively low resistance 
Rotahaler and Diskhaler DPIs increased at the higher IFR with reduced inter- and intra-
device variations. No significant differences in dose emission were noticed with the 
medium resistance Turbuhaler DPI at the two tested IFRs (60 and 100 l/min). 
Research has principally linked the efficacy of the DPIs, in terms of dose emission and 
FPF, to the PIF achieved through the DPI (deBoer et al., 1996a). However, the powder 
dose output was shown to be more dependent on the initial inhalation acceleration rate 
rather than on PIF when different DPIs were in-vitro assessed (deBoer et al., 1997; 
Everard et al., 1997; Kamin et al., 2002). Moreover, the early and total inhalation 
volumes through a DPI are also crucial with this regard (Everard et al., 1997; Kamin et 
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al., 2002). Everard and Co-workers (1997) have shown that, to a large extent, the 
particle size distribution from a Turbuhaler
®
 is affected by the early flow achieved in 
the inspiratory effort, and that the dose output is not entirely dependent on the PIF. The 
flow achieved within the first 150 ml inhaled volume appeared to be more important 
than the attained PIF, provided that the minimal IFR (30 l/min) through the Turbuhaler
®
 
is achieved, as it is likely that the whole powder dose might have left the inhaler by the 
time this inhaled volume had been inspired and before the PIF has been reached. In the 
same context, de-agglomeration of the powder formulation takes place before 0.1 
seconds of the start of inhalation through the DPI, therefore, a maximal inspiratory 
effort should be generated by the patient immediately after commencing the inhalation 
manoeuvre (Cegla, 2004). By using the maximal inspiratory effort, it has been shown 
that increasing the resistance will result in a decrease in the PIF and the flow 
acceleration rate, whilst the time to PIF and the inhalation period are increased. 
However, the total inhaled volume (the area under the IFR-time curve) remained 
constant when different resistance values were used (de Koning et al., 2002). The main 
limitation, however, to evaluate the inhalation profiles and acceleration rates through 
inhaler devices is the availability of the proper instrumentation capable of measuring 
these inhalation profiles. 
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2.3.1.2.(b) Peak Inhalation Flow and Inhaled Volume through 
DPIs 
The literature has clearly demonstrated that dose emission from the DPIs is flow 
dependent, and that the patient‟s inhalation flow is a critical determinant of lung 
deposition from a DPI (Pauwels et al., 1997; Chrystyn, 2009). It is, therefore, crucially 
important to determine the achievable inhalation flows by the patients, of different age 
groups and respiratory disease severity, through the various DPIs available on the 
market. From this perspective, more attention needs to be directed to the minimum 
acceptable PIF achieved through a DPI than to the optimal PIF of each device, because 
this has „real-life‟ implications on both the DPIs‟ prescription practices and the patients 
compliance (Borgstrom, 2001; Crompton et al., 2006; Chrystyn, 2009). Similarly, the 
inhaled volume through the DPIs is also an important parameter of the inhalation profile 
when these inhalers are used by the patients, as well as when being in-vitro tested 
(Everard et al., 1997; Kamin et al., 2002). 
A number of research studies have reported the PIF (with the inhaled volume when 
measured) through different currently available DPIs. Table 2-6 shows the mean (SD) 
PIFs of asthma and COPD patients, classified according to their age and disease 
severity, when they inhaled through different inhaler devices (adapted from (Chrystyn, 
2009)). A summary of some of the published PIFs and inhaled volumes is presented in 
table 2-7.  
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Table 2-6: Mean (SD) IFR of asthma and COPD patients of different disease severity and age 
                        groups through various inhaler devices.  
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Table 2-7: Some published PIFs and inhaled volumes through various DPIs. 
Study Population DPI Type 
PIF (SD) 
(l/min) 
Inhaled Volume 
(L) 
Reference 
Asthmatic 
Children 
n=33 
Turbuhaler 74.4 (16.5) ** 
(Bentur et al., 2004) 
Diskhaler 91.1 (18.9) ** 
n=38 
(3-6 yrs) 
Turbuhaler 57 ** 
(Stahl et al., 1996) 
n=39 
(7-10 yrs) 
Turbuhaler 70 ** 
n=13 
Rotahaler
†
 Range: 25 - 65 ** 
(Pedersen, 1986) 
Rotahaler
††
 Range: 60 - 145 ** 
Asthmatic 
Adults 
n=20 
(severe) 
Turbuhaler 76.8 (26.2) 2.4 (0.8) 
(Tarsin et al., 2006) 
Accuhaler (Diskus) 94.7 (32.9) 2.8 (1.1) 
n=10
*
 
Turbuhaler 82.1 (3.4) 3.1 (0.3) 
(Broeders et al., 2003a) 
Accuhaler (Diskus) 115.3 (4.9) 3.3 (0.3) 
n=24
*
 Turbuhaler 54.7 (17.6) 1.94 (0.62) (Hawksworth et al., 2000) 
COPD 
n=84
*
 
Turbuhaler 47.4 (14.4) ** 
(Al-Showair et al., 2007a) Accuhaler (Diskus) 57.3 (17.0) ** 
Handihaler 28.3 (8.9) ** 
n=16 
(Moderate) 
Turbuhaler 84.4 (2.7) 2.9 (0.3) 
(Broeders et al., 2003a) 
Accuhaler (Diskus) 121.3 (3.0) 3.1 (0.2) 
n= 100 
(severe) 
Turbuhaler 53 (12) ** (Dewar et al., 1999) 
             * PIF values were post-verbal training on the correct inhaler technique.  
             ** Not measured/reported. 
               † PIF during wheezy conditions. ††: PIF during stable respiratory conditions. 
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2.3.1.2.(c) Examples of branded DPIs    
2.3.1.2.c.1 Spinhaler® DPI: 
The Spinhaler
®
 (Fisons Pharmaceutical Ltd., UK) was the first DPI to be introduced in 
1971. It is a single-dose unit inhaler, where the drug is formulated in a gelatine capsule 
that is loaded in the inhaler‟s rotor and pierced with metal needles. Inhalation through 
the device causes the pierced capsule to revolve with the rotor, thus dispersing the drug 
powder through the holes on the sides of the capsule walls into the inhaler‟s air 
channels, then through its mouthpiece (Vidgren et al., 1988). The Spinhaler
®
 has a 
relatively low specific airflow resistance (0.051 (cmH2O)
0.5
 min/l) (Clark and 
Hollingworth, 1993) (0.052 (cmH2O)
0.5
 min/l) (Assi and Chrystyn, 2001). Limitations 
with the single-dose unit DPIs include the need for reloading before use which is 
inconvenient to the patients, and sometimes the inhalation process has to be repeated to 
completely empty the dose from the capsule which might lead to underdosing and dose 
variability (Virchow et al., 2008). Figure 2-18 illustrates the Spinhaler
®
 DPI (left) 
(www.admit-online.info/fileadmin/materials/images/devices/spinhaler.jpg) and a 
schematic diagram of its key components (right) (Concessio and Hickey, 1997). 
 
Figure 2-18: The Spinhaler
®
 DPI (Fisons Pharmaceutical Ltd., UK). 
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2.3.1.2.c.2 Handihaler® DPI: 
The Handihaler
®
 (Boehringer Ingelheim/Pfizer, USA) is a single-dose unit DPI. The 
inhaler is loaded with a capsule placed in a chamber after both the device cap and the 
mouthpiece are opened. Then, the mouthpiece is closed before a side button is 
depressed to pierce the capsule, leaving the powder dose ready for inhalation (Chodosh 
et al., 2001). The Handihaler
®
 is a high resistance device (0.158 (cmH2O)
0.5
 min/l) (Assi 
and Chrystyn, 2001). This inhaler has been designed to deliver the anticholinergic 
bronchodilator; tiotropium, on a daily dose of 18 µg per capsule (SPIRIVA
®
) ([Anon], 
2004; van Noord et al., 2009). Figure 2-19 presents the Handihaler
®
 DPI 
(www.spiriva.co.nz/images/HandiHaler-3-4-smallShad.gif).    
 
Figure 2-19: The Handihaler
®
 DPI (Boehringer Ingelheim/Pfizer, USA). 
 
2.3.1.2.c.3 Accuhaler™ DPI (known as Diskus™ outside the UK): 
The Accuhaler
™
/ Diskus
™
 DPI (GlaxoSmithKline, UK) is a 60-dose DPI that uses a 
strip of foil drug containing blisters that cannot be reloaded (Virchow et al., 2008). To 
use the inhaler, the side lever is pushed to the further end (away from the mouthpiece) 
to make the dose ready for inhalation. The Diskus
™
 is described as a moderate 
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resistance inhaler (0.078 (cmH2O)
0.5
 min/l) (Assi and Chrystyn, 2001). Figure 2-20 
shows the Diskus/Accuhaler DPI (Website: 
http://emc.medicines.org.uk/medicine/4416). 
 
Figure 2-20: The Accuhaler
™
 (Diskus
™
) DPI (GlaxoSmithKline, UK). 
 
2.3.1.2.c.4 Turbuhaler® DPI: 
The Turbuhaler
®
 DPI (AstraZeneca, UK) was introduced in 1988 as a multiple dose 
(reservoir-type) DPI device (Virchow et al., 2008). It is characterized by having a 
relatively moderate to high airflow resistance (0.110 – 0.120 (cmH2O)
0.5
 min/l) 
depending on Mark2 or Mark3 version of the Turbuhaler device (Mark3 has a lower 
resistance) (Assi and Chrystyn, 2001). The powder dose is loaded by twisting the 
turning grip at the base of the inhaler. Priming the device at > 45
○
 from the vertical 
position is a common mistake made by the patients (Virchow et al., 2008). Figure 2-21 
presents the Turbuhaler DPI (left) with a schematic drawing (right) (Websites: 
http://www.mims.com/PIC/Thailand/24307.gif and 
http://www.asthma.ca/images/adults/treatment/turbuhaler.gif).  
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Figure 2-21: The Turbuhaler
®
 DPI (AstraZeneca, UK). 
 
2.3.1.2.c.5 Spiromax™ DPI: 
The Spiromax™ (TEVA Pharmaceuticals, UK) is a recently introduced multi-dose 
(reservoir-type) DPI. For dose metering, the Spiromax has an air pump located above a 
funnel-shaped dry powder drug reservoir (Figure 2-22). This air pump is connected to- 
and activated by the inhaler‟s mouthpiece cap. When this cap is opened, the air pump 
generates a controlled air pressure on the powder reservoir, thus, causing a metered 
amount of the drug powder blend to enter the dose cup underneath. The controlled air 
pressure of the pump ensures a precise and consistent metering of the drug doses into 
the cup each time the mouthpiece cover is opened.  The Spiromax has unique cyclone-
separator channels, once the patient inhales through the mouthpiece the metered dose 
enters the separator in a cyclonic turbulent flow that results in the fine drug particles to 
be detached from the larger carrier (lactose) particles, and to be released from the device 
first. The Spiromax has also a dose counter that is indexed by the patient‟s opening of 
the mouthpiece cover (Zeng et al., 2002a; Zeng et al., 2002b). This inhaler is considered 
as a moderate resistance DPI with a specific airflow resistance of 0.0924 (cmH2O)
0.5
 
min/l which has been shown to be independent of the type and mass of the formulation 
blend in the hopper (Zeng et al., 2002a). At present budesonide Spiromax (strengths of 
100, 200 and 400 µg) are available in some European countries. Salbutamol Spiromax 
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has never been launched as formoterol Spiromax 6 and 12 µg were before withdrawn 
due to additional clinical studies needed to meet current regulatory requirements. 
  
 
Figure 2-22: A schematic drawing of the Spiromax™ DPI (Zeng et al., 2002a). 
 
2.4 Health-Related Quality of Life (HRQL) 
Patients with asthma or COPD are not only concerned with their respiratory symptoms, 
but also with the limitations that their illnesses cause to their lifestyle functions 
including impairments in daily activities (e.g. physical, occupational and social), 
emotional problems (e.g. depression, worry and panic), sleep disturbances and 
exacerbations associated with exposure to environmental stimuli (e.g. dust, pollen and 
weather conditions) (Jones, 1995a; Juniper, 1995; Rosenzweig et al., 2004). 
Collectively, these functional impairments affect the quality of life of asthmatic adults 
(Juniper, 1995) and children (Juniper, 1997) and of COPD patients (Jones, 1995a). 
Health-related quality of life (HRQL), also known as health status, can be defined as 
“the functional effect of an illness and its consequent therapy upon a patient, as 
perceived by the patient” (Rutishauser et al., 1998). The HRQL can be evaluated using 
specially designed questionnaires (instruments) (Jones, 1995b). These instruments are 
capable of quantifying the influence of a disease on various functional aspects of the 
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patients‟ everyday lives in a standardized format. Since early 1990s and, in part, due to 
the growing body of evidence showing the weak, to at most moderate, correlation 
between the conventional clinical (spirometry) measures and how asthma and COPD 
patients feel and capable to function in their day-to-day life, there has been an increased 
interest in using various HRQL instruments in both clinical research and practice to 
complement the conventional clinical measures in the assessment of the effect a medical 
or therapeutic intervention, provided that the clinically significant changes in these 
conventional measures are not always reflected on the quality of life that the patients 
may experience, and vice versa (Rowe and Oxman, 1993; Jones, 1995a; Juniper, 1995; 
Rutten-van Molken et al., 1995; Spencer et al., 2001; Rosenzweig et al., 2004). 
Generally, when a HRQL instrument (questionnaire) needs to be used in a research 
study, its content validity should first be assessed for that particular study. In other 
words, the items of that instrument should evaluate all the areas of function as seen 
important by the patients themselves. Thereafter, and depending on the nature of the 
research, the measurement properties of the selected instrument should be evaluated. 
Discriminative instruments, which are commonly used in cross-sectional surveys to 
distinguish between individual patients or groups of patients, should have the 
measurement properties of reliability and cross-sectional construct validity. Whereas, 
evaluative instruments, which are most commonly used in longitudinal (clinical) studies 
to detect changes within an individual or groups of patients over certain periods of time, 
should have the measurement properties of responsiveness and longitudinal construct 
validity. Evaluative instruments must be responsive to small but clinically important 
changes that take place either spontaneously or as a result of an intervention. In the 
published literature, there is a huge number of HRQL instruments which are categorized 
under either generic or disease-specific instruments. There is no “best” instrument as all 
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of them have their own strengths and weaknesses. Researchers, therefore, should select 
the instrument that best answers their research question (Juniper, 1995).  
2.4.1 Generic HRQL Instruments 
Many generic HRQL instruments (health-profiles) have been developed and validated to 
be used in clinical research to assess the effect of an intervention on the quality of life of 
participating patients (Juniper, 1995). Of these generic health profiles, the most 
commonly used ones are the Medical Outcomes Study (MOS) Short Form 36 Health 
Survey (the SF-36), the Sickness Impact Profile (SIP) (Bergner et al., 1981), the 
Nottingham Health Profile and the McMaster Health Index Questionnaire (Juniper, 
1995). 
Although the generic HRQL instruments allow the comparison of quality of life across 
different diseases and patient populations, and attempt to assess all the related important 
areas, these instruments may fail to measure aspects of limitations specific to a 
particular disease condition which are considered important by the patients themselves. 
Moreover, generic instruments may not be responsive to small, yet important, changes 
when used in clinical studies (Juniper, 1995). As far as asthma is concerned, both the 
SIP and the SF-36 instruments are discriminative with satisfactory measurement 
properties (Juniper, 1995). However, the SIP had weak responsive measurements and 
failed to detect differences between the intervention groups in two asthma clinical 
studies (Jones, 1994; Rutten-van Molken et al., 1995). The SIP and the SF-36 have 
shown acceptable cross-sectional correlation with the conventional asthma clinical 
indices and moderate correlation with FEV1 % predicted. These shortcomings of the 
generic tools have led to the development of more specialized measures; the disease-
specific HRQL instruments (Juniper, 1995). 
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2.4.2 Disease-Specific HRQL Instruments in Asthmatic Adults 
Disease-specific HRQL instruments have been constructed in a way that they have the 
ability to evaluate and measure clinically sensible areas of function which are 
considered crucially important to patients with a particular illness, which is the reason 
why these instruments do not allow the comparison of the degree of impairment across 
different disease conditions (Rutishauser et al., 1998). Elizabeth Juniper (1995 and 
1997) discussed a number of asthma-specific HRQL instruments available for 
researchers‟ use in adult and children patients, and compared their degree of validity 
and measurement properties. Asthma investigators, hence, need to carefully select the 
best instrument for their research population which simultaneously has the ability to 
address their research question. 
2.4.2.1 The Asthma Quality of Life Questionnaire (AQLQ) 
Juniper and her Colleagues (1992) developed the Asthma Quality of Life Questionnaire 
(AQLQ) as an instrument that can be used in clinical research involving adult 
asthmatics aged over 17 years. The AQLQ covers the areas of quality of life 
impairments as seen important by the patients themselves. It contains 32 items 
distributed over four domains: asthma symptoms (12 items), emotional function (5 
items), activity limitation (11 items) and exposure to environmental stimuli (4 items). 
Except the activity limitation, all other domains have been standardized. Five of the 11 
activity limitation items are individualized where each participant is asked -at the 
beginning of the research- to select 5 important, regularly performed activities which 
are kept, thereafter, the same throughout the research period. This feature is considered 
to improve the instrument‟s content validity, relevance in clinical practice and can 
accommodate cultural variations among the studied asthma populations. The AQLQ is 
available in both interviewer- and self-administered format. When administered, the 
patients are asked to recall what functional limitations they had experienced over the 
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past two weeks, and then to respond to each of the 32-questionnaire items by choosing 
one option on the 7-point scale provided (1 represents maximal impairment and 7 
represents no impairment). On average, it takes 15 minutes to complete the 
questionnaire (Juniper et al., 1992; Juniper et al., 1993).  
To facilitate the analysis and interpretation of the AQLQ results, all the items of the 
questionnaire are equally weighted (Juniper et al., 1993). Thus, the instrument results 
are directly analyzed from the patient chosen scores, and presented as the mean score 
per item for each of the four domains as well as for the overall quality of life. In other 
words, the range of the mean score will be between 1 and 7 for both individual domains 
as well as for the overall AQLQ scores. For a meaningful interpretation of the results, 
the minimal important difference (“the smallest difference in score in the domain of 
interest which patients perceive as beneficial and would mandate, in the absence of 
troublesome side effects and excessive cost, a change in patient’s management”) has 
been determined as a change in score of 0.5 per item for both individual domains and 
for overall asthma quality of life (Juniper et al., 1993; Juniper et al., 1994). 
Improvement or deterioration changes in quality of life scores were found to be similar; 
where differences of 1.0 represent moderate changes, while differences greater than 1.5 
represent large changes (Juniper et al., 1994). The AQLQ development and validation 
studies have shown that this instrument is both responsive and reliable, with construct 
validity. Furthermore, the AQLQ showed good reproducibility in stable asthmatic 
patients. However, no significant relationship was shown between the AQLQ scores and 
the FEV1 % predicted values (Juniper et al., 1993). Moreover, a number of research 
studies have also confirmed the strong measurement characteristics of the AQLQ as 
both an evaluative and a discriminative quality of life instrument (Rowe and Oxman, 
1993; Rutten-van Molken et al., 1995; vanderMolen et al., 1997; Leidy and Coughlin, 
1998; Mancuso et al., 2001), with an evidence supporting the validity of the translated 
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AQLQ versions made into languages other than the original English version (Stahl et 
al., 2003a). 
The AQLQ has been used in many research studies as one of the outcome measures. Of 
the 5 quality of life instruments used, Rutten-van Molken and Colleagues (1995) have 
shown that the AQLQ was the most sensitive and responsive instrument to detect health 
status improvement caused by the inhaled long-acting β2-agonist; salmeterol, when 
compared to salbutamol in asthmatic patients. Similarly, the AQLQ gave a 
comprehensive evaluation of the health status changes when it was used alongside the 
conventional asthma outcome measures to compare the treatment effectiveness of the 
short- and long-acting β2-agonists; salbutamol versus salmeterol (Juniper et al., 1995), 
and terbutaline versus formoterol (Stahl et al., 2003b), as well as when was utilized to 
investigate the therapeutic efficacy of different dosage strengths of inhaled budesonide 
with or without the long-acting β2-agonist; formoterol (Juniper et al., 1999e), and in 
different inhaled Salmeterol/fluticasone combinations versus fluticasone alone 
(Bateman et al., 2004). The AQLQ has shown that a 400 µg/day dose of 
hydrofluoroalkane (HFA)-beclomethasone was as efficient as an 800 µg/day dose of 
chlorofluorocarbon (CFC)-beclomethasone in maintaining asthma control in moderately 
diseased asthmatics (Juniper et al., 1999b). As a summary, the Juniper AQLQ is a valid, 
evaluative and discriminative instrument that can be employed with confidence as one 
of the outcome measures in asthma clinical trials to complement the picture that the 
conventional clinical variables provide. 
However, when using the AQLQ in large, long-term clinical trials, the 5 patient-selected 
items of the activity domain may pose a burden on the investigators, as these 
individualized items need to be kept the same throughout the research period which is a 
quite challenge as in practice patients‟ preference to their initially chosen activities may 
change over time. To overcome this issue, the same research group has, therefore, 
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developed a standardized version of the original AQLQ; the AQLQ(S), in which 5 
generic activities replaced the previous 5 patient-selected ones (Juniper et al., 1999a). 
The new standardized activities include: strenuous exercise, moderate exercise, work-
related activities, social activities and sleep. It has been shown that the AQLQ(S) has 
similar measurement properties to those of the original AQLQ and is valid as an HRQL 
instrument in adult asthmatics (Juniper et al., 1999a). The self-administered version of 
the AQLQ(S) is presented in APPENDIX A-4 (refer to the enclosed DVD). 
2.4.2.2 The Mini Asthma Quality of Life Questionnaire (Mini-            
AQLQ) 
In large clinical trials and surveys, a simple, short and time efficient quality of life 
instrument is preferably needed. In this regard, a Mini version of the  Asthma Quality of 
Life Questionnaire (Mini-AQLQ) has been developed (Juniper et al., 1999c). The Mini-
AQLQ is a self-administered instrument which includes 15 standardized questions 
distributed over four domains: symptoms (5 items), activity limitation (4 items), 
emotional function (3 items) and environmental stimuli (3 items). Upon administration,  
adult asthmatics are asked to recall their asthma-related impairments over the past two 
weeks before responding to each of the 15-questionnaire items where they need to 
choose one option on the 7-point scale provided (1=maximal limitation, and 7=no 
limitation). The Mini-AQLQ is presented in APPENDIX A-5 (refer to the enclosed 
DVD). 
A 9-week validation study of 40 asthmatic adults has shown that the correlation 
between the Mini-AQLQ and the original 32-item AQLQ was high, with a strong 
construct validity for both of them (Juniper et al., 1999c). The reliability in stable 
patients and the responsiveness were acceptable for the Mini-AQLQ but were not as 
good as those of the original AQLQ. Furthermore, the precision of measurement and the 
power of the shortened questionnaire were less than that of the original one. However, 
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the evaluative and discriminative measurement properties of the Mini-AQLQ are strong 
enough to allow investigators confidently use this instrument in both large asthma 
clinical studies and in cross-sectional surveys (Juniper et al., 1999c). Reliability and 
validity of the Mini-AQLQ were also supported when this instrument was administered 
online as part of a web-based self-management intervention in asthmatic adults (Baghi 
and Atherton, 2004). Moreover, the excellent concordance found between the scores 
obtained by postal and supervised (clinic) self-completion of the Mini-AQLQ gives the 
investigators the flexibility to choose the administration mode that best suits their 
research needs (Pinnock et al., 2004; Pinnock et al., 2005).  
Many asthma research studies have utilized the Mini-AQLQ alongside the conventional 
clinical endpoint measures.  In a recent 1-year randomized study, the improved Mini-
AQLQ scores have complemented the obtained clinical and objective results in 
confirming the efficacy of using omalizumab, an anti-immunoglobulin IgE antibody 
therapy, as an add-on medication to the standard combination of an ICS and a LABA 
treatment in inadequately controlled severe persistent allergic asthma (Niven et al., 
2008). Similarly, the Mini-AQLQ was utilized to assess the efficacy of high doses of 
inhaled ciclesonide and fluticasone corticosteroids (Lee et al., 2005), as well as that of 
the LABA; formoterol, delivered from a novel DPI (Certihaler
®
) (LaForce et al., 2005). 
In a non-pharmacological study, an improvement in the Mini-AQLQ scores was noticed 
when a pMDI technique training tool; the 2ToneTrainer
®
, was studied and proved to 
potentially maintain the recommended inhalation technique in the trained asthmatic 
patients (Al-Showair et al., 2007b). Furthermore and in  two large non-therapeutic 
asthma surveys, the Mini-AQLQ was employed to study the association between asthma 
control and quality of life of asthmatics treated in primary health care settings (Lisspers 
et al., 2007), and to investigate the association between obesity (measured by the body 
mass index) and both asthma control and quality of life (Mosen et al., 2008).            
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2.4.3 Disease-Specific HRQL Instruments in Asthmatic Children  
It is needless to say that children with asthma are troubled by their respiratory 
symptoms (wheezing, cough, chest tightness and shortness of breath), which greatly 
interfere with- and limit their everyday activities such as sports, playing with peers 
and/or pets, social and school activities. Moreover, these functional impairments have 
emotional impacts on the asthmatic children which would altogether negatively affect 
their quality of life (Townsend et al., 1991; Juniper, 1997). The conventional clinical 
and physiological outcome measures of asthma are important, however, these alone do 
not give the full picture of the medical intervention, specifically how the asthmatic 
children are feeling and to which degree they are functionally impaired by their 
respiratory condition. With the emergence of the HRQL instruments‟ use in adults with 
asthma, many paediatricians and asthma researchers are increasingly keen to use similar 
instruments in their clinical practices and in children-involving asthma trials (Osman 
and Silverman, 1996; Juniper, 1997; Juniper et al., 1997). 
2.4.3.1 The Paediatric Asthma Quality of Life Questionnaire             
(PAQLQ) 
The AQLQ research group has developed and validated a similar asthma-specific 
HRQL instrument for children; the Paediatric Asthma Quality of Life Questionnaire 
(PAQLQ) (Juniper et al., 1996a). The PAQLQ is a 23-question interviewer-
administered instrument that can be used in asthmatic children aged between 7 and 17 
years. These questions are distributed over 3 domains: symptoms (10 items), activity 
limitation (5 items) and emotional function (8 items). Three of the activity limitation 
domain items are individualized, where at the commencement of the clinical trial, the 
asthmatic child is asked to identify 3 most important, frequently done activities with 
which they are troubled by their asthma. These activities are retained throughout the 
research. Upon administration, the patient is asked to recall their asthma related 
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experiences during the past week, then the interviewer (investigator) reads each 
question clearly to the child who responds by choosing one option on a 7-point scale (1 
represents maximal impairment and 7 represents no impairment) stated on either a blue 
or a green card (depending on the question being asked). To minimize parental 
influence, each child should respond to the PAQLQ questions on their own without the 
parents being around. As in the adults‟ AQLQ, all the PAQLQ items are equally 
weighted. Thus, the instrument results are directly analyzed from the chosen scores, and 
presented as the mean score per item for each of the three domains as well as for the 
overall quality of life (i.e. the range of the mean score will be between 1 and 7 for the 
individual domains as well as for the overall quality of life). On average, it takes 10-15 
minutes to complete the questionnaire (Juniper et al., 1996a). The PAQLQ is presented 
in APPENDIX A-6 (refer to the enclosed DVD). 
A 9-week validation study has shown that the PAQLQ is valid as both an evaluative and 
a discriminative instrument with good measurement properties (Juniper et al., 1996a). 
The instrument showed excellent responsiveness which would, even with small sample 
sizes, enable the investigators to detect small, yet significant, changes in quality of life. 
Furthermore, the PAQLQ was reproducible and showed a high level of reliability in 
patients who remained stable. Correlation attempts showed moderate correlation 
between changes in peak flows and changes in quality of life, on the other hand, no 
correlation was found between the later and the change in FEV1 % predicted (Juniper et 
al., 1996a). Several cultural and linguistic adaptations of the original English PAQLQ 
proved to have equivalent measurement properties (Tauler et al., 2001; Raat et al., 2005; 
Ricci et al., 2009). In summary, the PAQLQ is a valid, evaluative and discriminative 
quality of life instrument that can be used in both clinical practice and research. 
The perception of asthma by the asthmatic children themselves and that by their 
caregivers (normally the parents) may vary (Osman and Silverman, 1996; Guyatt et al., 
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1997; Rutishauser et al., 1998). To highlight the relationship between the parental and 
their asthmatic child‟s reporting of the childhood asthma, Guyatt and his Colleagues 
(1997) have shown that the parents of asthmatic children do not always accurately 
reflect their children‟s HRQL at various ages. However, in 7-11 year-old children the 
parental input is considered an important complementary information to that reported by 
the children about their asthma experiences, while for those aged over 11 years, the 
paediatricians and the researchers can rely on the children‟s feedback only (Guyatt et 
al., 1997), provided that, in any age group, the children have the minimum reading and 
numeric skills required to reliably complete the administered HRQL instrument (Juniper 
et al., 1997). 
2.4.3.2 The Paediatric Asthma Caregiver‟s Quality of Life   
Questionnaire (PACQLQ) 
The childhood asthma not only affects the asthmatic children themselves, but also 
impacts the quality of life of their families, particularly their primary caregivers 
(normally the parents) with limitations in their activity, social and emotional functions 
(Townsend et al., 1991; Juniper et al., 1996b; Osman and Silverman, 1996). Asthma 
investigators, therefore, are increasingly interested in including quality of life 
instruments in their clinical trials to evaluate the daily life impairments of the asthmatic 
children‟s parents. One of the most commonly used instruments is the Paediatric 
Asthma Caregivers‟ Quality of Life Questionnaire (PACQLQ) (Juniper et al., 1996b). 
The PACQLQ is a self-administered 13-item instrument. These items are distributed 
over two domains: activity limitations (4 questions) and emotional function impairment 
(9 questions). Caregivers are asked to recall their limitation experiences during the 
previous week and then to respond to the questionnaire items on a 7-point scale 
(1=severe impairment and 7=no impairment). The items of the PACQLQ are equally 
weighted and, thus, the results are expressed as the mean score per item for each of the 
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two domains as well as for the overall quality of life; therefore, the scores for both the 
individual domains and the overall quality of life range between 1 and 7. The minimal 
important difference for the overall quality of life is 0.50 with similar values for both 
the activity limitation and the emotional function domains. When tested for its 
evaluative and discriminative properties, the PACQLQ was a valid instrument with both 
high responsiveness and reliability criteria. The PACQLQ was also able to detect 
quality of life changes in caregivers whose quality of life changed and to differentiate 
those from others whose remained stable. The instrument was reproducible in the 
parents whose quality of life remained stable. Weak correlations were found between 
the PACQLQ scores and both changes in the asthmatic children‟s peak expiratory flows 
and FEV1 % predicted values supporting the viewpoint that this instrument is a measure 
of paediatric asthma caregiver‟s quality of life changes and that the peak expiratory 
measures alone are inadequate reflectors of changes in asthma severity. In summary, the 
PACQLQ is a valid, reliable and responsive instrument that can be utilized in clinical 
trials as well as in cross-sectional surveys to spotlight the impact of paediatric asthma 
on their primary caregiver‟s quality of life (Juniper et al., 1996b). The PACQLQ is 
presented in APPENDIX A-7 (refer to the enclosed DVD). 
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2.4.4 COPD-Specific HRQL Instruments   
2.4.4.1 The St. George‟s Respiratory Questionnaire (SGRQ)  
The St. George‟s Respiratory Questionnaire (SGRQ) is a self-administered standardized 
quality of life questionnaire that has been originally developed to assess the health 
status of patients with chronic airflow limitation conditions; namely asthma or COPD 
(Jones et al., 1992). The SGRQ has 76 questions distributed over 3 domains: the 
symptoms domain (which covers the level and frequency of the disease symptoms), the 
activity domain which is concerned with the physical activities that either cause or are 
limited by the respiratory symptoms, and the impact domain which covers the disease 
impact on various aspects like employment, being in control of health, panic, 
medication use and its side effects and the prognosis of the disease. For results‟ 
interpretation, each item is assigned a certain weight based on an estimate of the distress 
caused by the symptom or the impact being asked for in that item. Responses to the 
SGRQ are scored for each of the individual domains as well as for the overall quality of 
life. The scores range from zero to 100% (0 represents no impairment in quality of life) 
(Jones et al., 1992). The minimum clinically significant change in the SGRQ score has 
been shown to be about 4 units (Jones, 1995a; Schunemann et al., 2003; Jones, 2005). 
The SGRQ is presented in APPENDIX A-8 (refer to the enclosed DVD). 
Several studies have shown that the SGRQ is a valid HRQL instrument for use in 
clinical research with an acceptable repeatability and ability to detect changes in health 
status in adult patients  with  asthma, COPD  (Jones et al., 1992), or bronchiectasis 
(Wilson et al., 1997). Similar conclusions were also drawn after the SGRQ was adapted 
to different languages and cultures other than the original English version (Ferrer et al., 
1996; Engstrom et al., 1998). A number of comparison studies among HRQL 
instruments had been carried out; one study has shown that both the SGRQ and the 
Juniper‟s AQLQ were more sensitive than the “Global Diary Questions of Asthma 
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Severity Estimates” (Barley and Jones, 1999). A direct comparison between the two 
most commonly used asthma-specific HRQL instruments; the SGRQ and Juniper‟s 
AQLQ, has shown that the two questionnaires have high overall validity, reliability and 
responsiveness when used in asthmatic patients of various severity levels (with the 
exception of the symptoms domain of the SGRQ which showed neither acceptable 
longitudinal validity nor sensitivity to change) (Sanjuas et al., 2002). This comparison 
has also confirmed the weak correlation between the two instruments and the measured 
FEV1, and that both the SGRQ and the AQLQ performed equally well.            
When utilized in long-term, placebo-controlled, multicentre clinical trials, the SGRQ 
was able to detect improvements in health status following a prophylactic treatment 
with nedocromil sodium in adult asthmatics (Jones, 1994), and to demonstrate the 
reduction in health status decline caused by inhaled fluticasone propionate in COPD 
patients (Spencer et al., 2001). Moreover, the health status of COPD patients was 
improved as measured by the SGRQ when mometasone furoate 800 µg DPI was 
administered once daily, and was comparable to half that dose when administered twice 
a day (Calverley et al., 2008). Similar improvement in health status was detected by the 
SGRQ when two dosage strengths of a combination of budesonide/formoterol – HFA 
pMDI were administered to COPD patients (Rennard et al., 2009). The SGRQ was also 
employed in non-pharmacological trials to investigate the effect of patient education 
intervention in asthmatic and COPD patients on HRQL over a 12-month period 
(Gallefoss et al., 1999). 
In summary, the SGRQ is a valid, responsive and reliable self-administered disease-
specific HRQL instrument that is widely used as an outcome measure to evaluate the 
health status of adult asthmatics and/or COPD patients in both clinical practice and 
clinical research. 
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2.5 Summary 
A review of the literature clearly shows that asthma and COPD patients have issues 
using their MDI and DPI devices correctly; a problem that crucially jeopardises the 
maximum therapeutic benefit these patients can get from their inhaled medicines. The 
current piece of work in this PhD thesis will investigate the use of various MDI 
technique training tools and their potential impact on maintaining the desirable 
inhalation technique with special emphasis on the achieved inhalation flow rate, as well 
as on the patients‟ quality of life and respiratory disease control.  
Moreover, the literature demonstrates the dependency of dose emission from the DPIs, 
and consequently lung deposition on the patients‟ inhalation characteristics. However, 
many patients fail to inhale sufficiently through their DPIs. In the current work, realistic 
asthma and COPD patients‟ inhalation profiles and acceleration rates through a novel 
DPI will be investigated and assessed in comparison with the international guidelines‟ 
recommendations for the DPIs‟ use and in-vitro testing.          
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Chapter 3: Training Asthmatic Patients 
on How to Use Metered Dose Inhalers: 
Does it Improve Asthma Control and 
Quality of Life? 
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3.0 Introduction 
Asthma is characterised by variable airways obstruction and bronchial hyper-
responsiveness.  Classical symptoms include coughing, wheezing, chest tightness and 
breathlessness.  Airways obstruction is caused by airway inflammation, mucosal 
oedema, bronchoconstriction and mucus plugging.  A distinguishing feature of asthma 
is that airways obstruction is reversible; either spontaneously or with treatment 
(BTS/SIGN, 2005; GINA, 2006). 
Drug treatment of asthma is primarily targeted to the airways because this is the site of 
the pathophysiological change. In this regard, the metered dose inhaler (MDI) is the 
most widely used drug delivery device due to many advantages over other forms of 
inhalers (Everard et al., 1995; Virchow et al., 2008). However, patients often misuse 
MDIs and studies into poor MDI technique show wide variations in results due to 
differences in study design.  However, two studies highlight the magnitude of the 
problem. It has been shown that 77.5% to 89.2% of patients made at least one error 
while using the MDI, and that slow and deep inhalation over at least 2 seconds, was an 
error made by 17.8% to 30.3% of the patients when using MDIs (Larsen et al., 1994). 
Another earlier study showed that 14% of the patients misused their MDI (Paterson and 
Crompton, 1976). 
Many patients fail to achieve full therapeutic benefit because of poor MDI technique.  
This potentially may result in a sub-therapeutic response or prevent relief during an 
acute exacerbation of the disease, as well as wasted medicine (and money from the 
limited healthcare budget). A study showed that poor technique can lead to less than 
50% of children benefiting from MDI treatment (Pedersen et al., 1986).  Indeed, poor 
MDI technique may result in only slightly better efficacy than placebo (Lahdensuo and 
Muittari, 1986). 
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Pharmacist counselling can significantly improve MDI technique, increasing adequate 
MDI technique from 31% before counselling, to 72% immediately after (Horsley and 
Bailie, 1988).  Improved inhaler technique can result in a positive pharmacodynamic 
change as detected by a decrease in specific airway resistance (Orehek et al., 1976). 
Such studies justify the time and resources spent on counselling patients on MDI 
technique. However, even after MDI technique counselling and subsequent 
demonstration by the patient of a perfect technique, only 50% will use their MDI 
correctly 1 to 30 days later (Shim and Williams, 1980).  Therefore, it is crucial that 
patients receive repeated counselling. 
Doctors and other healthcare professionals rely heavily on bronchodilator outcome 
measures to assess the progress of asthma.  However, assessment of the asthma effect 
on the patients‟ day-to-day activities is required. Therefore, health-related quality of life 
questionnaires are used to determine the functional effects of an illness and its 
consequent therapy upon a patient, as perceived by the patient themselves (Schipper H 
et al., 1996). 
One of the goals of asthma treatment is to improve the patient well being.  In the past it 
was assumed that the conventional clinical outcome measures could provide an insight 
into well being.  However, there is increasing evidence that there is only a weak 
correlation between these clinical measures and the asthmatic patient well being 
(Bateman et al., 2001; Rosenzweig et al., 2004). 
The Juniper Asthma Quality of Life Questionnaire (AQLQ) (Juniper et al., 1992) and its 
subsequent shortened version (Mini-AQLQ) (Juniper et al., 1999c) are disease-specific 
instruments designed specifically for use in clinical trials. The questionnaires‟ items are 
in four domains: symptoms, emotional function, exposure to environment stimuli and 
activity limitations. Patients rate the impairments they experienced during the previous 
14 days and respond to each item on a 7 point scale (1 = maximum impairment, 7 = no 
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impairment).  The AQLQ has been shown to have good measurement properties and is 
valid as both an evaluative and a discriminative instrument (Juniper et al., 1993; Rowe 
and Oxman, 1993; Rutten-van Molken et al., 1995; Sanjuas et al., 1995; Leidy and 
Coughlin, 1998; Apter et al., 1999). The Juniper Paediatric Asthma Quality of Life 
(PAQLQ) has been developed for children 7-17 years old (Juniper et al., 1996a) with 
the parents completing the Paediatric Asthma Caregiver‟s Quality of Life Questionnaire 
(PACQLQ) (Juniper et al., 1996b). 
The Asthma Control Test (ACT) is a 5-item patient-administered questionnaire which 
has been developed and validated to provide a simple, yet reliable and responsive, rapid 
tool that helps in assessing changes in asthma control over time in patients ≥12 years of 
age, with or without pulmonary function measurement. A cut-off score of 19 or less in 
the ACT indicates a poorly controlled asthma (Nathan et al., 2004; Schatz et al., 2006). 
A similar 7-item ACT has been developed for use in asthmatic children 4 to 11 years of 
age (Liu et al., 2007). However, due to recent copyright issue the use of the ACT is now 
minimal. The use of the Royal College of Physicians (RCP) “3 Key Questions” 
(Pearson and Bucknall, 1999; Thomas et al., 2009a) has been recently recommended by 
the British Asthma Management Guidelines to assess asthma control (BTS/SIGN, 
2009). 
A common property of MDIs is the dependence of the resulting lung dose on the 
inhalation flow rate used. It has been shown that a slower inhalation (10 l/min) results in 
a greater relative bioavailability of salbutamol to the lungs, compared to a faster 
inhalation (50 l/min) (Hindle et al., 1993).  Another study showed that when inhalation 
flow rate was increased from 37 to 151 l/min, total lung deposition decreased from 11.2 
to 7.2% (Newman et al., 1995).  Using gamma scintigraphy and a microprocessor 
controlled metered dose inhaler, it was shown that an inhalation rate of 90 l/min 
produced the best lung deposition (Farr et al., 1995).  These reports indicate that the 
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lung deposition when using a MDI is dependent on flow and that inhalation rates below 
90 l/min are the most desirable. 
In conclusion the majority of studies have found that the optimal inhalation flow rate is 
30 l/min and that a flow rate of approximately 100 l/min and above is too fast.  A recent 
study has shown that when patients used MDIs the mean peak inspiratory flow rate was 
greater than 100 l/min (Chrystyn H et al., 2002). The current study had, therefore, been 
designed to use the asthma control and health-related quality of life instruments to 
determine whether there is any clinical benefit in using the most desirable inhaler 
technique.  The results of this study can then be used to improve the clinical practice of 
counselling patients on the correct MDI technique. 
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3.1 Research Objectives 
3.1(a) Primary Objective: 
The primary objective of this study was to determine if counselling patients on how to 
use their metered dose inhaler using the most desirable MDI technique, with emphasis 
on the speed of inhalation, improves asthma control and, thus the patients‟ health-
related quality of life. 
3.1(b) Secondary Objectives: 
The secondary objectives of this study were: 
 To identify asthmatic patients who had poor inhaler technique and to counsel these 
patients on the most desirable inhaler technique. 
 To determine if a simple MDI training aid (the 2ToneTrainer®, Clement Clarke 
International, UK) helps patients to control their inhalation flow rate when using 
an MDI. 
 To determine whether there is any improvement in the patients‟ quality of life or 
the asthma control before and after patients counselling to use the most desirable 
inhaler technique. 
 To investigate if there are any correlations between the asthma quality of life 
instruments, the asthma control test and the Royal College of Physicians (RCP) “3 
Questions”.  
3.2 Methodology 
3.2.1 Study Population 
3.2.1.(a) Patient Recruitment and Sample Size 
Two approaches were followed to recruit asthmatic patients in this research study; 
patients with asthma who collected their prescriptions from a community pharmacy 
(below is a list of the community pharmacies which were involved with the study) were 
directly invited to take part in the study. The investigator checked the 
   
112 
inclusion/exclusion criteria of those patients when they presented their asthma 
prescriptions of metered dose inhalers. Eligible patients were then briefed about the 
study objectives and procedures using the patient information sheets [APPENDIX A-9, 
A-10 and A-11 (refer to the enclosed DVD)], and were allowed sufficient time to 
consider participation whilst they were at the pharmacy. If they preferred to think about 
participation after they had left, they were given a contact number should they decide to 
take part in the study. The second approach for patients enrolment was sending out 
invitation letters, based on the pharmacies database, to the potential patients (who 
fulfilled the study inclusion criteria) asking them to participate in the research. Those 
who positively replied were contacted by phone to arrange their research appointments 
at the pharmacies. 
The study was carried out according to the good clinical practice (ICH/GCP), and was 
approved by the Bradford Research Ethics Committee (United Kingdom). 
The Community Pharmacies which were involved as research sites: 
 Cullingworth Pharmacy, Bradford, West Yorkshire, UK. 
 Tesco Pharmacy, Halifax Road, Bradford, West Yorkshire, UK. 
 Healthy Living Pharmacy, 40 Reevy Road West, Bradford, West Yorkshire, UK. 
 Steeton Pharmacy, The Health Centre, Chapel Road, Steeton, Keighley, West    
Yorkshire, UK. 
 Denholme Pharmacy, 40 Main Road, Denholme, Bradford, West Yorkshire, UK. 
A previous study revealed that the mean (SD) inhalation rate of 398 outpatients of 
Leeds Teaching Hospitals NHS Trust, when they inhaled through a metered dose 
inhaler, was 107(20) l/min.  According to tables provided by Altman, reduction of the 
inhalation flow rate by 20%, with a 90% power at the 5% significance level, would 
require 30 subjects.  (Altman AG. Practical Statistics for Medical Research. Chapman & 
Hall 1997 3
rd
 Edition.).  Data is not presented for a greater reduction that should be 
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achievable in this study.  We, therefore, aimed at recruiting 40 asthmatic adults (>17 
years) in each of the 3 study groups, and a similar number of asthmatic children (≤ 17 
years). 
3.2.1.(b) Patient Definition: 
3.2.1.(b).1 Inclusion Criteria:  
Patients who met all the following criteria were potential candidates for recruitment:  
 Male or female patient with asthma. 
 Patient using at least one MDI without a spacer device. 
 Prescribed a preventer (corticosteroid) MDI among their asthma treatment. 
 Age groups: Asthmatic children 3-6 years and 7-17 years; asthmatic adults 
18 – 55 years. 
 Signed informed consent form [APPENDIX A-12 (refer to the enclosed 
DVD)]. 
3.2.1.(b).2 Exclusion Criteria:  
Patients who met any of the following criteria were excluded from participation: 
 Patients experienced an acute exacerbation of asthma or received oral 
prednisolone in the four weeks prior to recruitment. 
 Patients with other illnesses adversely affecting the respiratory system or had 
an evidence of fixed respiratory obstruction. 
 Patients with hearing problems or unable to distinguish between the one and 
two tones produced by the 2ToneTrainer tool. 
 Patients with chronic obstructive pulmonary disease (COPD). 
3.2.2 Study Design and Schematic   
This was a parallel-grouped, randomized clinical study to assess the effect of pMDI 
technique on asthma control and quality of life of asthmatic patients. This study was 
divided into two groups - an intervention group and a control group. Allocation of 
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subjects to either the control or intervention groups was according to their inhaler 
technique (see Chapter 2 - section 2.3.1.1.(b)). Those with correct MDI technique 
formed the control (CT) group, whereas those identified with poor technique formed the 
intervention group.  The intervention group was sub-divided into two groups; those who 
were verbally counselled (VC) on the most desirable MDI technique, and those who 
were both verbally counselled and given the 2ToneTrainer
®
 (Clement Clarke 
International, UK) MDI Inhalation technique training aid – see schematic design below. 
 
 
Study Week:  1                   6 
 
 
      Follow-up Period 
Visit:            1                   2 
                (Enrolment)                                                                                                          (End of Study) 
 
3.2.3 Study Procedures 
3.2.3.(a) Visit 1 (enrolment/day 1) 
Prior to performing any protocol related procedures, a signed informed consent form 
was taken from all the eligible patients who agreed to take part in the study. In the 
 
MDI Technique 
Assessment 
Good 
MDI Technique 
(IFR <90 l/min) 
Poor 
MDI Technique 
(IFR ≥90 l/min) 
 
 
Control Group 
(CT) 
 
Verbally Counselled 
Group (VC) 
 
 
VC + 2ToneTrainer 
Group (2TT)  
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patient‟s case report form (CRF), the demographic data, including the patient‟s age, 
gender and height, was taken. Asthma medications at enrolment were recorded. Lung 
function parameters (PEFR, FEV1 and FVC) were measured using a portable 
spirometer. Then, the patients completed the Asthma Quality of Life Questionnaire 
(AQLQ) according to their age group as follows: 
 18-55 years: Mini-AQLQ [APPENDIX A-5 (refer to the enclosed DVD)]. 
 7-17 years: PAQLQ (answered by the asthmatic child) [APPENDIX A-6],     
and PACQLQ [APPENDIX A-7 (refer to the enclosed DVD)] (completed by the 
parent/guardian). 
 3-6 years: PACQLQ (completed by the parent/guardian). 
The patients were also asked to complete the ACT or C-ACT according to their age 
group [APPENDIX A-2 and A-3 (refer to the enclosed DVD)], and the three key 
questions of the RCP questionnaire (see Chapter 2 - section 2.2.1.4.(d)). The 
parent/guardian of asthmatic children <7 years old answered the three questions of the 
RCP. Then, the patients‟ inhalation flow rate (IFR) through an MDI was measured 
using the In-Check meter (Clement Clark International, UK). Those with good inhaler 
technique (good co-ordination, and an IFR <90 l/min) formed the control (CT) group, 
whilst those with a poor MDI technique (poor co-ordination, and an IFR ≥ 90 l/min) 
were recruited into the intervention area of the research. 
Patients in the intervention groups were randomised (based on a previously constructed 
randomization table – APPENDIX A-13 (refer to the enclosed DVD)) into either the 
verbally counselled (VC) group or the 2TT group that received the same verbal 
counselling and were given/trained on using the 2ToneTrainer
®
 MDI training aid. The 
2TT group patients were instructed to practice with this aid three times a day.  The 
verbal counselling focused on how to use the most desirable MDI inhalation technique 
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with emphasis on the correct speed of inhalation. The patients, thereafter, were allowed 
to demonstrate the correct MDI technique using a placebo inhaler until a satisfactory 
performance was achieved; moreover, the IFR was also measured afterwards. 
3.2.3.(b) Visit 2 (end of study, week 6) 
The second (follow-up) visit of the study was scheduled 6 weeks after enrolment in the 
research (visit 1). The same tests/questionnaires, performed on visit 1, were repeated 
during this visit. A two-week visit window was allowed for participants who could not 
make their originally scheduled appointments due to extenuating reasons.  
The same investigator carried out the tests/measurements on the two visits. 
3.2.4 Patients Withdrawal and Early Termination 
The participants were free to withdraw from the study at anytime. They also could have 
been withdrawn from the study at the discretion of the investigator if they violated the 
study plan, were unable to abide by the protocol procedures and/or for any other safety 
or clinical reasons that mandated their exclusion. 
3.2.5 Confidentiality of Patients Identity and Data    
Data collected in this research study was strictly confidential. For the statistical data 
analysis, each patient was only identified by a unique code number. A list of the 
patients‟ details (names and contact information) has been kept in strict confidence 
along with the study documents. 
3.2.6 Data Collection 
Data was collected from the 3 study groups (the CT, VC and 2TT groups) at visit 1 to 
allow a baseline to be established with which the subsequent data collected at visit 2 
was compared.  
The primary outcome measure was: 
 Change in the inhalation flow rate (IFR) through the MDI. 
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The secondary outcome measures were: 
 Changes in the scores of the Asthma Quality of Life Questionnaires (Mini-
AQLQ, PAQLQ and PACQLQ; as appropriate). 
 Changes in the scores of the Asthma Control Test (ACT and C-ACT; as 
appropriate). 
 Changes in the answers to the RCP “three key questions”. 
 Changes in the lung function; determined by the FEV1 % predicted.  
3.2.7 Statistical Analysis  
The statistical analysis of the study data was carried out using the Statistical Package for 
Social Sciences (SPSS for Windows, Version 15) software. The study data was first 
classified into scale, categorical (nominal) or ordinal categories, as appropriate, and an 
SPSS dataset was then set up for the analysis. The statistical analysis was performed 
and presented as follows: 
 Descriptive statistics: presented as mean (standard deviation), median (25%; 
75% quartiles), minimum and maximum values, frequencies and percentages; as 
appropriate. 
 For scale data; normal distribution of the data was examined using histograms 
and the statistical tests for normality; the Kolmogorov-Smirnov and Shapiro-
Wilk tests. 
 Comparisons (differences) of measurements within the same study group (visit 1 
vs. visit 2) were performed using the related (paired)-samples t-test (for 
parametric data) and the Wilcoxon test (for non-parametric data). 
 Comparisons (differences) of measurements between different study groups 
were performed using the independent-samples t-test (for parametric data) and 
the Mann-Whitney U test (for non-parametric data).  
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 For categorical (nominal) data; correlations/comparisons were made using cross-
tabulation and the Chi-square (χ2) test. 
 Correlations between various study outcome measures were investigated using 
the Pearson correlation test.  
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3.3 Results 
3.3.1 Study Subjects 
Fifty six asthmatic patients (39 adults and 17 children) were recruited into this study 
from all the community pharmacies that agreed to be involved as research sites for this 
clinical trial. The 39 asthmatic adults (11 (28.2%) males, 28 (71.8%) females; mean 
(SD) age, 40.7 (9.7) years) were enrolled into one of the three study groups; Control 
(CT) group (5 patients), Verbal Counselling (VC) group (17 patients) and 2ToneTrainer 
(2TT) group (17 patients). However, 34 (87.2%) patients completed the two study visits 
as per protocol; the CT group (5 patients), VC group (14 patients) and 2TT group (15 
patients). A summary of the patients‟ demographic data, FEV1 % predicted and asthma 
severity classification at study enrolment (visit 1) is presented in table 3-1. Detailed 
demographic data for all asthmatic adults in the 3 study groups is presented in 
APPENDIX B-1, B-2 and B-3 (refer to the enclosed DVD). 
A total of 17 asthmatic children [11 (64.7%) males, 6 (35.3%) females; mean (SD) age, 
10.2 (3.2) years] were recruited into this study. However, 16 (94.1%) patients 
completed the two visits of the research as per protocol; the CT group (5 patients), the 
VC group (5 patients) and the 2TT group (6 patients). A summary of the asthmatic 
children‟s demographic data, FEV1 % predicted and asthma severity classification at 
study enrolment (visit 1) is presented in table 3-2. Detailed demographic data for all the 
asthmatic children in the 3 study groups is presented in APPENDIX B-4, B-5 and B-6 
(refer to the enclosed DVD). 
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Table 3-1: Demographic data of the asthmatic adults at study enrolment (visit 1). 
Characteristics 
Study Group 
All 
Patients 
CT  
Group 
VC  
Group 
2TT  
Group 
Number (n) 5 17 17 39 
Mean (SD) Age , years 
42.6 
(13.2) 
42.4 
(7.2) 
38.5 
(10.8) 
40.7 
(9.7) 
Sex (M/F) 0/5 7/10 4/13 11/28 
Mean (SD) Height, cm 
167.1 
(4.7) 
169.2 
(9.9) 
168.4 
(9.5) 
168.5 
(9.1) 
Mean (SD)  
FEV1 % predicted  
89.9 (9.1) 90.5 (18.2) 96.6 (19.8) 93.1 (17.9) 
Asthma 
Severity* 
(n) 
Mild 4 13 14 31 
Moderate 1 3 2 6 
Severe 0 1 1 2 
* Asthma severity classification was based on GINA (2008) Guidelines. 
 
 
 
Table 3-2: Demographic data of the asthmatic children at study enrolment (visit 1). 
Characteristics 
Study Group 
All 
Patients 
CT  
Group 
VC  
Group 
2TT  
Group 
Number (n) 5 6 6 17 
Mean (SD) Age, years 
7.2 
(3.1) 
11.2 
(2.4) 
11.7 
(2.4) 
10.2  
(3.2) 
Sex (M/F) 3/2 4/2 4/2 11/6 
Mean (SD) Height, cm 
129.2 
(16.6) 
147.0 
(12.1) 
158.2 
(19.7) 
145.7 
(19.5) 
Mean (SD)  
FEV1 % predicted  
 
102.8
**
 
(10.1) 
92.2 (16.8) 88.9 (18.0) 93.0 (16.1) 
Asthma 
Severity* 
(n) 
Mild 3 5 5 13 
Moderate 0 0 1 1 
Severe 0 1 0 1 
* Asthma severity classification was based on GINA (2008) Guidelines. 
** Two children in the CT group were ≤ 5 years old and had no spirometry results. 
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3.3.2 Results of Asthmatic Adults 
To assess the distribution of the asthmatic adults‟ data, histograms and normality 
distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) were used. These 
tests showed that the following data were normally distributed; the FEV1 % predicted 
and Mini-AQLQ scores. Whilst, the IFR, the ACT scores and the 3 RCP “key 
questions” scores were not normally distributed. Accordingly, the appropriate statistical 
test was applied for the asthmatic adults‟ data analysis and presentation. 
3.3.2.1 Lung Function (FEV1 % predicted)  
The mean (SD) of the FEV1 % predicted for the CT, VC and 2TT groups at visits 1 and 
2, along with that of the change (∆) in FEV1 % predicted between the two visits are 
presented in table 3-3. Frequencies of the patients at various asthma severity levels are 
shown in table 3-4, asthma severity classification was based on the FEV1 % predicted 
categories of the GINA (2008) guidelines. Details of all patients‟ measured FEV1 
values, predicted FEV1 and FEV1 % predicted for the CT, VC and 2TT groups (at visits 
1 and 2) are presented in APPENDIX B-1, B-2 and B-3, respectively (refer to the 
enclosed DVD).  
Table 3-3: Mean (SD) FEV1 % predicted for all study groups at visits 1 and 2, and 
  of the change (∆) in FEV1 % predicted between the two visits. 
Study 
Group 
FEV1 % pred, Visit 1 
Mean (SD) 
FEV1 % pred, Visit 2 
Mean (SD)  
∆ FEV1 % pred.* 
Mean (SD)  
CT 
(n = 5) 
89.9 (9.1) 86.5 (8.6) -3.5 (4.5) 
VC 
(n = 14) 
90.4 (20.1) 87.2 (20.4) -3.2 (10.1) 
2TT 
(n = 15) 
96.5 (21.1) 96.3 (17.6)[ -0.17 (13.0) 
* ∆: Change in FEV1 % predicted between visits 1 and 2. 
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Table 3-4: Asthma severity frequencies for each study group (asthmatic adults) at 
                   visits 1 and 2.     
Study Group Study Visit 
Asthma Severity Levels* – n (%) 
Mild  Moderate Severe 
CT 
(n = 5) 
Visit 1 
(baseline) 
4 (80%) 1 (20%) 0 
Visit 2 4 (80%) 1 (20%) 0 
VC 
(n = 14) 
Visit 1 
(baseline) 
10 (71.4%) 3 (21.4%) 1 (7.1%) 
Visit 2 9 (64.3%) 4 (28.6%) 1 (7.1%) 
2TT 
(n = 15) 
Visit 1 
(baseline) 
12 (80%) 2 (13.3%) 1 (6.7%) 
Visit 2 12 (80%) 3 (20%) 0 
* Asthma severity classification according to FEV1 %predicted categories of the GINA (2008)    
Guidelines. 
Histograms and tests of normal distribution (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) (table 3-5) showed that the FEV1 % predicted data was normally distributed. 
Comparison of the FEV1 % predicted between visit 1 and visit 2 within the CT, VC and 
2TT groups (using the related-samples t-test) is presented in table 3-6. The results 
showed that there was no significant difference in FEV1 % predicted between the two 
study visits within all study groups. 
Table 3-5: Tests of normality for FEV1 % predicted at visits 1 and 2 for all study 
                   groups (asthmatic adults). 
 
 
Study 
Group 
Kolmogorov-Smirnov
(a)
 Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
FEV1 % Pred. 
(Visit 1) 
 
CT 0.215 5 0.200
(*)
 0.917 5 0.513 
VC 0.106 14 0.200
(*)
 0.976 14 0.948 
2TT 0.124 15 0.200
(*)
 0.941 15 0.400 
FEV1 % Pred. 
(Visit 2) 
 
CT 0.234 5 0.200
(*)
 0.956 5 0.779 
VC 0.151 14 0.200
(*)
 0.979 14 0.971 
2TT 0.137 15 0.200
(*)
 0.950 15 0.524 
* This is a lower bound of the true significance.     a)  Lilliefors Significance Correction 
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Table 3-6: Comparison of the FEV1 % predicted between V1 and V2 within each 
                   of the study groups (asthmatic adults).  
Study Group 
Related-Samples t-test for FEV1 % predicted (V1 & V2) 
Mean Difference (95% CI) / p-value (2-tailed) 
CT  Group 3.5 (-2.2; 9.1) / p = 0.162 
VC Group 3.2 (-2.6; 9.1) / p = 0.253 
2TT Group 0.17 (-7.1; 7.4) / p = 0.961 
 
Pairwise comparison of the FEV1 % predicted at visit 1 and visit 2 among the CT, VC 
and 2TT groups using the independent-samples t-test is presented in table 3-7. 
Moreover, pairwise comparison of the change (∆) in FEV1 % predicted between the two 
visits among the 3 groups using the independent-samples t-test is also presented in table 
3-7. The results showed no statistically significant differences in FEV1 % predicted or in 
the change in FEV1 % predicted among the CT, VC and 2TT groups. 
Table 3-7: Pairwise comparison of the FEV1 % predicted among all study groups 
                   (asthmatic adults) at visits 1 and 2. 
Study Group 
Independent-samples t-test for FEV1 % predicted  
Mean Difference (95% CI) / p-value (2-tailed) 
CT vs. VC (visit 1) -0.496 (-20.4; 19.4) / p = 0.959 
CT vs. 2TT (visit 1) -6.6 (-27.3; 14.2) / p = 0.514 
VC vs. 2TT (visit 1) -6.1 (-21.8; 9.7) / p = 0.435 
CT vs. VC (visit 2) -0.747 (-20.9; 19.4) / p = 0.939 
CT vs. 2TT (visit 2) -9.9 (-27.3; 7.5) / p = 0.249 
VC vs. 2TT (visit 2) -9.1 (-23.6; 5.4) / p = 0.207 
Independent-samples t-test for the change (∆) in FEV1 % predicted (between V1 & V2) 
CT vs. VC  -0.251 (-10.3; 9.8) / p = 0.958 
CT vs. 2TT  -3.3 (-16.0; 9.4) / p = 0.590 
VC vs. 2TT  -3.1 (-12.0; 5.9) / p = 0.488 
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3.3.2.2 The Inhalation Flow Rate (IFR)  
Of the 34 asthmatic adults who completed the two study visits as per protocol, 29 
(85.3%) patients inhaled at an IFR ≥ 90 l/min through an MDI at study enrolment (visit 
1), and thus were randomised into either the VC (14 patients) or 2TT (15 patients) 
intervention groups (table 3-8). All the 29 (85.3%) patients in the intervention (VC and 
2TT) groups inhaled at a rate < 90 l/min when the IFR was measured immediately after 
they had been verbally counselled on the correct MDI technique at visit 1. At the second 
follow-up visit, 24 (82.8%) patients of the VC and 2TT groups inhaled at a rate < 90 
l/min through an MDI; 11 patients in the VC group and 13 patients in the 2TT group 
(table 3-8).  
Five (14.7%) patients inhaled at an IFR < 90 l/min at visit 1, and therefore formed the 
CT group. Four (80%) patients in the CT group continued to inhale at a rate < 90 l/min 
at visit 2; whereas one patient inhaled at a faster rate (≥ 90 l/min), (table 3-8). The 
median (25%; 75% quartiles) of the IFR at visit 1 and visit 2, along with that for the 
change in IFR (∆ IFR, between V1 and V2), for the CT, VC and 2TT groups are 
summarized in table 3-9. Figure 3-1 shows that the means of the IFR at visit 2 for the 
patients in the VC and 2TT groups were less than 90 l/min, and far less than that at visit 
1. Details of the IFR values and ∆ IFR (between V1 and V2) for all the patients in the 
CT, VC and 2TT groups are presented in APPENDIX B-7, B-8 and B-9, respectively 
(refer to the enclosed DVD). 
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Table 3-8: Frequencies (n, %) in the IFR categories for the CT, VC and 2TT 
                   groups (visits 1 and 2) (asthmatic adults). 
Study Group 
IFR (l/min) 
Category 
Visit 1 (n, %) 
(baseline) 
Visit 2 (n, %) 
CT Group 
(n=5) 
<30 0 0 
30 – 60 2 (40.0%) 2 (40.0%) 
61 – 89 3 (60.0%) 2 (40.0%) 
≥90 0 1 (20.0%) 
 
VC Group 
(n=14) 
IFR (l/min) 
Category 
Visit 1 (n, %) 
Visit 2 (n, %) Before 
VC 
After  
VC 
<30 0 0 0 
30 – 60 0 11 (78.6%) 9 (64.3%) 
61 – 89 0 3 (21.4%) 2 (14.3%) 
≥90 14 (100%) 0 3 (21.4%) 
 
2TT Group 
(n=15) 
IFR (l/min) 
Category 
Visit 1 (n, %) 
Visit 2 (n, %) Before  
VC 
After  
VC 
<30 0 0 0 
30 – 60 0 11 (73.3%) 6 (40.0%) 
61 – 89 0 4 (26.7%) 7 (46.7%) 
≥90 15 (100%) 0 2 (13.3%) 
 
 
Table 3-9: Median (25%; 75% quartiles) of IFR (V1 and V2) and of ∆ IFR for all 
                   study groups (asthmatic adults).                 
Study 
Group 
IFR (l/min), Visit 1 
[Median (25%, 75%)] 
(baseline) 
IFR (l/min), Visit 2 
[Median (25%, 75%)] 
∆ IFR (l/min) 
[Median (25%, 75%)] 
 
CT 
(n = 5) 
 
 68.0 (45.0, 78.0) 88.0 (45.0, 109.0)  12.0 (-6.0, 41.0) 
 
VC 
(n = 14) 
 
 200.0 (181.2, 225.0)  48.5 (42.5, 93.7)  -143.5 (-176.2, -50.0) 
 
2TT 
(n = 15) 
 
 240.0 (150.0, 300.0) 65.0 (45.0, 80.0)  -165.0 (-225.0, -80.0) 
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Figure 3-1: Mean IFR at visits 1 and 2 for all study groups (asthmatic adults). 
Histograms and the normality distribution tests (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the IFR data was not normally distributed. Therefore, the 
Wilcoxon matched-pairs, signed ranks test was used to investigate the differences in 
the IFR between the two study visits within each group. For the CT group, the 
Wilcoxon test showed that the difference between the IFR at visit 1 (M=62.8; 
SD=18.5) and the IFR at visit 2 (M=79.2; SD=36.0) was not statistically significant: 
exact p = 0.375 (two-tailed). The sum of ranks were 1.50 and 8.50 for the negative and 
positive ranks, respectively, therefore W = 1.50. For the VC group, the Wilcoxon test 
showed that the difference between the IFR at visit 1 (M= 203.6; SD=52.2) and that at 
visit 2 (M=73.2; SD=50.5) was statistically significant: exact p < 0.0001 (two-tailed). 
The sum of ranks were 105.0 and zero for the negative and positive ranks, respectively, 
therefore W = Zero. For the 2TT group, the Wilcoxon test showed that the difference 
between the IFR at visit 1 (M= 235.3; SD=82.5) and that at visit 2 (M=80.0; SD=60.2) 
was statistically significant: exact p < 0.0001 (two-tailed). The sum of ranks were 119.0 
and 1.0 for the negative and positive ranks, respectively, therefore W = 1.0. 
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Comparison of the IFR (visit 1, visit 2 and the change in IFR between the two visits) 
among the three study groups was done using the independent-samples, non-parametric 
Mann-Whitney U test, table 3-10. The results showed that, at visit 1, there was a 
significant difference in the IFR between the CT group and both the VC and 2TT 
groups, whereas there was no difference in the IFR between the VC and 2TT groups. 
On the other hand, no significant difference in the IFR was found among the 3 groups 
at visit 2. For the change in the IFR (∆ IFR) over the follow-up period, there was a 
significant difference between the CT group and both the VC and 2TT groups, whereas 
no difference between the VC and 2TT groups was found.  
Table 3-10: Pairwise comparison of IFR (V1 and V2) and ∆ IFR among all study 
                     groups (asthmatic adults).  
Study Group 
Mann-Whitney U Test: U-Value (exact p: 2-tailed) for the 
IFR 
Visit 1 (baseline) Visit 2 ∆ IFR (V1 & V2) 
CT vs. VC 0.0 (p < 0.01)* 26.5 (p = 0.456) 1.0 (p < 0.01)* 
CT vs. 2TT 0.0 (p < 0.01)* 30.5 (p = 0.565) 2.0 (p < 0.01)* 
VC vs. 2TT 79.0 (p = 0.265) 82.5 (p = 0.334) 89.5 (p = 0.511) 
    * Difference is statistically significant. 
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3.3.2.3 The Mini-AQLQ   
For the three study groups, a summary of the mean (SD) of the Mini-AQLQ scores 
(overall and its four domains: Symptoms, Activity Limitation, Emotional Function and 
Environmental Stimuli) at visit 1 and visit 2, and of the mean (SD) of the scores‟ change 
between the two visits is presented in tables 3-11, 3-12 and 3-13, respectively. The 
detailed Mini-AQLQ scores of all the patients in each of the CT, VC and 2TT groups 
are presented in APPENDIX B-11, B-13 and B-15, respectively (refer to the enclosed 
DVD). The change in the overall AQLQ scores and its domains between visits 1 and 2, 
of all the patients in the CT, VC and 2TT groups is presented in APPENDIX B-12, B-
14 and B-16, respectively (refer to the enclosed DVD). 
Table 3-11: Mean (SD) of the Mini-AQLQ scores at visit 1 for all study groups. 
Mini-AQLQ Domains 
(Visit 1) 
Mean (SD) Score – Visit 1 
CT Group VC Group 2TT Group 
Overall AQLQ 5.0 (0.57) 4.9 (0.98) 5.2 (0.94) 
Symptoms 5.0 (0.59) 4.7 (1.09) 4.9 (1.36) 
Activity Limitation 5.9 (0.82) 6.0 (0.99) 6.0 (0.85) 
Emotional Function 4.7 (1.03) 4.4 (1.27) 5.0 (1.43) 
Environmental Stimuli 4.0 (1.20) 4.3 (1.40) 5.0 (1.23) 
 
Table 3-12: Mean (SD) of the Mini-AQLQ scores at visit 2 for all study groups. 
Mini-AQLQ Domains 
(Visit 2) 
Mean (SD) Score – Visit 2 
CT Group VC Group 2TT Group 
Overall AQLQ 4.9 (0.63) 5.7 (1.17) 5.7 (0.74) 
Symptoms 4.8 (0.73) 5.4 (1.29) 5.5 (0.90) 
Activity Limitation 5.4 (0.84) 6.3 (1.07) 6.1 (1.01) 
Emotional Function 5.0 (0.78) 5.5 (1.20) 5.6 (0.96) 
Environmental Stimuli 4.4 (1.32) 5.2 (1.55) 5.4 (0.94) 
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Table 3-13: Mean (SD) of the change (∆) in Mini-AQLQ scores for all study 
                     groups. 
∆ Mini-AQLQ Domains 
(betweenV1 & V2) 
Mean (SD) ∆ Mini-AQLQ Score  
CT Group VC Group 2TT Group 
∆ Overall AQLQ - 0.053 (0.38) 0.748 (1.08) 0.409 (0.90) 
∆ Symptoms - 0.200 (0.51) 0.729 (1.26) 0.573 (1.13) 
∆ Activity Limitation - 0.500 (0.47) 0.339 (1.16) 0.050 (0.93) 
∆ Emotional Function 0.333 (0.41) 1.143 (1.14) 0.622 (1.25) 
∆ Environmental 
Stimuli 
0.400 (0.37) 0.929 (1.39) 0.400 (1.29) 
∆: Change in the domain scores between visits 1 and 2. 
 
For the three study groups, table 3-14 shows the frequencies and percentages of the 
patients whose scores change (∆) in Mini-AQLQ and its domains (between visit 1 and 
visit 2) was greater than the minimal important difference (MID ≥ 0.5). Four (80%) 
patients in the CT group had a change in the overall Mini-AQLQ scores below the MID 
(< 0.5). On the other hand, 7 (50%) and 8 (53.3%) patients in the VC and 2TT groups, 
respectively, had a change in the overall Mini-AQLQ scores greater than the MID (≥ 
0.5).  
Histograms and normality distribution tests (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the Mini-AQLQ scores were normally distributed. Within each 
study group, a comparison using the related-samples t-test of the overall Mini-AQLQ 
and its four domain scores between visit 1 and visit 2 is presented in table 3-15 [as a 
mean difference (95% confidence interval), p-value (2-tailed)]. The results show that 
within the CT group no significant difference between visits 1 and 2 was found in the 
overall Mini-AQLQ and its domains. For the VC group, the difference between visits 1 
and 2 in the overall Mini-AQLQ and its domains was statistically significant, except for 
that in the activity limitation domain. On the other hand, none of the differences 
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between visits 1 and 2 in the overall Mini-AQLQ and its domains was significant within 
the 2TT group.  
Using the independent-samples t-test, a pairwise comparison among the CT, VC and 
2TT groups for the Mini-AQLQ scores (overall and the 4 domains) at visit 1 and visit 2 
is presented in tables 3-16 and 3-17, respectively. The results show no significant 
difference among the 3 groups in any of the Mini-AQLQ scores at both visit 1 and visit 
2.  Similar comparison was made for the change in the Mini-AQLQ scores between visit 
1 and visit 2 (table 3-18); which also shows no significant difference among the 3 
groups in the change in any of the Mini-AQLQ domains.  
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Table 3-14: Frequencies (n, %) of patients achieved a MID in Mini-AQLQ domains for all study groups. 
Study 
Group 
∆ AQLQ 
Category 
∆ Overall  
(n, %) 
∆ Symptoms 
(n, %) 
∆ Activity 
Limitation 
(n, %) 
∆ Emotional 
Function 
(n, %) 
∆ Environmental 
Stimuli 
(n, %) 
CT Group 
(n=5) 
≤ -0.5 0 2 (40.0%) 4 (80.0%) 0 0 
-0.49 – 0.49 4 (80.0%) 3 (60.0%) 1 (20.0%) 4 (80.0%) 4 (80.0%) 
0.5 – 1.0 1 (20.0%) 0 0 1 (20.0%) 1 (20.0%) 
> 1.0 0 0 0 0 0 
VC Group 
(n=14) 
≤ -0.5 2 (14.3%) 2 (14.3%) 3 (21.4%) 1 (7.1%) 3 (21.4%) 
-0.49 – 0.49 5 (35.7%) 4 (28.6%) 6 (42.9%) 4 (28.6%) 3 (21.4%) 
0.5 – 1.0 2 (14.3%) 3 (21.4%) 0  4 (28.6%) 2 (14.3%) 
> 1.0 5 (35.7%) 5 (35.7%) 5 (35.7%) 5 (35.7%) 6 (42.9%) 
2TT 
Group 
(n=15) 
≤ -0.5 3 (20.0%) 3 (20.0%) 6 (40.0%) 2 (13.3%) 4 (26.7%) 
-0.49 – 0.49 4 (26.7%) 3 (20.0%) 3 (20.0%) 6 (40.0%) 4 (26.7%) 
0.5 – 1.0 5 (33.3%) 4 (26.7%) 4 (26.7%) 2 (13.3%) 2 (13.3%) 
> 1.0 3 (20.0%) 5 (33.3%) 2 (13.3%) 5 (33.3%) 5 (33.3%) 
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Table 3-15: Comparison of the Mini-AQLQ scores between visit 1 and 2 within 
                     each study group. 
 
Mini-AQLQ 
Domains 
 
Mean Difference (95% CI) / p-value (2-tailed) 
Study Group  
CT  Group VC Group 2TT Group 
Overall AQLQ 
0.053 (-0.41; 0.52) 
p = 0.767 
-0.748 (-1.37; -0.12) 
p = 0.022* 
-0.409 (-0.91; 0.09) 
p = 0.099 
Symptoms 
0.200 (-0.43; 0.83) 
p = 0.430 
-0.729 (-1.46; -0.002) 
p = 0.050* 
-0.573 (-1.20; 0.05) 
p = 0.070 
Activity 
Limitation 
0.500 (-0.08; 1.08) 
p = 0.075  
-0.339 (-1.01; 0.33) 
p = 0.295 
-0.050 (-0.56; 0.46) 
p = 0.837 
Emotional 
Function 
-0.333 (-0.84; 0.17)  
p = 0.142 
-1.143 (-1.80; -0.48) 
p = 0.003** 
-0.622 (-1.32; 0.07) 
p = 0.075 
Environmental 
Stimuli 
-0.400 (-0.85; 0.05)  
p = 0.070 
-0.929 (-1.73; -0.12) 
p = 0.027* 
-0.400 (-1.12; 0.32) 
p = 0.250 
* P ≤0.050; ** P < 0.01 
 
Table 3-16: Pairwise comparison of the Mini-AQLQ domains at visit 1 (baseline) 
                     among the study groups. 
Mini-AQLQ 
Independent-samples t-test  - Visit 1 
Mean Difference (95% CI) / p-value (2-tailed) 
CT vs. VC CT vs. 2TT VC vs. 2TT 
Overall  
0.077 (-0.91; 1.07) 
p = 0.871 
-0.262 (-1.21; 0.69) 
p = 0.568 
-0.339 (-1.07; 0.39) 
p = 0.350 
Symptoms 
0.326 (-0.77; 1.42) 
p = 0.540 
0.147 (-1.19; 1.48) 
p = 0.820 
-0.179 (-1.12; 0.76) 
p = 0.700 
Activity 
Limitation 
-0.100 (-1.15; 0.95) 
p = 0.843 
-0.150 (-1.06; 0.76) 
p = 0.734 
-0.050 (-0.75; 0.65) 
p = 0.885 
Emotional 
Function 
0.262 (-1.07; 1.60) 
p = 0.685 
-0.356 (-1.82; 1.11) 
p = 0.616 
-0.617 (-1.65; 0.41) 
p = 0.230 
Environmental 
Stimuli 
-0.286 (-1.77; 1.20) 
p = 0.690 
-1.00 (-2.33; 0.33) 
p = 0.132 
-0.71 (-1.72; 0.29) 
p = 0.155 
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Table 3-17: Pairwise comparison of the Mini-AQLQ domains at visit 2 among the 
                     study groups.  
Mini-AQLQ 
Independent-samples t-test  - Visit 2 
Mean Difference (95% CI) / p-value (2-tailed) 
CT vs. VC CT vs. 2TT VC vs. 2TT 
Overall  
-0.724 (-1.90; 0.45) 
p = 0.212 
-0.724 (-1.50; 0.05) 
p = 0.065 
0.00 (-0.74; 0.74) 
p = 0.999 
Symptoms 
-0.603 (-1.90; 0.70) 
p = 0.341 
-0.627 (-1.56; 0.31) 
p = 0.176 
-0.024 (-0.87; 0.82) 
p = 0.954 
Activity 
Limitation 
-0.939 (-2.06; 0.18) 
p = 0.095 
-0.700 (-1.76; 0.36) 
p = 0.182 
0.239 (-0.55; 1.03) 
p = 0.541 
Emotional 
Function 
-0.548 (-1.78; 0.68) 
p = 0.360 
-0.644 (-1.65; 0.36) 
p = 0.195 
-0.097 (-0.92; 0.73) 
p = 0.812 
Environmental 
Stimuli 
-0.814 (-2.46; 0.83) 
p = 0.312 
-1.000( -2.13; 0.13) 
p = 0.079 
-0.186 (-1.16; 0.78) 
p = 0.698 
 
 
Table 3-18: Pairwise comparison of the change (∆) in the Mini-AQLQ domains 
                     (between visits 1 and 2) among the study groups. 
∆ Mini-AQLQ 
Independent-samples t-test   
Mean Difference (95% CI) / p-value (2-tailed) 
CT vs. VC CT vs. 2TT VC vs. 2TT 
∆ Overall  
-0.801 (-1.86; 0.26) 
p = 0.129 
-0.462 (-1.34; 0.42) 
p = 0.284 
0.339 (-0.42; 1.09) 
p = 0.365 
∆ Symptoms 
-0.929 (-2.17; 0.31) 
p = 0.133 
-0.773 (-1.89; 0.34) 
p = 0.162 
0.155 (-0.76; 1.07) 
p = 0.730 
∆ Activity 
Limitation 
-0.839 (-1.98; 0.31) 
p = 0.140 
-0.550 (-1.47; 0.37) 
p = 0.224 
0.289 (-0.51; 1.09) 
p = 0.464 
∆ Emotional 
Function 
-0.810 (-1.93; 0.31) 
p = 0.146 
-0.289 (-1.51; 0.93) 
p = 0.624 
0.521 (-0.40; 1.44) 
p = 0.254 
∆ Environmental 
Stimuli 
-0.529 (-1.88; 0.82) 
p = 0.421 
0.00 (-1.25; 1.25) 
p = 1.000 
0.529 (-0.49; 1.55) 
p = 0.298 
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3.3.2.4 The Asthma Control Test (ACT)  
For the CT, VC and 2TT groups, the median (25%, 75% quartiles) of the ACT scores at 
visits 1 and 2, and of the change (∆) in the ACT scores between the two visits are 
presented in table 3-19. Details of the ACT scores of all patients in the CT, VC and 2TT 
groups are shown in APPENDIX B-29, B-30 and B-31 (refer to the enclosed DVD). 
The results showed that the mean change in the ACT scores was positive, which means 
that the ACT scores were, generally, higher at visit 2. 
Table 3-20 presents the frequencies and percentages of the patients in different cut-off 
ACT score categories, at both visit 1 and visit 2. For the CT group, frequencies 
(percentages) of patients within the insufficiently- (0-19) and well-controlled (20-24) 
asthma remained almost the same at the two study visits. For the VC group, 6 (42.9%) 
patients were in the well- and completely-controlled asthma categories at visit 2, 
compared to 4 (28.7%) patients at visit 1. For the 2TT group, 9 (60%) patients were in 
the well- and completely-controlled asthma categories at visit 2, compared to 5 (33.3%) 
patients at visit 1.  
Table 3-19: Median (25%, 75% quartiles) of the ACT scores at visits 1 and 2, and 
                     of ∆ ACT scores for all study groups. 
Study 
Group 
ACT, Visit 1 
[Median (25%, 75%)] 
ACT, Visit 2 
[Median (25%, 75%)] 
∆ ACT 
 [Median (25%, 75%)] 
CT 
(n = 5) 
18.0 (15.0; 20.0) 19.0 (18.0; 20.5) 3.0 (-1.0; 3.5) 
VC 
(n = 14) 
15.5 (13.5; 20.25) 17.5 (14.75; 22.0) 2.5 (-1.25; 5.25) 
2TT 
(n = 15) 
18.0 (17.0; 21.0) 21.0 (17.0; 21.0) 0.0 (-1.0; 4.0) 
∆: Change in the ACT scores between visits 1 and 2. 
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Table 3-20: Frequencies (n, %) in the ACT categories for the CT, VC and 2TT 
                     groups (visits 1 and 2). 
 
Study Group 
 
ACT Category Visit 1 (n, %) Visit 2 (n, %) 
CT Group 
(n=5) 
0 - 19 4 (80%) 3 (60%) 
20 - 24 1 (20%) 2 (40%) 
25 0 0 
VC Group 
(n=14) 
ACT Category Visit 1 (n, %) Visit 2 (n, %) 
0 - 19 10 (71.4%) 8 (57.1%) 
20 - 24 4 (28.6%) 5 (35.7%) 
25 0 1 (7.1%) 
2TT Group 
(n=15) 
ACT Category Visit 1 (n, %) Visit 2 (n, %) 
0 - 19 10 (66.7%) 6 (40%) 
20 - 24 4 (26.7%) 9 (60%) 
25 1 (6.7%) 0 
 
Histograms and normality distribution tests (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the ACT scores were not normally distributed. Comparison 
using the related-samples, non-parametric Wilcoxon test of the ACT scores between 
visit 1 and visit 2 within each study group was performed; the results showed that the 
difference in the ACT scores between visit 1 and visit 2 was not significant (p > 0.05), 
in all the study groups. The independent-samples, non-parametric Mann-Whitney U test 
was used to compare the ACT scores across the three groups at visit 1 and visit 2, as 
well as to compare the change in the ACT scores over the study follow-up period; the 
results showed non-significant difference (p > 0.05) in the ACT and ∆ ACT scores 
among the CT, VC and 2TT groups.  
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3.3.2.5 The Royal College of Physicians (RCP) „3 Key 
Questions‟  
The responses of the patients to the RCP “3 Questions” (1 = Yes; 0 = No) at visits 1 and 
2 are presented in table 3-21. A negative response to the 3 questions suggests a well-
controlled asthma, whereas one or more positive (yes) answers suggest an inadequately 
controlled condition. In general, less positive responses were given by the patients in the 
VC and 2TT groups at visit 2 compared with visit 1 suggesting better asthma control 
and symptoms. However, the Pearson Chi-Square statistic showed insignificant changes 
in responses to the RCP “3 questions” between the two visits (although the small 
frequencies were a drawback for the cross-tabulation test). The responses to the RCP “3 
Questions” by the CT, VC and 2TT groups (at visits 1 and 2) are presented APPENDIX 
B-33, B-34 and B-35, respectively (refer to the enclosed DVD).  
Table 3-21: Frequencies (n, %) of the positive responses to the RCP “3 Key 
                     Questions” for the CT, VC and 2TT groups (visits 1 and 2). 
Study Group 
Number of 
“Yes” 
Responses* 
Visit 1 (n, %) Visit 2 (n, %) 
CT Group 
(n=5) 
0 0 0 
1 1 (20%) 2 (40%) 
2 2 (40%) 1 (20%) 
3 2 (40%) 2 (40%) 
VC Group 
(n=14) 
Number of 
“Yes” 
Responses* 
Visit 1 (n, %) Visit 2 (n, %) 
0 0 1 (7.1%) 
1 5 (35.7%) 6 (42.9%) 
2 4 (28.6%) 4 (28.6%) 
3 5 (35.7%) 3 (21.4%) 
2TT Group 
(n=15) 
Number of 
“Yes” 
Responses* 
Visit 1 (n, %) Visit 2 (n, %) 
0 1 (6.7%) 1 (6.7%) 
1 3 (20%) 6 (40%) 
2 5 (33.3%) 6 (40%) 
3 6 (40%) 2 (13.3%) 
* Number of positive (Yes) responses to the RCP “3 Questions” (Yes = 1; No = 0). A zero score suggests 
a well-controlled asthma; while a score ≥ 1.0 suggests inadequately controlled condition. 
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3.3.2.6 Correlation between the Asthma Quality of Life and          
Asthma Control Instruments  
Correlation between the ACT and RCP “3 Key Questions” with the Mini-AQLQ 
(Overall and its 4 domains) was investigated using the Pearson Correlation test. The 
results showed that the ACT has a significant positive correlation with the overall 
AQLQ at both visits 1 and 2; r = 0.641 and 0.703 (p <0.01), respectively. Moreover, ∆ 
ACT has also a significant positive correlation with ∆ overall AQLQ, r = 0.688 (p < 
0.01). The details of the correlation of the ACT with all the Mini-AQLQ domains at 
visit 1 and visit 2, along with the correlation of the change in their scores over the study 
period are presented in tables 3-22, 3-23 and 3-24, respectively. Similarly, the RCP “3 
Questions‟ showed a significant negative correlation with the overall AQLQ at both 
visits 1 and 2, r = - 0.544 and r = - 0.693 (p < 0.01), respectively. The details of the 
correlation of the RCP “3 Questions” with all the Mini-AQLQ domains are presented in 
tables 3-22, 3-23 and 3-24.  
The two asthma control instruments; the ACT and RCP “3 Questions” had a significant 
negative correlation with each other (r = - 0.499 and - 0.574, p < 0.01) at visit 1 and 
visit 2, respectively. The change of these scores over the study follow-up period showed 
a similar trend of correlation, table 3-25. 
Pearson correlation testing of the FEV1 % predicted and its change over the two study 
visits with the Mini-AQLQ scores (overall and its 4 domains), ACT score and the RCP 
“3 Questions” was also performed; no significant correlation was found, except weak 
positive correlations between the FEV1 % predicted and the ACT scores at visit 1, and 
between the change in FEV1 % predicted and the symptoms domain of the quality of 
life questionnaire (p < 0.05).  
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Table 3-22: Correlation of Mini-AQLQ with ACT and RCP “3 Questions” at visit 
                     1. 
 
Mini-AQLQ Domains 
 
Pearson Correlation (r) – Visit 1 
ACT RCP “3 Questions” 
Overall AQLQ 0.641
*
 - 0.544
*
 
Symptoms 0.628
*
 - 0.547
*
 
Activity Limitation 0.553
*
 - 0.448
*
 
Emotional Function 0.551
*
 - 0.369
**
 
Environmental Stimuli 0.252
†
 - 0.313
†
 
 * Correlation is significant at 0.01 level (2-tailed). ** Correlation is significant at 0.05 level (2-tailed). 
 † Correlation is not significant. 
 
Table 3-23: Correlation of Mini-AQLQ with ACT and RCP “3 Questions” at visit 
                     2. 
 
Mini-AQLQ Domains 
 
Pearson Correlation (r) – Visit 2 
ACT RCP “3 Questions” 
Overall AQLQ 0.703
*
 - 0.693
*
 
Symptoms 0.689
*
 - 0.740
*
 
Activity Limitation 0.570
*
 - 0.541
*
 
Emotional Function 0.544
*
 - 0.455
*
 
Environmental Stimuli 0.588
*
 - 0.583
*
 
  * Correlation is significant at the 0.01 level (2-tailed). 
 
Table 3-24: Correlation of ∆ Mini-AQLQ with ∆ ACT and ∆ RCP “3 Questions”. 
Change (∆) in 
Mini-AQLQ Domains 
Pearson Correlation (r) 
∆ ACT  ∆ RCP “3 Questions” 
∆ Overall AQLQ 0.688
*
 - 0.600
*
 
∆ Symptoms 0.660
*
 - 0.618
*
 
∆ Activity Limitation 0.623
*
 - 0.502
*
 
∆ Emotional Function 0.469
*
 - 0.367
**
 
∆ Environmental Stimuli 0.507
*
 - 0.462
*
 
  * Correlation is significant at 0.01 level (2-tailed).  ** Correlation is significant at 0.05 level (2-tailed). 
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Table 3-25: Correlation of the ACT and RCP “3 Questions”. 
 
 
Pearson Correlation (r)  
ACT – V1 ACT – V2 ∆ ACT 
RCP “3 Questions” – V1 - 0.499
*
 --- --- 
RCP “3 Questions” – V2 --- - 0.574
*
 --- 
 ∆ RCP “3 Questions”  --- --- - 0.709
*
 
   * Correlation is significant at the 0.01 level (2-tailed). 
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3.3.2.7 Patients Self-Rating of their Asthma Control 
The patients‟ personal assessment of their asthma control (poor, fair, good, very good 
and excellent) at visits 1 and 2, is presented in table 3-26 and figure 3-2. In general, 
there was an improvement in the VC and 2TT groups‟ rating of their asthma control 
level at visit 2 compared with that at visit 1. Cross-tabulation of the patients‟ self-
perception of asthma control level at visits 1 and 2 was performed; correlation using the 
Pearson Chi-Square test showed no significant difference in the patients‟ perception of 
their asthma control between the two visits, in all study groups, table 3-27. 
Pearson correlation test between the patients self-reporting of asthma control level with 
the overall Mini-AQLQ, ACT and RCP “3 Questions” scores showed a significant 
correlation at both visit 1 and visit 2; Pearson correlation coefficients along with their 
significance levels are presented in tables 3-28 and 3-29.  
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Table 3-26: Patients self-reporting of their asthma control level at visit 1 and visit 2 
                     (asthmatic adults). 
Study Group 
Patients AC 
Rating* 
Visit 1 (n, %) Visit 2 (n, %) 
CT Group 
(n=5) 
Poor 0 0 
Fair 1 (20%) 0 
Good 2 (40%) 1 (20%) 
Very Good 2 (40%) 4(80%) 
Excellent 0 0 
VC Group 
(n=14) 
Patients AC 
Rating* 
Visit 1 (n, %) Visit 2 (n, %) 
Poor 2 (14.3%) 0 
Fair 2 (14.3%) 4 (28.6%) 
Good 6 (42.9%) 1 (7.1%) 
Very Good 3 (21.4%) 5 (35.7%) 
Excellent 1 (7.1%) 4 (28.6%) 
2TT Group 
(n=15) 
Patients AC 
Rating* 
Visit 1 (n, %) Visit 2 (n, %) 
Poor 2 (13.3%) 0 
Fair 2 (13.3%) 1 (6.7%) 
Good 2 (13.3%) 4 (26.7%) 
Very Good 7 (46.7%) 9 (60%) 
Excellent 2 (13.3%) 1 (6.7%) 
 * Patients personal rating of their asthma control. 
 
Table 3-27: Correlation of the patients self-reporting of their asthma control 
                     between visits 1 and 2 (asthmatic adults). 
Study Group Pearson Chi-Square χ2 (p-value, 2-tailed) 
CT  Group 5.000 (p = 0.200)* 
VC Group 12.483 (p = 0.512)* 
2TT Group 11.488 (p = 0.645)* 
   * Difference is not significant. 
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Figure 3-2: Patients self-reporting of asthma control level at visits 1 and 2. 
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Table 3-28: Correlation of the patients self-reporting of asthma control level with 
                     Mini-AQLQ, ACT and RCP “3 Questions” at visit 1 (asthmatic 
                     adults). 
 
Mini-AQLQ Domains 
 
Pearson Correlation (r) – Visit 1 
Self-Reporting of Asthma 
Control 
Overall AQLQ 0.689
*
 
Symptoms 0.668
*
 
Activity Limitation 0.437
*
 
Emotional Function 0.615
*
 
Environmental Stimuli 0.399
**
 
ACT 0.746
*
 
RCP “3 Questions” - 0.393
**
 
     * Correlation is significant at 0.01 level (2-tailed). ** Correlation is significant at 0.05 level (2-tailed). 
        
 
Table 3-29: Correlation of the patients self-reporting of asthma control level with 
                     Mini-AQLQ, ACT and RCP “3 Questions” at visit 2 (asthmatic 
                     adults). 
 
Mini-AQLQ Domains 
 
Pearson Correlation (r) – Visit 2 
Self-Reporting of Asthma 
Control 
Overall AQLQ 0.462
*
 
Symptoms 0.486
*
 
Activity Limitation 0.299
†
 
Emotional Function 0.296
†
 
Environmental Stimuli 0.473
*
 
ACT 0.666
*
 
RCP “3 Questions” - 0.362
**
 
     * Correlation is significant at 0.01 level (2-tailed). ** Correlation is significant at 0.05 level (2-tailed). 
     † Correlation is not significant. 
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3.3.2.8 MDI Technique Training History  
Five (100%), 10 (71.4%) and 13 (86.7%) patients in the CT, VC and 2TT groups, 
respectively, had a previous MDI technique training by their healthcare providers as 
part of their routine medical care, table 3-30. 
Table 3-30: Frequencies of patients with previous MDI Training in the past. 
Study Group 
Previous MDI 
Technique Training 
Visit 1 (n, %) 
CT Group 
(n=5) 
Yes 5 (100%) 
No 0 
VC Group 
(n=14) 
Previous MDI 
Technique Training 
Visit 1 (n, %) 
Yes 10 (71.4%)  
No 4 (28.6%) 
2TT Group 
(n=15) 
Previous MDI 
Technique Training 
Visit 1 (n, %) 
Yes 13 (86.7%) 
No 2 (13.3%) 
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3.3.2.9 The MDI Technique Assessment  
All asthmatic adults in the three study groups had their MDI technique checked, using a 
placebo inhaler, according to the most desirable MDI technique steps (total 11 steps), at 
both visit 1 and visit 2. The median (quartiles) of the incorrect MDI technique steps at 
visit 1 was: 3 (1; 3.5) for the CT group, 5.5 (5; 7) for the VC group and 5 (3; 6) for the 
2TT group. Whereas, at visit 2 the median (quartiles) of the incorrect MDI technique 
steps was: 2 (1; 2.5) for the CT group, 0 (0; 1) for the VC group and 1 (0; 2) for the 2TT 
group. Summaries of the frequencies of patients with incorrect MDI steps at both visits, 
for the CT, VC and 2TT groups are presented in tables 3-31, 3-32 and 3-33, 
respectively. None of the study patients performed all the steps correctly at either visit 1 
or visit 2. For the CT group, the most incorrectly performed steps were 8, 10 and 11 at 
visit 1; and steps 9 and 10 at visit 2. For the VC group, the most incorrectly performed 
steps were 6 and 7 at visit 1, and steps 7 and 11 at visit 2. For the 2TT group, the most 
incorrectly performed steps were 6 and 7 at visit 1, and steps 10 and 11 at visit 2. 
Comparison made by the non-parametric, paired-samples Wilcoxon test showed non 
significant differences in the incorrect MDI steps between visits 1 and 2, within the CT 
group, whilst the difference was statistically significant for the VC and 2TT groups (p < 
0.01). Pairwise comparison using the independent-samples Mann-Whitney U test 
showed a significant difference (p < 0.01) in the incorrectly preformed MDI steps 
between the CT group and both intervention groups (VC and 2TT) at visit 1. Whereas 
no significant difference in the incorrect MDI steps was found at visit 2 among the CT, 
VC and 2TT groups. 
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Table 3-31: Frequencies (n, %) of asthmatic adults with incorrect MDI steps in the 
                     CT group at visits 1 and 2. 
The most Desirable MDI Technique Steps 
CT Group (n = 5) 
n (%)  
Incorrect Steps 
Visit 1  Visit 2 
1) Remove the cap from the mouthpiece. 0 0 
2) Shake the inhaler. 1 (20%) 1 (20%) 
3) Breathe out slowly, as far as comfortable to empty your lungs. 1 (20%) 0 
4) Place the mouthpiece of the inhaler between your lips. 0 0 
5) Close your lips around the mouthpiece creating a seal. 0 0 
6) Start to breathe in slowly, through your mouth and immediately 
             press the aerosol canister to release a dose (puff). 
0 0 
7) Breathe in slowly until your lungs are full of air (as far as you 
can), the breath in step should take you about 5 seconds 
0 1 (20%) 
8) Remove the inhaler from your mouth and seal your lips. 2 (40%) 1 (20%) 
9) Hold your breath for 10 seconds. 0 3 (60%) 
10)  Breathe out slowly. 2 (40%) 3 (60%) 
11)  Repeat steps 1 to 10 after 30 seconds if another dose is  
        necessary. 
2 (40%) 0 
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Table 3-32: Frequencies (n, %) of asthmatic adults with incorrect MDI steps in the 
                     VC group at visits 1 and 2. 
The most Desirable MDI Technique Steps 
VC Group (n=14) 
n (%)  
Incorrect Steps 
Visit 1  Visit 2 
1) Remove the cap from the mouthpiece. 0 0 
2) Shake the inhaler. 
4 
(28.6%) 
0 
3) Breathe out slowly, as far as comfortable to empty your lungs. 
10 
(71.4%) 
0 
4) Place the mouthpiece of the inhaler between your lips. 0 0 
5) Close your lips around the mouthpiece creating a seal. 
1  
(7.1%) 
0 
6) Start to breathe in slowly, through your mouth and 
immediately  
       press the aerosol canister to release a dose (puff). 
14 
(100%) 
0 
7) Breathe in slowly until your lungs are full of air (as far as you 
can), the breath in step should take you about 5 seconds 
14 
(100%) 
3 
(21.4%) 
8) Remove the inhaler from your mouth and seal your lips. 
3 
(21.4%) 
1 
(7.1%) 
9) Hold your breath for 10 seconds. 
11 
(78.6%) 
2 
(14.3%) 
10)  Breathe out slowly. 
13 
(92.9%) 
2 
(14.3%) 
11)  Repeat steps 1 to 10 after 30 seconds if another dose is 
        necessary. 
12 
(85.7%) 
3 
(21.4%) 
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Table 3-33: Frequencies (n, %) of asthmatic adults with incorrect MDI steps in the 
                     2TT group at visits 1 and 2. 
The most Desirable MDI Technique Steps 
2TT Group 
(n=15) 
n (%)  
Incorrect Steps 
Visit 1  Visit 2 
1) Remove the cap from the mouthpiece. 0 0 
2) Shake the inhaler. 
2 
(13.3%) 
0 
3) Breathe out slowly, as far as comfortable to empty your lungs. 
11 
(73.3%) 
1  
(6.7%) 
4) Place the mouthpiece of the inhaler between your lips. 0 0 
5) Close your lips around the mouthpiece creating a seal. 0 0 
6) Start to breathe in slowly, through your mouth and 
immediately 
       press the aerosol canister to release a dose (puff). 
15 
(100%) 
3 
 (20%) 
7) Breathe in slowly until your lungs are full of air (as far as you 
can), the breath in step should take you about 5 seconds 
15 
(100%) 
3  
(20%) 
8) Remove the inhaler from your mouth and seal your lips. 
1  
(6.7%) 
0 
9) Hold your breath for 10 seconds. 
12 
(80%) 
2 
(13.3%) 
10)  Breathe out slowly. 
11 
(73.3%) 
6 
(40%) 
11)  Repeat steps 1 to 10 after 30 seconds if another dose is 
        necessary. 
9  
(60%) 
6 
(40%) 
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3.3.3 Results of Asthmatic Children 
To assess the distribution of the asthmatic children‟s data, histograms and normality 
distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) were used. These 
tests showed that the following data were normally distributed; the FEV1 % predicted 
and PAQLQ scores. Whilst, the IFR, PACQLQ scores, C-ACT scores and the 3 RCP 
“key questions” scores were not normally distributed. Accordingly, the appropriate 
statistical test was applied for the children‟s data analysis and presentation 
3.3.3.1 Lung Function (FEV1 % predicted)  
The mean (SD) of the FEV1 % predicted for the CT, VC and 2TT groups at visits 1 and 
2, along with that of the change (∆) in FEV1 % predicted between the two visits are 
presented in table 3-34. Frequencies of the patients at various asthma severity levels are 
shown in table 3-35, asthma severity classification was based on the FEV1 % predicted 
categories of the GINA (2008) guidelines. Details of all patients‟ measured FEV1 
values, predicted FEV1 and FEV1 % predicted for the CT, VC and 2TT groups (at visits 
1 and 2) are presented in APPENDIX B-4, B-5 and B-6, respectively (refer to the 
enclosed DVD). 
Table 3-34: Mean (SD) FEV1 % predicted for all study groups (asthmatic 
                     children) at visits 1 and 2, and of the change (∆) in FEV1 % predicted 
                     between the two visits.   
Study 
Group 
FEV1 % pred, Visit 1 
Mean (SD) 
FEV1 % pred, Visit 2 
Mean (SD) 
∆ FEV1 % pred.* 
Mean (SD)  
CT** 
(n = 3) 
102.8 (10.1) 103.3 (6.4) 0.53 (4.1) 
VC 
(n = 5) 
90.4 (18.1) 94.1 (4.8) 3.7 (18.1) 
2TT 
(n = 6) 
88.9 (18.0) 90.9 (14.3) 2.0 (8.7) 
 * ∆: Change in FEV1 % predicted between visits 1 and 2.  
** Two children in the CT group were ≤ 5 years old and had no spirometry results. 
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Table 3-35: Asthma severity frequencies for each study group (asthmatic children) 
                     at visits 1 and 2.     
Study 
Group 
Study Visit 
Asthma Severity Levels* – n (%) 
Mild  Moderate Severe 
CT** 
(n = 3) 
Visit 1 3 (100%) 0 0 
Visit 2 3 (100%) 0 0 
VC 
(n = 5) 
Visit 1 4 (80%) 0 1 (20%) 
Visit 2 5 (100%) 0 0 
2TT 
(n = 6) 
Visit 1 5 (83.3%) 1 (16.7%) 0 
Visit 2 4 (66.7%) 2 (33.3%) 0 
* Asthma severity classification according to FEV1 %predicted categories of the GINA (2008) 
    Guidelines. 
** Two children in the CT group were ≤ 5 years old and had no spirometry results. 
Histograms and tests of normal distribution (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) (table 3-36) showed that the FEV1 % predicted data was normally 
distributed. Comparison of the FEV1 % predicted between visit 1 and visit 2 within the 
CT, VC and 2TT groups (using the related-samples t-test) is presented in table 3-37. 
The results showed that there was no significant difference in FEV1 % predicted 
between the two study visits within all study groups. 
Table 3-36: Tests of normality for FEV1 % predicted at visits 1 and 2 for all study 
                     groups (asthmatic children). 
 
 
Kolmogorov-Smirnov(a) Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
FEV1 %Pred. 
(Visit 1) 
0.171 14 0.200
*
 .905 14 0.134 
FEV1 %Pred. 
(Visit 2) 
0.125 14 0.200
*
 .947 14 0.519 
           * This is a lower bound of the true significance.     a)  Lilliefors Significance Correction 
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Table 3-37: Comparison of the FEV1 % predicted between V1 and V2 within each 
                     of the study groups (asthmatic children).  
Study Group 
Related-Samples t-test for FEV1 % predicted (V1 & V2) 
Mean Difference (95% CI) / p-value (2-tailed) 
CT  Group - 0.53 (- 10.6; 9.6) / p = 0.841 
VC Group - 3.7 (- 26.2; 18.8) / p = 0.671 
2TT Group - 2.0 (- 11.2; 7.2) / p = 0.599 
 
Pairwise comparison of the FEV1 % predicted at visit 1 and visit 2 among the CT, VC 
and 2TT groups using the independent-samples t-test is presented in table 3-38. 
Moreover, comparison of the change in FEV1 % predicted (between the two visits) 
among the 3 groups using the independent-samples t-test is also presented in table 3-38. 
The results showed no statistically significant differences in FEV1 % predicted or in the 
change in FEV1 % predicted among the CT, VC and 2TT groups. 
Table 3-38: Pairwise comparison of the FEV1 % predicted among all study groups 
                     (asthmatic children) at visits 1 and 2. 
Study Group 
Independent-samples t-test for FEV1 % predicted  
Mean Difference (95% CI) / p-value (2-tailed) 
CT vs. VC (visit 1) 12.35 (-16.0; 40.7) / p = 0.328 
CT vs. 2TT (visit 1) 13.9 (-13.2; 40.9) / p = 0.265 
VC vs. 2TT (visit 1) 1.52 (-23.2; 26.3) / p = 0.893 
CT vs. VC (visit 2) 9.18 (-0.46; 18.8) / p = 0.059 
CT vs. 2TT (visit 2) 12.4 (-8.6; 33.4) / p = 0.205 
VC vs. 2TT (visit 2) 3.22 (-12.0; 18.5) / p = 0.645 
Independent-samples t-test for the change (∆) in FEV1 % predicted (between V1 & 
V2) 
CT vs. VC  -3.17 (-29.9; 23.6) / p = 0.782 
CT vs. 2TT  -1.47 (-14.3; 11.4) / p = 0.795 
VC vs. 2TT  1.70 (-17.1; 20.5) / p = 0.842 
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3.3.3.2 Inhalation Flow Rate (IFR)  
Of the 16 asthmatic children who completed the two study visits as per protocol, 11 
(68.7%) patients inhaled at an IFR ≥ 90 l/min through an MDI at study enrolment (visit 
1), and thus were randomised into either the VC (5 patients) or 2TT (6 patients) 
intervention groups (table 3-39). All the 11 patients in the intervention (VC and 2TT) 
groups inhaled at a rate < 90 l/min when the IFR was measured immediately after they 
had been verbally counselled on the correct MDI technique at visit 1. At the second 
follow-up visit, 10 (90.9%) patients of the VC and 2TT groups inhaled at a rate < 90 
l/min through an MDI; 4 patients in the VC group and all 6 patients in the 2TT group 
(table 3-39).  
Five (31.3%) patients inhaled at an IFR < 90 l/min at visit 1, and therefore formed the 
CT group. Four (80%) patients in the CT group continued to inhale at a rate < 90 l/min 
at visit 2; whereas one patient inhaled at a faster rate (≥ 90 l/min), table 3-39. The 
median (25%; 75% quartiles) of the IFR at visit 1 and visit 2, along with that for the 
change in IFR (∆ IFR, between V1 and V2), for the CT, VC and 2TT groups are 
summarized in table 3-40. Figure 3-3 shows that the mean IFR at visit 2 for the patients 
in the VC and 2TT groups was less than 90 l/min, and far less than that of visit 1. 
Details of the IFR values and ∆ IFR (between V1 and V2) for all the patients in the CT, 
VC and 2TT groups are presented in APPENDIX B-10 (refer to the enclosed DVD). 
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Table 3-39: Frequencies (n, %) in the IFR categories for the CT, VC and 2TT 
                     groups (asthmatic children), (visits 1 and 2). 
Study Group 
IFR (l/min) 
Category 
Visit 1 (n, %) Visit 2 (n, %) 
CT Group 
(n=5) 
<30 0 0 
30 – 60 4 (80%) 1 (20%) 
61 – 89 1 (20%) 3 (60%) 
≥90 0 1 (20%) 
 
VC Group 
(n=5) 
IFR (l/min) 
Category 
Visit 1 (n, %) 
Visit 2 (n, %) Before 
VC 
After  
VC 
<30 0 0 0 
30 – 60 0 4 (80%) 3 (60%) 
61 – 89 0 1 (20%) 1 (20%) 
≥90 5 (100%) 0 1 (20%) 
 
2TT Group 
(n=6) 
IFR (l/min) 
Category 
Visit 1 (n, %) 
Visit 2 (n, %) Before  
VC 
After  
VC 
<30 0 0 0 
30 – 60 0 4 (66.7%) 2 (33.3%) 
61 – 89 0 2 (33.3%) 4 (66.7%) 
≥90 6 (100%) 0 0 
 
Table 3-40: Median (25%; 75% quartiles) of IFR (V1 and V2) and of ∆ IFR for all 
                    study groups (asthmatic children).                
Study 
Group 
IFR (l/min), Visit 1 
[Median (25%, 75%)] 
IFR (l/min), Visit 2 
[Median (25%, 75%)] 
∆ IFR (l/min) 
[Median (25%, 75%)] 
CT 
(n = 5) 
50.0 (42.5; 62.5) 70.0 (54.0; 100.0) 18.0 (0.0; 50.0) 
VC 
(n = 5) 
110.0 (93.5; 200.0) 60.0 (35.0; 90.0) - 80.0 (- 120.0; -33.5) 
2TT 
(n = 6) 
130.0 (97.7; 172.5) 78.0 (50.0; 81.2) - 58.5 (- 107.5; - 19.2) 
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Figure 3-3: Mean IFR at visits 1 and 2 for all study groups (asthmatic children). 
Histograms and the normality distribution tests (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the IFR data was not normally distributed. Therefore, the 
Wilcoxon matched-pairs, signed ranks test was used to investigate the differences in 
the IFR between the two study visits within each group. For the CT group, the 
Wilcoxon test showed that the difference between the IFR at visit 1 (M = 52.0; SD = 
13.5) and the IFR at visit 2 (M = 75.6; SD = 28.9) was not statistically significant: p = 
0.104 (two-tailed). The sum of ranks were 1.50 and 13.50 for the negative and positive 
ranks, respectively, therefore W = 1.50. For the VC group, the Wilcoxon test showed 
that the difference between the IFR at visit 1 (M = 139.4; SD = 56.2) and that at visit 2 
(M = 62.0; SD = 28.6) was statistically significant: p = 0.043 (two-tailed). The sum of 
ranks were 15.0 and zero for the negative and positive ranks, respectively, therefore W 
= Zero. For the 2TT group, the Wilcoxon test showed that the difference between the 
IFR at visit 1 (M= 140.2; SD=53.5) and that at visit 2 (M = 70.2; SD = 15.8) was 
statistically significant: p = 0.028 (two-tailed). The sum of ranks were 21.0 and zero for 
the negative and positive ranks, respectively, therefore W = zero. 
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Pairwise comparison of the IFR (visit 1, visit 2 and the change in IFR between the two 
visits) among the three study groups was done using the independent-samples non-
parametric Mann-Whitney U test, table 3-41. The results showed that, at visit 1, there 
was a significant difference in the IFR between the CT group and both the VC and 2TT 
groups, whereas there was no difference in the IFR between the VC and 2TT groups. 
On the other hand, no significant difference in the IFR was found among the 3 groups 
at visit 2. For the change in the IFR (∆ IFR) over the follow-up period, there was a 
significant difference between the CT group and both the VC and 2TT groups, whereas 
no difference between the VC and 2TT groups was found.  
Table 3-41: Pairwise comparison of IFR (V1 and V2) and of ∆ IFR among all study 
                     groups (asthmatic children).  
Study Group 
Mann-Whitney U Test: U-Value (exact p: 2-tailed) for the 
IFR 
Visit 1 (baseline) Visit 2 ∆ IFR (V1 & V2) 
CT vs. VC 0.0 (p=0.008)* 9.0 (p=0.516) 0.0 (p=0.008)* 
CT vs. 2TT 0.0 (p=0.004)* 14.5 (p=0.961) 0.0 (p=0.004)* 
VC vs. 2TT 14.0 (p=0.892) 12.5 (p=0.684) 12.0 (p=0.628) 
    * Difference is statistically significant. 
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3.3.3.3 The Paediatric Asthma Quality of Life Questionnaire  
For the three study groups, a summary of the mean (SD) of the PAQLQ scores (overall 
and its three domains: Symptoms, Activity Limitation and Emotional Function) at visit 
1 and visit 2, and of the mean (SD) of the scores‟ change between the two visits is 
presented in tables 3-42, 3-43 and 3-44, respectively. The detailed PAQLQ scores of all 
the patients in each of the CT, VC and 2TT groups are presented in APPENDIX B-17, 
B-19 and B-21, respectively (refer to the enclosed DVD). The change in the overall 
PAQLQ scores and its domains (between visits 1 and 2) of all the patients in the CT, 
VC and 2TT groups is presented in APPENDIX B-18, B-20 and B-22, respectively 
(refer to the enclosed DVD). 
Table 3-42: Mean (SD) of the PAQLQ scores at visit 1 for all study groups 
                     (asthmatic children). 
PAQLQ Domains 
(Visit 1) 
Mean (SD) Score – Visit 1 
CT Group* VC Group 2TT Group 
Overall PAQLQ 4.3 (0.98) 5.0 (1.40) 5.4 (0.94) 
Symptoms 3.9 (1.12) 4.9 (1.45) 5.1 (1.15) 
Activity Limitation 4.7 (0.42) 4.8 (1.40) 5.2 (0.85) 
Emotional Function 4.5 (1.25) 5.4 (1.48) 5.8 (0.88) 
     * Two children in the CT group were < 7 years old and had no PAQLQ scores. 
 
Table 3-43: Mean (SD) of the PAQLQ scores at visit 2 for all study groups 
                     (asthmatic children). 
PAQLQ Domains 
(Visit 2) 
Mean (SD) Score – Visit 2 
CT Group* VC Group 2TT Group 
Overall PAQLQ 4.4 (1.83) 5.4 (1.58) 5.7 (0.76) 
Symptoms 4.7 (1.50) 5.4 (1.46) 5.5 (0.90) 
Activity Limitation 4.4 (2.11) 5.6 (1.24) 5.6 (0.77) 
Emotional Function 4.1 (2.29) 5.4 (2.01) 6.2 (0.78) 
     * Two children in the CT group were < 7 years old and had no PAQLQ scores. 
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Table 3-44: Mean (SD) of the change (∆) in PAQLQ scores for all study groups 
                    (asthmatic children). 
∆ PAQLQ Domains* 
(betweenV1 & V2) 
Mean (SD) ∆ PAQLQ Score  
CT Group** VC Group 2TT Group 
∆ Overall PAQLQ 0.159 (0.87) 0.391 (0.45) 0.362 (0.40) 
∆ Symptoms 0.800 (0.56) 0.500 (0.23) 0.367 (0.54) 
∆ Activity Limitation - 0.333 (1.86) 0.800 (1.14) 0.333 (0.57) 
∆ Emotional Function - 0.333 (1.19) 0.0 (0.58) 0.375 (0.24) 
   * ∆: Change in the domain scores between visits 1 and 2.  
  ** Two children in the CT group were < 7 years old and had no PAQLQ scores. 
 
For the three study groups, table 3-45 shows the frequencies and percentages of the 
patients whose scores‟ change (∆) in PAQLQ and its domains (between visit 1 and visit 
2) was greater than the minimal important difference (MID ≥ 0.5). One (33.3%) patient 
in the CT group had a change in the overall PAQLQ score below the MID (< 0.5). On 
the other hand, 1 (20%) and 2 (33.3%) patients in the VC and 2TT groups, respectively, 
had a change in the overall PAQLQ scores greater than the MID (≥ 0.5).  
Histograms and normality distribution tests (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the PAQLQ scores were normally distributed. Within each 
study group, a comparison using the related-samples t-test of the overall PAQLQ and its 
three domain scores between visit 1 and visit 2 is presented in table 3-46 [as a mean 
difference (95% confidence interval), p-value (2-tailed)]. The results showed that within 
the CT group no significant difference between visits 1 and 2 was found in the overall 
PAQLQ and its domains. For the VC group, the difference between visits 1 and 2 in the 
overall PAQLQ and its domains was not statistically significant, except for that in the 
symptoms domain. None of the differences between visits 1 and 2 in the overall 
PAQLQ and its domains was significant within the 2TT group, except that for the 
emotional function domain.  
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Using the independent-samples t-test, a pairwise comparison among the CT, VC and 
2TT groups for the PAQLQ scores (overall and the 3 domains) at visit 1 and visit 2 is 
presented in tables 3-47 and 3-48, respectively. The results showed no significant 
difference among the 3 groups in any of the PAQLQ scores at both visit 1 and visit 2.  
Similar comparison was made for the change (∆) in the PAQLQ scores (between visit 1 
and visit 2) (table 3-49); which also showed no significant difference among the 3 
groups in any of the PAQLQ domains.  
Table 3-45: Frequencies (n, %) of patients achieved a MID in PAQLQ domains for 
                     all study groups (asthmatic children). 
Study 
Group 
∆ PAQLQ 
Category 
∆ 
Overall  
(n, %) 
∆ 
Symptoms 
(n, %) 
∆ Activity 
Limitation 
(n, %) 
∆ 
Emotional 
Function 
(n, %) 
CT 
Group 
(n=3)* 
≤ -0.5 1 (33.3%) 0 1 (33.3%) 1 (33.3%) 
-0.49 – 0.49 1 (33.3%) 1 (33.3%) 1 (33.3%) 1 (33.3%) 
0.5 – 1.0 0 1 (33.3%) 0 1 (33.3%) 
> 1.0 1 (33.3%) 1 (33.3%) 1 (33.3%) 0 
VC 
Group 
(n=5) 
≤ -0.5 0 0 0 1 (20%) 
-0.49 – 0.49 4 (80%) 3 (60%) 3 (60%) 2 (40%) 
0.5 – 1.0 0 2 (40%) 1 (20%) 2 (40%) 
> 1.0 1 (20%) 0 1 (20%) 0 
2TT 
Group 
(n=6) 
≤ -0.5 0 1 (16.7%) 0 0 
-0.49 – 0.49 4 (66.7%) 2 (33.3%) 4 (66.7%) 4 (66.7%) 
0.5 – 1.0 2 (33.3%) 2 (33.3%) 1 (16.7%) 2 (33.3%) 
> 1.0 0 1 (16.7%) 1 (16.7%) 0 
          * Two children in the CT group were < 7 years old and had no PAQLQ scores. 
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Table 3-46: Comparison of the PAQLQ scores between visit 1 and 2 within each 
                     study group (asthmatic children). 
 
PAQLQ 
Domains 
 
Mean Difference (95% CI) / p-value (2-tailed) 
Study Group  
CT  Group VC Group 2TT Group 
Overall 
PAQLQ 
- 0.159 (-2.33; 2.01) 
p = 0.782 
- 0.391 (-0.95; 0.16) 
p = 0.122 
- 0.362 (-0.78; 0.06) 
p = 0.076 
Symptoms 
- 0.800 (-2.18; 0.58) 
p =  0.131 
- 0.500 (-0.79; -0.21) 
p = 0.009* 
- 0.367 (-0.93; 0.20) 
p = 0.154 
Activity 
Limitation 
0.333 (-4.28; 4.95) 
p =  0.785 
- 0.800 (-2.22; 0.62) 
p = 0.192 
- 0.333 (-0.94; 0.27) 
p = 0.215 
Emotional 
Function 
0.333 (-2.62; 3.28) 
p =  0.675 
0.0 (-0.72; 0.72) 
p = 1.000 
- 0.375 (-.62; -0.13) 
p = 0.012* 
  * Statistically significant difference. 
 
Table 3-47: Pairwise comparison of the PAQLQ domains at visit 1 among the 
                     study groups (asthmatic children). 
PAQLQ 
Domains 
 
Independent-samples t-test  - Visit 1 
Mean Difference (95% CI) / p-value (2-tailed) 
CT vs. VC CT vs. 2TT VC vs. 2TT 
Overall 
PAQLQ 
-0.76 (-3.0, 1.5) 
p = 0.448 
-1.12 (-2.7; 0.46) 
p = 0.138 
-0.37 (-2.0; 1.2) 
p = 0.616 
Symptoms 
-0.99 (-3.4; 1.4) 
p = 0.352 
-1.25 (-3.2; 0.66) 
p = 0.165 
-0.26 (-2.0; 1.5) 
p = 0.750 
Activity 
Limitation 
-0.03 (-2.1; 2.1) 
p = 0.976 
-0.50 (-1.8; 0.76) 
p = 0.380 
-0.47 (-2.0; 1.1) 
p = 0.507 
Emotional 
Function 
-0.92 (-3.4; 1.6) 
p = 0.407 
-1.35 (-3.0; 0.32) 
p = 0.098 
-0.44 (-2.1; 1.2) 
p = 0.558 
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Table 3-48: Pairwise comparison of the PAQLQ domains at visit 2 among the 
                     study groups (asthmatic children). 
PAQLQ 
Domains 
 
Independent-samples t-test  - Visit 2 
Mean Difference (95% CI) / p-value (2-tailed) 
CT vs. VC CT vs. 2TT VC vs. 2TT 
Overall 
PAQLQ 
-0.98 (-4.0; 2.0) 
p = 0.447 
-1.33 (-3.3; 0.63) 
p = 0.152 
-0.34 (-2.0; 1.3) 
p = 0.651 
Symptoms 
-0.69 (-3.3; 1.9) 
p = 0.543 
-0.82 (-2.7; 1.0) 
p = 0.331 
-0.12 (-1.7; 1.5) 
p = 0.867 
Activity 
Limitation 
-1.16 (-4.0; 1.7) 
p = 0.354 
-1.17 (-3.3; 1.0) 
p = 0.246 
-0.006 (-1.4; 1.4) 
p = 0.992 
Emotional 
Function 
-1.25 (-5.0; 2.5) 
p = 0.448 
-2.06 (-4.4; 0.3) 
p = 0.075 
-0.81 (-2.8; 1.2) 
p = 0.382 
 
 
Table 3-49: Pairwise comparison of the change (∆) in the PAQLQ domains among 
                    the study groups (asthmatic children). 
∆ PAQLQ 
Domains 
 
Independent-samples t-test   
Mean Difference (95% CI) / p-value (2-tailed) 
CT vs. VC CT vs. 2TT VC vs. 2TT 
∆ Overall 
PAQLQ 
-0.23 (-1.3; 0.9) 
p = 0.628 
-0.20 (-1.17; 0.76) 
p = 0.634 
0.03 (-0.55; 0.60) 
p = 0.912 
∆ Symptoms 
0.30 (-0.37; 0.97) 
p = 0.314 
0.43 (-0.47; 1.34) 
p = 0.295 
0.13 (-0.45; 0.72) 
p = 0.620 
∆ Activity 
Limitation 
-1.13 (-3.7; 1.4) 
p = 0.317 
-0.67 (-2.52; 1.18) 
p = 0.422 
0.47 (-0.73; 1.66) 
p = 0.400 
∆ Emotional 
Function 
-0.33 (-1.8; 1.2) 
p = 0.604 
-0.71 (-1.82; 0.41) 
p = 0.176 
-0.38 (-0.96; 0.21)  
p = 0.179 
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3.3.3.4 The PACQLQ  
For the three study groups, a summary of the mean (SD) of the PACQLQ scores 
(overall and its two domains: Activity Limitation and Emotional Function) at visit 1 and 
visit 2, and of the mean (SD) of the PACQLQ scores‟ change (∆) between the two visits 
is presented in tables 3-50, 3-51 and 3-52, respectively. The detailed PACQLQ scores of 
all the caregivers in each of the CT, VC and 2TT groups are presented in APPENDIX 
B-23, B-25 and B-27, respectively (refer to the enclosed DVD). The change (∆) in the 
overall PACQLQ scores and its domains (between visits 1 and 2) of all the caregivers in 
the CT, VC and 2TT groups is presented in APPENDIX B-24, B-26 and B-28, 
respectively (refer to the enclosed DVD). 
Table 3-50: Mean (SD) of the PACQLQ scores at visit 1 for all study groups.                      
PACQLQ Domains 
(Visit 1) 
Mean (SD) Score – Visit 1 
CT Group VC Group 2TT Group 
Overall PACQLQ 5.9 (0.72) 5.7 (1.04) 5.6 (0.45) 
Activity Limitation 6.3 (0.58) 6.0 (1.17) 5.8 (0.58) 
Emotional Function 5.6 (0.83) 5.5 (0.99) 5.5 (0.44) 
 
Table 3-51: Mean (SD) of the PACQLQ scores at visit 2 for all study groups.                     
PACQLQ Domains 
(Visit 2) 
Mean (SD) Score – Visit 2 
CT Group VC Group 2TT Group 
Overall PACQLQ 6.0 (0.71) 5.2 (1.19) 6.3 (0.26) 
Activity Limitation 6.5 (0.40) 5.6 (1.28) 6.8 (0.33) 
Emotional Function 5.7 (0.92) 5.1 (1.25) 6.0 (0.30) 
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Table 3-52: Mean (SD) of the change (∆) in PACQLQ scores for all study groups. 
∆ PACQLQ Domains* 
(betweenV1 & V2) 
Mean (SD) ∆ PACQLQ Score  
CT Group VC Group 2TT Group 
∆ Overall PACQLQ 0.108 (0.38) - 0.431 (0.91) 0.679 (0.40) 
∆ Activity Limitation 0.150 (0.28) - 0.400 (1.21) 0.958 (0.58) 
∆ Emotional Function 0.089 (0.48) - 0.444 (0.95) 0.556 (0.43) 
  * ∆: Change in the domain scores between visits 1 and 2.  
For the three study groups, table 3-53 shows the frequencies and percentages of the 
caregivers whose scores‟ change (∆) in PACQLQ and its domains (between visit 1 and 
visit 2) was greater than the minimal important difference (MID ≥ 0.5). Four (80%) 
caregivers in the CT group had a change in the overall PACQLQ score below the MID 
(< 0.5). On the other hand, 1 (20%) and 4 (66.7%) caregivers in the VC and 2TT 
groups, respectively, had a change in the overall PACQLQ scores greater than the MID 
(≥ 0.5).  
Histograms and normality distribution tests (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the PACQLQ scores were not normally distributed. Within each 
study group, a comparison using the Wilcoxon Signed Ranks test of the overall 
PACQLQ and its two domain scores between visit 1 and visit 2 was performed; the 
results showed that within the CT and VC groups no significant difference (p > 0.05) 
between visits 1 and 2 was found in the overall PACQLQ and its domains. Differences 
between visits 1 and 2 in the overall PACQLQ and activity limitation domain scores 
were significant (p = 0.031) within the 2TT group, whereas, it was not significant for 
the emotional function domain (p > 0.05).  
Using the independent-samples, non-parametric Mann-Whitney U test, a pairwise 
comparison among the CT, VC and 2TT groups for the PACQLQ scores (overall and 
the 2 domains) at visit 1 and visit 2 was performed; the results showed no significant 
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difference (p > 0.05) among the 3 groups in any of the PACQLQ scores at both visit 1 
and visit 2.  Similar comparison was made for the change (∆) in the PACQLQ scores 
between visit 1 and visit 2; a significant difference (p < 0.05) was only found in the 
change of the Overall and Activity Limitation scores, between the CT vs. 2TT groups; 
and the VC vs. 2TT groups. 
Table 3-53: Frequencies (n, %) of paediatric asthma caregivers achieved a MID in 
                     PACQLQ domains for all study groups. 
Study Group 
∆ PACQLQ 
Category 
∆ Overall  
(n, %) 
∆ Activity 
Limitation 
(n, %) 
∆ Emotional 
Function 
(n, %) 
CT Group 
(n=5) 
≤ -0.5 1 (20%) 0 1 (20%) 
-0.49 – 0.49 4 (80%) 4 (80%) 4 (80%) 
0.5 – 1.0 0 1 (20%) 0 
> 1.0 0 0 0 
VC Group 
(n=5) 
≤ -0.5 2 (40%) 1 (20%) 2 (40%) 
-0.49 – 0.49 2 (40%) 3 (60%) 2 (40%) 
0.5 – 1.0 1 (20%) 1 (20%) 1 (20%) 
> 1.0 0 0 0 
2TT Group 
(n=6) 
≤ -0.5 0 0 0 
-0.49 – 0.49 2 (33.3%) 2 (33.3%) 3 (50%) 
0.5 – 1.0 2 (33.3%) 1 (16.7%) 2 (33.3%) 
> 1.0 2 (33.3%) 3 (50%) 1 (16.7%) 
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3.3.3.5 The Childhood Asthma Control Test (C-ACT)  
For the asthmatic children, the C-ACT was used in 4 – 11 year-old age group, whilst the 
ACT was used in those ≥ 12 years old. Both the C-ACT and ACT have similar score 
analysis and interpretation cut-off points. In this section, the abbreviation “C-ACT” is 
just used to differentiate between the children‟s and the adults‟ asthma control sections. 
For the CT, VC and 2TT groups, the median (25%, 75% quartiles) of the C-ACT scores 
at visits 1 and 2, and of the change in the C-ACT scores between the two visits are 
presented in table 3-54. Details of the C-ACT scores of all patients in the CT, VC and 
2TT groups are shown in APPENDIX B-32 (refer to the enclosed DVD).  
Table 3-55 presents the frequencies and percentages of the patients in different cut-off 
C-ACT score categories, at both visits 1 and 2. For the CT group, frequencies 
(percentages) of patients within the insufficiently- (0-19) and well-controlled (20-24) 
asthma remained the same at the two study visits. For the VC group, 4 (80%) patients 
were in the well- and completely-controlled asthma categories at visit 2, compared to 3 
(60%) patients at visit 1. For the 2TT group, 4 (66.7%) patients were in the well- and 
completely-controlled asthma categories at visit 2, compared to 2 (33.3%) patients at 
visit 1.   
Table 3-54: Median (25%, 75% quartiles) of the C-ACT scores at visits 1 and 2, 
                     and of ∆ C-ACT scores for all study groups. 
Study 
Group 
C-ACT, Visit 1 
[Median (25%, 75%)] 
C-ACT, Visit 2 
[Median (25%, 75%)] 
∆ C-ACT 
 [Median (25%, 75%)] 
CT 
(n = 5) 
22.0 (13.5; 23.0) 22.0 (15.5; 23.0) 1.0 (- 0.50; 2.00) 
VC 
(n = 5) 
23.0 (12.5; 23.0) 24.0 (15.5; 24.5) 1.00 (1.00; 3.50) 
2TT 
(n = 6) 
18.0 (15.25; 21.25) 21.5 (17.0; 25.0) 2.50 (0.0; 5.50) 
  ∆: Change in the C-ACT scores between visits 1 and 2. 
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Table 3-55: Frequencies (n, %) in the C-ACT categories for the CT, VC and 2TT 
                     groups (visits 1 and 2). 
 
Study Group 
 
C-ACT 
Category 
Visit 1 (n, %) Visit 2 (n, %) 
CT Group 
(n=5) 
0 - 19 2 (40%) 2 (40%) 
20 - 24 3 (60%) 3 (60%) 
25 - 27 0 0 
VC Group 
(n=5) 
C-ACT 
Category 
Visit 1 (n, %) Visit 2 (n, %) 
0 - 19 2 (40%) 1 (20%) 
20 - 24 3 (60%) 3 (60%) 
25 - 27 0 1 (20%) 
2TT Group 
(n=6) 
C-ACT 
Category 
Visit 1 (n, %) Visit 2 (n, %) 
0 - 19 4 (66.7%) 2 (33.3%) 
20 - 24 2 (33.3%) 2 (33.3%) 
25 - 27 0 2 (33.3%) 
 
Histograms and normality distribution tests (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the C-ACT scores were not normally distributed. Comparison 
using the related-samples, non-parametric Wilcoxon test of the C-ACT scores between 
visit 1 and visit 2 within each study group was performed; the results showed that the 
difference in the C-ACT scores between visit 1 and visit 2 was non significant (p > 
0.05), in the 3 study groups. The independent-samples Mann-Whitney U test was used 
to compare the C-ACT scores across the three groups at visit 1 and visit 2, as well as to 
compare the change in the C-ACT scores over the study follow-up period; the results 
showed a non significant difference (p > 0.05) in the C-ACT and ∆ C-ACT scores 
among the CT, VC and 2TT groups.  
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3.3.3.6 The Royal College of Physicians (RCP) „3 Key 
Questions‟  
The responses of the patients to the RCP “3 Questions” (1 = Yes; 0 = No) at visits 1 and 
2 are presented in table 3-56. A negative response to the 3 questions suggests a well-
controlled asthma, whereas one or more positive (yes) answers suggest an inadequately 
controlled condition. In general, the responses were almost similar at the two visits, for 
all study groups. The detailed RCP “3 Questions” scores of all patients (visits 1 and 2) 
in the CT, VC and 2TT groups are presented in APPENDIX B-36 (refer to the enclosed 
DVD).  
Table 3-56: Frequencies (n, %) of the positive responses to the RCP “3 Key 
                     Questions” for the CT, VC and 2TT groups (visits 1 and 2) (asthmatic 
                     children). 
Study Group 
Number of 
“Yes” 
Responses* 
Visit 1 (n, %) Visit 2 (n, %) 
CT Group 
(n=5) 
0 0 0 
1 2 (40%) 2 (40%) 
2 1 (20%) 3 (60%) 
3 2 (40%) 0 
VC Group 
(n=5) 
Number of 
“Yes” 
Responses* 
Visit 1 (n, %) Visit 2 (n, %) 
0 0 0 
1 1 (20%) 2 (40%) 
2 2 (40%) 2 (40%) 
3 2 (40%) 1 (20%) 
2TT Group 
(n=6) 
Number of 
“Yes” 
Responses* 
Visit 1 (n, %) Visit 2 (n, %) 
0 0 0 
1 2 (33.3%) 2 (33.3%) 
2 3 (50%) 3 (50%) 
3 1 (16.7%) 1 (16.7%) 
   * Number of positive (Yes) responses to the RCP “3 Questions” (Yes = 1; No = 0). A zero score 
suggests a well-controlled asthma; while a score ≥ 1.0 suggests inadequately controlled condition. 
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3.3.3.7 Correlation between the Asthma Quality of Life and            
Asthma Control Instruments  
Correlation between the C-ACT and RCP “3 Key Questions” with the PAQLQ (Overall 
and its 3 domains) was investigated using the Pearson correlation test. The results 
showed that the C-ACT had a significant strong positive correlation with the overall 
PAQLQ at both visits 1 and 2; r = 0.829 and 0.874 (p <0.01), respectively. However, 
the ∆ C-ACT had no significant correlation with the ∆ overall PAQLQ. The details of 
the correlation of the C-ACT with all the PAQLQ domains at visit 1 and visit 2, along 
with the correlation of the change in their scores over the study period are presented in 
tables 3-57, 3-58 and 3-59, respectively. On the other hand, the RCP “3 Questions‟ 
showed a significant negative correlation with the overall PAQLQ at visit 1 only (r = - 
0.596, p < 0.05). The details of the correlation of the RCP “3 Questions” with all the 
PAQLQ domains are presented in tables 3-57, 3-58 and 3-59.  
The two asthma control instruments; the C-ACT and RCP “3 Questions” had a 
significant negative correlation with each other (r = - 0.656, p < 0.01) at the visit 1 only, 
the details are presented in table 3-60.  
Correlation between the C-ACT and RCP “3 Key Questions” with the PACQLQ 
(Overall and its 2 domains) was also investigated using the Pearson correlation test. In 
general, no significant correlation was found between the PACQLQ (overall and its 2 
domains) with the RCP “3 Questions” at visit 1 and visit 2. Whereas the C-ACT did 
correlate significantly with the overall PACQLQ and its emotional function domain at 
visit 1; tables 3-61 and 3-62. The change in these questionnaire scores over the study 
follow-up period did not show any significant correlation as well; table 3-63. 
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Table 3-57: Correlation of PAQLQ with C-ACT and RCP “3 Questions” at visit 1. 
 
PAQLQ Domains 
 
Pearson Correlation (r) – Visit 1 
C-ACT RCP “3 Questions” 
Overall PAQLQ 0.829
*
 - 0.596
**
 
Symptoms 0.792
*
 - 0.527
†
 
Activity Limitation 0.648
**
 - 0.372
†
 
Emotional Function 0.858
*
 - 0.720
*
 
  * Correlation is significant at 0.01 level (2-tailed). ** Correlation is significant at 0.05 level (2-tailed). 
  † Correlation is not significant. 
 
Table 3-58: Correlation of PAQLQ with C-ACT and RCP “3 Questions” at visit 2. 
 
PAQLQ Domains 
 
Pearson Correlation (r) – Visit 2 
C-ACT RCP “3 Questions” 
Overall PAQLQ 0.874* - 0.264
†
 
Symptoms 0.913* - 0.231
†
 
Activity Limitation 0.740* - 0.143
†
 
Emotional Function 0.812* - 0.321
†
 
   * Correlation is significant at the 0.01 level (2-tailed). † Correlation is not significant. 
 
Table 3-59: Correlation of ∆ PAQLQ with ∆ C-ACT and ∆ RCP “3 Questions”. 
Change (∆) in 
PAQLQ Domains 
Pearson Correlation (r) 
∆ C-ACT  ∆ RCP “3 Questions” 
∆ Overall PAQLQ - 0.005
†
 0.401
†
 
∆ Symptoms - 0.049
†
  - 0.056
†
 
∆ Activity Limitation 0.014
†
 0.320
†
 
∆ Emotional Function 0.016
†
 0.588
**
 
  ** Correlation is significant at 0.05 level (2-tailed). † Correlation is not significant. 
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Table 3-60: Correlation of the C-ACT and RCP “3 Questions”. 
 
 
Pearson Correlation (r) 
C-ACT – V1 C-ACT – V2 ∆ C-ACT 
RCP “3 Questions” – V1 - 0.656
*
 --- --- 
RCP “3 Questions” – V2 --- - 0.246
†
 --- 
 ∆ RCP “3 Questions”  --- --- - 0.007
†
 
   * Correlation is significant at the 0.01 level (2-tailed). † Correlation is not significant. 
 
Table 3-61: Correlation of PACQLQ with C-ACT and RCP “3 Questions” at visit 
                     1. 
 
PACQLQ Domains 
 
Pearson Correlation (r) – Visit 1 
C-ACT RCP “3 Questions” 
Overall PACQLQ 0.500
**
 - 0.406
†
 
Activity Limitation 0.413
†
 - 0.286
†
 
Emotional Function 0.517
**
 - 0.444
†
 
    ** Correlation is significant at 0.05 level (2-tailed). † Correlation is not significant. 
 
Table 3-62: Correlation of PACQLQ with C-ACT and RCP “3 Questions” at visit 
                     2. 
 
PACQLQ Domains 
 
Pearson Correlation (r) – Visit 2 
C-ACT RCP “3 Questions” 
Overall PACQLQ 0.482
†
 - 0.417
†
 
Activity Limitation 0.294
†
 - 0.460
†
 
Emotional Function 0.524
**
 - 0.365
†
 
    ** Correlation is significant at the 0.05 level (2-tailed). † Correlation is not significant. 
 
Table 3-63: Correlation of ∆ PACQLQ with ∆ C-ACT and ∆ RCP “3 Questions”. 
Change (∆) in 
PACQLQ Domains 
Pearson Correlation (r) 
∆ C-ACT  ∆ RCP “3 Questions” 
∆ Overall PACQLQ - 0.110
†
 0.280
†
 
∆ Activity Limitation - 0.282
†
 0.197
†
 
∆ Emotional Function 0.0
†
 0.292
†
 
     † Correlation is not significant. 
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3.3.3.8 Patients Self-Rating of their Asthma Control  
The patients‟ personal evaluation of their asthma control level (poor, fair, good, very 
good and excellent) at visits 1 and 2, is presented in table 3-64 and figure 3-4. Cross-
tabulation of the patients‟ self-perception of asthma control level at visits 1 and 2 was 
performed; correlation, using the Pearson Chi-Square test, showed a significant 
difference within the VC group only, table 3-65. 
Pearson correlation test between the asthmatic children‟s self-reporting of asthma 
control with the overall PAQLQ, C-ACT and RCP “3 Questions” scores showed a 
significant correlation at both visit 1 and visit 2; the Pearson correlation coefficients 
along with their significance levels are presented in tables 3-66 and 3-67.  
Table 3-64: Patients self-reporting of their asthma control level at visit 1 and visit 2 
                     (asthmatic children). 
Study Group 
Patients AC 
Rating* 
Visit 1 (n, %) Visit 2 (n, %) 
CT Group 
(n=5) 
Poor 0 0 
Fair 0 0 
Good 2 (40%) 2 (40%) 
Very Good 1 (20%) 1 (20%) 
Excellent 2 (40%) 2 (40%) 
VC Group 
(n=5) 
Patients AC 
Rating* 
Visit 1 (n, %) Visit 2 (n, %) 
Poor 1 (20%) 1 (20%) 
Fair 0 0 
Good 1 (20%) 1 (20%) 
Very Good 2 (40%) 1 (20%) 
Excellent 1 (20%) 2 (40%) 
2TT Group 
(n=6) 
Patients AC 
Rating* 
Visit 1 (n, %) Visit 2 (n, %) 
Poor 0 0 
Fair 0 1 (16.7%) 
Good 2 (33.3%) 1 (16.7%) 
Very Good 3 (50%) 2 (33.3%) 
Excellent 1 (16.7%) 2 (33.3%) 
     * Patients personal rating of their asthma control. 
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Table 3-65: Correlation of the patients self-reporting of their asthma control 
                     between visits 1 and 2 (asthmatic children). 
Study Group Pearson Chi-Square χ2 (p-value, 2-tailed) 
CT  Group 0.750 (p = 0.144) 
VC Group 0.965 (p = 0.008)* 
2TT Group 0.644 (p = 0.161) 
     * Difference is significant. 
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Figure 3-4: Asthmatic children self-reporting of asthma control level at V1 & V2. 
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Table 3-66: Correlation of the asthmatic children self-reporting of asthma control 
                     level with PAQLQ, C-ACT and RCP “3 Questions” at visit 1. 
 
PAQLQ Domains 
 
Pearson Correlation (r) – Visit 1 
Self-Reporting of Asthma 
Control 
Overall PAQLQ 0.694
*
 
Symptoms 0.656
**
 
Activity Limitation 0.441
†
 
Emotional Function 0.777
*
 
C-ACT 0.863
*
 
RCP “3 Questions” - 0.614
**
 
     * Correlation is significant at 0.01 level (2-tailed). ** Correlation is significant at 0.05 level (2-tailed). 
       † Correlation is not significant. 
 
Table 3-67: Correlation of the asthmatic children self-reporting of asthma control 
                     level with PAQLQ, C-ACT and RCP “3 Questions” at visit 2. 
 
PAQLQ Domains 
 
Pearson Correlation (r) – Visit 2 
Self-Reporting of Asthma 
Control 
Overall PAQLQ 0.775
*
 
Symptoms 0.752
*
 
Activity Limitation 0.621
**
 
Emotional Function 0.785
*
 
C-ACT 0.670
*
 
RCP “3 Questions” - 0.539
**
 
     * Correlation is significant at 0.01 level (2-tailed). ** Correlation is significant at 0.05 level (2-tailed). 
       † Correlation is not significant. 
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3.3.3.9 MDI Technique Training History  
Four (80%), 4 (80%) and 5 (83.3%) patients in the CT, VC and 2TT groups, 
respectively, had previous MDI technique training by their healthcare providers as part 
of their routine medical care, table 3-68. 
Table 3-68: Frequencies of patients with previous MDI Training in the past. 
Study Group 
Previous MDI 
Technique 
Training 
Visit 1 (n, %) 
CT Group 
(n=5) 
Yes 4 (80%) 
No 1 (20%) 
VC Group 
(n=5) 
Previous MDI 
Technique 
Training 
Visit 1 (n, %) 
Yes 4 (80%) 
No 1 (20%) 
2TT Group 
(n=6) 
Previous MDI 
Technique 
Training 
Visit 1 (n, %) 
Yes 5 (83.3%) 
No 1 (16.7%) 
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3.3.3.10 The MDI Technique Assessment  
All asthmatic children in the three study groups had their MDI technique checked, using 
a placebo inhaler, according to the most desirable MDI technique steps (11 steps), at 
both visit 1 and visit 2. The median (quartiles) of the incorrect MDI technique steps at 
visit 1 was: 2 (1.5; 4) for the CT group, 8 (6.5; 8) for the VC group and 6 (5.5; 7.25) for 
the 2TT group. Whereas, at visit 2 the median (quartiles) of the incorrect MDI technique 
steps was: 3 (2; 4.5) for the CT group, 1 (0; 3.5) for the VC group and 1.5 (0; 2.25) for 
the 2TT group. Summaries of the frequencies of the children with incorrect MDI steps 
at both visits, for the CT, VC and 2TT groups are presented in tables 3-69, 3-70 and 3-
71, respectively. None of the study patients performed all the steps correctly at either 
visit 1 or visit 2. For the CT group, the most incorrectly performed steps were 9 and 11 
at visit 1, and steps 9 and 10 at visit 2. For the VC group, the most incorrectly 
performed steps were 6, 7, 9, 10 and 11 at visit 1, and steps 9 and 11 at visit 2. For the 
2TT group, the most incorrectly performed steps were 6, 7 and 9 at visit 1, and steps 9, 
10 and 11 at visit 2. 
Comparison made by the non-parametric, paired-samples Wilcoxon test showed non 
significant differences in the incorrect MDI steps between visits 1 and 2, within the CT 
group, whilst the difference was statistically significant (p < 0.05) within the VC and 
2TT groups. Pairwise comparison using the independent-samples Mann-Whitney U test 
showed a significant difference (p < 0.01) in the incorrectly preformed MDI steps 
between the CT group and both intervention groups (VC and 2TT) at visit 1. Whereas 
no significant difference in the incorrect MDI steps was found at visit 2 among the CT, 
VC and 2TT groups. 
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Table 3-69: Frequencies (n, %) of asthmatic children with incorrect MDI steps in 
                     the CT group at visits 1 and 2. 
The most Desirable MDI Technique Steps 
CT Group (n = 
5) 
n (%)  
Incorrect Steps 
Visit 1  Visit 2 
1) Remove the cap from the mouthpiece. 0 0 
2) Shake the inhaler. 
1 (20%) 
1 
(20%) 
3) Breathe out slowly, as far as comfortable to empty your lungs. 
1 (20%) 
2 
(40%) 
4) Place the mouthpiece of the inhaler between your lips. 0 0 
5) Close your lips around the mouthpiece creating a seal. 1 (20%) 0 
6) Start to breathe in slowly, through your mouth and immediately  
       press the aerosol canister to release a dose (puff). 
0 0 
7) Breathe in slowly until your lungs are full of air (as far as you 
can), the breath in step should take you about 5 seconds 
0 0 
8) Remove the inhaler from your mouth and seal your lips. 
2 (40%) 
2 
(40%) 
9) Hold your breath for 10 seconds. 
3 (60%) 
4 
(80%) 
10)  Breathe out slowly. 
2 (40%) 
4 
(80%) 
11)  Repeat steps 1 to 10 after 30 seconds if another dose is  
        necessary. 
3 (60%) 
3 
(60%) 
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Table 3-70: Frequencies (n, %) of asthmatic children with incorrect MDI steps in 
                     the VC group at visits 1 and 2. 
The most Desirable MDI Technique Steps 
VC Group (n=5) 
n (%)  
Incorrect Steps 
Visit 1  Visit 2 
1) Remove the cap from the mouthpiece. 0 0 
2) Shake the inhaler. 3 (60%) 0 
3) Breathe out slowly, as far as comfortable to empty your lungs. 4 (80%) 
1 
(20%) 
4) Place the mouthpiece of the inhaler between your lips. 0 0 
5) Close your lips around the mouthpiece creating a seal. 3 (60%) 
1 
(20%) 
6) Start to breathe in slowly, through your mouth and immediately 
       press the aerosol canister to release a dose (puff). 
5 
(100%) 
0 
7) Breathe in slowly until your lungs are full of air (as far as you 
can), the breath in step should take you about 5 seconds 
5 
(100%) 
0 
8) Remove the inhaler from your mouth and seal your lips. 2 (40%) 
1 
(20%) 
9) Hold your breath for 10 seconds. 
5 
(100%) 
2 
(40%) 
10)  Breathe out slowly. 
5 
(100%) 
1 (20 
%) 
11)  Repeat steps 1 to 10 after 30 seconds if another dose is 
        necessary. 
5 
(100%) 
2 
(40%) 
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Table 3-71: Frequencies (n, %) of asthmatic children with incorrect MDI steps in 
                     the 2TT group at visits 1 and 2. 
The most Desirable MDI Technique Steps 
2TT Group (n=6) 
n (%)  
Incorrect Steps 
Visit 1  Visit 2 
1) Remove the cap from the mouthpiece. 0 0 
2) Shake the inhaler. 3 (50%) 0 
3) Breathe out slowly, as far as comfortable to empty your lungs. 
5 
(83.3%) 
1 
(16.7%) 
4) Place the mouthpiece of the inhaler between your lips. 0 0 
5) Close your lips around the mouthpiece creating a seal. 0 0 
6) Start to breathe in slowly, through your mouth and immediately 
       press the aerosol canister to release a dose (puff). 
6 
(100%) 
0 
7) Breathe in slowly until your lungs are full of air (as far as you 
can), the breath in step should take you about 5 seconds 
6 
(100%) 
1 
(16.7%) 
8) Remove the inhaler from your mouth and seal your lips. 
2 
(33.3%) 
0 
9) Hold your breath for 10 seconds. 
6 
(100%) 
2 
(33.3%) 
10)  Breathe out slowly. 
4 
(66.7%) 
2 
(33.3%) 
11)  Repeat steps 1 to 10 after 30 seconds if another dose is 
        necessary. 
5 
(83.3%) 
2 
(33.3%) 
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3.4 Discussion 
Inhalation is the principal route for drug delivery in asthma treatment (Keating and 
Faulds, 2002). Many inhaler devices have, therefore, been developed and introduced to 
deliver various therapeutic agents to the lung. The metered dose inhaler (MDI) has 
many advantages over other inhaler systems available on the market (Keller, 1999), and 
thus is still the most commonly prescribed and used device (Virchow et al., 2008). The 
efficiency of the MDI, in terms of the extent and distribution of lung deposition, is 
influenced by many factors (Goldberg and Lourenco, 1973; Newman et al., 1981b; 
Ganderton, 1997). The patients‟ MDI inhalation technique is one of the main factors 
affecting the fraction of the inhaled aerosol depositing in the lung along with its 
distribution ([Anon] et al., 1999). 
When using their pressurized inhaler; asthmatic patients are generally advised to follow 
the MDI manufacturers‟ instructions enclosed in the package pamphlet. The apparently 
simple MDI use is, in reality, deceptive and confusing to the patients and their 
healthcare providers. Many published research studies have, therefore, investigated 
different MDI inhalation manoeuvres; however the optimal MDI technique is still 
debated because insufficient MDI use may lead to sub-maximal therapeutic effect 
(Newman et al., 1981b; Everard et al., 1995; [Anon] et al., 1999; Virchow et al., 2008). 
In fact, poor MDI technique may result in less than 50% of the children (Pedersen et al., 
1986) and adult (Crompton, 1990) patients benefiting from their inhaled medicine. This 
is critically more important with the ICSs than the inhaled bronchodilators; because the 
ICSs lack the immediate therapeutic feedback that the inhaled bronchodilators have, 
where insufficient bronchodilation can be compensated for by taking additional doses 
(puffs) (Everard, 2003). 
Published research has proposed various MDI techniques in an attempt to improve the 
peripheral lung deposition whilst minimizing the oropharyngeal impaction. Shaking the 
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MDI canister before use is very important to have consistent and reproducible emitted 
doses; which were adversely affected when the MDI was left overnight and was not 
shaken immediately before use (Everard et al., 1995). Early aerosol inhalation from the 
functional residual capacity (FRC) to the total capacity of the lung results in a better 
lung deposition than late inhalation relative to the lung volume (Newman et al., 1981b). 
However, it is crucially important that the patients inhale slowly and deeply when using 
their MDI because high IFRs reduce lung deposition and increase the fraction of the 
aerosol dose in the oropharynx (Goldberg and Lourenco, 1973; Newman et al., 1981b; 
Clarke et al., 1982). An optimal IFR through the MDI is still controversial. Dolovich et 
al. (1981) have suggested an IFR <60 l/min for an optimal lung deposition. Indeed, the 
relative bioavailability of salbutamol to the lung was greater at a slower IFR (10 l/min) 
than at a higher flow (50 l/min) (Hindle et al., 1993). Similarly, Newman et al. (1995) 
showed that the total lung deposition decreased from 11.2 to 7.2% when the IFR was 
increased from 37 to 151 l/min. Moreover, a gamma scintigraphy study demonstrated 
that the best lung deposition when using an MDI was achieved with an IFR of 90 l/min 
(Farr et al., 1995). Pharmacokinetic studies have also shown that a slow and deep 
inhalation through an MDI, followed by a 10-second breath-holding would result in the 
maximal lung deposition (Hindle et al., 1993; Tomlinson et al., 2005). These studies, 
therefore, confirm that the lung deposition when using an MDI is flow dependent and 
that that IFRs < 90 l/min are the most recommended. 
Due to differences in study design, the results of studies into poor MDI technique 
demonstrate wide variations. Epstein et al. (1979) have shown that only 10.8% of the 
asthmatic and COPD patients performed all the MDI technique manoeuvres correctly, 
whilst 24.7% failed to perform more than half of the manoeuvres sufficiently. In an 
earlier study, 14% of the asthmatic patients misused their MDI (Paterson and Crompton, 
1976). Another study showed that 77.5% to 89.2% of the patients made at least one 
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error while using their MDI (Larsen et al., 1994). In addition, it has been reported that 
92% of the 476 assessed patients failed to use a slow inhalation with good inhaler 
coordination (Al-Showair et al., 2007b).   
Limited research has been done to identify the problems of MDI use in asthmatic 
children; however two studies have highlighted the magnitude of the problem (Pedersen 
et al., 1986; Dolovich, 1999). These studies showed that < 2% of the pressurized 
bronchodilator dose deposited in the lungs of the infants and young children; this was 
justified by their small tidal volumes, variable breathing patterns, nasal breathing and 
high IFRs. In the current study, 82.3% of the asthmatic adults and 81.2% of the 
asthmatic children had been previously instructed on their MDI use as part of their 
routine medical care (prior to enrolment in this study); however, none of these patients 
in any of the study groups (CT, VC and 2TT groups) performed all the MDI technique 
manoeuvres (11 steps) correctly at either enrolment (visit 1) or at visit 2. Those in the 
CT group did, however, inhale slowly with good MDI coordination. 
Correct MDI technique improves lung deposition and consequently the therapeutic 
outcome of the inhaled medicine (Everard, 2003). This justifies the importance of 
counselling and training the respiratory patients on how to use the correct inhalation 
technique when using their MDI. It has been shown that patient counselling 
significantly improved the MDI technique from 31% before counselling to 72% 
immediately after (Horsley and Bailie, 1988). Moreover training asthmatic children and 
their parents/caregivers improved the percentage of adequate MDI users from 8% 
before training to 81% after (Burkhart et al., 2005). Various methods have been 
suggested to improve and maintain good inhalation technique; Savage and Goodyer 
(2003) have shown that a brief multimedia training method was at least as good as 
reading the MDI package leaflet in improving the patients‟ proper MDI manoeuvres. 
Sestinti et al. (2006) have stated that verbal and/or written MDI instructions alone were 
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not sufficient, and that better results were achieved when the patients‟ verbal training 
was coupled with a demonstration of the correct MDI technique by healthcare 
providers. This has been also confirmed in a previous study into poor MDI use in 
asthmatic children (Kamps et al., 2000).  
The current research was designed as a parallel-grouped, intervention-randomized 
controlled study that investigated whether counselling asthmatic adults and children on 
the most desirable MDI technique in a community pharmacy setting would improve and 
maintain adequate inhaler use, with emphasis on the slow inhalation flow rate 
manoeuvre. Moreover, asthma control and health-related quality of life were also 
assessed. Asthmatic adults and children with poor MDI use (as defined in the research 
protocol) were randomized, according to a previously constructed randomization table 
based on the table of random numbers (Bolton, 1997), into either the verbally 
counselled (VC) group or the 2ToneTrainer (2TT) group. All the asthmatic adults [VC: 
14 patients; 2TT: 15 patients] inhaled at an IFR < 90 l/min immediately after receiving 
the verbal counselling and demonstrated the most desirable 11-step MDI technique at 
study enrolment (visit 1). At visit 2 (6-8 weeks later), 11 (78.6%) patients in the VC 
group and 13 (86.7%) patients in the 2TT group maintained the slow IFR (< 90 l/min). 
Similarly, all the asthmatic children [VC: 5 patients; 2TT: 6 patients] inhaled at an IFR 
< 90 l/min immediately after receiving the verbal counselling and demonstrated the 
most desirable 11-step MDI technique at study enrolment (visit 1). At visit 2 (6-8 weeks 
later), 4 (80%) children in the VC group and all the 6 (100%) children in the 2TT group 
maintained an IFR < 90 l/min. For both the asthmatic adults and children (within each 
of the VC and 2TT groups); the difference in the IFR before counselling (visit 1) and 
that 6-8 weeks (visit 2) after the verbal counselling, was statistically significant. 
However, the difference in the incorrectly performed MDI manoeuvres by the asthmatic 
adults and children in the VC, 2TT and CT groups at the follow-up visit (visit 2), was 
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not statistically significant. These results confirm the importance of the MDI technique 
training in improving and maintaining the patients‟ good MDI use, and are in line with 
those of the previously published studies. 
Patients tend to forget the correct MDI inhalation instructions, and revert to their poor 
inhaler use. It has been shown that 50% of the verbally trained patients used their MDI 
incorrectly 1 to 30 days after their MDI technique counselling session (Shim and 
Williams, 1980), whilst 20% of the instructed asthmatic children did so (Burkhart et al., 
2005). Thus, in order to maintain the correct inhalation technique patients should be 
repeatedly trained on and monitored for correct MDI use (Lindgren et al., 1987; Farr et 
al., 1995; Walia et al., 2006; Virchow et al., 2008). However, this may impose cost and 
time burdens on the healthcare system. The Aerosol Drug Management Improvement 
Team (ADMIT) have stated that a multiple feedback mechanism for the correctly 
performed inhalation would be a useful method of adequate inhaler use reassurance 
(Crompton et al., 2006). The 2ToneTrainer
®
 (Canday Medical Ltd., UK) is an MDI-like 
handheld tool that has been developed to give a distinctive audible feedback for the 
optimal inhalation speed (30 – 60 l/min) through an MDI. In this regard, one recent 
study has shown that the 2ToneTrainer device helped the previously trained asthmatic 
adults attending an outpatient clinic to maintain the desirable MDI technique and IFR 
over the study follow up period, with improvement in their quality of life (Al-Showair 
et al., 2007b). In the current study, the 2ToneTrainer has helped both the asthmatic 
adults and children significantly improve and maintain the verbally trained MDI use and 
inhalation speed over the recruitment period at a community pharmacy setting. 
Practising the 2ToneTrainer by the patients (at home) was at least as good as the verbal 
training alone in maintaining the acceptable slow IFR through the MDI. 
Optimal asthma control is the ultimate goal of asthma management guidelines (GINA, 
2008; BTS/SIGN, 2009). Inadequate patient education on the correct inhaler use leads 
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to poor asthma control (Horne et al., 2007; Haughney et al., 2008), which is 
subsequently interpreted into quality of life impairments (Schatz et al., 2007a; Garris et 
al., 2008). The lung function test alone may not reflect the actual asthma control level 
(Bateman et al., 2001) and correlates poorly with the patients‟ quality of life (Juniper et 
al., 1993; Juniper et al., 1996a). The ACT (Nathan et al., 2004; Schatz et al., 2006) and 
the C-ACT (Liu et al., 2007) are simple, reliable and valid asthma control instruments 
that can be used in clinical research to evaluate the effect of an intervention on asthma 
control levels with a cut-off score ≥ 19 representing adequately controlled asthma. 
Moreover, the Royal College of Physicians (RCP) (London) has suggested a “3 Key 
Questions” instrument that can be utilized to assess asthma control (Pearson and 
Bucknall, 1999). The total score of the RCP 3 questions can  range between 0 and 3; 
where a zero score indicates well controlled asthma (Thomas et al., 2009a).The Mini-
AQLQ (Juniper et al., 1999c), PAQLQ (Juniper et al., 1996a) and PACQLQ (Juniper et 
al., 1996b) are valid, evaluative and discriminative instruments that can be employed in 
clinical research to evaluate the quality of life of asthmatic adults, children and their 
caregivers, respectively. A score change of ≥ 0.5 is considered the minimal important 
difference (MID) to result in a clinically significant improvement in quality of life.  
In the current study and in agreement with the published literature, the change in the 
lung function test (presented as FEV1 % predicted) between visits 1 and 2 was not 
significant in both the VC and 2TT groups (for asthmatic adults and children), therefore 
the lung function test did not reflect the significant improvement in the patients‟ MDI 
use (particularly in the inhalation flow rate). Moreover, the FEV1 % predicted and its 
change over the study follow-up period did not significantly correlate with any of the 
quality of life or asthma control instruments. For the asthmatic adults in the VC group, 
the mean difference between visits 1 and 2 in the overall Mini-AQLQ score and its 
domains significantly exceeded the MID, except for the activity limitation domain. For 
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the adults in the 2TT group; the changes in the symptoms and emotional function 
quality of life domains were above the MID, however, the change in the overall quality 
of life was not statistically significant. For the asthmatic children, although the mean 
changes in the scores of the overall PAQLQ and its domains indicate an improvement in 
quality of life only the changes in the symptoms domain (VC group) and in the 
emotional function (2TT group) were statistically significant. For the paediatric asthma 
caregivers (parents), the mean change in the overall PACQLQ and its two domains were 
not significant for the VC group, whereas, the differences in the overall PACQLQ and 
the activity limitation domain were significant for the 2TT group. For the asthma 
control instruments, the changes in the ACT, C-ACT and RCP “3 Key Questions” 
between visits 1 and 2, and among the VC and 2TT groups were not significant for both 
the asthmatic adults and children. The lack of a significant improvement in asthma 
control as a reflection to that in the patients‟ MDI technique and inhalation speed can be 
explained by the shortcomings encountered in this research, which are discussed later. 
Correlation testing, however between the scores of the adults‟ asthma control 
instruments and those of the quality of life ones, used in this study, showed significant 
moderate to strong relationships. This is in agreement with the findings of a previously 
published study (Schatz et al., 2007a). 
As a controlled study, it was ethically impossible to recruit asthmatic adults and 
children with poor MDI technique into the control group of the current research, and 
follow them up without correcting their MDI use. Therefore, only asthmatics with 
adequate MDI technique and inhalation flow rate < 90 l/min were enrolled as control 
subjects. The insignificant changes in all the study outcome measures (between visit 1 
and visit 2), for the control asthmatic patients, confirm that any differences detected in 
the intervention area (the VC and 2TT groups) of the research were a reflection of the 
investigated intervention procedures. This was also supported by the fact that the 
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asthma medications used by the study patients remained the same over the study follow-
up period, and that the same investigator carried out all the research measurements at 
the two study visits – to eliminate the human measuring error and bias. However, there 
were a number of shortcomings and limitations encountered in this study. Firstly, the 
number of recruited patients was small. Every effort was made to recruit the research 
target number of patients; through having as many community pharmacies as possible 
involved as research sites, flexibility in the research appointments and extending the 
patient enrolment period up to 15 months. However, the funding and time constraints as 
well as the long period in time needed to get the required ethical and administrative 
approvals to carry out this clinical research adversely affected patient recruitment. 
Moreover, many eligible patients declined participation in this study due to work or 
school commitments, which would have also prevented them attending the second 
(follow-up) visit. In addition to that, the majority of the screened patients had a poor 
MDI technique, which explains the limited number of patients in the control group.  
Secondly, due to the patient recruitment hurdles; patients‟ enrolment was extended over 
a 15-month period; seasonal health conditions such as hay fever, common cold and flu, 
may have adversely affected the asthma symptoms, and thus influenced the patients‟ 
response to the asthma control and quality of life questionnaires, which would explain 
their insignificant change despite the significant improvement in the patients‟ MDI use. 
Thirdly, the majority of the recruited patients had mild asthma (at recruitment), which 
might have reduced the possibility of spotting a significant improvement in asthma 
control and quality of life. Finally, the follow-up period between visit 1 and visit 2 may 
have been relatively short (6 – 8 weeks) to detect significantly important changes in the 
asthma control and quality of life measures. 
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3.5 Conclusion 
The MDI is the most widely prescribed inhaler device. Incorrect MDI use, particularly a 
fast inhalation flow rate through the inhaler, adversely affects lung deposition and thus 
the therapeutic outcome. Despite repeated training, the majority of asthmatic adults and 
children misuse their MDI. The main findings of the present study were:  
 Verbal training of the patients on the correct MDI technique followed by a 
demonstration of an adequate inhaler use by the patients themselves at a 
community pharmacy setting significantly improved the patients‟ MDI 
manoeuvre and inhalation flow rate, and potentially improved their overall 
asthma-related quality of life. 
 Many patients did forget the correct MDI use over time and revert to their old 
habits of high inhalation flow.  
 The 2ToneTrainer®, an MDI technique training tool with an audible feedback 
mechanism of correct inhalation flow, helped the verbally trained patients 
improving and maintaining the slow inhalation flow when using their MDI. 
 Being available to the patients all the time, practicing the 2ToneTrainer tool may 
have a role in maintaining the asthmatic adults and children‟s correct MDI use, 
and reduce the need for a regular MDI technique check up and training on every 
routine clinic visit. 
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Chapter 4: Measuring the Specific Flow 
Resistance of a Novel Dry Powder 
Inhaler: the Spiromax
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4.0 Introduction 
Dry powder inhalers (DPIs) have emerged as breath-activated inhalation systems to 
overcome the issues associated with the pressurized metered dose inhalers (MDIs); 
these particularly are the environment (Pitcairn et al., 1994) and MDI technique (Prime 
et al., 1999; Virchow et al., 2008) related problems. The DPIs are generally formulated 
by mixing the micronized drug particles with a carrier powder (e.g. lactose) forming 
larger powder aggregates which have better dose metering and powder flow properties 
inside the inhaler device (Steckel and Muller, 1997b). The currently available DPIs are 
well known for their flow-dependent dose emission characteristics (Tarsin et al., 2006; 
Chrystyn, 2009). However, the patient‟s inspiratory effort, and thus the generated 
inhalation flow rate (IFR) through the DPI, is the only energy responsible for 
disaggregating the metered dose of  the large powder complexes into fine (respirable) 
particles (< 5 µm in diameter) which will have the potential for  depositing onto their 
targets in the lung periphery (Steckel and Muller, 1997b; Srichana et al., 1998b; 
Chrystyn, 2009). Clark and Hollingworth (1993) have shown that the energy generated 
inside a DPI is a function of its specific internal flow resistance and the inhalation flow 
rate across the inhaler; this relationship was expressed by the following equation: √∆P = 
R.Q (∆P is the change in pressure across the DPI, R is the specific resistance and Q is 
the IFR).   
During the development stages, each DPI should be in vitro tested for its efficiency in 
terms of the total dose and fine particle fraction emission characteristics. The 
Pharmacopoeial Standards, thus, recommend that these DPI characteristics should be in 
vitro tested at an IFR equivalent to 4kPa pressure drop and an inhalation volume of 4L. 
The aim of the current work was to in vitro measure the specific internal airflow 
resistance of two novel versions of a DPI; the Spiromax
™
 (TEVA Pharmaceuticals, 
UK). These differ by the size of the dose metering cup inside the device which is 
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determined by the dose of the drug. Moreover, the IFR equivalent to 4 kPa pressure 
drop could be also determined. 
4.1 Materials and Methods 
Two versions of the Spiromax DPI were supplied by TEVA Pharmaceuticals, UK; these 
two versions of the device differ by the size of the dose metering cup (DCS). The first 
DPI was coded with a green mouthpiece cap and had a DCS of 2.7; whilst the second 
inhaler had a brown mouthpiece cap and a DCS of 4.0. The used method for DPI 
internal resistance determination was previously published (Clark and Hollingworth, 
1993; Assi and Chrystyn, 2001). Five different devices of each Spiromax version were 
tested, and the measurement through each device was repeated five times each on 
different occasion. Although the supplied Spiromax inhalers were empty, the 
manufacturer‟s instruction for dose metering (priming) was followed before each 
measurement. For each determination, the inhaler device was attached to a setup of a 
vacuum flow pump (High Capacity Pump HC5, Copley Scientific Ltd., UK) and a dry 
powder flow controller (TPK 2000, Copley Scientific Ltd., UK). The flow rate was 
measured using a digital flow meter (DFM 2000, Copley Scientific Ltd., UK). Then, the 
flow rate, equivalent to a pressure drop across the inhaler ranging from 0.50 to 10 kPa 
(5.1 – 102.0 cmH2O), was measured. The mean flow rate was then used to calculate the 
specific internal resistance of each Spiromax DPI version using the equation published 
by Clark and Hollingworth (1993). 
4.2 Results 
The mean (SD) flow rates measured through the green and brown Spiromax DPIs, with 
their corresponding pressure drop values, are presented in table 4-1. Figures 4-1 and 4-2 
show the relationship between the √∆P (cmH2O)
1/2 
and mean flow rate (l/min) for the 
green and brown Spiromax inhalers, respectively. Thus, the specific internal resistance 
values were calculated from the slope of these relationships; and were found to be 
   
191 
0.0983 [(cmH2O)
1/2
. min/l] for the green Spiromax DPI; and 0.0966 [(cmH2O)
1/2
. min/l] 
for the brown Spiromax. Since the specific resistance of the two Spiromax versions are 
almost similar, the inhalation flow rate equivalent to 4kPa pressure drop across the 
Spiromax DPI is about 65 l/min. 
Table 4-1: The mean flow rates with their corresponding pressure drop through 
                   the Spiromax DPIs. 
Pressure Drop (∆P)  Mean (SD) Flow Rate (l/min) 
kPa cmH2O 
Green Spiromax DPI 
(n=5) 
Brown Spiromax DPI 
(n=5) 
0.5 5.1 20.5 (0.25) 20.7 (0.15) 
1.0 10.2 29.2 (0.31) 29.4 (0.20) 
1.5 15.3 36.3 (0.50) 36.6 (0.35) 
2.0 20.4 42.2 (0.57) 42.6 (0.40) 
3.0 30.6 52.1 (0.68) 52.7 (0.60) 
4.0 40.8 60.3 (0.68) 60.9 (0.65) 
5.0 51.0 68.4 (0.67) 69.2 (0.57) 
6.0 61.2 75.4 (1.00) 76.4 (0.83) 
7.0 71.4 82.1 (1.02) 83.2 (0.84) 
8.0 81.6 88.5 (1.00) 89.6 (0.85) 
9.0 91.8 94.7 (1.18) 96.0 (0.89) 
10.0 102.0 100.8 (1.22) 102.3 (0.99) 
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Figure 4-1: Pressure Drop – Flow Rate relationship through the Green Spiromax DPI 
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Brown Spiromax DPI
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Figure 4-2: Pressure Drop – Flow Rate relationship through the Brown Spiromax DPI 
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4.3 Discussion and Conclusion  
All DPIs have flow-dependent dose emission behaviour, and the patient‟s inspiratory 
profile through a DPI determines the total and fine particle fraction of the emitted 
powder dose (deBoer et al., 1996b; Pauwels et al., 1997; Chrystyn, 2009). The design of 
the DPI device affects its specific internal resistance to the inhalation flow rates 
achievable by the patients through that particular inhaler (Clark and Hollingworth, 
1993; deBoer et al., 1996b; Virchow et al., 2008). In this regard, it has been shown that 
the IFR through a DPI is adversely related to the specific airflow resistance of that 
device (deBoer et al., 1996b). Therefore, to ensure efficient drug delivery; the DPIs 
should be in vitro tested under the Pharmacopoeial recommended conditions of an IFR 
equivalent to 4kPa pressure change across the inhaler, and an inhalation volume of 4L. 
In the current work, the specific flow resistance of two novel versions of the Spiromax 
DPI was determined as well as the IFR corresponding to the Pharmacopoeial 
recommended pressure drop of 4kPa. Although the two Spiromax DPIs differ by the 
size of their dose metering cup, their specific resistance values are almost the same, and 
are very close to that previously published for the Airmax
™
 DPI (the former brand name 
of the Spiromax) (0.0924 (cmH2O)
1/2
. min/l) (Zeng et al., 2002a). The determined 
Spiromax DPIs‟ specific resistance values are within the range of those categorized as 
medium resistance DPIs described earlier in the literature (Clark and Hollingworth, 
1993; Assi and Chrystyn, 2001; Chrystyn, 2009). 
In conclusion, the Spiromax DPI is a recently introduced powder inhalation system with 
a medium (moderate) internal resistance to inhalation flow. However, further research is 
needed to investigate the inhalation characteristics achievable by the respiratory patients 
through this novel DPI. 
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Chapter 5: Clinical Evaluation of 
Inhalation Profiles and Acceleration 
Rates of Asthmatic Adults and Children, 
and of COPD Patients through Two 
Novel Versions of Spiromax
™
 DPI 
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5.0 Introduction 
Inhalation is considered the main route for drug delivery in the treatment of patients 
with asthma (Keating and Faulds, 2002) and COPD (Lavorini et al., 2007). Most of the 
medications used for the management of these diseases, including short- and long-acting 
bronchodilators as well as corticosteroids, have been formulated so that they can be 
administered via inhalation to be directly delivered to their sites of action in the lung. 
The metered dose inhaler (MDI) is the most commonly prescribed inhalation device 
(Pauwels et al., 1997). However, many patients find it difficult to use their MDI 
correctly as they need to co-ordinate the device actuation with inhalation, a mistake that 
most patients make (Broeders et al., 2003a). To overcome these MDI issues, therefore, 
different breath-activated dry powder inhalers (DPIs) have been developed and 
introduced (Keating and Faulds, 2002; Lavorini et al., 2007). 
All currently available DPIs have a flow-dependent dose emission property. It has been 
shown that the inspiratory efforts and thus the inspiratory flows achieved by the patient 
through each DPI will significantly affect the amount of the drug emitted and hence 
deposited in the lung. The main factor that controls the inhalation flow (IF) through a 
DPI is the specific internal resistance of that inhaler which is inversely related to the 
peak inhalation flow (PIF) the patient can achieve through that particular inhaler (Clark 
and Hollingworth, 1993; Pauwels et al., 1997; Al-Showair et al., 2007; Chrystyn, 2009).  
Studies have shown that stable patients (ranging from children with asthma to elderly 
patients with COPD) have problems achieving the recognised minimum PIF for 
effective use of different DPIs (Pedersen, 1994; Persson et al., 1997; Malmstrom et al., 
1999; Chrystyn et al., 2002; Bentur et al., 2004; Vogelberg et al., 2004; Crompton et al., 
2006). It has also been shown that the initial acceleration rate and inhaled volume 
during the patient‟s inhalation manoeuvre are more important than the achieved PIF 
(Everard et al., 1997). Little attention, however, has been placed on the inhalation 
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acceleration rates of the patients through the DPIs due to the unavailability of a suitable 
measuring device.  We have, therefore, designed a method to measure the complete 
inhalation profile of a patient when they use an inhaler.  The current work focused on 
the inhalation profiles through a novel DPI; the Spiromax
™
.   
The Spiromax
™
 is a recently introduced multi-dose DPI that has been designed to use an 
active-metering, cyclone-separator technology. Unlike other available DPIs, the 
Spiromax uses a controlled air pressure system, connected to and activated by the 
mouthpiece cap, to measure out a drug dose (Zeng et al., 2002a; Zeng et al., 2002b). It 
has been shown that drug delivery via the Spiromax was less dependent on airflow than 
via the Turbuhaler with a greater budesonide and formoterol dose consistency (Keating 
and Faulds, 2002). The objective of this current research study was to clinically 
investigate the inhalation profiles and acceleration rates of asthmatic adults and 
children, and of COPD patients through two novel versions of the Spiromax
™
 DPI.  
5.1 Research Objectives 
5.1.(a) Primary Objective:  
The primary objective of this research study was to obtain inhalation profiles and 
acceleration rates of asthmatic adults and children, and of COPD patients through two 
novel versions of the Spiromax
™
 DPI. These differ by the size of the metering cup 
inside the device which is determined by the amount of drug in the dose. 
5.1.(b) Secondary Objective(s):    
The secondary objectives were to determine if the measured inhalation profiles and 
acceleration rates can be correlated to: 
(a) Lung function determined by the FEV1 and FEV1 % predicted, 
(b) Disease severity levels, 
(c) Patients‟ demographics (age and gender),  
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(d) Scores of the Asthma Control Questionnaire (ACQ) – asthma patients 
only, 
(e) Scores of the St George‟s Respiratory Questionnaire (SGRQ) – COPD 
patients only. 
5.2 Methodology 
5.2.1 Study Population 
5.2.1.1 Patient Recruitment and Sample Size      
Stable asthmatic (adults and children) and COPD patients receiving regular care at the 
respiratory out-patient clinics of NHS Hospitals - UK (see the list of research sites 
below), and fulfilling the protocol‟s patient definition criteria were invited to take part 
in this research study. The study objectives and procedures were described to the 
patients (and their parents/guardians in case of the asthmatic children) using the relevant 
patient information sheets [APPENDIX A-14, A-15 and A-16 (refer to the enclosed 
DVD)]. They kept a copy of these patient information sheets and were given as much 
time as they needed to consider participation. After their agreement to take part in the 
study, a signed informed consent form [APPENDIX A-17 (refer to the enclosed DVD)] 
was obtained prior to performing any protocol related procedures. To improve the 
asthmatic children enrolment, invitation letters, enclosing the patient information sheets, 
were posted to the parents/guardians of eligible asthmatic children (based on the clinics‟ 
database) with contact details should they considered participation in the research.  
A number of previous studies have been conducted to investigate the PIFs and/or 
inhalation profiles through the DPIs recruiting different asthmatic/COPD patient 
populations. The population sizes enrolled in those studies ranged from 10 patients in a 
single-centre study up to 137 patients in a multi-centre study, healthy volunteers had 
been enrolled in some studies as well (Clark and Hollingworth, 1993; Everard et al., 
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1997; Bisgaard et al., 1998; Broeders et al., 2001; Burnell et al., 2001; Broeders et al., 
2003b; Broeders et al., 2004; Vogelberg et al., 2004; Tarsin et al., 2006).  
Therefore, to account for any drop outs, the target sample size of this research study 
was: 60 asthmatic children, 60 adult asthmatics and 60 COPD patients. Hence, 60x3 
groups of patients (total 180) were to be recruited.  
The NHS Teaching Hospitals which were involved as research sites:  
 Airedale General Hospital, Steeton, West Yorkshire, UK. 
 Leeds General Infirmary, Leeds, UK. 
 St. James‟s University Hospital, Leeds, UK 
 Bradford Royal Infirmary, Bradford, West Yorkshire, UK. 
 St. Luke‟s Hospital, Bradford, West Yorkshire, UK.  
The current research study was conducted according to the “Good Clinical Practice” 
guidelines (ICH/GCP), and was approved by both the Bradford Research Ethics 
Committee (United Kingdom), and the Research and Development department within 
each of the involved NHS Hospitals.   
5.2.1.2 Patient Definition:  
            5.2.1.2.(a) Inclusion Criteria:  
An individual meeting all the following criteria was considered eligible for recruitment 
into this study: 
 Male or female, with stable asthma or COPD. 
 Patient inhaled medication. 
 Age groups: 4-17 years asthmatic children, 18-70 years asthmatic adults, and > 
55 years COPD patients. 
 Signed informed consent (by the parent/guardian in case of an asthmatic child). 
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             5.2.1.2.(b) Exclusion Criteria: 
An individual meeting any of the following criteria was excluded from participation:     
 Prescribed inhaled medication for less than 4 weeks prior to enrolment. 
 Limited ability to understand/implement the study procedures and instructions. 
 Other pulmonary diseases (e.g. pneumonia, TB) at study enrolment or any other 
severe conditions that may adversely affect the respiratory system or quality of 
life. 
 An acute asthma/COPD exacerbation or oral prednisolone use (except oral 
prednisolone dependent patients) during the last 4 weeks prior to enrolment. 
 Patient participating in another clinical research study at the time of- or in the 
past 3 months prior to enrolment. 
5.2.2 Study Design     
This research was an investigational, prospective, comparison-randomized study that 
clinically investigated the inhalation profiles and acceleration rates of asthmatic adults 
and children, and of COPD patients through two novel versions of the Spiromax
™
 DPI. 
The inhalation profiles and acceleration rates of eligible asthmatic adults and children, 
and of COPD patients who had given a written informed consent were measured 
through two novel versions of the Spiromax
™
 DPI; version 1 with a 2.7 dose cup size 
(DCS) (green mouthpiece cap) and version 2 with a 4.0 DCS (brown mouthpiece cap). 
Measurements were performed using an empty (contain no active drug or carrier 
powder) Spiromax DPI device. The order of the Spiromax device version to be tested 
first was according to a previously constructed randomization table [APPENDIX A-18 
(refer to the enclosed DVD)].  
During the patients‟ enrolment period, they were scheduled into 2 study visits; visit 1 
(Enrolment, Day 1), and visit 2 (End of study, after 6 weeks of enrolment). Every effort 
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was made to have the patients (and their parent/guardian in case of an asthmatic child) 
returned to the clinic on the scheduled visit day. If they could not make their 
appointments due to extenuating circumstances, a two-week visit window was allowed. 
The same measurements/tests with the same comparison-randomization order were 
repeated on visit 2 to assess the inhalation profiles and acceleration rates 
reproducibility. On each study visit, the patients were instructed to use the standard “as 
hard and deep as you can” inhalation manoeuvre through both inhaler versions. 
 
 
Study week:   1                                        6 
 
 
 
Visit:    1                                        2 
                    (Enrolment)                                                                                    (Last visit/End of study) 
                                                                                                 
The study design did not interfere with the patients‟ pharmacotherapy regimen. Any 
changes to each patient‟s therapy, if needed, were made by their physician as part of the 
patient‟s routine medical care. These changes were documented in the patient‟s case 
report form (CRF) as appropriate.  
When possible (for ethical reasons), the recruited patients were instructed to abstain 
from their inhaled short-acting bronchodilators for ≥6 hrs, and inhaled long-acting 
bronchodilators and/or corticosteroids for ≥12 hrs before their study visits.  
After enrolment at visit 1 
Spiromax DPI 2.7 DCS 
(Green Cap) 
Spiromax DPI 4.0 DCS 
(Brown Cap) 
 
By comparison 
randomization  
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5.2.3 Study Procedures      
5.2.3.(a) Visit 1 (Enrolment/Day 1)  
For all screened eligible patients who were willing to participate in the study, a signed 
informed consent form was obtained prior to performing any protocol related 
procedures. In each patient‟s CRF, the investigator recorded the patient‟s age, gender, 
height, weight and BMI. Asthma/COPD medications were also recorded. Expiratory 
flow parameters (lung function measurements) including PEFR, FEV1 and FVC were 
measured using a portable spirometer to assess disease severity. The asthmatic adults 
and children completed the Asthma Control Questionnaire (ACQ) (Juniper et al., 1999d; 
Juniper et al., 2006)  [APPENDIX A-1 (refer to the enclosed DVD)]. COPD patients 
completed the St George‟s Respiratory Questionnaire (SGRQ) [APPENDIX A-8 (refer 
to the enclosed DVD)].  
For each patient, the inhalation profiles and acceleration rates were measured through 
the two versions of the Spiromax
™
 DPI; version 1 with a 2.7 DCS (green mouthpiece 
cap) and version 2 with 4.0 DCS (brown mouthpiece cap). Measurements were 
performed via empty (contain no active drug or carrier powder) Spiromax DPI devices 
using a specially designed inhalation profile recorder. The order of the Spiromax device 
version tested first was according to a previously constructed randomization table 
[APPENDIX A-18 (refer to the enclosed DVD)]. The inhalation profile measurements 
through each device version were taken in triplicate with approximately 1-2 minutes rest 
apart. The patient was allowed approximately 5-10 minutes rest between the inhalations 
through the two devices. No inhaler device practice was allowed prior to the actual 
inhalation profiles measurements.  
The patients were instructed to inhale using the standard “as hard and deep as you can” 
inhalation manoeuvre through the Spiromax DPIs.  
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5.2.3.(b) Visit 2 (End study, after 6 weeks of enrolment)  
To assess the inhalation profiles and acceleration rates reproducibility, the same 
measurements/tests performed during visit 1 were repeated during the second visit. The 
same comparison-randomization order of the two Spiromax versions was also repeated 
during this visit. 
The patients were instructed to inhale using the standard “as hard and deep as you can” 
inhalation manoeuvre through the Spiromax DPIs.  
The same investigator carried out the tests/measurements on the two visits. 
5.2.4 Patients Withdrawal and Early Termination       
Patients were free to withdraw at any time from the study. They could also be 
withdrawn from the study by their doctor or at the discretion of the investigator if they 
violated the study plan, were unable to follow the protocol procedures and/or for any 
other safety or clinical reasons. 
5.2.5 Data Collection     
The data was collected from all study groups at enrolment (visit 1), with which the 
subsequently collected data (visit 2) was compared and correlated. 
The primary measures were: 
 The peak inhalation flow (PIF), 
 The inhalation profiles parameters (including the IFRs at different time points, 
time to reach these IFRs and the inspired volumes till these time points), 
 The acceleration rates (slopes of the inhalation profiles) at various time points. 
The secondary measures were: 
 The lung function test (presented as the FEV1 and FEV1 %predicted), 
 The scores of the ACQ – Asthmatic adults and children only, 
 The scores of the SGRQ – COPD patients only. 
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5.2.6 Confidentiality of the Patients Identity and Data    
The data collected in this research study is considered strictly confidential. Each patient 
was identified by a unique code number should their data be used in any publications, 
and the patient‟s full name, initials, DOB or any other identifiers were not used for this 
purpose. A list of the participants‟ names and contact details is kept along with the study 
documents in strict confidence.  
5.2.7 Data Analysis 
5.2.7.(a) Determination of the Inhalation Profile Parameters 
To obtain the inhalation profiles of the patients through the Spiromax DPIs, each 
version of the Spiromax device was adapted in a way so that it can be connected to a 
specially designed electronic pressure change recorder which was developed in 
collaboration with Canday Medical Ltd., UK. This recorder consisted of 3 pressure 
change sensors of a low, medium and high sensitivity. When the Spiromax was attached 
to the recorder and the patient inhaled through its mouthpiece, these sensors detected the 
pressure drop across the inhaler and thus generated a pressure profile using special 
software installed on the recorder‟s laptop. This pressure profile was then saved in the 
format of pressure vs. time MS Excel worksheet, from which the inhalation profile (IFR 
vs. time) was obtained using the equation √∆P = R.Q (∆P is the change in pressure 
across the DPI, R is the specific resistance and Q is the IFR) and the previously 
determined internal resistance values of the two Spiromax DPI versions (from chapter 
4). 
To determine the required inhalation parameters, the inhalation profile was then fed into 
MATLAB
™
 for processing. The MATLAB
™
 (Matrix Laboratory) (MathWorks
™
 Inc., 
Massachusetts; USA) is a software package that is capable of performing powerful 
simulations and numerical calculations. It has gained a wide acceptance and use in 
many fields of science due to its ability to perform linear and non-linear calculations, 
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display information graphically in 2D and 3D and solve many math and calculus 
problems in science and engineering areas using a specialized programming language 
(Reference: http://www.mathworks.com).  
For the purpose of the present study, two codes were written, using MATLAB Release 
7.0, one for each of the two Spiromax versions (due to the difference in their internal 
flow resistance), to perform several numerical operations on the measured inhalation 
profiles. The MATLAB code was designed to calculate the best polynomial equation of 
the inhalation profile curve from which a number of inhalation parameters were 
determined. These parameters were; the peak inhalation flow (PIF) (l/min), the time to 
reach the PIF (sec), the inhalation flow rates (IFRs) and the time to reach these IFRs at 
several points on the inhalation profile (75% and 90% of the PIF, and at 0.2 seconds of 
commencing the inhalation through the inhaler). Furthermore, the MATLAB code 
performed a trapezoidal integration for the inhalation profile equation to determine the 
total area under inhalation profile curve which represented the total inhalation volume 
(L). Similarly, the inhalation volumes till 75% of PIF and 90% of PIF, and at 0.2 
seconds of the inhalation manoeuvre were also calculated. Moreover, the MATLAB 
code performed a linear curve fitting (to get the best slope) for the inhalation profile 
curve which represented the inhalation acceleration rate (l/sec
2
). These slopes 
(inhalation acceleration rates) were calculated over the same time points; until 75% of 
PIF, until 90% of PIF and at 0.2 seconds of the inhalation through the inhaler device.  
5.2.7.(b) Statistical Data Analysis 
The statistical analysis of the study data was carried out using the Statistical Package for 
Social Sciences (SPSS for Windows, Version 15) software. The study data was first 
classified into scale, categorical (nominal) or ordinal categories, as appropriate. An 
SPSS dataset was then set up for the analysis. The statistical analysis was performed 
and presented as follows: 
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 Descriptive statistics: presented as mean (standard deviation), median (25%; 
75% quartiles), minimum and maximum values, frequencies and percentages; as 
appropriate. 
 For scale data; normal distribution of the data was examined using histograms 
and the statistical tests for normality; the Kolmogorov-Smirnov and Shapiro-
Wilk tests. 
 Comparisons (differences) of measurements within the same study group (visit 1 
vs. visit 2) were performed using the related (paired)-samples t-test (for 
parametric data), or the Wilcoxon test (for non-parametric data). 
 For categorical (nominal) data; correlations/comparisons were made using cross-
tabulation and the Chi-square (χ2) test. 
 Correlations between various study outcome measures were investigated using 
the Pearson correlation test.  
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5.3 Results 
5.3.1 Study Population 
A total of 184 patients were recruited into this research study: 58 (31.5%) asthmatic 
children, 63 (34.2%) asthmatic adults and 63 (34.2%) COPD patients. Thirty five 
(60.3%) asthmatic children, 46 (73%) asthmatic adults and 44 (69.8%) COPD patients 
completed the two study visits as per protocol. A summary of the patients‟ 
demographics, lung function (presented as FEV1 % predicted) and disease severity 
classification at study enrolment (visit 1) is presented in table 5-1. Details of the 
demographic data of all asthmatic children and adults, and of COPD patients are 
presented in APPENDIX B-37, B-39 and B-41, respectively (refer to the enclosed 
DVD). 
Table 5-1: Demographic data of all study patients at enrolment (visit 1). 
Characteristics 
Asthmatic 
Children 
Asthmatic 
Adults 
COPD 
Patients 
Number (n) 58 63 63 
Mean (SD) Age, years 9.9 (3.0) 42.7 (12.6) 64.7 (8.5) 
Sex (M/F) 36/22 19/44 29/34 
Mean (SD) Height, cm 141.8 (19.1) 165.4 (9.4) 166.1 (10.8) 
Mean (SD) FEV1 % predicted  91.1
  
(17.3)
 **
 87.5 (26.9) 56.9 (20.4)
 ***
 
Disease 
Severity* 
(n) 
Mild 39 42 8 
Moderate 12 11 29 
Severe 2 10 18 
Very Severe N/A N/A 7 
  *   Asthma and COPD severity classification was based on the FEV1 % predicted categories of the 
       GINA 
       (2008) and GOLD (2006) guidelines, respectively. 
 **  Five asthmatic children were ≤ 5 years old and had no spirometry results. 
*** One COPD patient had missing lung function data. 
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5.3.2 Results of Asthmatic Children 
5.3.2.1 Lung Function Test (FEV1 % predicted) 
The mean (SD) of the FEV1 % predicted at visits 1 and 2, along with that of the change 
(∆) in FEV1 % predicted between the two visits are presented in table 5-2. Frequencies 
of the patients at various asthma severity levels are shown in table 5-3, asthma severity 
classification was based on the FEV1 % predicted categories of the GINA (2008) 
guidelines. The Chi-square (χ2) statistic showed non-significant differences (p > 0.050) 
in these frequencies between visit 1 and visit 2 for the mild (χ2 = 0.376) and moderate 
(χ2 = 1.6) severity levels. The χ2 statistic could not be calculated for the severe asthma 
level due to the small frequency numbers. Details of all patients‟ measured FEV1 
values, predicted FEV1 and FEV1 % predicted (at visits 1 and 2) are presented in 
APPENDIX B-37 and B-38, respectively (refer to the enclosed DVD). 
Table 5-2: Mean (SD) FEV1 % predicted of asthmatic children at visits 1 and 2, 
                   and of the change (∆)* in FEV1 % predicted between the two visits.   
 
Asthmatic 
Children 
 (n = 31)
**
 
FEV1 % pred, Visit 1 
Mean (SD)  
FEV1 % pred, Visit 2 
Mean (SD)  
∆ FEV1 % pred. 
Mean (SD)  
90.5 (18.5) 94.7 (18.2) 4.2 (12.6) 
* ∆: Change in FEV1 % predicted between visits 1 and 2. ** Descriptive statistics of the lung function 
were calculated for the asthmatic children who attended the two study visits and had spirometry results 
(i.e. > 5 years old). 
 
Table 5-3: Asthmatic children frequencies for disease severity at visits 1 and 2.     
Asthmatic 
Children 
(n = 31) 
Study Visit 
Asthma Severity Levels* – n (%) 
Mild  Moderate Severe 
Visit 1 23 (74.2%) 6 (19.4%) 2 (6.5%) 
Visit 2 25 (80.6%) 5 (16.1%) 1 (3.2%) 
* Asthma severity classification according to FEV1 % predicted categories of the GINA (2008) 
   Guidelines. 
Histograms and tests of normality distribution (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the FEV1 % predicted data was normally distributed. 
Comparison of the FEV1 % predicted between visit 1 and visit 2 (using the related-
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samples t-test) is presented in table 5-4. The results showed that there was no significant 
difference (p = 0.071) in FEV1 % predicted between the two study visits. 
Table 5-4: Comparison of the FEV1 % predicted between V1 and V2 – asthmatic 
                   children.  
Asthmatic 
Children 
(n = 31) 
Related-Samples t-test for FEV1 % predicted (V1 & V2) 
Mean Difference (95% CI) / p-value (2-tailed) 
-4.23 (-8.84; 0.38) / p = 0.071 
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5.3.2.2 Inhalation Profiles through the Spiromax™ DPIs 
On each study visit, each recruited asthmatic child inhaled through the two Spiromax 
DPI devices. Therefore, the inhalation profiles were measured through the two versions 
of the Spiromax DPI; version 1 with a 2.7 dose cup size (DCS) (green mouthpiece cap) 
and version 2 with a 4.0 DCS (brown mouthpiece cap). The specific internal resistance 
values of these Spiromax inhalers were previously determined in our laboratory, and 
were found to be very similar; For the Green Spiromax: 0.0983 (cmH2O)
0.5 
min/l; while 
for the Brown Spiromax: 0.0966 (cmH2O)
0.5 
min/l. The inhalation profiles‟ parameters 
(along with their descriptive statistics) of all asthmatic children, measured at visit 1 are 
presented in tables 5-5, 5-6 and 5-7. The following abbreviations were used in these 
tables, and in subsequent sections, where appropriate: 
 PIF: Peak inhalation flow (l/min), 
 TPIF: Time to reach the PIF (sec), 
 Inhaled Volume (IV): the total volume inhaled through the DPI (L), 
 IFX%PIF: the inhalation flow rate at X% of the PIF (l/min), 
 IVX%PIF: the inhaled volume till X% of PIF (L), 
 TX%PIF: time to reach X% of the PIF (sec), 
 ACCX%PIF: the inhalation acceleration rate till X% of the PIF (l/sec
2
), 
 IF(till 0.2sec), IV(till 0.2sec) and ACC(till 0.2sec): these are the IF, IV and ACC, 
respectively, after 0.2 sec of commencing the inhalation manoeuvre through the 
DPI. 
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Table 5-5: Inhalation profiles parameters through the Spiromax DPIs at visit 1 (part 1) – asthmatic children 
Asthmatic Children – Inhalation Profiles (part 1) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
1 100.0 0.60 0.9109 90.0 0.38 3.692 95.4 0.53 0.8846 85.9 0.34 5.038 
2 73.8 0.80 3.7088 66.4 0.25 3.714 68.2 0.20 2.4724 61.4 0.13 5.6697 
3 46.6 0.47 0.5391 41.9 0.42 1.284 33.9 1.04 0.4481 30.5 0.92 0.486 
4 105.0 0.60 1.9068 94.5 0.38 4.743 100.8 0.76 2.1720 90.7 0.47 3.084 
5 75.4 1.29 0.7717 67.8 1.16 0.610 73.1 0.43 0.6450 65.8 0.32 3.860 
6 92.4 1.21 1.8580 83.2 1.02 1.240 101.3 0.49 1.6751 91.2 0.32 5.079 
7 63.1 0.85 1.1216 56.8 0.66 1.176 63.1 0.92 0.9987 56.8 0.70 1.603 
8 84.2 0.35 0.9518 75.8 0.21 7.328 82.5 0.37 0.8564 74.3 0.24 5.757 
9 70.6 0.25 1.7657 63.6 0.11 8.438 82.2 0.17 1.8463 74.0 0.11 10.216 
10 57.6 0.14 0.4734 51.8 0.07 9.759 47.9 0.12 0.4358 43.1 0.05 5.304 
11 53.9 0.36 1.3242 48.5 0.13 1.478 60.5 0.53 1.6347 54.4 0.32 3.166 
12 42.2 0.33 0.3130 38.0 0.27 2.297 66.7 0.45 1.0315 60.0 0.15 4.992 
13 89.4 0.56 2.6149 80.4 0.27 4.834 91.0 0.63 2.4050 81.9 0.31 3.733 
14 102.5 0.40 3.7341 92.3 0.20 8.019 108.2 0.58 3.9292 97.4 0.29 6.061 
15 88.8 0.30 1.3785 79.9 0.15 8.615 83.8 0.77 1.7450 75.4 0.67 1.101 
16 89.1 0.56 1.1009 80.2 0.20 6.878 90.1 0.34 1.0469 81.1 0.24 6.162 
17 93.7 0.36 2.6810 84.4 0.17 8.816 85.0 0.22 2.5444 76.5 0.12 9.673 
18 98.7 0.40 2.4555 88.8 0.22 5.862 94.0 0.32 2.2507 84.6 0.20 4.925 
19 98.4 0.22 1.3109 88.6 0.12 10.960 96.7 0.24 1.2286 87.1 0.14 8.965 
20 79.4 0.44 0.8818 71.4 0.32 3.671 69.9 0.64 0.8364 62.9 0.49 2.032 
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Asthmatic Children – Inhalation Profiles (part 1) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
21 81.8 0.38 1.2103 73.6 0.24 5.521 65.0 0.57 1.0416 58.5 0.37 2.847 
22 93.0 0.63 2.3267 83.7 0.44 3.511 85.2 0.38 2.0094 76.7 0.25 5.628 
23 92.3 0.83 2.6719 83.1 0.23 4.225 88.8 0.62 2.3087 79.9 0.37 2.759 
24 80.5 0.81 2.0167 72.4 0.51 2.641 80.7 0.44 1.8338 72.7 0.27 4.620 
25 85.0 0.40 1.4666 76.5 0.26 5.720 79.7 0.95 1.2368 71.7 0.79 0.927 
26 75.3 0.90 1.0673 67.8 0.77 1.345 72.5 0.51 0.7670 65.3 0.40 2.866 
27 72.3 0.40 1.6625 65.1 0.32 3.847 77.4 0.46 1.4845 69.7 0.29 4.757 
28 106.3 0.20 1.8734 95.7 0.12 11.174 101.1 0.26 2.0185 91.0 0.15 8.693 
29 85.9 0.23 1.7703 77.3 0.13 8.229 91.1 0.29 1.6160 81.9 0.20 7.766 
30 52.0 0.42 0.9855 46.8 0.28 2.853 55.1 0.29 1.4227 49.6 0.20 3.217 
31 66.1 0.41 2.0863 59.5 0.20 3.973 67.3 0.40 1.8796 60.6 0.26 3.577 
32 39.8 0.86 0.6091 35.8 0.75 0.727 47.8 0.91 0.9126 43.0 0.78 0.765 
33 93.9 0.25 2.4546 84.5 0.13 10.198 97.8 0.23 2.6562 88.0 0.13 9.371 
34 93.2 0.52 1.8560 83.9 0.31 5.232 92.6 0.35 1.7536 83.4 0.25 6.182 
35 34.6 0.89 1.0837 31.1 0.41 1.158 47.4 1.36 2.7256 42.6 0.81 0.768 
36 81.2 0.41 1.6762 73.1 0.27 4.700 76.5 0.27 1.4571 68.8 0.16 8.177 
37 89.5 0.62 1.8856 80.6 0.30 4.976 84.9 0.56 1.7670 76.4 0.29 4.928 
38 106.3 0.20 3.4004 95.7 0.13 11.553 106.7 0.47 2.9136 96.1 0.17 8.381 
39 71.7 0.48 1.2820 64.5 0.34 2.768 71.2 0.33 1.6639 64.0 0.21 5.494 
40 92.4 0.74 1.2030 83.2 0.61 2.385 77.9 0.42 1.0222 70.1 0.23 4.905 
41 106.4 0.18 3.1612 95.7 0.13 11.969 104.6 0.49 2.3713 94.1 0.18 8.277 
42 55.5 0.65 2.4991 50.0 0.39 2.455 60.2 1.07 2.0210 54.1 0.62 1.413 
43 83.7 0.17 1.4304 75.4 0.09 10.855 85.5 0.79 1.6687 76.9 0.60 1.835 
   
213 
Asthmatic Children – Inhalation Profiles (part 1) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
44 82.6 0.26 1.0098 74.4 0.14 7.804 79.0 0.33 1.2383 71.1 0.18 5.440 
45 59.0 0.49 1.3611 53.1 0.29 2.915 48.6 0.55 0.7662 43.8 0.45 1.317 
46 94.2 0.49 1.6130 84.8 0.34 4.286 99.5 0.51 1.9887 89.6 0.28 4.628 
47 63.3 0.40 1.5936 57.0 0.26 3.137 73.5 0.77 1.7836 66.2 0.35 2.676 
48 84.0 0.77 2.0759 75.6 0.41 3.723 78.8 1.24 2.2828 70.9 0.59 2.389 
49 94.8 0.29 1.2477 85.3 0.21 7.552 93.8 0.37 1.1971 84.4 0.26 5.492 
50 81.9 0.50 1.7511 73.7 0.26 4.301 83.7 0.43 1.2888 75.3 0.36 3.802 
51 65.5 0.52 0.7294 58.9 0.37 2.495 65.3 0.61 0.7686 58.8 0.46 1.992 
52 50.9 0.83 1.0608 45.8 0.38 2.082 43.5 0.27 1.1828 39.1 0.17 3.824 
53 81.4 0.52 1.1675 73.2 0.35 3.793 62.2 0.81 1.0743 55.9 0.47 2.139 
54 94.0 0.25 2.2841 84.6 0.14 9.014 102.3 0.35 2.3205 92.1 0.18 6.808 
55 102.6 0.19 2.6094 92.3 0.10 12.560 104.0 0.22 3.0107 93.6 0.10 13.177 
56 85.6 0.30 1.5411 77.1 0.15 7.307 90.1 0.26 1.5654 81.1 0.17 7.571 
57 106.3 0.54 3.8368 95.7 0.36 4.848 108.2 0.30 4.1416 97.4 0.19 8.111 
58 79.1 0.35 1.5039 71.2 0.28 4.555 82.1 0.45 1.5161 73.9 0.33 4.300 
Mean 80.5 0.50 1.7046 72.4 0.31 5.272 79.8 0.51 1.6856 71.8 0.33 4.806 
SD 18.3 0.25 0.8247 16.5 0.21 3.247 18.1 0.27 0.7757 16.3 0.20 2.763 
Min 34.6 0.14 0.3130 31.1 0.07 0.610 33.9 0.12 0.4358 30.5 0.05 0.486 
Max 106.4 1.29 3.8368 95.7 1.16 12.560 108.2 1.36 4.1416 97.4 0.92 13.177 
n 58 58 58 58 58 58 58 58 58 58 58 58 
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Table 5-6: Inhalation profiles parameters through the Spiromax DPIs at visit 1 (part 2) – asthmatic children 
Asthmatic Children – Inhalation Profiles (part 2) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
1 0.3531 75.0 0.27 4.265 0.2035 0.2105 71.6 0.27 4.889 0.1215 
2 0.1970 55.4 0.14 5.535 0.0835 0.1017 51.2 0.06 12.694 0.0330 
3 0.1611 34.9 0.38 1.253 0.1341 0.2437 25.4 0.73 0.471 0.1597 
4 0.3612 78.7 0.23 6.213 0.1422 0.4640 75.6 0.32 4.208 0.2544 
5 0.3153 56.5 1.11 0.485 0.2578 0.1492 54.8 0.24 3.154 0.0736 
6 0.6885 69.3 0.88 1.180 0.5141 0.2538 76.0 0.25 5.299 0.1532 
7 0.4258 47.3 0.43 1.605 0.2207 0.3004 47.3 0.53 1.513 0.1512 
8 0.1087 63.2 0.17 7.028 0.0625 0.1137 61.9 0.20 5.219 0.0722 
9 0.0795 53.0 0.07 11.063 0.0395 0.0905 61.6 0.07 14.372 0.0417 
10 0.0438 43.2 0.03 16.963 0.0162 0.0303 35.9 0.02 6.026 0.0125 
11 0.0952 40.4 0.03 1.800 0.0200 0.1649 45.3 0.22 3.657 0.0787 
12 0.0967 31.7 0.21 2.417 0.0581 0.1043 50.0 0.09 6.020 0.0538 
13 0.2334 67.0 0.17 6.494 0.1136 0.3031 68.2 0.16 6.416 0.1206 
14 0.1912 76.9 0.12 10.563 0.0888 0.2793 81.2 0.19 7.444 0.1321 
15 0.1251 66.6 0.10 10.700 0.0644 0.1877 62.9 0.63 0.702 0.1350 
16 0.1622 66.8 0.14 8.531 0.0850 0.1817 67.6 0.17 7.071 0.0970 
17 0.1376 70.3 0.12 10.246 0.0722 0.0977 63.8 0.08 11.623 0.0525 
18 0.2168 74.0 0.14 7.673 0.1098 0.2062 70.5 0.13 6.651 0.1115 
19 0.1182 73.8 0.08 14.121 0.0597 0.1393 72.5 0.09 12.091 0.0682 
20 0.2133 59.5 0.25 3.902 0.1361 0.3157 52.4 0.36 2.442 0.1866 
21 0.1769 61.4 0.16 6.797 0.0837 0.2047 48.8 0.26 3.437 0.1086 
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Asthmatic Children – Inhalation Profiles (part 2) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
22 0.2831 69.8 0.35 3.332 0.1657 0.1847 63.9 0.17 6.860 0.0962 
23 0.2477 69.3 0.11 8.097 0.0867 0.3502 66.6 0.23 3.819 0.1733 
24 0.2311 60.4 0.42 2.221 0.1310 0.1973 60.6 0.19 5.621 0.1099 
25 0.1604 63.7 0.19 5.661 0.0807 0.1962 59.8 0.73 0.523 0.1265 
26 0.2712 56.5 0.70 1.099 0.1891 0.1729 54.4 0.34 2.499 0.1095 
27 0.1455 54.2 0.26 3.419 0.0809 0.1646 58.0 0.21 4.821 0.0755 
28 0.1330 79.7 0.08 14.899 0.0665 0.1547 75.8 0.09 12.523 0.0717 
29 0.1183 64.4 0.07 13.100 0.0490 0.1163 68.3 0.17 7.432 0.0716 
30 0.1018 39.0 0.23 2.639 0.0651 0.1057 41.4 0.14 3.504 0.0666 
31 0.1447 49.5 0.10 6.962 0.0566 0.1792 50.5 0.16 5.185 0.0790 
32 0.2523 29.9 0.57 0.695 0.1499 0.3514 35.9 0.58 0.933 0.2215 
33 0.1192 70.4 0.08 13.968 0.0566 0.1319 73.3 0.07 13.882 0.0591 
34 0.2090 69.9 0.24 5.379 0.1196 0.1778 69.5 0.19 6.455 0.1022 
35 0.1442 25.9 0.24 2.017 0.0638 0.3652 35.5 0.57 0.884 0.2089 
36 0.2054 60.9 0.17 6.152 0.0924 0.0936 57.4 0.12 8.693 0.0531 
37 0.2377 67.1 0.20 6.278 0.1182 0.2161 63.7 0.19 6.123 0.0963 
38 0.1288 79.7 0.09 13.717 0.0718 0.1865 80.0 0.10 12.401 0.0820 
39 0.1121 53.8 0.30 2.093 0.0755 0.1260 53.4 0.15 6.127 0.0671 
40 0.2637 69.3 0.52 1.778 0.1418 0.1753 58.4 0.15 6.442 0.0840 
41 0.1246 79.8 0.09 14.302 0.0689 0.1889 78.4 0.10 11.986 0.0782 
42 0.1682 41.6 0.28 2.479 0.0829 0.4056 45.1 0.28 2.932 0.1093 
43 0.0826 62.8 0.06 14.936 0.0398 0.1703 64.1 0.54 1.173 0.0897 
44 0.1174 62.0 0.09 10.009 0.0598 0.1387 59.2 0.13 6.180 0.0820 
45 0.1814 44.2 0.14 5.349 0.0615 0.1341 36.5 0.40 1.074 0.0996 
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Asthmatic Children – Inhalation Profiles (part 2) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
46 0.2937 70.6 0.23 5.616 0.1511 0.2866 74.6 0.18 6.286 0.1380 
47 0.1667 47.5 0.17 4.178 0.0853 0.2677 55.1 0.21 4.194 0.1321 
48 0.3036 63.0 0.25 4.687 0.1064 0.4034 59.1 0.36 3.060 0.1567 
49 0.1497 71.1 0.16 7.779 0.0880 0.1919 70.4 0.21 5.479 0.1190 
50 0.2106 61.4 0.17 5.903 0.1133 0.2179 62.7 0.30 3.937 0.1537 
51 0.2045 49.1 0.30 2.622 0.1402 0.3039 49.0 0.27 2.740 0.1320 
52 0.1825 38.2 0.24 2.570 0.0806 0.0598 32.6 0.13 3.860 0.0367 
53 0.1979 61.0 0.29 3.651 0.1239 0.2819 46.6 0.27 2.972 0.1065 
54 0.1307 70.5 0.09 11.750 0.0668 0.1961 76.7 0.12 9.503 0.0984 
55 0.1121 76.9 0.05 24.131 0.0385 0.1134 78.0 0.06 21.268 0.0457 
56 0.1342 64.2 0.10 9.891 0.0652 0.1487 67.6 0.12 9.628 0.0754 
57 0.2299 79.8 0.30 4.259 0.1377 0.1965 81.1 0.13 9.908 0.1019 
58 0.1790 59.3 0.21 5.060 0.1075 0.1844 61.6 0.26 4.214 0.1095 
Mean 0.1927 60.4 0.23 6.750 0.1042 0.2013 59.8 0.24 6.043 0.1041 
SD 0.1012 13.7 0.20 4.919 0.0728 0.0908 13.5 0.17 4.144 0.0471 
Min 0.0438 25.9 0.03 0.485 0.0162 0.0303 25.4 0.02 0.471 0.0125 
Max 0.6885 79.8 1.11 24.131 0.5141 0.4640 81.2 0.73 21.268 0.2544 
n 58 58 58 58 58 58 58 58 58 58 
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Table 5-7: Inhalation profiles parameters through the Spiromax DPIs at visit 1 (part 3) – asthmatic children 
Asthmatic Children – Inhalation Profiles (part 3) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
1 60.7 0.1199 4.777 51.6 0.0512 3.705 
2 64.3 0.1460 4.647 68.0 0.1787 4.144 
3 24.5 0.0495 1.904 7.2 0.0245 0.513 
4 70.0 0.1029 6.027 65.2 0.1112 5.765 
5 4.8 0.0109 0.220 37.2 0.0391 2.089 
6 18.0 0.0339 1.274 62.0 0.0980 5.186 
7 31.4 0.0680 2.127 6.8 0.0125 0.274 
8 72.9 0.1033 7.053 64.6 0.0720 5.300 
9 69.6 0.1767 4.916 81.4 0.2120 5.803 
10 55.9 0.1652 2.834 46.2 0.1458 1.251 
11 50.3 0.1522 1.139 42.8 0.0666 3.535 
12 31.3 0.0555 2.393 64.7 0.1574 4.377 
13 71.8 0.1467 5.838 73.2 0.1625 5.519 
14 91.8 0.1956 7.774 83.1 0.1420 7.287 
15 83.3 0.1963 6.577 7.7 0.0248 0.398 
16 79.9 0.1592 6.665 74.1 0.1307 6.489 
17 87.3 0.1863 7.386 84.0 0.2065 6.142 
18 86.9 0.1918 6.324 83.8 0.2001 5.336 
19 97.7 0.2408 7.030 94.4 0.2265 6.831 
20 50.5 0.0944 4.097 38.3 0.0669 3.016 
21 67.5 0.1241 5.985 42.2 0.0626 3.336 
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Asthmatic Children – Inhalation Profiles (part 3) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
22 24.6 0.0407 1.643 69.8 0.1264 6.175 
23 82.2 0.2056 5.334 63.5 0.1443 4.320 
24 7.7 0.0141 0.237 62.1 0.1143 5.476 
25 65.7 0.0899 5.504 8.2 0.0204 0.431 
26 6.4 0.0197 0.241 18.1 0.0288 1.202 
27 36.0 0.0363 2.433 56.0 0.0647 4.602 
28 106.3 0.2628 7.516 98.5 0.2394 6.858 
29 84.4 0.2168 5.457 80.8 0.1142 7.445 
30 32.7 0.0461 2.352 52.0 0.1100 3.349 
31 59.1 0.1453 4.104 55.2 0.1170 4.439 
32 12.4 0.0273 0.533 20.5 0.0398 1.874 
33 91.5 0.2269 6.681 96.7 0.2461 6.341 
34 57.9 0.0768 4.964 72.5 0.1137 6.239 
35 24.8 0.0459 2.234 26.3 0.0374 2.277 
36 66.2 0.1274 5.582 72.5 0.1438 6.617 
37 66.1 0.1165 6.023 66.2 0.1111 5.834 
38 106.3 0.2479 8.311 98.7 0.2373 7.280 
39 13.4 0.0260 0.868 62.5 0.1117 5.463 
40 4.8 0.0171 0.123 65.5 0.1359 5.430 
41 106.4 0.2531 8.243 95.7 0.2218 7.494 
42 27.5 0.0384 1.994 36.8 0.0572 2.981 
43 82.4 0.2258 5.328 2.8 0.0107 0.010 
44 79.9 0.1890 6.019 73.2 0.1615 5.267 
45 49.7 0.1057 4.044 11.9 0.0299 0.736 
   
219 
Asthmatic Children – Inhalation Profiles (part 3) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
46 65.2 0.1168 5.854 78.6 0.1667 5.995 
47 51.7 0.1116 3.817 54.1 0.1203 4.295 
48 51.2 0.0595 4.156 26.1 0.0314 1.636 
49 83.5 0.1426 7.316 67.0 0.1086 5.373 
50 65.3 0.1423 5.053 45.6 0.0629 3.878 
51 37.5 0.0667 2.888 40.4 0.0774 2.919 
52 32.1 0.0565 2.578 40.9 0.0784 3.513 
53 38.5 0.0511 2.861 36.1 0.0591 2.978 
54 93.0 0.2188 6.918 95.0 0.2200 6.691 
55 102.6 0.2598 6.322 103.5 0.2764 6.684 
56 83.0 0.1942 6.018 84.8 0.1839 6.797 
57 35.1 0.0421 2.203 97.4 0.2086 7.804 
58 57.3 0.0981 4.924 45.1 0.0561 3.525 
Mean 57.9 0.1221 4.374 57.9 0.1169 4.423 
SD 28.8 0.0746 2.337 27.2 0.0703 2.172 
Min 4.8 0.0109 0.123 2.8 0.0107 0.010 
Max 106.4 0.2628 8.311 103.5 0.2764 7.804 
n 58 58 58 58 58 58 
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5.3.2.3 Comparison of the Inhalation Profiles through the Two         
Spiromax DPI Versions 
The normality distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) 
showed that the IP parameters were not normally distributed. Comparison, therefore, 
between the various parameters of the inhalation profiles through the Green and Brown 
versions of the Spiromax DPI was made using the related-samples, nonparametric 
Wilcoxon test. The results showed no significant difference (p > 0.05) in the inhalation 
profiles through the two Spiromax devices. Figures 5-1, 5-2 and 5-3 compare the means 
of various PIF, IV and ACC, respectively, between the two Spiromax versions. 
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Figure 5-1: Mean inhalation flows through the two Spiromax DPI versions – asthmatic children. 
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Figure 5-2: Mean inhaled volumes through the two Spiromax DPI versions - asthmatic children. 
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Figure 5-3: Mean inhalation acceleration rates through the two Spiromax DPI versions - asthmatic 
children. 
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5.3.2.4 Reproducibility of the Inhalation Profiles through the 
Brown Spiromax DPI over Visit 1 and Visit 2 
The two Spiromax DPI versions have similar flow specific resistance, and the statistical 
analysis showed no difference in the inhalation profiles through them. Thus, the 
reproducibility of the inhalation profiles through the brown Spiromax version (with a 
4.0 DCS) over the two study visits is only presented in this thesis. Table 5-8 
summarizes the descriptive statistics of the IP parameters achieved by the asthmatic 
children through the brown Spiromax at visit 1 and visit 2.  
The normality distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) 
showed that the IP parameters were not normally distributed. The difference, therefore, 
in the various parameters of the inhalation profiles between visits 1 and 2 was studied 
using the related-samples, nonparametric Wilcoxon test. The results showed a 
statistically significant difference in almost all the IP parameters including the PIF, 
ACC90%PIF (p < 0.01) and the total inhaled volume (p < 0.05). The results are presented 
in table 5-9. 
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Table 5-8: Comparison of the mean (SD) IP parameters through the Brown Spiromax at visit 1 and visit 2 – asthmatic children 
Asthmatic Children – Inhalation Profiles (n = 35)* 
 
Brown Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 2 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
Mean 77.4 0.54 1.5806 69.7 0.36 4.461 82.1 0.50 1.6757 73.9 0.29 5.841 
SD 18.4 0.28 0.76 16.6 0.23 2.65 16.6 0.26 0.72 15.0 0.20 3.64 
Min 33.9 0.12 0.4358 30.5 0.05 0.486 41.8 0.13 0.5884 37.6 0.07 0.741 
Max 108.2 1.36 3.9292 97.4 0.92 10.216 108.3 1.12 3.2827 97.4 0.99 15.773 
       * Thirty five children attended the two study visits and had inhalation profiles through the Spiromax on the two occasions.  
Asthmatic 
Children 
(n = 35) 
Brown Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 2 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
Mean 0.2063 58.0 0.26 5.378 0.1093 0.1945 61.6 0.21 7.621 0.1030 
SD 0.10 13.8 0.19 3.62 0.05 0.11 12.5 0.17 5.19 0.07 
Min 0.0303 25.4 0.02 0.471 0.0125 0.0652 31.3 0.05 0.791 0.0326 
Max 0.4640 81.2 0.73 14.372 0.2544 0.5868 81.2 0.84 20.679 0.4578 
 
Asthmatic 
Children 
(n = 35) 
Brown Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 2 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
Mean 54.5 0.1080 4.150 64.1 0.1378 4.907 
SD 26.4 0.07 2.17 27.1 0.07 2.12 
Min 6.8 0.0125 0.274 4.8 0.0119 0.203 
Max 98.7 0.2373 7.494 106.5 0.2708 8.615 
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Table 5-9: Difference in the inhalation profiles through the brown Spiromax DPI 
                   between visits 1 and 2 – asthmatic children. 
Inhalation Profiles Parameters 
(n=35) 
W (Sum of Ranks)
† 
/ Exact p-value (2-
tailed) 
PIF 114.0 (114.0; 516.0) / 0.001** 
TPIF 251.5 (378.5; 251.5) / 0.304 
Inhaled Volume (Total) 171.5 (171.5; 458.5) / 0.018* 
IF90%PIF 114.5 (114.5; 515.5) / 0.001** 
T90%PIF 196.0 (434.0; 196.0) / 0.051 
IV90%PIF 268.0 (362.0; 268.0) / 0.451 
ACC90%PIF 140.0 (140.0; 490.0) / 0.003** 
IF75%PIF 113.5 (113.5; 516.5) / 0.001** 
T75%PIF 185.5 (409.5; 185.5) / 0.055 
IV75%PIF 248.0 (382.0; 248.0) / 0.280 
ACC75%PIF 123.0 (123.0; 507.0) / 0.001** 
IF(till 0.2 sec) 166.0 (166.0; 464.0) / 0.013* 
IV(till 0.2 sec) 146.0 (146.0; 484.0) / 0.005** 
ACC(till 0.2 sec) 149.0 (149.0; 481.0) / 0.006** 
   † Sum of ranks for the negative and positive ranks, respectively. 
   * Statistically significant at p ≤ 0.05 level.  
  ** Statistically significant at p ≤ 0.01 level. 
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5.3.2.5 The Asthma Control Questionnaire (ACQ) 
Thirty five asthmatic children completed the ACQ on the two study visits. The median 
(25%, 75% quartiles) of the ACQ scores at visits 1 and 2, and of the change in the ACQ 
scores between the two visits are presented in table 5-10. Details of the ACQ scores of 
all asthmatic children are shown in APPENDIX B-43 (refer to the enclosed DVD). The 
normality distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) showed 
that the ACQ scores were not normally distributed. Comparison, using the related-
samples, non-parametric Wilcoxon test, of the ACQ scores between visit 1 and visit 2 
showed that the change in the ACQ scores was not statistically significant (p = 0.136). 
Table 5-11 presents the frequencies and percentages of the asthmatic children in 
different ACQ score categories at visit 1. The difference in the PIF, IV and ACC(90%PIF) 
through the brown Spiromax among the ACQ severity categories at visit 1 was 
investigated using the Mann-Whitney test; the only significant difference found was in 
the ACC(90%PIF) between the well controlled and not well controlled categories (p = 
0.034). Figures 5-4, 5-5 and 5-6 show the comparisons of the mean PIF, IV and ACC, 
respectively, among the ACQ severity cut-point categories.    
Table 5-10: Median (percentiles 25%, 75%) of the ACQ scores at visits 1 and 2, 
                     and of ∆ ACQ scores – asthmatic children. 
 
Asthmatic 
Children 
(n = 35) 
ACQ, Visit 1 
Median (25%, 75%) 
ACQ, Visit 2 
 Median (25%, 75%) 
∆ ACQ* 
 Median (25%, 75%) 
 1.00 (0.50; 2.83)  1.67 (0.33; 2.83)  0.00 (- 0.33; 0.67) 
  * ∆: Change in the ACQ scores between visits 1 and 2.  
Table 5-11: Frequencies of the asthmatic children in the ACQ categories (visit 1). 
Asthmatic Children 
(n = 58)* 
ACQ Categories Frequency n (%) 
≤ 0.75 
(well controlled) 
23 (39.7%) 
0.75 – 1.50 
(not well controlled) 
9 (15.5%) 
≥ 1.50 
(uncontrolled) 
26 (44.8%) 
     * Fifty eight asthmatic children had ACQ scores at visit 1. 
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Figure 5-4: Comparison of the mean PIF among the ACQ severity categories 
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Figure 5-5: Comparison of the mean IV among the ACQ severity categories 
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Figure 5-6: Comparison of the mean ACC (90%PIF) among the ACQ severity categories 
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5.3.2.6 Correlation among the Inhalation Profiles, Patients‟          
Demographics, Lung Function and the ACQ 
Correlation between the inhalation profile parameters through the brown Spiromax DPI 
(visit 1) with the asthmatic children‟s age, FEV1 % predicted and the ACQ scores was 
investigated using the Pearson Correlation test. The results showed that the correlation 
between the inhalation profiles and the patients‟ FEV1 % predicted and the ACQ scores 
was not statistically significant. However, the age of the asthmatic children had a 
statistically significant (p < 0.01) positive correlation with the PIF (r = 0.668), total 
inhaled volume (r = 0.616), IF90%PIF (r = 0.669) and IF75%PIF (r = 0.669). 
No significant correlation was found between the children‟s age and FEV1 % predicted 
with the ACQ score.  
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5.3.3 Results of the Asthmatic Adults 
5.3.3.1 Lung Function Test (FEV1 % predicted) 
The mean (SD) of the FEV1 % predicted at visits 1 and 2, along with that of the change 
(∆) in FEV1 % predicted between the two visits are presented in table 5-12. Frequencies 
of the patients at various asthma severity levels are shown in table 5-13, asthma severity 
classification was based on the FEV1 % predicted categories of the GINA (2008) 
guidelines. The Chi-square (χ2) statistic showed non-significant differences (p > 0.050) 
in these frequencies between visit 1 and visit 2 for the mild (χ2 = 0.133) and moderate 
(χ2 = 1.017) severity levels. The χ2 statistic could not be calculated for the severe asthma 
level due to the small frequency numbers. Details of all patients‟ measured FEV1 
values, predicted FEV1 and FEV1 % predicted (at visits 1 and 2) are presented in 
APPENDIX B-39 and B-40, respectively (refer to the enclosed DVD).  
Table 5-12: Mean (SD) FEV1 % predicted of asthmatic adults at visits 1 and 2, and 
                     of the change (∆)* in FEV1 % predicted between the two visits.   
 
Asthmatic 
Adults 
  (n =46)
**
 
FEV1 % pred, Visit 1 
Mean (SD)  
FEV1 % pred, Visit 2 
Mean (SD)  
∆ FEV1 % pred. 
Mean (SD)  
89.1 (27.4) 90.0 (23.5) 0.91 (10.6) 
* ∆: Change in FEV1 % predicted between visits 1 and 2. ** Descriptive statistics of the lung function 
were calculated for the asthmatic adults who completed the two study visits (n=46). 
 
Table 5-13: Asthmatic adults’ frequencies in disease severity categories at visits 1 
                     and 2.     
Asthmatic 
Adults 
(n = 46) 
Study Visit 
Asthma Severity Levels* – n (%) 
Mild  Moderate Severe 
Visit 1 31 (67.4%) 8 (17.4%) 7 (15.2%) 
Visit 2 34 (73.9%) 7 (15.2%) 5 (10.9%) 
* Asthma severity classification according to FEV1 % predicted categories of the GINA (2008) 
   Guidelines. 
Histograms and tests of normality distribution (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the FEV1 % predicted data was not normally distributed. 
Comparison of the FEV1 % predicted between visit 1 and visit 2 (using the related-
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samples Wilcoxon test) is presented in table 5-14. The results showed that there was no 
significant difference (p = 0.770) in FEV1 % predicted between the two study visits. 
Table 5-14: Comparison of the FEV1 % predicted between V1 and V2 – asthmatic 
                     adults.  
Asthmatic 
Adults 
(n = 46) 
W (Sum of Ranks)* / Exact p-value (2-tailed) - FEV1 % 
predicted (V1 & V2) 
513.0 (568.0; 513.0) / p = 0.770 
    * Sum of ranks for the negative and positive ranks, respectively. 
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5.3.3.2 Inhalation Profiles through the Spiromax™ DPIs 
On each study visit, each recruited asthmatic adult inhaled through the two Spiromax 
DPI devices. Therefore, the inhalation profiles were measured through the two versions 
of the Spiromax DPI; version 1 with a 2.7 dose cup size (DCS) (green mouthpiece cap) 
and version 2 with a 4.0 DCS (brown mouthpiece cap). The specific internal resistance 
values of these Spiromax inhalers were previously determined in our laboratory, and 
were found to be very similar; For the Green Spiromax: 0.0983 (cmH2O)
0.5 
min/l; while 
for the Brown Spiromax: 0.0966 (cmH2O)
0.5 
min/l. The inhalation profiles‟ parameters 
(along with their descriptive statistics) of all asthmatic adults, measured at visit 1 are 
presented in tables 5-15, 5-16 and 5-17. The following abbreviations were used in these 
tables, and in subsequent sections, where appropriate: 
 PIF: Peak inhalation flow (l/min), 
 TPIF: Time to reach the PIF (sec), 
 Inhaled Volume (IV): the total volume inhaled through the DPI (L), 
 IFX%PIF: the inhalation flow rate at X% of the PIF (l/min), 
 IVX%PIF: the inhaled volume till X% of PIF (L), 
 TX%PIF: time to reach X% of the PIF (sec), 
 ACCX%PIF: the inhalation acceleration rate till X% of the PIF (l/sec
2
), 
 IF(till 0.2sec), IV(till 0.2sec) and ACC(till 0.2sec): these are the IF, IV and ACC, 
respectively, after 0.2 sec of commencing the inhalation manoeuvre through the 
DPI. 
   
232 
Table 5-15: Inhalation profiles parameters through the Spiromax DPIs at visit 1 (part 1) – asthmatic adults 
Asthmatic Adults – Inhalation Profiles (part 1) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
1 106.3 0.40 5.0914 95.6 0.20 5.545 101.5 0.41 5.0253 91.3 0.14 8.869 
2 96.8 0.33 1.9517 87.1 0.16 9.763 103.8 0.26 2.0029 93.4 0.15 9.717 
3 72.1 0.75 2.3016 64.9 0.44 2.705 62.4 0.81 2.3017 56.2 0.51 1.583 
4 91.9 0.50 3.2348 82.7 0.30 4.691 91.5 0.87 2.9336 82.3 0.46 3.188 
5 106.3 0.34 2.8883 95.7 0.13 10.694 101.5 0.41 2.5370 91.4 0.14 9.605 
6 84.7 0.54 3.6783 76.2 0.28 3.772 88.0 0.64 3.7183 79.2 0.27 5.728 
7 99.4 0.31 2.1922 89.4 0.20 7.909 100.5 0.27 1.2599 90.5 0.20 8.805 
8 98.7 0.39 3.3888 88.8 0.19 8.341 91.5 0.53 3.4281 82.4 0.21 4.651 
9 82.8 1.07 2.4419 74.5 0.42 3.207 76.3 0.59 2.5519 68.7 0.35 3.307 
10 56.1 1.43 1.8219 50.5 0.81 0.978 57.7 1.36 1.6407 51.9 0.91 0.928 
11 96.9 0.28 2.1898 87.2 0.14 10.759 97.9 0.42 2.0195 88.1 0.18 8.648 
12 51.3 0.47 2.1325 46.2 0.25 1.644 48.8 0.67 2.2895 43.9 0.40 1.948 
13 98.0 0.19 3.9959 88.2 0.09 15.671 100.7 0.37 4.4952 90.6 0.12 11.743 
14 94.0 0.45 2.0100 84.6 0.22 7.223 92.2 0.33 1.7151 82.9 0.18 7.265 
15 94.0 0.37 2.0469 84.6 0.22 6.465 98.4 0.28 2.0729 88.5 0.17 7.930 
16 61.0 0.61 0.8687 54.9 0.49 2.108 47.3 0.61 0.8286 42.5 0.48 1.572 
17 98.7 0.49 2.5505 88.9 0.34 4.802 98.6 0.41 2.5764 88.8 0.15 10.939 
18 89.3 1.09 2.1683 80.4 0.47 2.716 89.5 1.09 1.7781 80.6 0.57 1.863 
19 106.3 0.42 3.7466 95.7 0.24 6.554 108.0 0.41 4.0030 97.2 0.16 8.080 
20 85.2 1.27 1.9048 76.7 0.98 1.184 84.1 0.73 2.1502 75.7 0.42 2.703 
21 103.8 0.63 2.5269 93.4 0.44 3.871 102.9 0.95 2.2346 92.7 0.54 3.502 
22 97.1 0.87 2.2326 87.4 0.64 2.313 103.4 0.67 2.8408 93.0 0.42 3.282 
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Asthmatic Adults – Inhalation Profiles (part 1) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
23 105.1 0.30 3.6434 94.6 0.19 8.967 108.1 0.38 4.1104 97.3 0.30 5.869 
24 90.0 0.56 2.7581 81.0 0.47 2.655 86.3 0.37 2.5261 77.7 0.21 7.258 
25 83.2 1.14 2.6682 74.8 0.87 1.296 79.7 1.22 2.5242 71.7 0.74 1.413 
26 82.2 1.05 2.9711 74.0 0.33 3.285 81.9 0.35 3.0829 73.7 0.18 6.903 
27 104.2 0.36 2.5586 93.8 0.14 8.772 108.1 0.32 2.5436 97.3 0.16 9.433 
28 71.7 0.33 1.3950 64.6 0.17 6.089 72.5 0.29 1.2560 65.3 0.13 7.079 
29 105.6 0.39 2.3716 95.0 0.17 6.431 103.3 0.31 2.2125 93.0 0.14 8.377 
30 51.3 0.38 0.6320 46.2 0.14 4.834 88.9 0.14 1.6891 80.0 0.10 13.373 
31 106.3 0.32 3.5422 95.7 0.22 4.604 108.2 0.26 3.4126 97.3 0.13 10.438 
32 78.4 0.45 0.8750 70.5 0.27 4.734 82.0 0.76 1.1918 73.8 0.61 2.120 
33 84.0 1.09 3.2270 75.6 0.81 0.714 66.7 0.56 3.1232 60.0 0.36 2.071 
34 100.3 0.68 2.1777 90.3 0.33 5.569 108.2 0.38 1.8610 97.3 0.20 8.209 
35 94.4 0.59 2.1425 85.0 0.36 4.029 93.3 0.51 2.0877 84.0 0.30 4.308 
36 106.3 0.36 3.9345 95.7 0.05 23.827 108.2 0.44 3.9005 97.4 0.08 10.565 
37 101.1 0.45 2.4177 91.0 0.21 7.285 98.2 0.38 2.3117 88.4 0.18 7.359 
38 106.3 0.20 2.8121 95.7 0.12 11.506 108.2 0.22 2.1819 97.4 0.14 9.704 
39 66.6 0.43 3.0171 60.0 0.19 4.285 68.6 0.38 3.1961 61.7 0.21 4.056 
40 79.2 0.77 2.5062 71.3 0.40 3.405 84.0 0.74 2.0646 75.6 0.33 4.241 
41 83.8 0.61 2.0672 75.5 0.39 3.771 79.1 1.16 1.9251 71.2 0.56 2.473 
42 77.0 0.38 1.5324 69.3 0.21 5.027 62.3 0.67 1.3593 56.1 0.31 2.988 
43 97.9 0.28 1.9238 88.1 0.18 9.134 103.8 1.40 2.1397 93.4 1.26 0.583 
44 90.4 0.44 1.5115 81.3 0.25 5.974 90.8 0.38 1.7840 81.7 0.26 5.885 
45 93.2 0.68 1.9626 83.9 0.46 2.697 86.1 0.75 1.9537 77.5 0.48 1.927 
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Asthmatic Adults – Inhalation Profiles (part 1) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
46 95.8 0.20 3.6123 86.2 0.09 12.752 97.2 0.36 3.3409 87.4 0.19 6.960 
47 106.4 0.42 2.7970 95.7 0.21 8.472 106.0 0.37 2.1162 95.4 0.18 8.703 
48 91.6 0.85 2.3985 82.4 0.64 2.270 90.0 0.71 2.2186 81.0 0.51 3.003 
49 84.6 0.52 1.1396 76.1 0.32 4.829 100.7 0.50 1.3551 90.6 0.42 3.249 
50 106.3 0.14 1.3838 95.7 0.10 15.726 108.2 0.20 1.5254 97.4 0.12 12.272 
51 106.3 0.22 2.8437 95.7 0.11 12.532 108.2 0.42 2.4785 97.4 0.17 8.633 
52 61.7 0.29 2.4410 55.6 0.19 5.738 60.9 0.32 2.3257 54.8 0.26 3.454 
53 99.1 0.55 3.3821 89.2 0.28 6.483 102.0 0.35 4.0084 91.8 0.16 9.875 
54 95.7 0.53 2.1768 86.1 0.29 3.761 88.8 0.41 2.4491 79.9 0.30 5.022 
55 75.5 1.45 3.8670 68.0 0.68 1.963 77.5 1.39 4.5735 69.7 0.64 1.724 
56 82.3 1.20 1.9926 74.1 1.03 1.142 72.8 0.36 1.4524 65.5 0.25 4.620 
57 95.3 0.35 1.4466 85.7 0.15 10.063 94.6 0.39 1.5870 85.2 0.21 7.416 
58 106.4 0.32 1.5927 95.7 0.26 5.804 103.5 0.46 1.6450 93.2 0.25 7.569 
59 106.3 0.44 3.3166 95.7 0.35 4.809 108.2 0.42 3.1471 97.4 0.32 5.410 
60 92.2 0.49 3.1221 83.0 0.29 5.880 92.3 0.23 2.0927 83.1 0.10 12.169 
61 106.4 0.26 2.6658 95.7 0.19 8.884 108.2 0.18 3.1085 97.4 0.12 8.616 
62 106.3 0.26 1.1507 95.6 0.17 7.646 108.1 0.52 1.1484 97.3 0.39 2.822 
63 78.7 0.82 1.6008 70.9 0.45 2.460 77.0 0.87 2.7502 69.3 0.45 2.251 
Mean 90.9 0.55 2.4594 81.8 0.32 6.080 90.9 0.54 2.4470 81.8 0.31 5.972 
SD 14.7 0.32 0.8729 13.2 0.22 4.160 16.0 0.30 0.9126 14.4 0.21 3.383 
Min 51.3 0.14 0.632 46.2 0.05 0.714 47.3 0.14 0.8286 42.5 0.08 0.583 
Max 106.4 1.45 5.0914 95.7 1.03 23.827 108.2 1.40 5.0253 97.4 1.26 13.373 
n 63 63 63 63 63 63 63 63 63 63 63 63 
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Table 5-16: Inhalation profiles parameters through the Spiromax DPIs at visit 1 (part 2) – asthmatic adults 
Asthmatic Adults – Inhalation Profiles (part 2) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
1 0.2449 79.7 0.10 9.337 0.0922 0.1537 76.1 0.08 12.820 0.0696 
2 0.1310 72.6 0.11 11.088 0.0710 0.1444 77.8 0.10 11.406 0.0794 
3 0.2889 54.1 0.27 3.552 0.1220 0.3376 46.8 0.27 2.772 0.1325 
4 0.2609 68.9 0.19 6.396 0.1200 0.3961 68.6 0.29 4.376 0.1791 
5 0.1439 79.7 0.08 15.089 0.0663 0.1510 76.1 0.08 15.268 0.0620 
6 0.2691 63.5 0.14 7.058 0.0917 0.2061 66.0 0.16 7.461 0.0733 
7 0.1576 74.5 0.16 8.203 0.0931 0.1218 75.4 0.16 8.356 0.0757 
8 0.1886 74.0 0.09 14.236 0.0596 0.2326 68.6 0.08 11.956 0.0631 
9 0.3193 62.1 0.27 4.428 0.1459 0.2494 57.2 0.24 4.177 0.1286 
10 0.4325 42.1 0.54 1.229 0.2262 0.5228 43.2 0.51 1.372 0.2019 
11 0.1231 72.7 0.09 13.610 0.0626 0.1701 73.5 0.10 12.993 0.0662 
12 0.1578 38.5 0.07 6.935 0.0322 0.2010 36.6 0.19 3.200 0.0575 
13 0.0795 73.5 0.07 17.473 0.0458 0.1144 75.5 0.09 13.820 0.0630 
14 0.1900 70.5 0.13 10.486 0.0746 0.1742 69.1 0.09 14.463 0.0551 
15 0.1949 70.5 0.14 8.529 0.0932 0.1620 73.8 0.11 10.095 0.0831 
16 0.2113 45.8 0.38 2.027 0.1178 0.1921 35.5 0.36 1.843 0.1181 
17 0.3047 74.0 0.20 6.811 0.1212 0.1295 74.0 0.10 13.373 0.0616 
18 0.4283 67.0 0.26 4.330 0.1731 0.5768 67.1 0.26 4.184 0.1915 
19 0.2420 79.7 0.16 8.192 0.1203 0.1844 81.0 0.09 12.593 0.0789 
20 0.3342 63.9 0.84 0.727 0.1739 0.3617 63.1 0.25 4.097 0.1585 
21 0.4256 77.8 0.26 5.483 0.1604 0.4597 77.2 0.34 4.272 0.1717 
22 0.2805 72.8 0.54 1.628 0.1466 0.4719 77.5 0.20 6.639 0.1536 
23 0.1660 78.8 0.14 9.777 0.0907 0.2120 81.1 0.25 5.384 0.1295 
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Asthmatic Adults – Inhalation Profiles (part 2) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
24 0.2306 67.5 0.40 2.013 0.1480 0.1404 64.7 0.15 7.823 0.0700 
25 0.7039 62.4 0.58 1.679 0.3709 0.6038 59.8 0.44 2.082 0.2773 
26 0.2955 61.6 0.17 6.028 0.1045 0.1384 61.4 0.12 9.066 0.0670 
27 0.1493 78.1 0.09 10.757 0.0772 0.1757 81.1 0.10 12.795 0.0813 
28 0.1178 53.8 0.11 7.598 0.0586 0.0980 54.4 0.07 10.197 0.0443 
29 0.2164 79.2 0.07 15.198 0.0637 0.1622 77.5 0.07 14.836 0.0632 
30 0.0740 38.5 0.09 6.530 0.0342 0.0781 66.7 0.07 15.413 0.0438 
31 0.2746 79.7 0.09 11.952 0.0877 0.1512 81.1 0.08 15.401 0.0669 
32 0.1452 58.8 0.21 4.232 0.0823 0.2442 61.5 0.53 1.821 0.1595 
33 0.8533 63.0 0.23 2.943 0.1880 0.2542 50.0 0.24 2.890 0.1412 
34 0.2757 75.2 0.21 6.220 0.1057 0.2031 81.1 0.14 10.148 0.0995 
35 0.2829 70.8 0.27 4.140 0.1589 0.2228 70.0 0.24 3.997 0.1432 
36 0.0609 79.8 0.03 32.041 0.0293 0.1130 81.2 0.02 51.983 0.0213 
37 0.2045 75.9 0.13 10.240 0.0951 0.1794 73.6 0.11 9.831 0.0857 
38 0.1306 79.7 0.08 14.824 0.0674 0.1555 81.1 0.08 14.310 0.0717 
39 0.1277 50.0 0.13 5.145 0.0700 0.1442 51.4 0.14 4.944 0.0803 
40 0.3098 59.4 0.22 5.590 0.1023 0.1548 63.0 0.27 3.509 0.0853 
41 0.2295 62.9 0.30 3.682 0.1198 0.3758 59.3 0.38 2.995 0.1690 
42 0.1614 57.7 0.14 6.726 0.0801 0.1958 46.7 0.18 4.748 0.0791 
43 0.1355 73.4 0.14 9.541 0.0766 0.2517 77.9 1.21 0.382 0.1757 
44 0.1940 67.8 0.17 6.674 0.0891 0.1691 68.1 0.20 5.904 0.1020 
45 0.4330 69.9 0.28 3.698 0.2086 0.4613 64.6 0.26 3.305 0.1993 
46 0.0948 71.8 0.06 18.006 0.0438 0.1900 72.9 0.11 10.207 0.0837 
47 0.1893 54.3 0.09 7.664 0.0611 0.0961 54.8 0.07 11.237 0.0408 
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Asthmatic Adults – Inhalation Profiles (part 2) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
48 0.2692 68.7 0.54 1.731 0.1487 0.2798 67.5 0.42 2.685 0.1578 
49 0.1732 63.4 0.24 4.473 0.0879 0.1851 75.5 0.37 2.340 0.1140 
50 0.0947 79.7 0.07 18.246 0.0530 0.1301 81.1 0.08 16.122 0.0642 
51 0.1209 79.7 0.07 16.696 0.0591 0.1887 81.2 0.09 13.482 0.0786 
52 0.0751 46.3 0.15 5.551 0.0455 0.0917 45.7 0.23 3.025 0.0633 
53 0.2166 74.3 0.19 7.028 0.0896 0.1440 76.5 0.11 11.460 0.0774 
54 0.2908 71.8 0.18 4.790 0.1551 0.2390 66.6 0.18 6.674 0.1002 
55 0.4354 56.6 0.42 2.326 0.1675 0.4207 58.1 0.50 1.829 0.2696 
56 0.4996 61.7 0.91 1.003 0.3663 0.1642 54.6 0.17 5.803 0.0815 
57 0.1228 71.4 0.11 11.551 0.0670 0.1641 71.0 0.16 8.168 0.0885 
58 0.1220 79.8 0.23 4.749 0.0827 0.1612 77.6 0.19 6.980 0.0847 
59 0.2831 79.8 0.27 4.773 0.1706 0.2873 81.2 0.23 5.995 0.1579 
60 0.1721 69.1 0.22 5.392 0.0796 0.0959 69.2 0.06 17.680 0.0425 
61 0.1536 79.8 0.15 9.010 0.0960 0.1539 81.2 0.04 27.100 0.0379 
62 0.1952 79.7 0.10 12.199 0.0852 0.4662 81.1 0.23 4.167 0.2340 
63 0.3481 59.1 0.29 3.261 0.1727 0.3658 57.7 0.24 3.682 0.1467 
Mean 0.2387 67.8 0.22 7.818 0.1103 0.2289 67.8 0.21 8.793 0.1064 
SD 0.14 11.0 0.17 5.5 0.06 0.13 12.0 0.18 7.6 0.06 
Min 0.0609 38.5 0.03 0.727 0.0293 0.0781 35.5 0.02 0.382 0.0213 
Max 0.8533 79.8 0.91 32.041 0.3709 0.6038 81.2 1.21 51.983 0.2773 
n 63 63 63 63 63 63 63 63 63 63 
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Table 5-17: Inhalation profiles parameters through the Spiromax DPIs at visit 1 (part 3) – asthmatic adults 
Asthmatic Adults – Inhalation Profiles (part 3) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
1 95.3 0.2449 5.620 96.8 0.2418 6.659 
2 92.8 0.1938 7.986 100.2 0.2297 7.722 
3 42.6 0.0637 3.397 41.3 0.0823 3.246 
4 70.4 0.1312 6.053 54.3 0.0818 4.687 
5 101.7 0.2563 7.216 96.5 0.2422 6.870 
6 72.5 0.1646 5.413 70.0 0.1156 6.785 
7 88.3 0.1547 7.702 91.0 0.1282 8.442 
8 90.3 0.2089 7.553 82.0 0.2129 5.412 
9 53.2 0.0805 4.630 51.5 0.0924 4.400 
10 21.1 0.0382 1.622 18.4 0.0386 1.368 
11 93.8 0.2176 7.614 91.5 0.2059 7.523 
12 44.1 0.1235 2.453 37.7 0.0619 3.067 
13 98.0 0.2338 7.419 99.4 0.2384 7.701 
14 81.9 0.1626 7.541 85.6 0.1995 6.644 
15 82.6 0.1710 6.824 93.4 0.2114 6.950 
16 15.8 0.0255 1.098 24.8 0.0324 1.733 
17 74.2 0.1211 6.555 94.8 0.2100 8.008 
18 58.5 0.1085 4.814 61.2 0.1221 4.989 
19 89.1 0.1758 7.339 102.1 0.2564 6.733 
20 7.0 0.0164 0.349 56.7 0.1116 4.489 
21 64.5 0.0886 5.021 31.4 0.0333 2.013 
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Asthmatic Adults – Inhalation Profiles (part 3) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
22 5.6 0.0135 0.259 76.8 0.1498 6.536 
23 94.4 0.1746 8.484 60.3 0.0721 4.440 
24 17.5 0.0430 1.187 76.9 0.1338 7.013 
25 33.8 0.0606 2.443 36.8 0.0738 2.446 
26 66.4 0.1393 5.224 75.8 0.1639 6.239 
27 100.0 0.2507 6.419 100.6 0.2333 7.873 
28 66.7 0.1461 5.353 70.8 0.1796 4.711 
29 98.4 0.2588 5.932 98.8 0.2577 6.301 
30 46.4 0.1199 3.275 82.3 0.2251 6.484 
31 92.8 0.2420 5.622 104.7 0.2638 7.210 
32 55.3 0.0719 3.973 5.7 0.0120 0.253 
33 61.1 0.1508 3.678 46.7 0.1109 3.411 
34 72.8 0.0922 6.388 96.3 0.1963 8.138 
35 53.5 0.0836 4.281 58.3 0.0944 4.867 
36 104.0 0.3046 5.067 102.6 0.3052 4.893 
37 90.2 0.1888 7.542 89.7 0.2052 6.845 
38 106.3 0.2588 7.826 107.8 0.2656 7.244 
39 60.5 0.1352 4.330 60.5 0.1326 4.273 
40 56.5 0.0904 4.983 28.0 0.0297 1.813 
41 33.3 0.0371 2.309 26.8 0.0324 1.828 
42 68.4 0.1465 5.351 49.3 0.1007 3.912 
43 90.7 0.1609 8.281 5.5 0.0197 0.156 
44 74.7 0.1281 6.376 66.1 0.0970 5.734 
45 58.4 0.1208 4.236 59.5 0.1350 4.123 
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Asthmatic Adults – Inhalation Profiles (part 3) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
46 95.8 0.2535 6.109 88.6 0.2028 6.729 
47 63.4 0.1658 3.724 69.9 0.1844 4.475 
48 4.9 0.0115 0.198 10.4 0.0198 0.584 
49 47.5 0.0460 3.466 9.1 0.0264 0.436 
50 106.3 0.2727 7.964 108.2 0.2642 7.894 
51 105.7 0.2681 7.356 99.7 0.2450 7.280 
52 57.3 0.0898 5.353 35.2 0.0427 2.526 
53 77.0 0.1042 6.848 97.2 0.2071 8.179 
54 75.0 0.1731 4.974 68.4 0.1195 6.204 
55 17.8 0.0294 1.313 25.4 0.0515 1.692 
56 5.5 0.0095 0.275 57.4 0.1077 5.124 
57 91.6 0.1994 7.790 83.3 0.1464 7.375 
58 55.4 0.0428 3.284 80.2 0.0939 6.919 
59 57.4 0.0906 4.169 72.9 0.1191 5.855 
60 62.5 0.0584 4.767 87.0 0.2406 5.693 
61 97.3 0.1679 8.581 108.2 0.2978 6.009 
62 100.4 0.2398 7.094 77.1 0.1937 4.897 
63 47.9 0.0914 3.790 51.2 0.1065 4.012 
Mean 66.9 0.1383 5.081 68.2 0.1477 5.144 
SD 28.7 0.08 2.3 29.3 0.08 2.3 
Min 4.9 0.0095 0.198 5.5 0.0120 0.156 
Max 106.3 0.3046 8.581 108.2 0.3052 8.442 
n 63 63 63 63 63 63 
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5.3.3.3 Comparison of the Inhalation Profiles through the Two           
Spiromax DPI Versions 
The normality distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) 
showed that the IP parameters were not normally distributed. Comparison, therefore, 
between the various parameters of the inhalation profiles through the Green and Brown 
versions of the Spiromax DPI was made using the related-samples, nonparametric 
Wilcoxon test. The results showed a non-significant difference (p > 0.05) in all the 
inhalation profile parameters through the two Spiromax devices. Figures 5-7, 5-8 and 5-
9 compare the means of various PIF, IV and ACC, respectively, between the two 
Spiromax versions. 
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Figure 5-7: Mean inhalation flow through the two Spiromax DPI versions – asthmatic adults. 
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Figure 5-8: Mean inhaled volume through the two Spiromax DPI versions – asthmatic adults. 
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Figure 5-9: Mean inhalation acceleration rate through the two Spiromax DPI versions – asthmatic 
adults. 
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5.3.3.4 Reproducibility of the Inhalation Profiles through the 
Brown Spiromax DPI over Visit 1 and Visit 2 
The two Spiromax DPI versions have similar flow specific resistance, and the statistical 
analysis showed no difference in the inhalation profiles through them. Thus, the 
reproducibility of the inhalation profiles through the brown Spiromax version (with a 
4.0 DCS) over the two study visits is only presented in this thesis. Table 5-18 
summarizes the descriptive statistics of the IP parameters achieved by the asthmatic 
adults through the brown Spiromax at visit 1 and visit 2.  
The normality distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) 
showed that the IP parameters were not normally distributed. The difference, therefore, 
in the various parameters of the inhalation profiles between visits 1 and 2 was studied 
using the related-samples, nonparametric Wilcoxon test. No statistically significant 
difference (p > 0.05) in the inhalation profiles through the brown Spiromax DPI was 
found over the two study visits.  
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Table 5-18: Comparison of the mean (SD) IP parameters through the Brown Spiromax at visit 1 and visit 2 – asthmatic adults 
Asthmatic Adults – Inhalation Profiles (n = 46)* 
 
Brown Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 2 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
Mean 92.5 0.53 2.4485 83.2 0.29 6.245 92.2 0.53 2.5405 83.0 0.29 6.845 
SD 14.4 0.30 0.8310 13.0 0.21 3.331 13.9 0.28 0.8080 12.5 0.21 5.244 
Min 48.8 0.14 1.0321 43.9 0.08 0.583 54.0 0.20 1.1598 48.6 0.04 0.531 
Max 108.2 1.40 5.0253 97.4 1.26 13.373 108.3 1.48 5.2889 97.4 1.27 34.706 
       * Forty six asthmatic adults attended the two study visits and had inhalation profiles through the Spiromax on the two occasions.  
Asthmatic 
Adults 
(n = 46) 
Brown Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 2 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
Mean 0.2222 69.4 0.20 9.609 0.1015 0.2314 69.2 0.19 8.888 0.1059 
SD 0.1162 10.8 0.19 8.385 0.0529 0.1507 10.4 0.13 6.847 0.0662 
Min 0.0781 36.6 0.02 0.382 0.0213 0.0448 40.5 0.03 0.559 0.0227 
Max 0.5768 81.2 1.21 51.983 0.2696 0.8254 81.2 0.76 44.470 0.3838 
 
Asthmatic 
Adults 
(n = 46) 
Brown Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 2 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
Mean 70.8 0.1550 5.325 72.0 0.1504 5.613 
SD 28.8 0.0815 2.239 24.9 0.0743 2.018 
Min 5.5 0.0197 0.156 11.4 0.0238 0.681 
Max 108.2 0.3052 8.442 108.1 0.3187 9.439 
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5.3.3.5 The Asthma Control Questionnaire (ACQ) 
Forty six asthmatic adults completed the ACQ on the two study visits. The median 
(25%, 75% quartiles) of the ACQ scores at visits 1 and 2, and of the change in the ACQ 
scores between the two visits are presented in table 5-19. The normality distribution 
tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) showed that the ACQ scores 
were not normally distributed. Comparison, using the related-samples, non-parametric 
Wilcoxon test, of the ACQ scores between visit 1 and visit 2 is presented in table 5-20. 
The result showed that the difference in the ACQ scores between visit 1 and visit 2 was 
statistically significant (p = 0.009). Details of the ACQ scores of all asthmatic adults are 
shown in APPENDIX B-44 (refer to the enclosed DVD).  
Table 5-21 presents the frequencies and percentages of the asthmatic adults in different 
ACQ score categories at visit 1. The difference in the PIF, IV and ACC(90%PIF) through 
the brown Spiromax among the ACQ severity categories at visit 1 was investigated 
using the Mann-Whitney test; the only significant differences found were in the PIF 
between the well controlled group and the two other groups (p < 0.05), and in the 
ACC(90%PIF) between the well controlled and the uncontrolled groups (p = 0.05). Figures 
5-10, 5-11 and 5-12 compare the mean PIF, IV and ACC(90%PIF), respectively, among the 
ACQ severity cut-point categories.    
Table 5-19: Median (25%, 75% quartiles) of the ACQ scores at visits 1 and 2, and 
                    of ∆ ACQ scores – asthmatic adults. 
 
Asthmatic 
Adults 
(n = 46) 
ACQ, Visit 1 
[Median (25%, 75%)] 
ACQ, Visit 2 
[Median (25%, 75%)] 
∆ ACQ* 
[Median (25%, 75%)] 
2.00 (1.17; 3.17) 1.59 (0.67; 3.37) -0.34 (-0.67; 0.16) 
    * ∆: Change in the ACQ scores between visits 1 and 2. 
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Table 5-20: Comparison of the ACQ scores between V1 and V2–asthmatic adults. 
 
Asthmatic Adults 
(n = 46) 
W (Sum of Ranks)* / Exact p-value (2-tailed) - ACQ 
Score 
261.0 (685.0; 261.0) / p = 0.009** 
    *   Sum of ranks for the negative and positive ranks, respectively. 
    ** Statistically significant difference at p < 0.01. 
 
Table 5-21: Frequencies of the asthmatic adults in the ACQ categories (visit 1). 
Asthmatic Adults 
(n = 63)* 
ACQ Categories Frequency n (%) 
≤ 0.75 
(well controlled) 
6 (9.5%) 
0.75 – 1.50 
(not well controlled) 
15 (23.8%) 
≥ 1.50 
(uncontrolled) 
42 (66.7%) 
     * Sixty three asthmatic adults had ACQ scores at visit 1. 
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Figure 5-10: Comparison of the mean PIF among the ACQ severity categories 
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Figure 5-11: Comparison of the mean IV among the ACQ severity categories 
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Figure 5-12: Comparison of the mean ACC(90%PIF) among the ACQ severity categories 
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5.3.3.6 Correlation among the Inhalation Profiles, Patients‟            
Demographics, Lung Function and the ACQ 
Correlation between the inhalation profile parameters through the brown Spiromax DPI 
(visit 1) with the asthmatic adults‟ age, FEV1 % predicted and the ACQ scores was 
investigated using the Pearson Correlation test. The results showed that the correlation 
between the inhalation profiles and the patients‟ age, FEV1 % predicted and the ACQ 
scores was not statistically significant. However, the FEV1 % predicted of the asthmatic 
adults had a statistically significant negative correlation with the ACQ score (r = - 
0.522, p < 0.01), and a positive correlation with the total inhaled volume through the 
Spiromax DPI (r = 0.398, p < 0.01). 
No significant correlation was found between the patients‟ age and the ACQ score. 
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5.3.4 Results of the COPD Patients 
5.3.4.1 Lung Function Test (FEV1 % predicted) 
The mean (SD) of the FEV1 % predicted at visits 1 and 2, along with that of the change 
(∆) in FEV1 % predicted between the two visits are presented in table 5-22. Frequencies 
of the patients at various COPD severity levels are shown in table 5-23, COPD severity 
classification was based on the FEV1 % predicted categories of the GOLD (2006) 
guidelines. The Chi-square (χ2) statistic showed non-significant differences (p > 0.050) 
in these frequencies between visit 1 and visit 2 for the mild (χ2 = 0.889), moderate (χ2 = 
1.249), severe (χ2 = 1.678) severity levels. The χ2 statistic could not be calculated for the 
very severe asthma level due to the small frequency numbers. Details of all patients‟ 
measured FEV1 values, predicted FEV1 and FEV1 % predicted (at visits 1 and 2) are 
presented in APPENDIX B-41 and B-42, respectively (refer to the enclosed DVD).  
Table 5-22: Mean (SD) FEV1 % predicted of COPD patients at visits 1 and 2, and 
                     of the change (∆)* in FEV1 % predicted between the two visits.   
 
COPD 
Patients 
(n =44)
**
 
FEV1 % pred, Visit 1 
Mean (SD) 
FEV1 % pred, Visit 2 
Mean (SD)  
∆ FEV1 % pred. 
Mean (SD) 
55.5 (20.5) 56.0 (19.9) 0.51 (7.0) 
  * ∆: Change in FEV1 % predicted between visits 1 and 2. ** Descriptive statistics of the lung function 
were calculated for the COPD patients who completed the two study visits (n=44). 
Table 5-23: COPD patients’ frequencies in disease severity groups at visits 1 and 2.     
COPD 
patients 
 (n = 44) 
Study Visit 
COPD Severity Levels* – n (%) 
Mild  Moderate Severe Very Severe 
Visit 1 6 (13.6%) 19 (43.2%) 13 (29.5%) 6 (13.6%) 
Visit 2 6 (13.6%) 23 (52.3%) 11 (25.0%) 4 (9.1%) 
* COPD severity classification according to FEV1 % predicted categories of the GOLD (2006) guidelines. 
Histograms and tests of normality distribution (the Kolmogorov-Smirnov and Shapiro-
Wilk tests) showed that the FEV1 % predicted data was normally distributed. 
Comparison of the FEV1 % predicted between visit 1 and visit 2 (using the related-
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samples t-test) is presented in table 5-24. The results showed that there was no 
significant difference (p = 0.631) in FEV1 % predicted between the two study visits. 
Table 5-24: Comparison of the FEV1 % predicted between V1 and V2 – COPD 
                     patients.  
COPD 
Patients 
 (n = 44) 
Related-Samples t-test for FEV1 % predicted (V1 & V2) 
Mean Difference (95% CI) / p-value (2-tailed) 
-0.51 (-2.64; 1.62) / p = 0.631 
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5.3.4.2 Inhalation Profiles through the Spiromax™ DPIs 
On each study visit, each recruited COPD patient inhaled through the two Spiromax 
DPI devices. Therefore, the inhalation profiles were measured through the two versions 
of the Spiromax DPI; version 1 with a 2.7 dose cup size (DCS) (green mouthpiece cap) 
and version 2 with a 4.0 DCS (brown mouthpiece cap). The specific resistance values of 
these Spiromax inhalers were previously determined in our laboratory, and were found 
to be very similar; For the Green Spiromax: 0.0983 (cmH2O)
0.5 
min/l; while for the 
Brown Spiromax: 0.0966 (cmH2O)
0.5 
min/l. The inhalation profiles‟ parameters (along 
with their descriptive statistics) of all COPD patients, measured at visit 1 are presented 
in tables 5-25, 5-26 and 5-27. The following abbreviations were used in these tables, 
and in subsequent sections, where appropriate: 
 PIF: Peak inhalation flow (l/min), 
 TPIF: Time to reach the PIF (sec), 
 Inhaled Volume (IV): the total volume inhaled through the DPI (L), 
 IFX%PIF: the inhalation flow rate at X% of the PIF (l/min), 
 IVX%PIF: the inhaled volume till X% of PIF (L), 
 TX%PIF: time to reach X% of the PIF (sec), 
 ACCX%PIF: the inhalation acceleration rate till X% of the PIF (l/sec
2
), 
 IF(till 0.2sec), IV(till 0.2sec) and ACC(till 0.2sec): these are the IF, IV and ACC, 
respectively, after 0.2 sec of commencing the inhalation manoeuvre through the 
DPI. 
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Table 5-25: Inhalation profiles parameters through the Spiromax DPIs at visit 1 (part 1) – COPD patients 
COPD patients – Inhalation Profiles (part 1) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
1 99.2 0.37 1.2435 89.3 0.31 5.367 98.4 0.28 1.2358 88.6 0.18 8.822 
2 53.5 0.80 1.5493 48.2 0.42 2.045 55.3 0.72 1.5280 49.8 0.38 1.973 
3 60.6 0.40 1.1265 54.6 0.23 4.199 54.8 0.31 0.9091 49.3 0.22 3.198 
4 89.1 0.49 3.7508 80.2 0.29 4.536 93.9 0.67 5.7767 84.5 0.36 3.334 
5 78.8 0.36 2.2218 70.9 0.16 5.449 72.9 0.35 1.8035 65.6 0.17 4.659 
6 92.7 0.31 2.9226 83.4 0.14 9.171 91.8 0.30 2.9001 82.6 0.11 8.536 
7 79.7 0.42 2.0210 71.7 0.20 5.308 77.6 0.36 1.4795 69.8 0.15 6.384 
8 74.4 0.90 3.3331 67.0 0.45 2.016 71.7 1.14 4.1051 64.5 0.62 1.495 
9 99.8 0.70 2.9998 89.8 0.34 4.502 96.3 0.58 3.2431 86.6 0.27 5.053 
10 70.7 0.71 1.7253 63.7 0.39 2.215 64.3 0.40 1.8889 57.8 0.29 3.119 
11 53.0 0.51 1.1579 47.7 0.35 2.469 56.2 0.50 0.8879 50.5 0.35 2.650 
12 95.5 0.66 1.0456 86.0 0.57 2.840 87.6 0.70 1.7331 78.8 0.52 2.819 
13 77.9 0.42 2.5382 70.1 0.31 3.904 51.7 0.37 2.0973 46.5 0.29 2.720 
14 81.7 0.46 2.6916 73.5 0.19 5.444 88.3 0.53 2.9484 79.5 0.27 4.558 
15 77.9 0.47 2.1811 70.1 0.28 4.102 67.3 0.45 1.9441 60.6 0.23 3.981 
16 64.3 0.44 1.5923 57.8 0.30 2.837 57.1 0.66 1.5429 51.4 0.42 1.681 
17 78.0 0.57 1.5704 70.2 0.27 3.749 74.8 0.40 1.4439 67.3 0.28 3.907 
18 51.8 0.83 1.8532 46.6 0.63 1.378 53.5 0.52 1.3429 48.2 0.31 2.086 
19 61.4 0.18 0.6314 55.3 0.08 8.562 65.8 0.42 1.2225 59.2 0.26 2.777 
20 42.0 0.34 0.8496 37.8 0.25 2.519 40.6 0.60 1.1990 36.5 0.40 1.597 
21 83.6 0.45 1.5457 75.2 0.26 5.245 85.1 0.51 1.9724 76.6 0.28 4.367 
22 97.1 0.54 2.7704 87.4 0.26 4.885 95.6 0.42 2.2063 86.0 0.28 4.395 
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COPD patients – Inhalation Profiles (part 1) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
23 41.6 0.32 1.1997 37.5 0.16 3.873 29.7 0.43 1.0503 26.7 0.30 1.309 
24 79.4 0.38 1.8919 71.5 0.26 5.165 70.3 0.36 1.7239 63.3 0.21 5.222 
25 35.3 0.65 0.6310 31.8 0.53 0.468 33.5 0.42 0.6658 30.1 0.33 1.387 
26 63.5 0.27 1.5330 57.2 0.15 5.318 61.9 0.18 1.1807 55.7 0.10 8.061 
27 106.3 0.46 2.2603 95.7 0.28 4.405 95.5 0.55 2.3153 85.9 0.39 3.465 
28 91.0 0.86 3.0437 81.9 0.56 2.629 85.4 0.54 2.9075 76.9 0.31 5.052 
29 82.7 0.23 2.4682 74.4 0.13 7.795 81.1 0.27 1.7512 73.0 0.14 7.452 
30 72.4 0.66 3.0214 65.2 0.18 4.725 68.5 0.58 2.5038 61.6 0.21 4.653 
31 64.5 0.62 2.1228 58.1 0.35 2.728 72.4 0.27 2.1785 65.2 0.17 6.735 
32 60.6 0.53 1.6609 54.5 0.34 2.286 61.1 0.49 2.0051 55.0 0.31 2.754 
33 106.2 0.40 4.1132 95.6 0.30 5.757 108.1 0.44 3.7642 97.3 0.29 6.123 
34 92.1 0.29 1.9773 82.9 0.13 9.415 91.5 0.35 2.4643 82.3 0.15 7.520 
35 65.2 0.48 3.0390 58.7 0.26 2.152 67.4 0.43 2.6642 60.6 0.36 1.966 
36 50.8 0.52 1.3352 45.8 0.22 2.999 49.3 0.37 1.3693 44.4 0.19 4.297 
37 101.1 0.88 5.5552 91.0 0.31 5.176 99.5 0.71 5.4399 89.5 0.27 5.689 
38 77.3 0.35 2.8996 69.6 0.19 5.100 76.3 0.39 2.4099 68.7 0.22 3.961 
39 101.4 0.52 2.6217 91.3 0.19 8.531 88.7 0.27 2.8996 79.9 0.18 7.692 
40 45.0 1.59 2.1402 40.5 0.97 0.289 37.9 1.60 1.8316 34.1 1.21 0.245 
41 40.4 1.13 1.5380 36.4 0.45 1.050 35.5 0.89 2.1806 32.0 0.40 1.118 
42 97.6 0.23 2.3046 87.9 0.10 10.920 97.3 0.33 2.3463 87.6 0.15 7.210 
43 69.1 0.44 2.3018 62.2 0.23 4.196 88.6 0.34 2.8159 79.7 0.17 6.886 
44 70.0 1.61 2.1097 63.0 1.36 0.7234 63.3 0.85 1.9433 57.0 0.53 1.763 
45 85.5 0.38 1.9896 77.0 0.23 6.029 87.9 0.28 2.1523 79.1 0.21 7.057 
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COPD patients – Inhalation Profiles (part 1) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
46 85.1 0.33 2.0644 76.6 0.14 7.001 98.8 0.32 2.8679 89.0 0.15 7.401 
47 76.1 0.23 3.1809 68.5 0.11 10.984 74.5 0.13 3.4628 67.1 0.12 8.367 
48 82.8 0.32 1.4342 74.5 0.15 7.241 79.0 0.42 1.4913 71.1 0.20 5.316 
49 64.3 0.43 1.6221 57.9 0.24 3.689 63.4 0.46 1.3567 57.1 0.26 3.175 
50 64.4 0.68 1.8376 58.0 0.26 3.898 55.9 0.60 1.7036 50.3 0.32 2.268 
51 82.5 0.38 1.3312 74.3 0.21 5.681 80.1 0.52 1.2197 72.1 0.30 4.993 
52 73.1 0.82 1.8251 65.8 0.48 1.785 67.4 0.50 1.4888 60.7 0.33 2.837 
53 73.7 0.31 1.3624 66.3 0.14 6.763 77.3 0.35 1.5849 69.6 0.13 7.165 
54 72.6 0.53 1.6985 65.3 0.29 2.663 74.5 0.64 1.6838 67.0 0.19 6.246 
55 102.4 0.30 5.4793 92.2 0.13 7.970 105.7 0.40 4.8765 95.2 0.17 4.447 
56 76.1 0.54 3.3824 68.5 0.28 3.799 76.5 0.33 2.3665 68.9 0.19 4.563 
57 60.9 1.17 2.1667 54.8 0.54 1.404 63.0 1.18 2.0806 56.7 0.72 1.069 
58 84.1 0.79 2.8706 75.7 0.35 4.535 78.9 0.25 2.6129 71.0 0.13 7.136 
59 85.3 0.23 1.8526 76.8 0.13 7.966 81.1 0.22 1.4698 73.0 0.11 9.828 
60 65.2 0.64 1.6332 58.7 0.40 3.216 56.1 0.89 1.7057 50.5 0.78 0.500 
61 71.1 0.76 1.5409 64.0 0.58 2.131 74.6 1.21 1.7392 67.1 0.88 1.426 
62 104.1 0.21 1.3794 93.7 0.09 10.365 102.8 0.17 1.0158 92.6 0.08 9.738 
63 62.0 1.00 1.3276 55.8 0.76 1.500 57.5 0.70 1.0798 51.7 0.35 2.599 
Mean 75.4 0.55 2.1439 67.8 0.31 4.557 73.3 0.51 2.1235 66.0 0.30 4.457 
SD 17.6 0.30 0.9693 15.8 0.22 2.606 18.7 0.27 1.0259 16.8 0.20 2.475 
Min 35.3 0.18 0.6310 31.8 0.08 0.289 29.7 0.13 0.6658 26.7 0.08 0.245 
Max 106.3 1.61 5.5552 95.7 1.36 10.984 108.1 1.60 5.7767 97.3 1.21 9.828 
n 63 63 63 63 63 63 63 63 63 63 63 63 
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Table 5-26: Inhalation profiles parameters through the Spiromax DPIs at visit 1 (part 2) – COPD patients 
COPD patients – Inhalation Profiles (part 2) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
1 0.1733 74.4 0.25 4.571 0.0983 0.1492 73.8 0.13 9.855 0.0814 
2 0.2026 40.1 0.27 2.524 0.0957 0.2202 41.5 0.21 3.191 0.0890 
3 0.1146 45.5 0.17 4.547 0.0653 0.1319 41.1 0.11 5.658 0.0485 
4 0.2395 66.8 0.20 5.746 0.1299 0.3377 70.4 0.25 4.301 0.1878 
5 0.1421 59.1 0.08 9.987 0.0557 0.1399 54.7 0.09 7.888 0.0575 
6 0.1271 69.5 0.09 12.439 0.0618 0.1179 68.8 0.06 13.971 0.0481 
7 0.1595 59.8 0.13 6.654 0.0820 0.1240 58.2 0.09 9.254 0.0568 
8 0.3630 55.8 0.25 3.392 0.1506 0.4769 53.8 0.32 2.667 0.1785 
9 0.3105 74.9 0.22 5.593 0.1543 0.2465 72.2 0.18 5.954 0.1255 
10 0.3018 53.0 0.20 4.037 0.1180 0.1813 48.2 0.20 4.383 0.1009 
11 0.1235 39.8 0.27 2.015 0.0659 0.1620 42.1 0.25 2.882 0.0786 
12 0.3196 71.6 0.46 2.466 0.1772 0.2811 65.7 0.42 2.527 0.1680 
13 0.1679 58.4 0.25 3.478 0.1008 0.1107 38.8 0.25 2.736 0.0792 
14 0.1625 61.3 0.11 7.743 0.0751 0.2568 66.3 0.14 8.645 0.0890 
15 0.2057 58.4 0.19 5.173 0.1043 0.1584 50.5 0.14 5.754 0.0754 
16 0.1952 48.2 0.19 4.095 0.0963 0.2831 42.8 0.15 5.476 0.0603 
17 0.2254 58.5 0.15 5.873 0.0928 0.1985 56.1 0.18 5.124 0.0995 
18 0.2602 38.8 0.45 1.411 0.1293 0.1752 40.1 0.19 3.010 0.0850 
19 0.0576 46.1 0.04 13.984 0.0229 0.1850 49.4 0.17 3.625 0.0964 
20 0.0905 31.5 0.19 2.755 0.0530 0.1314 30.4 0.29 1.576 0.0662 
21 0.1906 62.7 0.18 6.436 0.1012 0.2376 63.8 0.17 6.199 0.1090 
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COPD patients – Inhalation Profiles (part 2) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
22 0.2614 72.8 0.16 6.974 0.1203 0.2717 71.7 0.18 5.940 0.1366 
23 0.0553 31.2 0.12 3.980 0.0333 0.0923 22.3 0.19 1.919 0.0439 
24 0.1495 59.6 0.20 5.102 0.0846 0.1193 52.7 0.16 5.336 0.0687 
25 0.2422 26.5 0.16 1.338 0.0560 0.1059 25.1 0.23 1.665 0.0583 
26 0.1015 47.6 0.09 7.388 0.0474 0.0630 46.4 0.07 10.547 0.0318 
27 0.3163 79.8 0.18 5.820 0.1662 0.3696 71.6 0.23 5.458 0.1612 
28 0.3187 68.3 0.43 1.943 0.1610 0.1962 64.1 0.21 5.037 0.0853 
29 0.1163 62.0 0.08 11.023 0.0535 0.1163 60.8 0.08 10.301 0.0554 
30 0.1398 54.3 0.10 7.317 0.0590 0.1419 51.4 0.13 6.702 0.0666 
31 0.2219 48.4 0.22 3.896 0.1054 0.1028 54.3 0.12 7.423 0.0585 
32 0.2192 45.4 0.20 3.369 0.0952 0.1845 45.8 0.19 3.724 0.0883 
33 0.2032 79.7 0.25 5.332 0.1301 0.2296 81.1 0.23 5.976 0.1325 
34 0.1268 69.1 0.08 14.146 0.0547 0.1455 68.6 0.08 11.801 0.0617 
35 0.2145 48.9 0.08 7.071 0.0464 0.2795 50.5 0.18 3.721 0.1058 
36 0.1105 38.1 0.14 3.117 0.0546 0.0759 37.0 0.15 4.735 0.0433 
37 0.2756 75.8 0.21 5.905 0.1352 0.2608 74.6 0.16 8.226 0.1125 
38 0.1535 58.0 0.11 7.476 0.0706 0.1831 57.2 0.11 6.738 0.0758 
39 0.1744 76.1 0.13 10.631 0.0864 0.1360 66.6 0.13 8.481 0.0759 
40 0.5663 33.8 0.32 0.876 0.1535 0.5537 28.4 0.49 0.735 0.1816 
41 0.1956 30.3 0.25 1.705 0.0819 0.1543 26.7 0.21 2.036 0.0615 
42 0.1152 73.2 0.05 19.412 0.0419 0.1654 73.0 0.08 11.635 0.0672 
43 0.1603 51.8 0.15 5.798 0.0792 0.1490 66.4 0.11 8.502 0.0778 
44 0.9389 52.5 0.83 1.095 0.4286 0.3432 47.5 0.22 3.509 0.0795 
45 0.0938 64.1 0.20 5.265 0.0613 0.0876 65.9 0.18 6.310 0.0578 
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COPD patients – Inhalation Profiles (part 2) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
46 0.1352 63.9 0.06 15.174 0.0427 0.1666 74.1 0.08 13.299 0.0647 
47 0.0706 57.1 0.08 12.417 0.0398 0.0895 55.9 0.07 12.698 0.0396 
48 0.1282 62.1 0.09 10.765 0.0577 0.1611 59.2 0.12 7.780 0.0747 
49 0.1472 48.2 0.17 4.287 0.0801 0.1772 47.6 0.15 5.190 0.0764 
50 0.1404 48.3 0.19 4.205 0.0774 0.1879 41.9 0.17 3.673 0.0775 
51 0.1738 61.9 0.13 7.948 0.0770 0.1927 60.1 0.19 5.876 0.0754 
52 0.3786 54.8 0.25 3.404 0.1538 0.2201 50.6 0.21 3.707 0.1074 
53 0.1083 55.2 0.09 9.686 0.0503 0.1125 58.0 0.07 12.684 0.0421 
54 0.2475 54.4 0.13 5.582 0.0807 0.1346 55.9 0.12 8.804 0.0605 
55 0.1631 76.8 0.04 24.480 0.0380 0.2280 79.3 0.05 18.081 0.0490 
56 0.1963 57.1 0.20 4.466 0.1124 0.1540 57.4 0.13 5.929 0.0848 
57 0.3693 45.7 0.24 3.313 0.1168 0.4862 47.2 0.41 1.838 0.2199 
58 0.2263 63.1 0.23 4.959 0.0886 0.1135 59.1 0.08 10.800 0.0497 
59 0.1221 64.0 0.07 14.281 0.0461 0.0899 60.8 0.07 13.702 0.0423 
60 0.2033 48.9 0.24 2.972 0.0596 0.5445 42.1 0.17 4.235 0.0760 
61 0.3450 53.3 0.41 2.659 0.1763 0.5068 55.9 0.66 1.452 0.2808 
62 0.1105 78.1 0.05 15.902 0.0450 0.1026 77.1 0.04 14.586 0.0412 
63 0.3337 46.5 0.54 1.474 0.1470 0.1648 43.1 0.26 2.785 0.0952 
Mean 0.2096 56.5 0.20 6.490 0.0941 0.2010 55.0 0.18 6.480 0.0877 
SD 0.13 13.2 0.13 4.72 0.06 0.11 14.0 0.11 3.85 0.05 
Min 0.0553 26.5 0.04 0.876 0.0229 0.0630 22.3 0.04 0.735 0.0318 
Max 0.9389 79.8 0.83 24.480 0.4286 0.5537 81.1 0.66 18.081 0.2808 
n 63 63 63 63 63 63 63 63 63 63 
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Table 5-27: Inhalation profiles parameters through the Spiromax DPIs at visit 1 (part 3) – COPD patients 
COPD patients– Inhalation Profiles (part 3) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
1 47.6 0.0441 2.941 91.3 0.1768 7.989 
2 31.2 0.0515 2.439 40.4 0.0812 3.216 
3 50.9 0.0908 4.309 48.3 0.1130 3.631 
4 67.2 0.1353 5.388 63.2 0.1373 4.959 
5 74.3 0.1894 4.748 67.9 0.1701 4.465 
6 90.7 0.2191 6.655 90.5 0.2443 5.362 
7 71.0 0.1540 5.410 74.6 0.1816 5.147 
8 51.6 0.1095 3.878 42.1 0.0827 3.350 
9 70.0 0.1276 5.566 76.8 0.1508 5.842 
10 52.9 0.1148 4.080 47.7 0.1001 4.219 
11 19.3 0.0309 1.195 35.3 0.0496 2.592 
12 11.9 0.0226 0.691 16.7 0.0248 1.094 
13 39.9 0.0581 2.803 31.4 0.0500 2.748 
14 74.6 0.1746 5.376 75.1 0.1658 6.188 
15 59.5 0.1136 4.961 57.6 0.1269 4.465 
16 48.8 0.1062 3.836 47.4 0.0983 4.132 
17 65.3 0.1422 4.913 57.8 0.1146 4.781 
18 11.6 0.0248 0.623 41.3 0.0929 2.893 
19 61.4 0.1533 3.658 54.2 0.1246 3.422 
20 33.1 0.0592 2.646 17.9 0.0312 1.179 
21 65.9 0.1191 5.912 67.7 0.1390 5.536 
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COPD patients– Inhalation Profiles (part 3) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
22 79.7 0.1727 6.108 75.0 0.1634 5.586 
23 40.3 0.0796 3.385 23.2 0.0494 1.785 
24 60.2 0.0867 5.006 61.8 0.1084 5.173 
25 28.7 0.0735 1.453 22.8 0.0463 1.746 
26 60.5 0.1455 4.305 60.6 0.1608 4.272 
27 83.4 0.1894 5.712 67.5 0.1246 5.724 
28 15.9 0.0358 0.975 60.0 0.0727 4.750 
29 79.6 0.2004 5.476 79.2 0.1940 5.536 
30 67.0 0.1657 4.475 60.9 0.1345 4.773 
31 45.7 0.0881 3.976 68.6 0.1386 5.898 
32 45.7 0.0968 3.335 46.0 0.0922 3.607 
33 56.7 0.0732 4.473 69.2 0.0963 5.538 
34 89.2 0.2218 6.390 87.6 0.2202 5.798 
35 57.2 0.1546 3.428 53.4 0.1264 3.507 
36 44.9 0.0939 3.193 44.3 0.0796 4.044 
37 73.7 0.1260 5.791 81.6 0.1602 7.056 
38 70.8 0.1670 4.994 66.9 0.1646 4.436 
39 91.9 0.1861 8.028 82.5 0.1633 7.008 
40 31.9 0.0883 1.798 24.5 0.0504 1.733 
41 26.7 0.0589 1.935 26.4 0.0557 2.095 
42 96.5 0.2617 5.646 91.3 0.2329 6.067 
43 59.0 0.1265 4.565 83.1 0.1877 6.148 
44 4.5 0.0168 0.125 42.4 0.0605 3.404 
45 68.1 0.0618 5.445 78.0 0.0821 6.844 
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COPD patients– Inhalation Profiles (part 3) – Visit 1 
Patient 
number 
Green Spiromax DPI Brown Spiromax DPI 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
46 81.9 0.2179 5.049 94.4 0.2422 5.997 
47 74.5 0.1815 5.965 72.3 0.1884 5.005 
48 79.3 0.1939 5.672 71.2 0.1653 5.202 
49 52.9 0.1051 4.097 53.6 0.1201 4.078 
50 50.5 0.0860 4.192 44.4 0.0972 3.229 
51 72.6 0.1566 5.924 61.4 0.0839 5.632 
52 51.0 0.1094 3.892 48.6 0.0971 3.701 
53 71.3 0.1740 5.101 74.4 0.1944 4.823 
54 60.8 0.1472 4.109 67.8 0.1440 5.635 
55 99.3 0.2746 5.583 97.4 0.2748 4.920 
56 57.0 0.1134 4.355 69.5 0.1610 4.711 
57 43.1 0.0844 3.786 37.7 0.0678 3.406 
58 53.8 0.0581 4.331 77.5 0.1952 5.117 
59 84.2 0.2169 5.519 81.0 0.2094 5.499 
60 32.9 0.0292 1.951 44.7 0.0990 3.514 
61 26.3 0.0280 1.775 7.3 0.0207 0.216 
62 103.7 0.2930 4.878 102.1 0.2971 4.410 
63 6.3 0.0086 0.275 33.9 0.0544 2.662 
Mean 56.8 0.1220 4.103 59.4 0.1291 4.405 
SD 23.5 0.07 1.72 22.0 0.06 1.57 
Min 4.5 0.0086 0.125 7.3 0.0207 0.216 
Max 103.7 0.2930 8.028 102.1 0.2971 7.989 
n 63 63 63 63 63 63 
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5.3.4.3 Comparison of the Inhalation Profiles through the Two         
Spiromax DPI Versions 
The normality distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) 
showed that the IP parameters were not normally distributed. Comparison, therefore, 
between the various parameters of the inhalation profiles through the Green and Brown 
versions of the Spiromax DPI was made using the related-samples, nonparametric 
Wilcoxon test. The results showed a non-significant difference in the inhalation profiles 
parameters, except in the PIF, IF90%PIF and IF75%PIF (p < 0.01). Figures 5-13, 5-14 and 5-
15 compare the means of various PIF, IV and ACC, respectively, between the two 
Spiromax versions. 
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Figure 5-13: Mean inhalation flow through the two Spiromax DPI versions – COPD patients. 
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Figure 5-14: Mean inhaled volume through the two Spiromax DPI versions – COPD patients. 
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Figure 5-15: Mean inhalation acceleration rate through the two Spiromax DPI versions – COPD 
patients. 
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5.3.4.4 Reproducibility of the Inhalation Profiles through the 
Brown Spiromax DPI over Visit 1 and Visit 2 
The reproducibility of the inhalation profile parameters through the brown Spiromax 
DPI (with a 4.0 DCS) over the two study visits is only presented in this thesis. Table 5-
28 summarizes the descriptive statistics of the IP parameters achieved by the COPD 
patients through the brown Spiromax at visit 1 and visit 2.  
The normality distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) 
showed that the IP parameters were not normally distributed. The difference, therefore, 
in the various parameters of the inhalation profiles between visits 1 and 2 was studied 
using the related-samples, nonparametric Wilcoxon test. No statistically significant 
difference (p > 0.05) in the inhalation profiles through the brown Spiromax DPI was 
found over the two study visits.  
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Table 5-28: Comparison of the mean (SD) IP parameters through the Brown Spiromax at visit 1 and visit 2 – COPD patients 
COPD Patients – Inhalation Profiles (n = 44)* 
 
Brown Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 2 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
Mean 74.3 0.49 2.1671 66.8 0.28 4.813 75.5 0.50 2.1413 68.0 0.28 5.259 
SD 19.2 0.28 0.9337 17.3 0.19 2.627 17.8 0.28 0.8750 16.1 0.20 3.492 
Min 29.7 0.13 0.6658 26.7 0.08 0.245 31.1 0.18 0.8566 28.0 0.06 0.432 
Max 108.1 1.60 5.7767 97.3 1.21 9.828 102.3 1.44 5.1069 92.1 1.14 19.823 
        * Forty four COPD patients attended the two study visits and had inhalation profiles through the Spiromax on the two occasions.  
COPD 
patients 
(n = 44) 
Brown Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 2 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
Mean 0.1927 55.7 0.17 6.900 0.0858 0.1893 56.6 0.17 7.587 0.0862 
SD 0.1102 14.4 0.09 3.872 0.0442 0.1017 13.4 0.12 5.755 0.0474 
Min 0.0630 22.3 0.04 0.735 0.0318 0.0510 23.3 0.03 0.639 0.0261 
Max 0.5537 81.1 0.49 14.586 0.2199 0.5332 76.7 0.69 30.105 0.2646 
 
COPD 
patients 
(n = 44) 
Brown Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 2 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
Mean 62.4 0.1376 4.596 62.4 0.1356 4.626 
SD 20.7 0.0617 1.404 21.0 0.0588 1.656 
Min 22.8 0.0463 1.733 7.3 0.0152 0.488 
Max 102.1 0.2971 7.989 100.0 0.2777 7.958 
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5.3.4.5 The SGRQ Scores 
Summaries of the mean (SD) of the SGRQ scores (overall and its three domains: 
Symptoms, Activity and Impacts) at visit 1 and visit 2, and of the mean (SD) of the 
scores‟ change between the two visits are presented in table 5-29. The mean change in 
the total SGRQ, activity and impacts scores was below the MID (MID = 4.0). The 
detailed SGRQ scores of all COPD patients are presented in APPENDIX B-45 and B-46 
(refer to the enclosed DVD). The change in the overall SGRQ scores and its domains 
(between visits 1 and 2) of all patients is presented in APPENDIX B-47 (refer to the 
enclosed DVD). 
The normality distribution tests (the Kolmogorov-Smirnov and Shapiro-Wilk tests) 
showed that the SGRQ scores were not normally distributed. Comparison of the SGRQ 
scores (all domains), using the non-parametric Wilcoxon test, showed that the 
difference in the total SGRQ, activity and impacts scores (between visit 1 and visit 2) 
was not statistically significant; table 5-30. 
Table 5-29: Mean (SD) of the SGRQ scores at visits 1 and 2, and of the change (∆) 
                     in scores between the two visits. 
SGRQ Domains 
(n =44) 
Mean (SD) Score  
Visit 1 Visit 2 ∆ 
Symptoms 58.3 (26.1) 62.4 (24.8) 4.2 (17.5) 
Activity  73.8 (25.9) 73.5 (23.4) -0.32 (10.9) 
Impacts 44.7 (22.9) 44.1 (23.3) -0.59 (9.5) 
Total SGRQ 55.8 (22.0) 56.1 (21.7) 0.29 (7.6) 
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Table 5-30: Difference in the SGRQ scores between visit 1 and visit 2. 
SGRQ Domains 
 (n=44) 
W (Sum of Ranks)
† 
/ Exact p-value (2-tailed) 
Symptoms 259.0 (259.0; 602.0) / 0.026
*
 
Activity  207.0 (289.0; 207.0) / 0.433 
Impacts 467.0 (467.0 ; 479.0) / 0.948 
Total SGRQ 451.0 (451.0 ; 539.0) / 0.613 
    † Sum of ranks for the negative and positive ranks, respectively. 
    * Statistically significant at 0.05 level. 
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5.3.4.6 The MRC “Degree of Breathlessness” 
Frequencies of the COPD patients in the MRC “Degree of Breathlessness” categories at 
visit 1 and visit 2 are presented in table 5-31. Comparison of the patients‟ rating of their 
degree of breathlessness over the two study visits was investigated using the Chi-square 
(χ2) test. The results showed a significant difference in the MRC degree of 
breathlessness over the two study visits (χ2= 46.8; p <0.001 (2-sided)).  
Table 5-31: Frequencies of COPD patients in the MRC “Degree of Breathlessness” 
                     categories. 
Degree of breathlessness related to activities Visit 1 Visit 2 
1. Not troubled by breathlessness except on strenuous exercise 3 (6.8%) 5 (11.4%) 
2. Short of breath when hurrying or walking up a slight hill 13 (29.5%) 11 (25.0%) 
3. Walks slower than contemporaries on level ground because 
of breathlessness, or has to stop for breath when walking at 
own pace 
15 (34.1%) 10 (22.7%) 
4. Stops for breath after walking about 100 m or after a few 
minutes on level ground 
10 (22.7%) 13 (29.5%) 
5. Too breathless to leave the house, or breathless when 
dressing or undressing 3 (6.8%) 5 (11.4%) 
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5.3.4.7 Correlation among the Inhalation Profiles, Patients‟           
Demographics, Lung Function and the SGRQ 
Correlation between the inhalation profiles parameters through the brown Spiromax DPI 
(visit 1) with the COPD patients‟ age, FEV1 % predicted, MRC and the SGRQ scores 
was investigated using the Pearson Correlation test. The results of statistically 
significant correlation are presented in table 5-32. 
No significant correlation was found between the COPD patients‟ age and their 
inhalation profiles through the Spiromax DPI. 
Table 5-32: Correlation among inhalation the profiles parameters, lung function, 
                     SGRQ and MRC – COPD patients. 
 
IP 
Parameters 
 
Pearson Correlation coefficient (r) 
FEV1 
% Pred. 
SGRQ 
MRC 
Symptoms Activity Impacts Total 
PIF 0.300* --- -0.294* --- -0.251* -0.341** 
TPIF --- --- --- --- --- --- 
Total IV 0.266* --- -0.413** --- -0.266* -0.514** 
IF90%PIF 0.300* --- -0.294* --- -0.251* -0.340** 
T90%PIF --- --- --- --- --- --- 
IV90%PIF --- --- --- --- --- --- 
ACC90%PIF --- --- --- --- --- --- 
IF75%PIF 0.300* --- -0.294* --- -0.251* -0.340** 
T75%PIF --- --- --- --- --- --- 
IV75%PIF --- --- --- --- --- --- 
ACC75%PIF --- --- --- --- --- -0.286* 
IF(till 0.2 sec) --- --- -0.270* --- --- -0.292* 
IV(till 0.2 sec) --- --- --- --- --- -0.327** 
ACC(till 0.2 sec) --- --- -0.261* --- --- --- 
FEV1% Pred. 1.000 --- -0.283* -0.254* -0.254* --- 
MRC --- 0.371** 0.685** 0.537** 0.613** 1.000 
* Correlation is significant at 0.05 level (2-tailed). ** Correlation is significant at 0.01 level (2-tailed). 
 --- Correlation is not significant. 
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5.3.5 Summary of the Inhalation Profile Parameters 
Tables 5-33, 5-34 and 5-35 summarize the descriptive statistics of the inhalation profile 
parameters achieved through the green and brown Spiromax DPIs at visit 1 by the 
asthmatic children, asthmatic adults and COPD patients, respectively. 
Figures 5-16, 5-17 and 5-18 illustrate a few examples of the variability in the attained 
inhalation profiles within the asthmatic children, asthmatic adults and COPD patient 
groups, respectively. These are examples of inhalation profiles measured through the 
brown Spiromax DPI at visit 1. 
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Table 5-33: Summary of the Mean (SD) IP Parameters through the two Spiromax DPIs at visit 1 – Asthmatic Children 
Asthmatic Children – Mean (SD) Inhalation Profiles (n = 58)* 
 
Green Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 1 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
Mean 80.5 0.50 1.7046 72.4 0.31 5.272 79.8 0.51 1.6856 71.8 0.33 4.806 
SD 18.3 0.25 0.8247 16.5 0.21 3.247 18.1 0.27 0.7757 16.3 0.20 2.763 
Min 34.6 0.14 0.3130 31.1 0.07 0.610 33.9 0.12 0.4358 30.5 0.05 0.486 
Max 106.4 1.29 3.8368 95.7 1.16 12.560 108.2 1.36 4.1416 97.4 0.92 13.177 
 
Asthmatic 
Children 
(n = 58) 
Green Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 1 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
Mean 0.1927 60.4 0.23 6.750 0.1042 0.2013 59.8 0.24 6.043 0.1041 
SD 0.1012 13.7 0.20 4.919 0.0728 0.0908 13.5 0.17 4.144 0.0471 
Min 0.0438 25.9 0.03 0.485 0.0162 0.0303 25.4 0.02 0.471 0.0125 
Max 0.6885 79.8 1.11 24.131 0.5141 0.4640 81.2 0.73 21.268 0.2544 
 
Asthmatic 
Children 
(n = 58) 
Green Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 1 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 
sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
Mean 57.9 0.1221 4.374 57.9 0.1169 4.423 
SD 28.8 0.0746 2.337 27.2 0.0703 2.172 
Min 4.8 0.0109 0.123 2.8 0.0107 0.010 
Max 106.4 0.2628 8.311 103.5 0.2764 7.804 
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Table 5-34: Summary of the Mean (SD) IP Parameters through the two Spiromax DPIs at visit 1 – Asthmatic Adults 
Asthmatic Adults – Mean (SD) Inhalation Profiles (n = 63)* 
 
Green Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 1 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
Mean 90.9 0.55 2.4594 81.8 0.32 6.080 90.9 0.54 2.4470 81.8 0.31 5.972 
SD 14.7 0.32 0.8729 13.2 0.22 4.160 16.0 0.30 0.9126 14.4 0.21 3.383 
Min 51.3 0.14 0.632 46.2 0.05 0.714 47.3 0.14 0.8286 42.5 0.08 0.583 
Max 106.4 1.45 5.0914 95.7 1.03 23.827 108.2 1.40 5.0253 97.4 1.26 13.373 
 
Asthmatic 
Adults 
(n = 63) 
Green Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 1 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
Mean 0.2387 67.8 0.22 7.818 0.1103 0.2289 67.8 0.21 8.793 0.1064 
SD 0.14 11.0 0.17 5.5 0.06 0.13 12.0 0.18 7.6 0.06 
Min 0.0609 38.5 0.03 0.727 0.0293 0.0781 35.5 0.02 0.382 0.0213 
Max 0.8533 79.8 0.91 32.041 0.3709 0.6038 81.2 1.21 51.983 0.2773 
 
Asthmatic 
Adults 
(n = 63) 
Green Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 1 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
Mean 66.9 0.1383 5.081 68.2 0.1477 5.144 
SD 28.7 0.08 2.3 29.3 0.08 2.3 
Min 4.9 0.0095 0.198 5.5 0.0120 0.156 
Max 106.3 0.3046 8.581 108.2 0.3052 8.442 
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Table 5-35: Summary of the Mean (SD) IP Parameters through the two Spiromax DPIs at visit 1 – COPD patients 
COPD patients – Mean (SD) Inhalation Profiles (n = 63)* 
 
Green Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 1 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
PIF 
(l/min) 
TPIF  
(sec) 
Inhaled 
Volume 
(L) 
IF90%PIF 
(l/min) 
T90%PIF  
(sec) 
ACC(90% PIF) 
(l/sec
2
) 
Mean 75.4 0.55 2.1439 67.8 0.31 4.557 73.3 0.51 2.1235 66.0 0.30 4.457 
SD 17.6 0.30 0.9693 15.8 0.22 2.606 18.7 0.27 1.0259 16.8 0.20 2.475 
Min 35.3 0.18 0.6310 31.8 0.08 0.289 29.7 0.13 0.6658 26.7 0.08 0.245 
Max 106.3 1.61 5.5552 95.7 1.36 10.984 108.1 1.60 5.7767 97.3 1.21 9.828 
 
COPD 
patients 
(n = 63) 
Green Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 1 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
IV90%PIF 
(L) 
IF75%PIF 
(l/min) 
T75%PIF  
(sec) 
ACC(75% PIF) 
(l/sec
2
) 
IV75%PIF 
(L) 
Mean 0.2096 56.5 0.20 6.490 0.0941 0.2010 55.0 0.18 6.480 0.0877 
SD 0.13 13.2 0.13 4.72 0.06 0.11 14.0 0.11 3.85 0.05 
Min 0.0553 26.5 0.04 0.876 0.0229 0.0630 22.3 0.04 0.735 0.0318 
Max 0.9389 79.8 0.83 24.480 0.4286 0.5537 81.1 0.66 18.081 0.2808 
 
COPD 
patients 
(n = 63) 
Green Spiromax DPI  - Visit 1 Brown Spiromax DPI – Visit 1 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
IF(till 0.2 sec) 
(l/min) 
IV(till 0.2 sec)  
(L) 
ACC(till 0.2 sec) 
(l/sec
2
) 
Mean 56.8 0.1220 4.103 59.4 0.1291 4.405 
SD 23.5 0.07 1.72 22.0 0.06 1.57 
Min 4.5 0.0086 0.125 7.3 0.0207 0.216 
Max 103.7 0.2930 8.028 102.1 0.2971 7.989 
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Figure 5-16: Examples of Inhalation Profiles – asthmatic children 
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Figure 5-17: Examples of Inhalation Profiles – asthmatic adults 
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Figure 5-18: Examples of Inhalation Profiles – COPD patients 
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5.4 Discussion 
The main aim of the current study was to obtain inhalation profiles and acceleration 
rates of asthmatic adults and children, and of COPD patients through two novel versions 
of the Spiromax
™ 
DPI, which differ by the size of the dose metering cup inside the 
device. All the currently available dry powder inhalers (DPIs) are breath-activated, and 
hence overcome the MDI inherited hand-lung coordination problem (Prime et al., 1999; 
Tarsin et al., 2006). However, an efficient delivery of the inhaled powder depends 
largely on sufficient peripheral lung deposition; and this not only is influenced by the 
design of the DPI device and the powder formulation, but also crucially by the 
inhalation characteristics achieved by the patients using these DPIs (Vidgren et al., 
1988; Steckel and Muller, 1997b; Kamin et al., 2002). The patient‟s inspiratory effort 
through a DPI, and thus the resultant inhalation flow, is the only energy responsible for 
the disaggregation of the metered powder dose, resulting in the dispersion of the fine 
drug particles in the inspired airstream (Steckel and Muller, 1997b). In this regard, the 
total emitted dose and particle size distribution from various DPIs have been linked to 
various parameters of the patients‟ inhalation profiles. 
The patient‟s peak inhalation flow (PIF) through a DPI is one of the parameters that has 
been extensively investigated, in the literature, in relation to the powder dose output 
from different DPIs. Due to design variations, each DPI device has a specific internal 
flow resistance that can be described of a low, medium or high value (Chrystyn, 2009). 
It has been earlier shown that the energy generated inside a DPI is a function of its 
resistance and the inhalation flow (Clark and Hollingworth, 1993). For each DPI, 
therefore, the patients should be able to generate inspiratory efforts sufficient to create 
the minimal IFR required to disperse the emitted powder into the fine (respirable) 
particle size range (1-5 µm) from that particular inhaler (Ross and Schultz, 1996; Tarsin 
et al., 2006; Virchow et al., 2008). For real-life implications, it has been, therefore, 
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recommended that research attention needs to be more directed to determine the 
achievable minimum acceptable PIF through a DPI (by patients of different age groups 
and respiratory disease conditions), rather than the optimal PIF (Borgstrom, 2001; 
Crompton et al., 2006). Generally, the minimal effective PIF for moderate resistance 
DPIs (e.g. Diskus (Accuhaler) and Turbuhaler) is ≥ 30 l/min, whereas their optimal PIF 
should be ≥ 60 l/min (Broeders et al., 2003a). Many studies have reported that the PIF 
mean (SD) l/min achieved by asthmatic adults through a Turbuhaler was 54.7 (17.6) 
(Hawksworth et al., 2000), 82.1 (3.4) (Broeders et al., 2003a) and 76.8 (26.2) (Tarsin et 
al., 2006). Similarly, COPD patients were able to inhale at a rate > 30 l/min through the 
Turbuhaler, however, did not manage to inhale optimally (> 60 l/min) all the time; 
reported PIF means (SD) l/min were 53 (12) (Dewar et al., 1999), 84.4 (2.7) (Broeders 
et al., 2003a) and 47.4 (14.4) (Al-Showair et al., 2007a). Similar trend was noticed 
when asthmatic adults and COPD patients inhaled through the Accuhaler (Diskus), 
however the PIFs were slightly higher through the Accuhaler (as it has a lower flow 
resistance than the Turbuhaler) (Broeders et al., 2003a; Van Der Palen, 2003; Tarsin et 
al., 2006; Al-Showair et al., 2007a). On the other hand, the asthmatic children who 
inhaled through the Turbuhaler were able to inhale optimally; 70 l/min (7-10 years of 
age) (Stahl et al., 1996) and 74.4 l/min (Bentur et al., 2004). However, Amirav et al. 
(2005) have reported that 32% of the asthmatic children could not inhale optimally 
through the Turbuhaler (≥ 60 l/min), whilst all of them were able to inhale > 30 l/min 
through both the Accuhaler and Turbuhaler. Similarly, Pedersen (1986) measured the 
asthmatic children‟s PIF through the low resistance Rotahaler DPI; and found that stable 
children were able to achieve a PIF between 60-145 l/min, whereas their PIF ranged 
between 25-65 l/min during wheezy conditions. 
In the current study, the PIF was determined from the inhalation profiles of asthmatic 
adults and children, and of COPD patients when they inhaled through two versions of 
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the Spiromax DPI (green and brown). In our previous lab work (chapter 4), the internal 
specific flow resistance of the Spiromax was determined; the two versions of the inhaler 
had almost the same internal flow resistance values (0.0966 and 0.0983 (cmH2O)
0.5 
min/l) which classify the Spiromax in the range of the medium resistance DPIs, and 
close to that previously reported for the Turbuhaler DPI (0.100 (cmH2O)
0.5 
min/l) (Clark 
and Hollingworth, 1993) and the Symbicort Turbuhaler (0.110 (cmH2O)
0.5 
min/l) (Assi 
and Chrystyn, 2001). In the present study, the inhalation profiles of the same patient 
group showed no significant difference between the two inhalers. The PIF results in the 
current study and their variability across the various patient groups are in agreement 
with those previously published in the literature for similar resistance DPIs; where the 
PIF mean (SD) l/min through the brown Spiromax (DCS 4.0) was 79.8 (18.1) for the 
asthmatic children, 90.9 (16.0) for the asthmatic adults and 73.3 (18.7) for the COPD 
patients. All the patients inhaled above the minimal sufficient PIF (> 30 l/min), except 
one patient with severe COPD. On the other hand, 87.9% of the asthmatic children, 
95.2% of the asthmatic adults and 76.2% of the COPD patients were able to inhale 
optimally (> 60 l/min) through the Spiromax DPI. 
Although the PIF remains currently the main determinant of the total dose and fine 
particle fraction output from the DPIs (deBoer et al., 1996a; Pauwels et al., 1997; 
Chrystyn, 2009), the initial inhalation acceleration rates and volumes of the patient‟s 
inhalation profile through DPIs may also have a considerable effect on the emitted dose 
characteristics (deBoer et al., 1997; Everard et al., 1997; Kamin et al., 2002). It has been 
suggested that the first 100 – 200 ml inhalation volume through the Turbuhaler is 
important in relation to dose emission, provided that an IFR > 30 l/min had been 
achieved when this volume was inspired (Pedersen, 1994). Another in vitro study has 
shown that the inhalation volume did not significantly affect the size of the particles 
emitted from the Turbuhaler, however the total emitted dose increased from 8 to 25% of 
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the nominal dose when the inhalation volume was increased from 150 ml to 1.0 L 
(Kamin et al., 2002). Everard and colleagues (1997) have, in vitro, shown that a high 
inhalation acceleration rate during the initial phase of the patient‟s inspiratory profile 
through a Turbuhaler DPI significantly improved the fine particle size distribution 
compared with a low acceleration rate, and that the IFR achieved within the first 150 ml 
inhaled volume appeared to be more important than the attained overall PIF, provided 
that this early IFR is ≥ 30 l/min, because it is likely that the powder dose might have left 
the inhaler by the time the first 150 ml inhaled volume had passed through the device 
and before the ultimate PIF has been reached. In the current work, the mean inhalation 
volumes (ml) with their corresponding mean IFR (l/min) achieved early at 75% of the 
PIF were (ml; l/min): (104; 59.8) for asthmatic children, (106; 67.8) for asthmatic adults 
and (87; 55.0) for COPD patients. The corresponding mean inhalation times (seconds) 
till 75% of PIF were 0.24, 0.21 and 0.18 for the children, adults and COPD patients, 
receptively. Whilst, at 90% of patients‟ PIFs; their mean inhalation volumes (ml) with 
their corresponding mean IFR (l/min) were (ml; l/min): (201; 71.8) for asthmatic 
children, (228; 81.8) for asthmatic adults and (201; 66.0) for COPD patients. The 
corresponding mean inhalation times (seconds) till 90% of the PIF were: 0.33, 0.31 and 
0.30 for the children, adults and COPD patients, receptively. Moreover, the IV and IFR 
were also determined at 0.2 seconds of commencing the inhalation through the 
Spiromax, the mean IV and IFR (ml; l/min) at 0.2 sec were: (116; 57.9) for asthmatic 
children, (147; 68.2) for asthmatic adults and (129; 59.4) for COPD patients. Our 
results, then, demonstrate that when the patients inhaled till 75% of their PIF, as well as 
after 0.2 seconds of commencing their inhalation through the Spiromax; they were not 
able to achieve the suggested initial 150 ml inhalation volume needed to release the 
powder dose from the inhaler, and marginally inhaled 200 ml even at 90% of their 
ultimate PIF, provided that at all these time points the patients inhaled > 30 l/min.     
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Similarly, previous in-vitro simulations of artificial inhalation profile parameters have 
confirmed the influence of the inhalation acceleration rate particularly on the total dose 
emission, where faster flow acceleration rates increased the powder dose output from 
the Turbuhaler by fivefold compared with the slower accelerations (Kamin et al., 2002). 
de Boer and co-workers (1997) have interestingly reported that the in-vitro maximum 
budesonide powder output (with a FPF > 40% of the nominal dose) from the Turbuhaler  
was obtained at an IFR of 40 l/min, provided that the initial inhalation acceleration rate 
was > 5 l/sec
2 
 (these inspiratory profiles were easily achieved by their study healthy 
adult volunteers). They also found that an early inhalation acceleration rate > 8 l/sec
2
 
did not improve the FPF, and that the PIF had no effect on the powder dose output, 
when compared at the same flow acceleration. In the present study, the mean inhalation 
acceleration rates (l/sec
2
) achieved at 75% and 90% of the PIF through the Spiromax 
was: (6.04 and 4.81 l/sec
2
) for asthmatic children, (8.79 and 5.97 l/sec
2
) for asthmatic 
adults and (6.48 and 4.46 l/sec
2
) for COPD patients. Moreover, the mean inhalation 
acceleration rates determined at 0.2 sec of inhalation through the Spiromax was: (4.42 
l/sec
2
) for asthmatic children, (5.14 l/sec
2
) for asthmatic adults and (4.41 l/sec
2
) for 
COPD patients. The current results, however, demonstrate the variability in the various 
inhalation profile parameters through the DPIs among different patient groups, and 
confirm the importance of instructing the patients to inhale “as fast and deep” as they 
can when using their DPI to achieve the sufficient inhalation through their inhaler. 
Moreover, further research is needed to assess the effect of the currently presented 
realistic inhalation acceleration rates and volumes (at different time points of the 
inspiratory profile) on the in-vitro performance of the DPIs.    
On the other hand, current Pharmacopoeial standards recommend that the in-vitro dose 
emission characteristics from DPIs should be tested at a single inhalation flow 
equivalent to a pressure drop of 4kPa across the inhaler with an inhalation volume of 
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4L. However, some regulatory authorities are changing this volume to 2L, as most 
patients cannot achieve these inhalation characteristics when using a DPI. Indeed, only 
1 (1.7%) asthmatic child, 6 (9.5%) asthmatic adults and 4 (6.3%) COPD patients in the 
present study had an inhalation volume ≥ 4 L through the Spiromax DPI. Moreover, the 
mean (SD) inhalation volumes (L) measured through the Spiromax DPI was: 1.69 (0.78) 
for the asthmatic children, 2.45 (0.91) for the asthmatic adults and 2.12 (1.03) for the 
COPD patients, which were less than the Pharmacopoeial recommended IV for DPIs 
evaluation. A 4kPa pressure drop across the Spiromax corresponds to an IFR of 65 
l/min; 46 (79.3%) asthmatic children, 57 (90.5%) asthmatic adults and 42 (66.7%) 
COPD patients had a PIF ≥ 65 l/min through the inhaler. Our results, therefore, are in 
agreement with reconsidering the Pharmacopoeial recommended optimal inhalation 
testing conditions, and suggest that these conditions should be based on the realistic 
inhalation characteristics achievable by the patients. 
Apart from the asthmatic children‟s; the inhalation profile parameters measured through 
the Spiromax DPI on the two study occasions (6-8 weeks apart) showed a high degree 
of reproducibility. Therefore, in the current study, instructing the patients to use the 
standard inhalation manoeuvre “as hard and deep as you can” when using their DPI 
resulted in reproducible and effective inhalation profiles, provided that their respiratory 
medicines and lung function (FEV1 % predicted) remained the same over the study 
period. Previous research has shown that verbal instruction on correct DPI use was 
effective in improving the patients‟ IFR (Persson et al., 1997; Al-Showair et al., 2007a), 
and in reducing their day-to-day inhalation manoeuvres‟ variability coupled with 
enhanced DPI technique reproducibility (Broeders et al., 2003a). However, the 
variability in the inhalation characteristics of the children when using various DPIs was 
previously reported (Borgstrom, 2001).  
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Investigation of correlation between the ACQ and SGRQ with the inhalation profiles of 
the asthmatic and COPD patients, respectively, showed various behaviours. In the 
asthmatic adults and children, no significant relationship was found between their IP 
and both their ACQ score and lung function. However the children‟s age had a positive 
correlation with their PIF and inhalation volume through the Spiromax. A similar 
correlation between the PIF and the age of healthy children was reported in a previous 
Turbuhaler study (Pedersen et al., 1990). Whereas, in the asthmatic adults, the lung 
function (FEV1 % predicted) had a moderate negative relationship with the ACQ score. 
Interestingly in the COPD patients, the PIF and IV had weak, yet significant, correlation 
with the lung function, SGRQ (total and activity domains) and MRC “breathlessness 
scale”. 
This study was designed as an investigational, comparison-randomized research during 
which realistic inhalation profiles of 184 stable asthmatic adults and children, and 
COPD patients were measured through two novel versions of the Spiromax DPI. 
However, there is a number of shortcomings and areas of improvement. Firstly, the 
majority of the recruited patients had either mild or moderate respiratory condition; 
whereas recruiting additional patients with severe airways obstruction would have given 
a broader picture of the results. Secondly, it would have been interesting if additional 
inhalation profiles of exacerbated asthma and COPD patients as well as of healthy 
subjects were collected and compared to those already measured in the stable patients. 
Thirdly, obtaining inhalation profiles of respiratory patients prior to being verbally 
instructed on the correct inhaler use would give a more day-to-day “real-life” 
assessment of the DPI use. However, funding and time constraints have limited 
recruiting those additional patients into the current study. These valid points will, 
therefore, be taken into consideration in future research. 
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5.5 Conclusion 
All currently available dry powder inhalers (DPIs) have the inherited flow-dependent 
dose emission criterion. At present, the peak inhalation flow (PIF) is the main studied 
parameter when assessing the powder dose output from DPIs. The main findings of the 
current study were: 
 Almost all the patients achieved the minimum acceptable peak inhalation flow 
of ≥ 30 l/min through the medium resistance Spiromax DPI. However, not all of 
them were able to inhale optimally through the device (> 60 l/min). 
 In addition to the peak inhalation flow, the effect of the initial inhalation 
acceleration rates and volumes of the patient‟s inspiratory profile through dry 
powder inhalers should be also investigated when evaluating the efficiency of 
the total dose emission and fine particle dose from DPIs. 
 Despite the similarity in the achieved PIF, variability in the inhalation 
acceleration rates and volumes was shown by patients within the same disease 
and age group. Therefore, further research is needed to assess the effect of the 
variability in these inhalation characteristics on the emitted powder dose.  
 The demonstrated variability (23% - 58%) in the peak inhalation flow, 
inhalation volume and acceleration rate among various patient groups when 
they inhaled through the Spiromax DPI suggests that the realistic inhalation 
characteristics achieved by the patients themselves, rather than the 
recommended Pharmacopoeial optimal single-standard testing condition, should 
be used when assessing the in-vitro dose emission from DPI devices.  
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6.0 Introduction 
Asthma is a chronic inflammatory disorder of the airways which is associated with a 
widespread but variable airflow obstruction that is often reversible, either spontaneously 
or with treatment. The classical symptoms of asthma include cough, wheezing, 
shortness of breath and chest tightness (BTS/SIGN, 2005; GINA, 2006). Inhaled 
therapy is the mainstay for drug delivery in the management of asthma; this is due to 
many advantages including smaller dosages, fewer side effects and rapid onset of action  
(Newman et al., 1981a; Pedersen et al., 1986; Minai et al., 2004). Metered dose inhalers 
(MDIs) are widely used for both maintenance therapy and treatment of acute attacks of 
asthma. Therefore, correct inhaler technique by the patients is critical for the success of 
the therapy (Horsley and Bailie, 1988; Larsen et al., 1994). In this regard, children and 
adults experience the same problems when using their inhaler, however, these problems 
are more pronounced in children with a greater number of errors seen in those aged 
under 6 years (Pedersen et al., 1986). Because of incorrect MDI technique, less than 
50% of the children receiving inhaler therapy benefit from it (Minai et al., 2004).  
Spacer (holding-chamber) devices are used with MDIs to overcome the common 
problem of hand-lung coordination associated with the MDI use (Dolovich et al., 1983; 
Demirkan et al., 2000; Burkhart et al., 2005). Inhalation of the dose through a spacer not 
only improves the lung deposition but also decreases the oropharyngeal impaction. 
When compared to the use of an MDI alone; the results of several studies have shown 
that an MDI plus a spacer device significantly improved the aerosol lung deposition 
(Newman et al., 1981a; Silkstone et al., 2002; Roller et al., 2007), the potency of the 
inhaled medications (Toogood et al., 1984; Demirkan et al., 2000), reduced the 
corticosteroid-induced oropharyngeal candidiasis (Toogood et al., 1984) and reduced 
the systemic side effects of high inhaled corticosteroid doses (Brown et al., 1990).  
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In asthmatic children (≤ 12 years old), a metered dose inhaler connected to a spacer 
device is the preferred method for drug delivery (BTS/SIGN, 2005; GINA, 2006). 
However, up to 40% of the children use their MDI inadequately even with a spacer 
(Kamps et al., 2000). Instruction on correct inhaler technique is effective in all age 
groups but only 50% of the patients were using the correct MDI technique 1-30 days 
after having been trained on- and demonstrated the correct MDI technique (Minai et al., 
2004). Therefore, a regular inhaler technique check up is needed even after a long 
period of inhaler use (van Beerendonk et al., 1998; Kamps et al., 2000; Crompton et al., 
2006), and this should be instituted as a standard practice of care (Larsen et al., 1994). 
Moreover, a multiple feedback mechanism for a sufficient inhaler use would be useful 
for the asthmatic patients and their caregivers, and should enhance the patients‟ 
compliance and thus asthma control (Crompton et al., 2006). Many patients inhale too 
fast when they use an MDI (Nimmo et al., 1993; Hesselink et al., 2001) and the flow 
used  should be < 90 l/min. It has been shown that an inhaler training tool giving an 
audible feedback helps the patients to maintain the trained MDI technique with a slow 
inhalation (Al-Showair et al., 2007b). The AeroChamber Plus
®
 spacer (Trudell Medical 
International, Ontario, Canada) also helps the patients use a slow inhalation by 
producing a sound when the inhalation flow exceeds 60 l/min. Recently, the feedback 
mechanism when using the AeroChamber Plus spacer has been enhanced by the 
inclusion of a visual feedback mechanism to indicate inhalation; the AeroChamber 
Plus
®
 VHC with Flow-Vu
®
 (Trudell Medical International, Ontario, Canada). This 
visual feedback also confirms a seal between the lips and the mouthpiece of the spacer, 
or between the face and the facemask (when using the facemask version of the spacer). 
The main aim, therefore, of the current research study was to determine if the routine 
use of the novel spacer device; the AeroChamber Plus
®
 with Flow-Vu
®
 would improve 
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asthma control in asthmatic children, compared with the use of the currently available 
spacer, the AeroChamber Plus
®
.   
6.1 Research Objectives 
6.1.(a) Primary Objective:  
The primary objective of this research study was to determine if the routine use of the 
novel AeroChamber Plus
®
 VHC with Flow-Vu
®
 (Trudell Medical International, 
Canada) would improve asthma control and thus quality of life in asthmatic children, 
compared with the use of the currently available spacer version; the AeroChamber 
Plus
®
. The facemask (yellow) version of these spacers was studied in the present 
research [Refer to Chapter 2; figures 2-14 and 2-15 to see the pictures of the used 
spacers]. 
6.1.(b) Secondary Objective(s):    
The secondary objectives of the current research were to determine if the routine use of 
this novel spacer would affect: 
 The health-related quality of life (HRQL) of the paediatric asthma caregivers 
(normally the parents). 
 The asthmatic children‟s inhalation flow rate (IFR) through a spacer. 
 The frequency of rescue inhaler and oral prednisolone use. 
6.2 Methodology 
6.2.1 Study Population 
6.2.1.1 Patient Recruitment and Sample Size      
Children with asthma receiving regular care at the asthma out-patient clinics of NHS 
hospitals (see below for the list of the NHS hospitals involved) and fulfilling the 
protocol‟s patient definition criteria were invited (through their caregivers – normally 
the parents) to take part in this research study. The study objectives and procedures 
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were explained to the asthmatic child caregiver using the patient information sheets 
[APPENDIX A-19 and A-20 (refer to the enclosed DVD)]. They kept a copy of these 
patient information sheets and were given as much time as they needed to consider 
participation. After their agreement to take part in the study, a signed informed consent 
form [APPENDIX A-21 (refer to the enclosed DVD)] was obtained prior to performing 
any protocol related procedures. Moreover and as a second approach for patient 
recruitment, letters, enclosing the patient information sheets, were posted to the 
parents/caregivers of eligible asthmatic children inviting them to take part in this 
research study. Those who replied positively were contacted by phone and given an 
appointment at the clinic for study enrolment.  
In a previous study by Juniper et al. (1996b), the mean difference (standard deviation) 
of 0.50 (0.51) was reported as the minimal important difference for the overall quality 
of life of paediatric asthma caregivers. The authors quote that using this data, 31 
subjects would be required in each group of a parallel study design to detect any 
difference at the 5% significance level with a 95% power. In the current research and to 
compensate for any subject withdrawals/dropouts, this study aimed at recruiting 40 
asthmatic children into each of the two spacer device groups. Hence, a total of 80 
patients were to be recruited into the study. 
The NHS Teaching Hospitals which were involved as research sites: 
 Leeds General Infirmary (LGI), Leeds, UK. 
 St. James‟s University Hospital, Leeds, UK. 
 Bradford Royal Infirmary, Bradford, UK. 
The current research study was conducted according to the “Good Clinical Practice” 
guidelines (ICH/GCP), and was approved by both the Bradford Research Ethics 
Committee (United Kingdom) and the Research and Development department within 
each of the involved NHS Hospitals. 
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6.2.1.2 Patient Definition:  
6.2.1.2.(a) Inclusion Criteria:  
An individual meeting all the following criteria was eligible to be enrolled into the 
study: 
 Male or female, 1-5 year-old child.  
 Partly controlled or uncontrolled asthma according to GINA, 2006 criteria 
[APPENDIX A-22 (refer to the enclosed DVD)]. 
 Patient using a preventer (corticosteroid) MDI. 
 Patient using at least one MDI with a spacer device under the direct supervision 
of their caregiver/parent, or willing to use one (a spacer device) throughout the 
study enrolment period. 
 Signed informed consent by the caregiver/parent (and the child if capable to sign 
their name). 
6.2.1.2.(b) Exclusion Criteria: 
An individual meeting any of the following criteria was excluded from enrolment:    
 Patient using the inhaled medication for less than 4 weeks prior to enrolment 
and/or the asthma treatment regimen has been changed over the last 4 weeks 
prior to enrolment. 
 Patient using a dry powder inhaler (DPI) or a breath-activated MDI. 
 Limited ability to understand/implement the study procedures and instructions. 
 Limited physical capacity to use the spacer device. 
 Other pulmonary diseases (e.g. pneumonia, TB) at study enrolment or any other 
severe conditions that may adversely affect the respiratory system or quality of 
life. 
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 Patient participating in another clinical research study at the time of- or in the 
past 3 months prior to enrolment. 
6.2.2 Study Design and Schematic    
This prospective, randomized, parallel-grouped comparative study investigated the 
effect of the routine use of the novel spacer, the AeroChamber Plus
®
 VHC with Flow-
Vu
®
 (designed with a visual feedback reassurance mechanism of an optimal inhalation), 
TMI, Canada, on asthma control levels in asthmatic children, compared with the routine 
use of the currently available spacer version, the AeroChamber Plus
®
 VHC. The 
facemask (yellow) version of these spacers was studied in the present research [Refer to 
Chapter 2; figures 2-14 and 2-15 to see the pictures of the used spacers]. The influence 
on the HRQL of the asthmatic children caregivers was assessed as well.  Eligible 
patients, whose parents/caregivers had given a written informed consent, were enrolled 
into a two-week run-in period (see study procedures below for details) before being 
randomized into one of the two study groups. 
The study consisted of 2 comparative groups: The AeroChamber Plus
®
 VHC with 
Flow-Vu
®
 group (FV); patients enrolled into the (FV) group used the novel 
AeroChamber spacer device connected to their MDIs. The second study group was the 
AeroChamber Plus
®
 VHC group (AC); patients enrolled into the AC group used the 
currently available AeroChamber device (which does not have the visual feedback). 
These two groups were the intervention area of the study and participating subjects were 
randomized, after completing the two-week run-in period, into one of these two groups 
using a previously constructed randomization table.  
During the patients‟ enrolment period, they were scheduled into 4 clinic study visits; 
visit 1 (enrolment/run-in period visit, Day 1), visit 2 (randomization visit, after 2 weeks 
of enrolment), visit 3 (after 8 weeks of enrolment) and visit 4 (End of study, after 14 
weeks of enrolment). Every effort was made for the patients and their caregivers to 
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return to the clinic on the scheduled visit day. If they could not make the appointment 
due to extenuating circumstances, a two-week visit window was allowed for visits 3 and 
4. For visit 2 only, a delay of 3 days was allowed. 
 
 
 
Study week: -2   0                                           6                                       12 
 
 
 
Visit:    1   2                                           3                                      4 
                                                                                                 
                 Run-In Period                                                  Intervention Period 
 
The study design did not interfere with the patient‟s pharmacotherapy regimen and any 
relevant changes, if needed, were only made at the discretion of the treating physician 
and were documented in the patient‟s case report form (CRF) as appropriate. 
6.2.3 Study Procedures      
6.2.3.(a) Visit 1 (enrolment/run-in period, Day 1)  
For all eligible patients who were willing to participate in the study, a signed informed 
consent form (by the parent/caregiver and the child if were capable to sign their name) 
was obtained prior to performing any study related procedures. In each patient‟s CRF, 
the investigator recorded the patient‟s age, gender, height and weight. Asthma 
Enrolment into a two-week run-in 
period (Visit 1) 
AeroChamber Plus with Flow-Vu 
Group (FV – Group) 
AeroChamber Plus VHC Group 
(AC - Group) 
By randomization at the 
end of the run-in period 
(at visit 2) 
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medications were also recorded. The inhalation flow rate (IFR) was measured using the 
In-Check Meter
®
 (Clement Clarke International Ltd, UK), mimicking the IFR achieved 
through an MDI connected to a spacer. The asthmatic child‟s parent/caregiver 
completed the first 6 items of the Asthma Control Questionnaire (ACQ) (Juniper et al., 
1999d; Juniper et al., 2006) [APPENDIX A-1] on their child‟s behalf. The 
parent/caregiver also completed the Juniper Paediatric Asthma Caregiver‟s Quality of 
Life Questionnaire (PACQLQ) (Juniper et al., 1996b) [APPENDIX A-7 (refer to the 
enclosed DVD)].    
Irrespective of the spacer device the child was using before enrolment, they were given 
an AeroChamber Plus spacer [the facemask (yellow) version]. Their parent/caregiver 
received a verbal training on how to use this spacer. The training session continued until 
the parent/child satisfactorily demonstrated the correct MDI plus spacer technique. 
Assessment of the inhalation technique was done against a modified checklist (to suit 
the facemask spacer use) to that previously published in the literature (Burkhart et al., 
2005) [APPENDIX A-23 (refer to the enclosed DVD)]. Those who could not use the 
correct inhalation method after a reasonable time were withdrawn from the study and 
referred to their doctor/practice nurse for inhaler device assessment. All 
parents/caregivers were instructed that their child‟s inhaled corticosteroid MDI should 
be attached to the spacer.  
6.2.3.(b) Visit 2 (randomization, after 2 weeks of enrolment) 
On this visit, the parent/child‟s inhaler technique, when a placebo MDI was attached to 
the AeroChamber Plus spacer, was checked against the checklist used on visit 1. The 
tests and questionnaires previously performed/completed on the first visit were also 
repeated on this occasion. Any changes to the asthmatic child‟s asthma medications 
since the last visit were checked and recorded with the reason for the change, as 
appropriate. 
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Each asthmatic child was then randomized into one of the two comparative study 
groups (FV or AC) according to the previously constructed randomization table 
[APPENDIX A-24 (refer to the enclosed DVD)]. All parents/caregivers along with their 
asthmatic children were trained to use the inhalation method they had been randomized 
to use. The training continued until satisfactory demonstration was provided. Those who 
could not demonstrate a satisfactory technique were withdrawn and referred to their 
doctor/practice nurse. 
6.2.3.(c) Visits 3 and 4 (after 8 and 14 weeks of enrolment)  
On these visits, the parent/child‟s MDI plus a spacer inhalation technique was checked 
against the previously used inhaler technique checklist. The tests and questionnaires 
previously performed on the last visit were also repeated on these visits. Any changes to 
the child‟s asthma medications since the last visit were checked and recorded, as 
appropriate, and the reason for any change was obtained.  
At the end of the study (visit 4), the parents/caregivers, in the AC and FV groups, 
completed the AeroChamber Plus Patient Satisfaction Questionnaire [APPENDIX A-25 
(refer to the enclosed DVD)].  
6.2.4 Study Flow Chart   
  Week number -2 0 6 12 
Clinic Visit  1 2 3 4 
Informed Consent and enrolment into run-in period Х    
Review Inclusion/Exclusion Х    
Demographic Data (age, gender, height and weight) Х    
Randomization into the AC or FV study groups   Х   
Asthma medications review Х Х Х Х 
IFR through MDI+Spacer (In-Check Meter) Х Х Х Х 
MDI plus spacer inhalation technique assessment Х Х Х Х 
ACQ (first 6 questions) Х Х Х Х 
PACQLQ Х Х Х Х 
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6.2.5 Patients Withdrawal and Early Termination       
The patients/caregivers were free to withdraw at any time from the study. They might 
have been withdrawn from the study by their doctor or at the discretion of the 
investigator if they violated the study plan, were unable to follow the study procedures 
and/or for any other safety or clinical reasons. 
6.2.6 Data Collection     
Data was collected from all enrolled patients at visit 1 to allow a baseline to be 
established with which the subsequently collected data during the follow-up visits was 
compared. 
The primary outcome measures were: 
 The Asthma Control Questionnaire (ACQ), the first 6 questions. 
 The PACQLQ. 
The secondary outcome measures were: 
 The inhalation flow rate (IFR) through a spacer. 
 Changes in the frequency of rescue inhaler use. 
 Oral prednisolone use, changes in inhaled corticosteroid dosing and 
hospitalizations due to acute asthma exacerbations. 
 Parents‟ satisfaction/convenience assessment for the new spacer device. 
6.2.7 Confidentiality of the Patients Identity and Data    
The data collected and generated by this research study is considered strictly 
confidential. Each patient was only identified by a unique code number. A list of all the 
participants is kept in confidence along with the study documents. 
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6.2.8 Data Analysis     
The statistical analysis was carried out using the Statistical Package for Social Sciences 
(SPSS for windows, V15) software. An SPSS dataset was set up for the analysis. The 
statistical analysis was performed and presented as follows: 
 Descriptive statistics: presented as mean (standard deviation), median (25%; 
75% quartiles), minimum and maximum values, frequencies and percentages; as 
appropriate. 
 For scale data; normal distribution of the data was examined using histograms 
and the statistical tests for normality; the Kolmogorov-Smirnov and Shapiro-
Wilk tests. These tests showed that the IFR, ACQ scores and PACQLQ scores 
were not normally distributed. 
 Within each study group, pairwise comparisons for each of these outcome 
measures (between study visits) were performed using the non-parametric, 
related-samples Wilcoxon test. The repeated measures, non-parametric, within-
subject ANOVA equivalent test; the Friedman test, was also used. 
 Comparisons between the AC and FV groups for each of the outcome measures 
at the baseline and follow-up visits were performed using the non-parametric, 
between-subject ANOVA equivalent test; the Kruskal-Wallis test. 
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6.3 Results  
6.3.1 Study Population 
A total of 21 asthmatic children were enrolled into this research study, however only 19 
children (12 males; 7 females) were randomized into either the AC (n=9) or FV (n=10) 
study groups. Detailed demographics are presented in table 6-1. 
   Table 6-1: Detailed Demographic data - The AeroChamber spacers study 
Patient 
Number 
 AC Group (n=9)  FV Group (n=10) 
Sex 
Age 
(years) 
Height 
(cm) 
Sex 
Age 
(years) 
Height 
(cm) 
1 Male 3 101.1 Male 3 98.5 
2 Male 4 109.0 Male 3 99.3 
3 Male 5 111.0 Male 3 101.5 
4 Female 5 117.8 Male 3 100.0 
5 Female 4 109.0 Female 2 84.2 
6 Male 3 100.3 Female 2 92.6 
7 Male 2 93.2 Female 1 73.0 
8 Male 4 108.1 Female 3 100.4 
9 Male 3 94.2 Female 1 79.8 
10 --- --- --- Male 2 90.0 
Mean --- 3.7 104.9 --- 2.3 91.9 
SD --- 1.0 8.2 --- 0.8 10.0 
Min --- 2 93.2 --- 1 73.0 
Max --- 5 117.8 --- 3 101.5 
n 9 9 9 10 10 10 
     * AC: AeroChamber Plus group; FV: AeroChamber Plus with Flow-Vu group. 
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6.3.2 Inhalation Flow Rate through the Spacer Device 
The baseline inhalation flow rates at visit 1, along with the subsequently obtained IFR at 
the randomization and follow-up visits are presented in tables 6-2 and 6-3 for the AC 
group and FV group, respectively. Normality distribution tests showed that the IFRs 
were not normally distributed. Therefore, comparison of the IFR between the AC and 
FV groups at the baseline visit (1) as well as at the subsequent follow-up visits (visit 2 
through visit 4) was investigated using the nonparametric, between-subject ANOVA 
equivalent statistical test; the Kruskal-Wallis test. The results, presented in table 6-4, 
showed non-significant differences in the IFRs between the two study groups at any of 
the study four visits. Moreover, pairwise comparisons of the IFR [obtained at visit 1 
(baseline) and randomization visit 2 with those obtained at visits 3 and 4] within each of 
the AC and FV groups (using the nonparametric, related-samples Wilcoxon test) 
showed non-significant differences in the IFR within each group. This was also 
confirmed when the repeated measures, non-parametric, within-subject ANOVA 
equivalent test; the Friedman test, was used. The Friedman test showed a non-
significant difference in the IFR within the AC group [χ2 (3) = 4.37; p = 0.226], or 
within the FV group [χ2 (3) = 0.551; p = 0.927] over the four study visits. The 
Friedman‟s mean ranks for the IFR are presented in tables 6-2 and 6-3 for the AC and 
FV groups, respectively.  
Given that the children‟s heights between the groups were significant, regression of the 
height on the IFR combining both the AC and FV groups was done. The relationship 
was significant and 25% of the variance in the IFR was accounted for by the height.  
Using the same analysis for both groups separately, the AC group alone had a 19% 
relationship  while that of the FV group was 20%. However, the difference in the 
heights overall was only on the order of 15% and this was offset by the fact that only 
about 5% of the variance in the IFR was unique to the height differences for these 
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groups. So, the height was basically a trivial predictor of the IFR, and therefore, we can 
ignore the height and age as factors explaining any group differences if originally 
existed. However, group differences in the IFR did not really exist as shown above.  
Table 6-2: The inhalation flow rate* (l/min) of the asthmatic children in AC group. 
Patient 
Number 
Study Group: AeroChamber Plus Spacer (AC) Group 
IFR (l/min) 
Visit 1 
(baseline) 
IFR (l/min) 
Visit 2 
(randomization) 
IFR (l/min) 
Visit 3 
IFR (l/min) 
Visit 4 
1 ** ** ** ** 
2 40 45 45 45 
3 40 50 60 50 
4 75 60 30 38 
5 40 30 42 40 
6 30 30 30 30 
7 40 40 60 30 
8 35 30 40 45 
9 30 30 35 30 
Median 40.00 35.00 41.00 39.00 
Percentile 
25% 
31.25 30.00 31.25 30.00 
Percentile 
75% 
40.00 48.75 56.25 45.00 
Mean 
Rank
***
 
2.19 2.19 3.19 2.44 
n 8 8 8 8 
     * IFR < 30 l/min were recorded as 30 l/min, as the In-Check meter scale was between 30 – 350 l/min. 
     ** Missing data as the asthmatic child refused to inhale through the In-Check meter. 
     *** Friedman‟s mean rank for the IFR. 
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Table 6-3: The inhalation flow rate* (l/min) of the asthmatic children in FV group. 
Patient 
Number 
Study Group: AeroChamber Plus with Flow-Vu Spacer (FV)  
IFR (l/min) 
Visit 1 
(baseline) 
IFR (l/min) 
Visit 2 
(randomization) 
IFR (l/min) 
Visit 3 
IFR (l/min) 
Visit 4 
1 30 35 35 40 
2 50 48 45 30 
3 35 35 70 45 
4 38 32 30 30 
5 30 30 ** 30 
6 30 30 30 40 
7 30 30 30 30 
8 40 30 30 30 
9 30 30 30 30 
10 30 30 30 ‡ 
Median 30.0 30.0 30.0 30.0 
Percentile 
25% 
30.0 30.0 30.0 30.0 
Percentile 
75% 
38.5 35.0 40.0 40.0 
Mean 
Rank
***
 
2.69 2.38 2.38 2.56 
n 10 10 9 9 
      * IFR < 30 l/min were recorded as 30 l/min, as the In-Check meter scale was between 30 – 350 l/min. 
     ** Missing data as the asthmatic child refused to inhale through the In-Check meter. 
   *** Friedman‟s mean rank for the IFR. 
      ‡ The patient did not turn up for the last (fourth) visit of the study. 
   
Table 6-4: Comparison of the IFR between the AC and FV groups.  
IFR 
The nonparametric Kruskal-Wallis test 
Chi-Square (χ2) Mean Ranks* 
Exact p-value  
(2-tailed) 
IFR (baseline-visit 1) 2.411 11.56; 7.85 0.124 
IFR (visit 2) 0.953 10.75; 8.50 0.348 
IFR (visit 3) 2.031 10.75; 7.44 0.165 
IFR (visit 4) 1.581 10.50; 7.67 0.245 
      * Kruskal-Wallis mean ranks for AC and FV groups, respectively. 
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6.3.3 The Asthma Control Questionnaire (ACQ) 
The baseline ACQ scores at visit 1, along with those scored at the randomization and 
follow-up visits are presented in tables 6-5 and 6-6 for the AC group and FV group, 
respectively. Normality distribution tests showed that the ACQ scores were not 
normally distributed. Therefore, comparison of the ACQ between the AC and FV 
groups at the baseline visit (1) as well as at the subsequent follow-up visits (visit 2 
through visit 4) was investigated using the nonparametric, between-subject ANOVA 
equivalent statistical test; the Kruskal-Wallis test. The results, presented in table 6-7, 
showed non-significant differences in the ACQ between the two study groups at any of 
the study four visits. Moreover, pairwise comparisons of the ACQ [obtained at visit 1 
(baseline) and randomization visit 2 with those obtained at visits 3 and 4] within each of 
the AC and FV groups (using the nonparametric, related-samples Wilcoxon test) 
showed non-significant changes in asthma control within each group over the study 
follow-up period. The repeated measures, non-parametric, within subject ANOVA 
equivalent test; Friedman test, showed also non-significant changes in the ACQ within 
the AC group [χ2 (3) = 7.43; p = 0.053] as well as within the FV group [χ2 (3) = 2.18; p 
= 0.555] over the study period. The frequencies of the AC and FV asthmatic children in 
various ACQ cut-point categories are also presented in table 6-8. 
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Table 6-5: The ACQ scores - AeroChamber Plus Spacer (AC) group 
Patient 
Number 
Study Group: AeroChamber Plus Spacer (AC) Group 
ACQ Score 
Visit 1 (baseline) 
ACQ Score 
Visit 2 
(randomization) 
ACQ Score 
Visit 3 
ACQ Score 
Visit 4 
1 0 0 0.50 0 
2 4.00 0 3.50 0.17 
3 3.17 0.67 3.00 0 
4 0.83 2.67 0.33 0.17 
5 1.33 0.50 0.33 1.67 
6 0.50 0.83 1.00 0.67 
7 3.33 1.67 3.33 2.17 
8 2.33 1.83 2.50 1.33 
9 2.33 2.00 3.67 2.00 
Median 2.33 0.83 2.50 0.67 
25
th*
  0.67 0.25 0.42 0.09 
75
th*
  3.25 1.92 3.42 1.84 
Mean 
Rank
**
 
2.94 2.06 3.17 1.83 
n 9 9 9 9 
 * The 25
th
 and 75
th
 percentiles.    ** Friedman‟s mean rank for the ACQ. 
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Table 6-6: The ACQ scores - AeroChamber Plus with Flow-Vu Spacer (FV) group 
Patient 
Number 
Study Group: AeroChamber Plus with Flow-Vu Spacer (FV) Group 
ACQ Score 
Visit 1  
(baseline) 
ACQ Score 
Visit 2 
(randomization) 
ACQ Score 
Visit 3 
ACQ Score 
Visit 4 
1 0 2.83 0 0.50 
2 3.17 0.67 0.40 0.67 
3 1.67 0.83 0.50 3.00 
4 1.00 1.00 4.17 2.50 
5 0.17 0.67 0 0 
6 3.33 1.83 1.17 3.50 
7 0.67 3.33 4.00 0.83 
8 0 0.17 0 1.17 
9 0.50 0.83 3.50 0.50 
10 2.17 1.33 1.33 ‡ 
Median 0.84 0.92 0.84 0.83 
25
th*
  0.13 0.67 0 0.50 
75
th*
  2.42 2.08 3.63 2.75 
Mean 
Rank
**
 
2.22 2.78 2.17 2.83 
n 10 10 10 9 
* The 25
th
 and 75
th
 percentiles.    ** Friedman‟s mean rank for the ACQ. 
‡ The asthmatic child and their parent did not turn up for the last (fourth) visit of the study. 
 
Table 6-7: Comparison in the ACQ between the AC and FV groups. 
ACQ 
The nonparametric Kruskal-Wallis test 
Chi-Square (χ2) Mean Ranks* 
Exact p-value  
(2-tailed) 
ACQ (visit 1) 1.412 11.61; 8.55 0.248 
ACQ (visit 2) 0.378 9.17; 10.75 0.561 
ACQ (visit 3) 0.329 10.78; 9.30 0.589 
ACQ (visit 4) 0.785 8.39; 10.61 0.399 
* The Kruskal-Wallis mean ranks for AC and FV groups, respectively. 
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  Table 6-8: Frequencies of AC and FV patients in various ACQ categories.    
Study 
Group 
ACQ Category 
Visit 1 
 n (%) 
Visit 2  
n (%) 
Visit 3  
n (%) 
Visit 4 
n (%) 
AC 
Group 
(n=9) 
≤ 0.75 
(well controlled) 
2 (22.2%) 4 (44.4%) 3 (33.3%) 5 (55.6%) 
0.75 – 1.50 
(not well controlled) 
2 (22.2%) 1 (11.1%) 1 (11.1%) 1 (11.1%) 
≥ 1.50 
(uncontrolled) 
5 (55.6%) 4 (44.4%) 5 (55.6%) 3 (33.3%) 
FV 
Group 
(n=10) 
ACQ Category 
Visit 1 
 n (%) 
Visit 2  
n (%) 
Visit 3  
n (%) 
Visit 4 
n (%)* 
≤ 0.75 
(well controlled) 
5 (50%) 3 (30%) 5 (50%) 4 (44.4%) 
0.75 – 1.50 
(not well controlled) 
1(10%) 4 (40%) 2 (20%) 2 (22.2%) 
≥ 1.50 
(uncontrolled) 
4 (40%) 3 (30%)  3 (30%) 3 (33.3%) 
        * One patient (FV group) did not turn up for the last (fourth) visit of the study. 
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6.3.4 The PACQLQ 
The baseline PACQLQ (overall, activity limitation and emotional function domains) 
completed at visit 1, along with those completed at the randomization and follow-up 
visits, are presented in tables 6-9 and 6-10 for the AC group and FV group, respectively. 
Frequencies of the AC and FV parents in various cut-point categories of the overall 
PACQLQ and its domains change (between the study visits) are presented in table 6-11. 
Normality distribution tests showed that the PACQLQ scores were not normally 
distributed. Therefore, comparison of the overall PACQLQ (and its two domains) 
between the AC and FV groups at the baseline (visit 1) as well as at the subsequent 
follow-up visits (visit 2 through visit 4) was investigated using the nonparametric, 
between-subject ANOVA equivalent statistical test; the Kruskal-Wallis test. The results, 
presented in table 6-12, showed non-significant differences in the overall PACQLQ 
(and its two domains) between the two study groups at any of the study four visits.  
Pairwise comparisons of the PACQLQ (and its 2 domains) obtained at visit 1 (baseline) 
and randomization visit 2 with those at the follow-up visits (3 and 4) within each of the 
AC and FV groups were studied using the nonparametric, related-samples Wilcoxon 
test. Within the AC group, the results showed statistically significant changes in the 
overall PACQLQ and its emotional function domain between visits 1 and 2 (p < 0.01); 
in the overall PACQLQ and its two domains between visits 1 and 4 (p < 0.05); and only 
in the emotional domain between visits 2 and 4 (p < 0.01). However, no significant 
changes in the overall PACQLQ and its two domains were detected between the study 
visits within the FV group. Similarly, the repeated measures, non-parametric, within 
subject ANOVA equivalent test; Friedman test, showed significant changes in the 
overall PACQLQ [χ2 (3) = 8.53; p = 0.030] and the emotional function domain [χ2 (3) = 
15.5; p < 0.001] only within the AC group. However, the Friedman test did not show 
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any significant changes in the overall PACQLQ [χ2 (3) = 1.97; p = 0.600] within the FV 
group or in its two domains (p > 0.050) over the study period. 
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Table 6-9: The PACQLQ scores of the asthmatic children’s parents - AC Group 
Patient 
Number 
Study Group: AeroChamber Plus Spacer (AC) Group 
PACQLQ Domains - Visit 1 PACQLQ Domains -Visit 2 PACQLQ Domains -Visit 3 PACQLQ Domains -Visit 4 
Overall Activity Emotional Overall Activity Emotional Overall Activity Emotional Overall Activity Emotional 
1 3.9 3.5 4.1 4.8 4.5 5.0 5.5 5.0 5.8 5.4 6.0 5.1 
2 2.9 3.0 2.9 6.4 6.8 6.2 2.8 2.5 2.9 6.5 7.0 6.3 
3 3.7 3.5 3.8 5.8 6.5 5.4 4.2 4.3 4.2 6.6 7.0 6.4 
4 4.4 4.8 4.2 5.2 3.5 6.0 7.0 7.0 7.0 7.0 7.0 7.0 
5 5.6 6.0 5.4 6.0 7.0 5.6 6.5 7.0 6.2 5.6 5.5 5.7 
6 7.0 7.0 7.0 6.9 6.8 7.0 6.9 6.8 7.0 6.9 6.8 7.0 
7 5.4 5.5 5.3 6.5 7.0 6.3 6.2 6.3 6.1 6.5 6.3 6.7 
8 5.2 5.3 5.1 5.8 6.0 5.8 5.3 4.5 5.7 6.1 6.5 5.9 
9 4.7 4.0 5.0 5.2 4.8 5.3 3.8 3.0 4.1 5.6 5.0 5.9 
Median 4.7 4.8 5.0 5.8 6.5 5.8 5.5 5.0 5.8 6.5 6.5 6.3 
25
th*
 3.8 3.5 3.9 5.2 4.6 5.4 4.0 3.6 4.2 5.6 5.8 5.8 
75
th*
 5.5 5.8 5.4 6.5 6.9 6.3 6.7 6.9 6.6 6.8 7.0 6.8 
Mean 
Rank
**
 
1.61 1.89 1.33 2.72 2.72 2.61 2.39 2.17 2.50 3.28 3.22 3.56 
n 9 9 9 9 9 9 9 9 9 9 9 9 
      * The 25
th
 and 75
th
 percentiles.   ** The Friedman‟s mean rank.    
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Table 6-10: The PACQLQ scores of the asthmatic children’s parents - FV Group 
Patient 
Number 
Study Group: AeroChamber Plus with Flow-Vu Spacer (FV) Group 
PACQLQ Domains - Visit 1 PACQLQ Domains -Visit 2 PACQLQ Domains -Visit 3 PACQLQ Domains -Visit 4 
Overall Activity Emotional Overall Activity Emotional Overall Activity Emotional Overall Activity Emotional 
1 6.3 6.8 6.1 3.8 4.5 3.4 6.9 7.0 6.9 6.5 7.0 6.2 
2 5.5 3.5 6.3 7.0 7.0 7.0 6.9 7.0 6.9 7.0 7.0 7.0 
3 3.5 4.8 2.9 3.7 6.0 2.7 3.8 6.3 2.8 4.8 5.5 4.4 
4 3.3 3.5 3.2 5.1 5.0 5.1 1.8 1.8 1.9 2.3 2.0 2.4 
5 6.2 6.8 6.0 6.5 6.8 6.3 6.7 6.5 6.8 6.8 6.8 6.9 
6 4.6 4.3 4.8 5.4 5.3 5.4 6.8 7.0 6.8 5.1 4.3 5.4 
7 6.6 7.0 6.4 4.8 4.0 5.2 4.6 3.8 5.0 6.8 7.0 6.8 
8 6.5 7.0 6.3 6.5 7.0 6.3 6.6 7.0 6.4 5.6 6.0 5.4 
9 7.0 7.0 7.0 6.9 7.0 6.9 5.2 4.5 5.4 6.9 7.0 6.9 
10 6.2 6.5 6.0 6.5 6.5 6.4 6.3 6.0 6.4 ‡ ‡ ‡ 
Median 6.2 6.6 6.1 5.9 6.3 5.9 6.5 6.4 6.4 6.5 6.8 6.2 
25
th*
 4.3 4.1 4.4 4.6 4.9 4.7 4.4 4.3 4.4 4.9 4.9 4.9 
75
th*
 6.6 7.0 6.4 6.6 7.0 6.6 6.9 7.0 6.8 6.9 7.0 6.9 
Mean 
Rank
**
 
2.06 2.33 2.28 2.50 2.78 2.33 2.56 2.39 2.44 2.89 2.50 2.94 
n 10 10 10 10 10 10 10 10 10 9 9 9 
    * The 25
th
 and 75
th
 percentiles.   ** The Friedman‟s mean rank.    
    ‡ The asthmatic child and their parent did not turn up for the last (fourth) visit of the study.  
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Table 6-11: Frequencies of AC and FV parents in the PACQLQ change categories over the study visits. 
Study 
Group 
∆ PACQLQ 
Category
**
 
Change (∆) in PACQLQ scores between study visits 
Visit 3 – Visit 2 Visit 4* – Visit 3 Visit 4* – Visit 2  
Overall  
n (%) 
Activity 
Limitation 
n (%) 
Emotional 
Function 
n (%) 
Overall  
n (%) 
Activity 
Limitation 
n (%) 
Emotional 
Function 
n (%) 
Overall  
n (%) 
Activity 
Limitation 
n (%) 
Emotional 
Function 
n (%) 
AC 
Group 
(n=9) 
≤ -0.5 4 (44.4) 5 (55.6) 3 (33.3) 1 (11.1) 1 (11.1) 2 (22.2) 0 2 (22.2) 0 
-0.49 – 0.49 3 (33.3) 2 (22.2) 3 (33.3) 4 (44.4) 3 (33.3) 3 (33.3) 6 (66.7) 3 (33.3) 6 (66.7) 
0.5 – 1.0 1 (11.1) 1 (11.1) 3 (33.3) 1 (11.1) 1 (11.1) 1 (11.1) 2 (22.2) 2 (22.2) 3 (33.3) 
> 1.0 1 (11.1) 1 (11.1) 0 3 (33.3) 4 (44.4) 3 (33.3) 1 (11.1) 2 (22.2) 0 
FV 
Group 
(n=10)
*
 
≤ -0.5 2 (20) 3 (30) 2 (20) 2 (22.2) 3 (33.3) 3 (33.3) 2 (22.2) 4 (44.4) 2 (22.2) 
-0.49 – 0.49 6 (60) 5 (50) 6 (60) 4 (44.4) 4 (44.4) 2 (22.2) 4 (44.4) 3 (33.3) 3 (33.3) 
0.5 – 1.0 0 0 0 1 (11.1) 0 1 (11.1) 0 0 1 (11.1) 
> 1.0 2 (20) 2 (20) 2 (20) 2 (22.2) 2 (22.2) 3 (33.3) 3 (33.3) 2 (22.2) 3 (33.3) 
                * One asthmatic child and their parent (FV group) did not turn up for the last (fourth) visit of the study. ** The MID is ≥ 0.5. 
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 Table 6-12: Comparison in the PACQLQ between the AC and FV groups. 
PACQLQ Domains 
The nonparametric Kruskal-Wallis test 
Chi-Square (χ2) Mean Ranks* 
Exact p-value  
(2-tailed) 
Overall (visit 1) 1.817 8.17; 11.65 0.188 
Activity (visit 1) 1.965 8.11; 11.70 0.171 
Emotional (visit 1) 1.933 8.11; 11.70 0.175 
Overall (visit 2) 0.015 10.17; 9.85 0.920 
Activity (visit 2) 0.015 9.83; 10.15 0.918 
Emotional (visit 2) 0.007 10.11; 9.90 0.953 
Overall (visit 3) 0.167 9.44; 10.50 0.719 
Activity (visit 3) 0.558 9.00; 10.90 0.476 
Emotional (visit 3) 0.060 9.67; 10.30 0.830 
Overall (visit 4) 0.159 10.00; 9.00 0.715 
Activity (visit 4) 0.008 9.61; 9.39 0.957 
Emotional (visit 4) 0.238 10.11; 8.89 0.649 
       * The Kruskal-Wallis mean ranks for AC and FV groups, respectively. 
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6.3.5 Asthmatic Children Caregivers‟ Spacer Evaluation 
At the end of the study (visit 4), the asthmatic children caregivers/parents completed a 
spacer satisfaction questionnaire including a ranking of the AeroChamber Plus with 
Flow-Vu spacer compared to the standard AeroChamber Plus spacer. The parents in the 
AC group had been shown the FV spacer before they rated the spacer, and vice versa. 
The results of the spacers‟ evaluation are shown in tables 6-13 and 6-14 for the parents 
in AC and FV groups, respectively. 
Table 6-13: The parents’ (in the AC group) rating of the AeroChamber Plus with 
                     Flow-Vu Spacer (FV) compared to the Standard AeroChamber Plus 
                     Spacer. 
Parents in the AC Group 
Rating Category Frequency (n, %)* 
Much better 5 (62.5%) 
Better  3 (37.5%) 
The same --- 
Worse --- 
Much worse --- 
                     * One parent in the AC group did not give a rating to the spacers. 
 
Table 6-14: The parents’ (in the FV group) rating of the AeroChamber Plus with 
                     Flow-Vu Spacer (FV) compared to the Standard AeroChamber Plus 
                     Spacer. 
Parents in the FV Group 
Rating Category Frequency (n, %)* 
Much better 6 (66.7%) 
Better  2 (22.2%) 
The same 1 (11.1%) 
Worse --- 
Much worse --- 
                         * One parent in the FV group did not attend the last (fourth) visit. 
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6.3.6 Asthma Medication and Hospitalization 
Asthma related medication and hospitalization were checked for throughout the research 
period. All, but 3 asthmatic children, had no change in their asthma inhalers and were 
not hospitalized for any reason. However, patient number 4 (FV group) had taken oral 
prednisolone for 4 days due to an asthma exacerbation on two occasions; about one 
week prior to visits 3 and 4, and was hospitalized for 3 days on the second occasion. 
The other asthma inhalers used by this patient remained the same throughout the study. 
The other two children (patients number 7 and 9, both in the FV group) had the same 
asthma medications over the study period, however took oral prednisolone for 4 days 
about one week before their third study visit, this was due to a common cold that 
interfered with their asthma symptoms, no hospitalization was reported. 
 
6.3.7 The MDI plus a Spacer Technique Assessment  
The asthmatic children/parents (in the AC and FV groups) had their MDI plus spacer 
technique checked, using a placebo inhaler, against an MDI plus spacer technique 
checklist, at the baseline visit as well as at the follow-up visits. All the participants, in 
both groups, did perform the inhalation technique steps sufficiently without any 
significant changes. Frequencies and percentages of the AC and FV participants who 
performed incorrect technique steps over the study four visits are presented in tables 6-
15 and 6-16.  
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Table 6-15: Frequencies of the AC group with incorrect MDI plus spacer technique steps. 
The most Desirable MDI plus spacer Technique Steps 
AC Group (n=9) 
Incorrect Steps n (%) 
Visit 1  Visit 2 Visit 3 Visit 4 
1. Remove the cap from the MDI mouthpiece. 0 0 0 0 
2. Insert the MDI mouthpiece into the spacer‟s back piece 
adapter, and then shake the inhaler/spacer unit vigorously. 
1 
(11.1%) 
0 0 0 
3. Place the facemask of the spacer around your child‟s mouth 
and nose. 
0 0 0 0 
4. Press the facemask tightly against the child‟s face.   0 
1 
(11.1%) 
0 0 
5. Press down the aerosol canister to release a dose (puff) and 
immediately instruct your child to continue breathing 
normally (slowly and deeply) and count 6 breaths through 
the spacer while keeping the facemask tightly pressed 
against your child‟s face. 
4 
(44.4%) 
0 0 0 
6. Repeat steps 1 to 5 after about 30 seconds if another dose is 
needed. 
2 
(22.2%) 
1 
(11.1%) 
1 
(11.1%) 
0 
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Table 6-16: Frequencies of the FV group with incorrect MDI plus spacer technique steps. 
The most Desirable MDI plus spacer Technique Steps 
FV Group (n=10) 
Incorrect Steps n (%) 
Visit 1  Visit 2 Visit 3 Visit 4
*
 
1. Remove the cap from the MDI mouthpiece. 0 0 0 0 
2. Insert the MDI mouthpiece into the spacer‟s back piece 
adapter, and then shake the inhaler/spacer unit vigorously. 
0 0 0 0 
3. Place the facemask of the spacer around your child‟s mouth 
and nose. 
0 0 0 0 
4. Press the facemask tightly against the child‟s face.   0 0 0 0 
5. Press down the aerosol canister to release a dose (puff) and 
immediately instruct your child to continue breathing 
normally (slowly and deeply) and count 6 breaths through 
the spacer while keeping the facemask tightly pressed 
against your child‟s face. 
2 (20%) 1 (10%) 1 (10%) 0 
6. Repeat steps 1 to 5 after about 30 seconds if another dose is 
needed. 
4 (40%) 2 (20%) 1 (10%) 0 
                                 * One asthmatic child and their parent (FV group) did not turn up for the last (fourth) visit of the study. 
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6.4 Discussion 
Respiratory patients who continue to have the problem of correctly coordinating the 
MDI activation with inhalation, even after repeated MDI technique training sessions, 
are commonly prescribed a spacer (holding-chamber) device to use with their 
pressurized inhalers (Burkhart et al., 2005; Dolovich et al., 2005). The national 
(BTS/SIGN, 2009) and international (GINA, 2008) asthma management guidelines state 
that in a non life-threatening exacerbations of asthma; an MDI connected to a spacer is 
more preferred than nebulizers to deliver the inhaled medications, and takes less 
treatment set-up and administration time (Mason et al., 2008). Moreover, in asthmatic 
children, where the issue of sufficient MDI technique is more evident, the inhaled 
respiratory medicine is recommended to be delivered via an MDI plus a spacer 
particularly in children aged under 12 years (GINA, 2008; BTS/SIGN, 2009). These 
recommendations and preferences towards the use of spacers have been based on the 
advantages these devices provide in terms of drug delivery and efficacy. 
Indeed, many studies have shown that a spacer device attached to an MDI improves the 
lung deposition of the inhaled therapy and reduces the unwanted oropharyngeal 
impaction in comparison with the use of the MDI alone. This have been demonstrated in 
a number of radiolabeled aerosol studies in adult respiratory patients (Newman et al., 
1981a), in adult healthy volunteers (Newman et al., 1989a) and more recently in 
asthmatic children via the AeroChamber Plus spacer (Roller et al., 2007). Furthermore, 
in-vivo pharmacokinetic studies have shown that the inhaled salbutamol via an MDI 
plus a spacer resulted in a greater lung bioavailability than the salbutamol inhaled 
through either the MDI alone (Hindle and Chrystyn, 1994; Silkstone et al., 2002; 
Mazhar and Chrystyn, 2008) or a jet nebulizer (Silkstone et al., 2002). It has been, 
therefore, suggested that the improved peripheral lung deposition following the 
pressurized aerosol inhalation through a spacer would enhance the clinical efficacy of 
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the inhaled corticosteroids (Toogood et al., 1984; Nair et al., 2008) and bronchodilators 
(Demirkan et al., 2000); and would reduce both the local oral candidiasis (Toogood et 
al., 1984; Nair et al., 2008) and the systemic side effects (Brown et al., 1990) induced 
by the high ICS dose strengths as a result of the decreased oropharyngeal impaction and 
the subsequent GIT steroid absorption, respectively. Finally, spacers provide additional 
space and time for the propellants to evaporate so that the patients do not feel the cold 
(freon) effect on the back of the mouth which usually makes them prematurely stop 
inhalation shortly after the MDI activation (Keller, 1999). 
Many spacer devices, with different make of material and shape, are available on the 
market. Metal spacers (e.g. Nebuchamber
®
) do not have the electrostatic charge issue 
which adversely affects the aerosol dose available for inhalation, and hence lung 
deposition; whereas the plastic spacers (Nebuhaler
®
 and Volumatic
®
) have had this 
problem which was overcome by spacer priming (Kenyon et al., 1998), or spacer 
washing/antistatic inner surface lining prior to the first time use (Clark and Lipworth, 
1996). Many in vitro studies (Barry and O'Callaghan, 1999; Williams et al., 2001) have 
evaluated the various available spacer devices in terms of their aerosol dose output 
characteristics under different testing conditions such as delay of inhalation after MDI 
actuation, different inhalation flow rates and spacer washing methods. However, it was 
difficult to compare the in vitro performance superiority among these spacers due to 
differences in study design, drugs/formulations used and the spacers‟ shape and size. On 
the other hand, a clinical study in 4-8 year-old asthmatic children has shown that the 
metal Nebuchamber and the plastic Volumatic and AeroChamber Plus spacers were 
equally effective in terms of the clinical efficacy of the delivered salbutamol 
(Dompeling et al., 2001). 
It has been, however, shown that the correct use of the MDI alone was equally effective 
to the use of an MDI plus a spacer in the children (Hodges et al., 1981) and adults 
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(Bloomfield et al., 1979; Dolovich et al., 1983) who have been trained to use their 
pressurized inhaler alone efficiently. However, patients do forget the correct MDI use; 
indeed only 50% of the patients maintained the good MDI use 1-30 days after their 
inhaler technique training session (Minai et al., 2004), and that up to 40% of the 
children make inhaler technique mistakes even with their spacers (Kamps et al., 2000). 
In this regard, a multiple feedback mechanism reassuring an adequate inhaler use is 
beneficial to both the patients themselves and their caregivers; this would also improve 
the patients‟ compliance and consequently their disease control (Crompton et al., 2006). 
Although the desirable IFR through an MDI should be < 90 l/min, the majority of the 
patients tend to inhale at a faster rate when using their inhaler (Nimmo et al., 1993; 
Hesselink et al., 2001). Recently, an MDI training tool; the 2ToneTrainer
®
, has been 
shown to help the patients maintain a slow IFR by producing a unique audible feedback 
of the acceptable IFR (Al-Showair et al., 2007b). Similarly, the AeroChamber Plus 
spacer helps the patients use a slow IFR as the spacer whistles when the patient exceeds 
an inspiratory flow of 60 l/min (Demirkan et al., 2000). Recently, the feedback 
mechanism of the AeroChamber Plus spacer has been enhanced by the inclusion of a 
visual indicator of inhalation and proper seal between the spacer and the lips or the face 
of the patient; the AeroChamber Plus
®
 with Flow-Vu
® 
(Trudell Medical International, 
Canada).  
The aim of the present study was to determine if the routine use of the novel 
AeroChamber Plus
®
 with Flow-Vu
®
 (FV) would improve asthma control and thus 
quality of life in preschool asthmatic children, compared with the use of the currently 
available spacer version; the AeroChamber Plus
® 
(AC). The quality of life of the 
asthmatic children‟s parents/caregivers was also assessed. In this research the facemask 
version (yellow) of the AeroChamber spacer was studied. The results showed that the 
median baseline inhalation flow rate (mimicking normal tidal breathing through a 
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spacer) at study enrolment (visit 1) was slow and well below 60 l/min for the two study 
groups (40 l/min AC group; 30 l/min FV group). Although the IFR of the FV group 
asthmatic children was generally slower than that of the AC group children, no 
significant difference in the IFR was demonstrated between the AC and FV groups, 
neither at the randomization visit (2) nor through the study follow-up period, where the 
IFR remained within the desirable slow inhalation flow.  
The asthma control of the children was assessed using the first 6 questions of the 
Asthma Control Questionnaire (ACQ) completed by their parents. Despite the high 
variability in the ACQ responses among the research visits (tables 6-5 and 6-6); the 
ACQ scores were not significantly different between the AC and FV groups neither at 
the randomization (visit 2) (median ACQ: 0.83 AC group; 0.92 FV group) nor at any of 
the subsequent study follow-up visits. Although the change in the asthma control was 
not statistically significant within each study group over the research follow-up period, 
55.6% and 44.4% of the AC and FV children, respectively, had a well-controlled ACQ 
score (≤ 0.75) at visit 4 compared with 44.4% and 30% of the AC and FV children who 
had a well-controlled ACQ score at randomization (visit 2) [table 6-8]. It is, however, 
worth mentioning that the ACQ was completed by the parents of the asthmatic children 
(due to their young age: ≤ 5 years), and that the ACQ has been originally developed and 
validated for asthmatic adults. However, the ACQ has been recently employed in an 
asthmatic children study (Thomas et al., 2009a), and that an interviewer-administered 
ACQ version for 6-11 year-old children has been very recently developed where the 
questionnaire items are almost the same as those of the original ACQ and the parents 
may help their children in completing the questionnaire. Although initially positive, 
validation results of the newly developed ACQ for children have not been published yet 
(source: www.qoltech.co.uk/references.html). 
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The quality of life of the asthmatic children‟s parents was evaluated using the 
PACQLQ. The PACQLQ scores (overall and its 2 domains) did not show a significant 
difference between the AC and FV groups. Within the AC group, the change in the 
overall PACQLQ (and its 2 domains) was significant between the baseline and end 
study visits, however it was only significant for the emotional function domain between 
the randomization and end study visits. Within the FV group, no significant change was 
found in the quality of life of the asthmatic children‟s caregivers over the research 
period. However, 33.3% of the AC and FV parents had an overall PACQLQ change 
greater that the minimal significant difference (≥ 0.5) over the study period (table 6-11). 
Despite the similarity between the current AeroChamber spacer and its new version 
with Flow-Vu in terms of the achieved paediatric asthma control levels and in their 
caregivers‟ asthma-related quality of life; the FV group parents have demonstrated more 
preference to the new FV spacer compared to the AC, where 66.7% of the parents 
ranked the FV as much better, whereas 22.2% ranked it as better. The FV group parents 
stated that with the visual flow indicator they could tell that their children were actually 
taking their “puff”; this was of a particular importance when their children were asleep 
while being given their inhaled medicine. Moreover, the FV group parents commented 
that they were able to confirm the exact number of breaths their children took through 
the spacer by counting the times the FV indicator moved. Similarly, the AC group 
parents were shown the FV spacer at the end of the study and were then asked about 
their opinion; 62.5% of them ranked the new spacer as much better than the current AC 
spacer, whilst 37.5% did rank it as better.     
The lack of significant changes in the children‟s asthma control and their parent‟s 
quality of life in the present research might be explained by a number of limitations; 
although several research sites were involved with this study and many patient 
recruitment methods were used, the current study was limited by the small sample size. 
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Provided that the participants‟ MDI plus spacer technique was well assessed and 
controlled throughout the study period, and that the asthma medications of the children 
remained the same during the same period. Then, any potential changes in the ACQ 
and/or PACQLQ measures should have been referred to the research intervention (i.e. 
the new Flow-Vu spacer version). However, the asthmatic children were recruited based 
on the GINA (2006) Guidelines criteria for partly- and un-controlled asthma; based on 
which these enrolled children were included as poorly controlled or completely 
uncontrolled asthmatics. However, there was a high variability in the ACQ responses 
over the study period, and the ACQ scores at the baseline and randomization visits did 
not reflect the GINA Guidelines‟ definition of partly- or un-controlled asthma. Indeed, 
the ACQ responses were below the optimal cut-point (≥ 1.50) of uncontrolled asthma 
for clinical trials use (according to the ACQ developers‟ recommendation). In 
agreement with the ACQ, the PACQLQ showed responses close to the good/high 
quality of life at study enrolment and randomization (tables 6-9 and 6-10). As a result of 
that there was no extra room left for any potential improvement on the ACQ and 
PACQLQ scales due to the study intervention. Finally, the present study was limited by 
the relatively short follow-up period, which can be justified by the funding and time 
limitations encountered in this PhD research study. These highlighted restrictions can 
be, therefore, overcome in future research. 
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6.5 Conclusion                           
Coordination of inhalation with MDI actuation is a critical manoeuvre that many 
children and adult patients cannot perform correctly even after repeated MDI technique 
training. A spacer device attached to the MDI provides an extra space and time to 
commence inspiration; therefore, the hand-lung synchronization is no longer crucial. 
The main findings of the current study were: 
 Both the AeroChamber® Plus® and the AeroChamber Plus® Flow-Vu® spacers 
maintained the verbally trained MDI plus spacer correct technique and slow 
inhalation flow. 
 The new AeroChamber Plus with Flow-Vu spacer was as efficient as the current 
AeroChamber Plus spacer in relation to the achieved asthma control levels in 
preschool asthmatic children, and in maintaining their parents‟ asthma-related 
quality of life. 
 The paediatric asthma parents showed more preference to the novel 
AeroChamber Plus with Flow-Vu spacer; as the visual inhalation indicator 
reassured them that their children did take their inhaled medicine sufficiently 
and that their MDI use was adequate. 
  Therefore, the visual feedback mechanism of inhalation and tight mask-face 
seal of the AeroChamber Plus Flow-Vu spacer should be helpful to the patients 
and their caregivers, and is expected to maintain their good MDI use and 
improve their therapy compliance. 
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Chapter 7: Summary 
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7.0 General Discussion 
Asthma and COPD patients are commonly prescribed either metered dose inhalers 
(MDIs) or dry powder inhalers (DPIs) as the principal drug administration methods. A 
successful inhaled therapy is, therefore, highly dependent on the correct inhaler 
technique used by the patients (Crompton et al., 2006; Haughney et al., 2008). Due to 
many advantages, the MDI is the most widely prescribed inhaler device; however, many 
patients are deceived by the apparent simplicity of the pressurized inhaler technique, 
and thus do not use their MDI sufficiently (Everard et al., 1995; [Anon] et al., 1999; 
Virchow et al., 2008). The most common MDI technique mistakes made by the patients 
are poor coordination between inhalation and activation of the inhaler canister, fast 
inhalation flow rate and failing to hold the breath for 10 seconds at the end of the 
inhalation manoeuvre (Crompton et al., 2006). Many studies into poor MDI technique 
have previously highlighted the magnitude of the problem. Paterson and Crompton 
(1976) showed that 14% of the patients misused their MDI, whereas Epstein et al. 
(1979) found that 24.7% of the asthma and COPD patients could not perform more than 
half of the recommended MDI technique steps correctly. The significance of the issue 
was even more evident in a more recent study; 77.5% to 89.2% of the 501 recruited 
patients made at least one MDI technique error (Larsen et al., 1994). The desirable 
inhalation manoeuvre through the MDI should be slow and deep to maintain an IFR < 
90 l/min and thus get the maximum lung deposition (Dolovich et al., 1981; Hindle et al., 
1993; Farr et al., 1995). It has been shown that the total terbutaline lung deposition 
decreased from 11.2% to 7.2% when the IFR increased from 37 to 151 l/min (Newman 
et al., 1995). Actually, less than optimal MDI use may lead to less than 50% of the 
children (Pedersen et al., 1986) and adult patients (Crompton, 1990) getting the 
maximal benefit of their aerosol therapy. 
   
323 
To overcome the poor MDI use, many patient training methods were previously 
investigated. Verbal training has been shown to improve the good MDI technique from 
31% before training to 72% immediately after (Horsley and Bailie, 1988), and training 
the asthmatic children and their parents improved their inhaler use from 8% before 
training to 81% after (Burkhart et al., 2005). Demonstration of the optimal inhaler 
technique by the healthcare provider before their patient (Sestinti et al., 2006) as well as 
by the patient themselves (Kamps et al., 2000) had positive results on enhancing the 
inhaler use. Furthermore, a multimedia training method was found at least as good as 
reading the MDI instruction pamphlet in improving the patients‟ awareness of the 
correct inhaler technique (Savage and Goodyer, 2003). These studies, therefore, justify 
the time and cost spent on improving the patients MDI use. However, the impact of the 
training was found to fade out with time; the patients did forget the proper inhaler 
technique and gradually reverted to the old bad MDI habits shortly after their training 
session. Shim and Williams (1980) have shown that only 50% of the patients continued 
to use their MDI correctly 1 to 30 days after their verbal counselling and demonstration 
session. Similarly, 20% of the trained asthmatic children used their MDI insufficiently 
shortly after their training (Burkhart et al., 2005). These results, thus, explain the need 
to regularly check-up the MDI technique of the patients and re-train them when 
necessary; which would consequently impose additional time, effort and cost burdens 
on the limited healthcare resources. 
A report by the Aerosol Drug Management Improvement Team (ADMIT) on the need 
to improve the inhalation technique in Europe has stated that inhalation devices 
enhanced with a multiple feedback mechanism to reassure the patients and their 
healthcare providers that the performed inhalation technique via an inhaler is sufficient 
should improve the overall correct inhaler use and ultimately disease control (Crompton 
et al., 2006). Moreover, these inhalation technique training and reassuring tools would 
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be expected to improve the patient compliance and preference (Crompton et al., 2006; 
Chrystyn, 2009). In this reference, the 2ToneTrainier
®
 (Canday Medical Ltd., UK) is an 
MDI-like inhalation technique training tool which produces a distinctive audible 
feedback depending on the used IFR; a monotone, low pitch sound when the patient is 
inhaling ideally through an MDI (30-60 l/min), or a two-tone, high pitch noise when the 
patient is inhaling incorrectly (too fast). One recent study has demonstrated the outcome 
of practicing the 2ToneTrainer tool by asthmatic adults managed at chest outpatient 
clinics (Al-Showair et al., 2007b). It has been shown that the 2ToneTrainer helped the 
verbally trained patients improving and maintaining their MDI technique, particularly 
maintaining the recommended slow IFR through the inhaler, these improvements were 
positively reflected on the patients‟ health-related quality of life. However, the 
2ToneTrainer device has not been assessed in other patient groups such as asthmatic 
children, or for its direct impact on asthma control using validated asthma control 
instruments. 
The current research study presented in Chapter 3 of this PhD thesis investigated if the 
verbal training of asthmatic children and adults (with or without practicing the 
2ToneTrainer tool) on the correct MDI technique, with emphasis on using the 
recommended slow IFR through their MDI, would improve and maintain the sufficient 
inhaler use. Furthermore, changes in asthma control and health-related quality of life 
were also assessed. Bradford Research Ethics Committee approved the study and all the 
participants gave a written informed consent. Asthmatic children and adults collecting 
their MDI prescription from a community pharmacy had their MDI technique assessed, 
those who had a fast IFR ≥ 90 l/min through an MDI (measured using the In-Check 
meter) were randomized into either the verbally counselled (VC) group or the 
2ToneTrainer (2TT) group. The patients who inhaled slowly < 90 l/min were enrolled in 
the control (CT) group and followed up without any intervention. At visit 1 and 
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immediately after the verbal training, all the asthmatic children and adults in the VC and 
2TT groups inhaled correctly < 90 l/min and demonstrated the 11 MDI technique steps 
correctly. At visit 2 (about 6 weeks later), 78.6% and 86.7% of the adults in the VC and 
2TT groups, respectively, maintained an IFR < 90 l/min. Whereas, 80% and 100% of 
the children in the VC and 2TT groups, respectively, maintained the desirable slow IFR 
(< 90 l/min). No significant change in the IFR was found in the CT group over the study 
follow-up period. These results are in line with the previously published studies that 
confirmed that the effect of the MDI verbal training wears off with time (Shim and 
Williams, 1980; Burkhart et al., 2005; Al-Showair et al., 2007b). This might be 
explained by that the patients did forget the correct MDI instruction with time and 
became uncertain about the inspiratory effort they needed to make through their MDI to 
attain the slow IFR, provided that the MDI has almost no internal flow resistance. On 
the other hand, practicing the 2ToneTrainer by the study patients at home did 
significantly help maintaining the recommended inhalation flow of the trained 
asthmatics. 
In Chapter 3 study, asthma control was assessed using the Asthma Control Test (ACT) 
(Nathan et al., 2004; Schatz et al., 2006) for asthmatic patients ≥ 12 years old, and the 
Childhood ACT (C-ACT) (Liu et al., 2007) for asthmatics 4-11 years old. No 
significant changes in asthma control were found over the study follow-up period within 
and between the CT, VC and 2TT groups. To evaluate the quality of life, Juniper‟s 
Mini-AQLQ (Juniper et al., 1999c) was used for the adults, whereas the PAQLQ 
(Juniper et al., 1996a) and PACQLQ (Juniper et al., 1996b) were used for the asthmatic 
children and their parents, respectively. For the asthmatic adults in the VC group, the 
mean difference between visits 1 and 2 in the overall Mini-AQLQ score and its domains 
significantly exceeded the minimal important difference (MID) (0.5), except for the 
activity limitation domain. For the adults in the 2TT group, the changes in the 
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symptoms and emotional function quality of life domains were above the MID, 
however, the change in the overall quality of life was not statistically significant. For the 
asthmatic children, although the mean changes in the scores of the overall PAQLQ and 
its domains indicate an improvement in quality of life; only the changes in the 
symptoms domain (VC group) and in the emotional function (2TT group) were 
statistically significant. For the paediatric asthma caregivers (parents), the mean change 
in the overall PACQLQ and its two domains were not significant for the VC group 
parents, whereas, the differences in the overall PACQLQ and the activity limitation 
domain were significant for the 2TT group parents. 
Correct inhaler use is expected to result in good asthma control (Horne et al., 2007; 
Haughney et al., 2008), which is consequently reflected on improved quality of life 
(Schatz et al., 2007a; Garris et al., 2008). In Chapter 3 study, despite the significant 
improvement in the MDI technique for both the VC and 2TT groups; significant 
improvements in asthma control and HRQL were not evident. Changes in these 
outcome measures might have been more considerable if patients with poorly-controlled 
or even uncontrolled asthma were enrolled in our study and followed-up over a longer 
period as there would be an extra room for any potential improvements to be observed. 
Unlike the results of Al-Showair et al. (2007b), there was no statistically significant 
superiority in the IFR reduction by the 2TT over the VC methods in our study (chapter 
3); however, the 2ToneTrainer tool has the advantage, over the MDI verbal training 
method, of being readily available to the patients to practice at home providing them 
with an immediate audible feedback of the correct inhalation when they are in doubt of 
their MDI use, and thus maintaining their correct MDI technique over time. 
The patients who continue to have MDI technique problems even after repeated training 
are usually prescribed a spacer device to use with their pressurized inhaler (Dolovich et 
al., 2005). Moreover, an MDI attached to a spacer is recommended by the Asthma 
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Management Guidelines in asthmatic children < 12 years old (GINA, 2008; BTS/SIGN, 
2009). However, up to 40% of the children still have MDI technique issues even with a 
spacer (Kamps et al., 2000). The AeroChamber
®
 Plus
®
 spacer (Trudell Medical 
International, Canada) (AC) is equipped with a whistle which helps the patients use a 
slow IFR via their MDI by producing a feedback sound when the patient inhales faster 
than 60 l/min (Demirkan et al., 2000). Recently, the feedback mechanism in the 
AeroChamber spacer has been enhanced by the inclusion of a visual indicator of 
inhalation and proper seal between the spacer‟s mask and the user‟s face; the 
AeroChamber
®
 Plus with Flow-Vu
®
 spacer (FV). To the best of our knowledge, this 
new spacer has not been clinically assessed yet. Therefore, the present study in Chapter 
6 of this thesis aimed at evaluating the impact of the routine use of the novel FV spacer 
on the MDI technique and asthma control in preschool asthmatic children, compared 
with the use of the currently available AC spacer. The asthma-related quality of life of 
the asthmatic children‟s parents/caregivers was also assessed. In this research the 
facemask version (yellow) of the AeroChamber spacer was studied. The results showed 
that the mean (SD) baseline inhalation flow rate (mimicking normal tidal breathing 
through a spacer) at study enrolment (visit 1) was slow and well below 60 l/min for the 
two study groups (41.3 (14.3) l/min AC group; 34.3 (6.7) l/min FV group). Although 
the IFR of the FV group asthmatic children was generally slower than that of the AC 
group children, no significant difference in the IFR was demonstrated between the AC 
and FV groups over the study follow-up period; the IFR remained within the desirable 
slow inhalation flow. The Asthma Control Questionnaire (ACQ) (Juniper et al., 1999d; 
Juniper et al., 2006) was used to assess the changes in asthma control levels in the 
children. The median ACQ scores at study randomization were 0.83 and 0.92 for the 
AC and FV groups respectively. At the end of the study (visit 4: 3 months of 
randomization) the ACQ scores were 0.67 and 0.83 for the AC and FV groups, 
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respectively. Although the ACQ scores were within the ACQ controlled asthma cut-
point (< 1.50), no significant changes were seen within or between the AC and FV 
groups over the study follow-up period. In agreement with the ACQ, the parents‟ 
overall PACQLQ showed a good to high quality of life scores over the study period 
without significant differences between the two study groups. However, 66.7% and 
62.5% of the parents in the FV and AC groups, respectively, did rank the new FV 
spacer as much better than the AC; whereas 22.2% of the FV parents and 37.5% of the 
AC parents ranked the FV spacer as better. The parents justified their preference by the 
reason that the visual inhalation feedback indicator of the FV spacer reassures them that 
their asthmatic children do take their inhaled therapy sufficiently. 
Dry powder inhalers (DPIs) have a specific internal flow resistance which varies from a 
low to high resistance according to the inhaler design (Clark and Hollingworth, 1993). 
Dose emission from the DPI is flow dependent; the patient‟s inspiratory effort, and thus 
the generated inhalation flow, is the principal energy responsible for the characteristics 
of the total and fine particle emitted dose (Clark and Hollingworth, 1993; Steckel and 
Muller, 1997b; Chrystyn, 2009). Accordingly, the patient using a DPI should be able to 
achieve a minimum PIF through that particular DPI device for adequate lung deposition 
and thus therapeutic benefit (Ross and Schultz, 1996; Tarsin et al., 2006; Virchow et al., 
2008). However, not all patients are able to inhale sufficiently via all DPIs, and the 
variability in the PIF through various DPI devices has been demonstrated in the 
literature (Dewar et al., 1999; Hawksworth et al., 2000; Broeders et al., 2003a; Van Der 
Palen, 2003; Amirav et al., 2005; Al-Showair et al., 2007a). Moreover, it has been 
shown that the early inhalation acceleration rates and volumes of the patient‟s inhalation 
profile through the DPI might have an important effect on both the emitted dose 
characteristics and the ultimate lung deposition; and these effects might be more critical 
than the overall achieved PIF (Everard et al., 1997; Kamin et al., 2002). However, little 
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attention has been paid to investigate the various inhalation profile parameters; this is 
mainly due to the unavailability of suitable measuring instrumentation. 
In the lab work presented in Chapter 4, the specific internal flow resistance was 
determined for two versions of a novel DPI, the Spiromax
®
 (TEVA Pharmaceuticals, 
UK). These differ in the size of the dose metering cup inside the inhaler. The results in 
Chapter 4 showed that the two versions of the Spiromax DPI have almost the same 
internal flow resistance values (0.0966 and 0.0983 (cmH2O)
0.5 
min/l), which classify the 
Spiromax in the range of the medium resistance DPIs (Clark and Hollingworth, 1993; 
Assi and Chrystyn, 2001; Chrystyn, 2009).  
Chapter 5 presented a research study in which realistic inhalation profiles and 
acceleration rates of asthmatic children and adults, and of COPD patients were obtained 
through the Spiromax DPI when it was connected to a specially designed electronic 
pressure change recorder. The inhalation flow rate versus time was then plotted, from 
which the PIF as well as the inhalation acceleration rates and volumes at various time 
points of the inhalation manoeuvre were determined. The mean (SD) PIFs (l/min) were 
79.8 (18.1), 90.9 (16.0) and 73.3 (18.7) for the asthmatic children, asthmatic adults and 
COPD patients, respectively. The median (range) total inhalation volumes (L) via the 
Spiromax were 1.65 (0.44 - 4.14) for the asthmatic children, 2.23 (0.83 – 5.03) for the 
asthmatic adults and 1.89 (0.67 – 5.78) for the COPD patients. Moreover, the inhalation 
acceleration rates and volumes at various time points of the inspiratory profile were 
presented in Chapter 5; tables 5-5, 5-6 and 5-7 for asthmatic children; tables 5-17, 5-18 
and 5-19 for asthmatic adults and tables 5-28, 5-29 and 5-30 for COPD patients. The 
variability in the inhalation parameters measured in this study among various patient 
groups highlights two critical issues; firstly, not all patients are able to inhale adequately 
through a DPI and, therefore, proper instrumentation capable of measuring the complete 
inhalation profile parameters are needed to assess the patient‟s ability to sufficiently use 
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a particular DPI before a prescription decision can be made. Secondly, it is 
recommended that the in-vitro assessment of dose emission from a DPI device takes 
into consideration the realistic inhalation characteristics achievable by the patients 
themselves, rather than using the recommended Pharmacopoeial standard conditions of 
a single inhalation flow equivalent to 4kPa pressure drop across the DPI, and an 
inhalation volume of 4 L.               
 
      
             
 
   
331 
7.1 General Conclusion 
Correct inhaler technique is very crucial to achieve the maximum lung deposition and 
consequently therapeutic benefit. The MDI users are recommended to inhale slowly and 
deeply to maintain an IFR < 90 l/min through their inhaler. Studies in the current PhD 
thesis have demonstrated that verbal training of asthmatic children and adults, at a 
community pharmacy setting, on the correct MDI technique, with a special emphasis on 
the desirable slow IFR, followed by a demonstration of a good inhaler use by the 
patients themselves did improve their MDI technique and IFR, with a potential 
improvement in their health-related quality of life. However, the effect of training faded 
out shortly after the counselling session, and many patients reverted to the inadequate 
MDI use. The 2ToneTrainer tool with its audible feedback mechanism helped the 
verbally trained patients use their MDI correctly with the recommended IFR. Being 
available for the patients to practice at home, the 2ToneTrainer has the potential to 
maintain the patients‟ good MDI technique over time; hence minimizing the need for 
frequent MDI technique reinforcement and re-training. 
The current work has shown that, when attached to an MDI, the routine use of the novel 
AeroChamber Plus with Flow-Vu spacer, enhanced with a visual feedback mechanism 
of inhalation and proper mask-face seal, provided and maintained similar asthma control 
levels in preschool asthmatic children to that provided by the currently available 
AeroChamber Plus spacer, and maintained the same health-related quality of life of 
their parents. The paediatric asthma parents preferred the new FV spacer as its visual 
feedback indicator reassured them of competent MDI use and sufficient aerosol 
inhalation by their asthmatic children which would potentially enhance their 
compliance. 
Dry powder inhalers should be used with a “fast and deep” inhalation manoeuvre as the 
inhaler‟s output is crucially dependent on the patient‟s inhalation flow through the 
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inhaler. However, not all patients with various disease conditions are able to achieve the 
minimal PIF for a good DPI use. In the current work, the realistic inhalation profile 
parameters measured via the Spiromax DPI confirm the variability in the PIF, IV and 
ACC among different patient groups, and suggest that suitable instruments are needed 
to assess the patient‟s inspiratory profile through a DPI before matching the patient to 
that inhaler. The inhalation acceleration rates and volumes may have a significant effect 
on the DPI output and, thus, need further investigation. It is also suggested that the 
realistic inhalation profile characteristics of the patients, rather than the recommended 
Pharmacopoeial standard flow conditions, should be taken into consideration when 
assessing a DPI dose emission in-vitro. 
In conclusion, the findings in the present work have demonstrated the efficiency of 
using tools enhanced with good inhalation technique feedback mechanisms. These 
findings, thus, may have implications on improving the clinical practice of adequate 
inhaler use.            
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8.0 Future Work 
The research studies in the current PhD thesis have demonstrated the efficiency of using 
inhalation tools with a feedback mechanism of a correct inhaler technique. The 
2ToneTrainer has been shown to help the verbally trained asthmatic children and adults 
improving and maintaining the recommended slow IFR when using their MDI, which 
would eventually reduce the need for frequent inhaler use check up and patient re-
training. The literature has shown that using the MDI with the recommended IFR would 
improve lung deposition and thus asthma control and quality of life. Therefore, it would 
be beneficial, in a future research, to enrol poorly controlled or completely uncontrolled 
asthmatics as defined by the cut-off points of the valid asthma control instruments and 
follow them up over a longer period (> 6 weeks) to clearly assess the outcome of the 
2ToneTrainer use on asthma control and quality of life measures. Evaluating the 
2ToneTrainer device in COPD patients would be also valid.  
In the current work, the facemask version of the novel AeroChamber Plus with Flow-Vu 
spacer has been shown to maintain adequate asthma control levels in preschool 
asthmatic children, and was the spacer of choice by their parents. It would be useful to 
extend this research to evaluate the mouthpiece version of the new FV spacer in school-
aged asthmatic children using the recently developed ACQ for 6-11 year-old children as 
well as using the relevant Juniper‟s HRQL instruments to assess any changes in their 
quality of life over sufficient follow-up periods. Inclusion of asthmatic adults in these 
future spacer comparison studies utilizing the relevant asthma control and quality of life 
questionnaires would be also important. 
The inhalation profiles and acceleration rates, obtained in the present work from the 
asthma and COPD patients when they inhaled through the Spiromax DPI, have 
highlighted the importance of other inhalation characteristics, in addition to the PIF, 
when the patients use a DPI. The PIF through the DPIs have been extensively in-vitro 
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studied in the literature. However, future research is needed to assess the impact of the 
inhalation acceleration rates and volumes at various time points of the inhalation profile 
on the DPI‟s output, and compare that with the PIF effect. The currently determined 
realistic inhalation profile parameters can be, therefore, replayed in the laboratory using 
a special vacuum pump and flow controller connected to a cascade impactor to study the 
in-vitro total and fine particle dose emission behaviour from various moderate 
resistance DPIs. The effect of the PIF, inhalation volume and acceleration rate can be 
then assessed and related to the ability of respiratory patients, with various disease 
severity conditions, to use their DPI efficiently. Similar clinical and lab studies can be 
also carried out in the future using low and high resistance DPIs. The outcome of these 
proposed studies may potentially suggest improvements in the DPI formulation, as well 
as improvements in the clinical practice by matching the patients to the DPI device they 
can best use.       
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